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Team-based careAbstract: An Expert Panel convened by the National Lipid Association previously developed a
consensus set of recommendations for the patient-centered management of dyslipidemia in clinical
medicine (part 1). These were guided by the principle that reducing elevated levels of atherogenic
cholesterol (non–high-density lipoprotein cholesterol and low-density lipoprotein cholesterol) reduces
the risk for atherosclerotic cardiovascular disease. This document represents a continuation of the
National Lipid Association recommendations developed by a diverse panel of experts who examined
the evidence base and provided recommendations regarding the following topics: (1) lifestyle thera-
pies; (2) groups with special considerations, including children and adolescents, women, older patients,
certain ethnic and racial groups, patients infected with human immunodeficiency virus, patients with
rheumatoid arthritis, and patients with residual risk despite statin and lifestyle therapies; and (3) stra-
tegies to improve patient outcomes by increasing adherence and using team-based collaborative care.
 2015 National Lipid Association. Published by Elseiver Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In 2014, the National Lipid Association (NLA)
convened an Expert Panel to develop a consensus set of
recommendations for the patient-centered management of
dyslipidemia (Part 1).1 The evidence base used was derived
from randomized controlled trials (RCTs), meta-analyses of
results from RCTs, and review of results from observa-
tional, genetic, metabolic, and mechanistic studies. Based
on the totality of evidence, the Part 1 NLA Recommenda-
tions for Patient-Centered Management of Dyslipidemia
laid out several conclusions and core principles.
1. An elevated level of cholesterol carried by circulating
apolipoprotein (apo) B-containing lipoproteins (non-
high-density lipoprotein cholesterol [non-HDL-C] and
low-density lipoprotein cholesterol [LDL-C], termed
atherogenic cholesterol) is a root cause of atheroscle-
rosis, the key underlying process contributing to most
clinical atherosclerotic cardiovascular disease (ASCVD)
events;
2. Reducing elevated levels of atherogenic cholesterol will
lower ASCVD risk in proportion to the extent that
atherogenic cholesterol is reduced;
3. The intensity of risk-reduction therapy should generally
be adjusted to the patient’s absolute risk for an ASCVD
event;
4. Atherosclerosis is a process that often begins early in
life and progresses for decades before resulting in a clin-
ical ASCVD event. Therefore, both intermediate-term
and long-term/lifetime risk should be considered when
assessing the potential benefits and hazards of risk-
reduction therapies;
5. For patients in whom lipid-lowering drug therapy is
indicated, statin treatment is the primary modality for
reducing ASCVD risk;
6. Treatment goals and periodic monitoring of atherogenic
cholesterol levels (non-HDL-C and LDL-C) are impor-
tant tools in the implementation of a successful treat-
ment strategy. These aid the clinician in assessing theadequacy of treatment and facilitate active participation
by the patient through feedback and reinforcement of
the beneficial effects of lifestyle and pharmaceutical
therapies; and
7. Non-lipid ASCVD risk factors should also be managed
appropriately, particularly high blood pressure, cigarette
smoking, and diabetes mellitus.
The NLA Part 1 Recommendations emphasize the
importance of taking a patient-centered approach in coun-
seling patients about the benefits and hazards of lifestyle
and drug therapies. Using the principle of shared decision
making, the patient should be an active participant in the
process, engaging with the clinician in a dialogue about
the objectives and potential benefits of therapy, as well as
risks, side effects, and costs. The initial step is a determina-
tion of the patient’s risk for an ASCVD event (Table 1).1
Lifestyle counseling is a key element of preventive efforts
at all levels of risk, and dietary adjuncts may be used to
enhance atherogenic cholesterol reduction. If lifestyle ther-
apies, including dietary adjuncts, are insufficient to achieve
desired levels of atherogenic cholesterol, evidence-based
drug therapy, particularly moderate- to high-intensity statin
therapy should be considered. If goal levels of atherogenic
cholesterol are not achieved with maximally tolerated statin
therapy, combining a statin with a second (and sometimes a
third) agent may be considered for selected patients. Alter-
native strategies may be needed for patients who are statin
intolerant, or who prefer not to use statin therapy. Lastly,
regular patient and lipid follow-up is warranted to assess
adherence and adequacy of the atherogenic cholesterol re-
sponses to therapy.
NLA Part 2 recommendations
The creation of the NLA Part 2 Recommendations for
Patient-Centered Management of Dyslipidemia was in-
tended to expand upon the NLA Part 1 Recommendations
in areas where clinicians may desire additional guidance,
particularly where the evidence base is less robust or is
Table 1 NLA Part 1 Recommendations for Patient-Centered Management of Dyslipidemia–Criteria for ASCVD risk assessment, treatment
goals for atherogenic cholesterol, and levels at which to consider drug therapy
Risk category Criteria





Low  0–1 major ASCVD risk factors ,130 $190
 Consider other risk indicators, if known ,100 $160
Moderate  2 major ASCVD risk factors ,130 $160
 Consider quantitative risk scoring ,100 $130
 Consider other risk indicators*
High  $3 major ASCVD risk factors ,130 $130
 Diabetes mellitus (type 1 or 2)† ,100 $100
B 0–1 other major ASCVD risk factors and
B No evidence of end-organ damage
 Chronic kidney disease stage 3B or 4‡
 LDL-C of $190 mg/dL (severe hypercholesterolemia)x
 Quantitative risk score reaching the high-risk thresholdjj
Very high  ASCVD ,100 $100
 Diabetes mellitus (type 1 or 2) ,70 $70
B $2 other major ASCVD risk factors or
B Evidence of end-organ damage{
For patients with ASCVD or diabetes mellitus, consideration should be given to use of moderate or high-intensity statin therapy,
irrespective of baseline atherogenic cholesterol levels.
ASCVD, atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
Taken from Jacobson TA, et al. J Clin Lipidol. 2015;9:129–169.1
*For those at moderate risk, additional testing may be considered for some patients to assist with decisions about risk stratification.
†For patients with diabetes plus 1 major ASCVD risk factor, treating to a non–HDL-C goal of ,100 mg/dL (LDL-C of ,70 mg/dL) is considered a
therapeutic option.
‡For patients with chronic kidney disease (CKD) stage 3B (estimated glomerular filtration rate [eGFR], 30–44 mL/min/1.73 m2) or stage 4 (eGFR, 15–
29 mL/min/1.73 m2) risk calculators should not be used because they may underestimate risk. Stage 5 CKD (or on hemodialysis) is a very high-risk con-
dition, but results from randomized, controlled trials of lipid-altering therapies have not provided convincing evidence of reduced ASCVD events in such
patients. Therefore, no treatment goals for lipid therapy have been defined for stage 5 CKD.
xIf LDL-C is $190 mg/dL, consider severe hypercholesterolemia phenotype, which includes familial hypercholesterolemia. Lifestyle intervention and
pharmacotherapy are recommended for adults with the severe hypercholesterolemia phenotype. If it is not possible to attain desirable levels of athero-
genic cholesterol, a reduction of at least 50% is recommended. For familial hypercholesterolemia patients with multiple or poorly controlled other major
ASCVD risk factors, clinicians may consider attaining even lower levels of atherogenic cholesterol. Risk calculators should not be used in such patients.
jjHigh-risk threshold is defined as $10% using Adult Treatment Panel III Framingham Risk Score for hard coronary heart disease (CHD; myocardial
infarction or CHD death), $15% using the 2013 Pooled Cohort Equations for hard ASCVD (myocardial infarction, stroke, or death from CHD or stroke), or
$45% using the Framingham long-term cardiovascular disease (myocardial infarction, CHD death or stroke) risk calculation. Clinicians may prefer to use
other risk calculators, but should be aware that quantitative risk calculators vary in the clinical outcomes predicted (eg, CHD events, ASCVD events, car-
diovascular mortality); the risk factors included in their calculation; and the timeframe for their prediction (eg, 5 years, 10 years, or long-term or life-
time). Such calculators may omit certain risk indicators that can be very important in individual patients, provide only an approximate risk estimate, and
require clinical judgment for interpretation.
{End-organ damage indicated by increased albumin-to-creatinine ratio ($30 mg/g), CKD (eGFR, ,60 mL/min/1.73 m2), or retinopathy.
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guide clinical decisions. Based on feedback from NLA
members and other important stakeholders, several major
content areas were identified for inclusion.
1. Lifestyle therapies–nutrition and exercise/physical
activity;
2. Groups with special considerations that span the lifespan
from children to seniors and from pregnancy to
menopause;
3. Ethnic groups including Hispanics/Latinos, African
Americans (AAs), South Asians (SAs), and American
Indians (AIs)/Alaska Natives (ANs);4. Groups with increased ASCVD risk, including patients
with human immunodeficiency virus (HIV), rheumato-
logic disease, and those with high residual risk despite
statin and lifestyle therapies; and
5. Strategies to improve patient outcomes centered on
improving adherence and maximizing team-based
collaborative care.
NLA Part 2 represents a continuation of previous NLA
recommendations developed by a diverse and interdisci-
plinary panel of experts. The process began with appoint-
ment of an executive Steering Committee. Section Chairs
and Expert Panel members with expertise in core topic
Table 2 NLA Part 2 Recommendations for Patient-Centered Management of Dyslipidemia–Expert Panel
NLA expert panel steering committee members
Terry A. Jacobson, MD, FNLA, Chair; Kevin C. Maki, PhD, CLS, FNLA; Carl Orringer, MD, FNLA; Peter Jones, MD, FNLA
I. Lifestyle therapies section
Nutrition
Penny Kris-Etherton, PhD, RDN, CLS, FNLA, Co-Chair; Geeta Sikand, MA, RDN, CLS, FNLA, Co-Chair; Kevin C. Maki, PhD, CLS, FNLA, Co-Chair;
Julie Bolick, MS, RDN, CLS, FNLA; Mary R. Dicklin, PhD; Carol Kirkpatrick, PhD, RDN, CLS, FNLA; Katherine Rhodes, PhD, RDN; Nancy T.
Smith, MS, RDN, CDE, CLS
Exercise
Ralph La Forge, MSc, FNLA, Chair; Kevin C. Maki, PhD, FNLA
II. The lifespan—children to seniors section
Children and adolescents
Stephen Daniels, MD, PhD, FNLA, Co-Chair; Don Wilson, MD, FNLA, Co-Chair; Piers Blackett, MD, FNLA; Sarah DeFerranti, MD; Samuel
Gidding MD, FNLA; Rae-Ellen W. Kavey, MD, MPH; Brian McCrindle, MD; Catherine McNeal, MD, PhD, FNLA; Elaine Urbina, MD
Women’s health
Pamela Morris, MD, FNLA, Chair
From pregnancy to menopause
Robert Wild, MD, MPH, PhD, FNLA, NCMP, Chair; Thomas Dayspring, MD, FNLA, NCMP; James A. Underberg, MS, MD, FNLA
Older patients
Carl Orringer, MD, FNLA, Co-Chair; Scott Grundy, MD, PhD, FNLA, Co-Chair; Joyce Ross, MSN, CRNP, FNLA
III. Ethnic and racial groups section
Hispanics/Latinos
Martha Daviglus, MD, PhD, Chair; J Antonio G. Lopez, MD, FNLA; Amber Pirzada, MD; Carlos Jose Rodriguez, MD, MPH, FACC
African Americans
Keith Ferdinand, MD, FNLA, Chair
South Asians
Kris Vijay, MD, FNLA, Co-Chair; Prakash Deedwania, MD, Co-Chair
American Indians/Alaska Natives
Kevin C. Maki, PhD, FNLA, Co-Chair; Ralph La Forge, MSc, FNLA, Co-Chair
IV. High-risk conditions and residual risk section
HIV-infected persons
Judith Aberg, MD, Chair; Carl J. Fichtenbaum, MD; Joel E. Gallant, MD; Michael A. Horberg, MD; Christopher T. Longenecker, MD;
Merle Myerson, MD, FNLA; E. Turner Overton, MD
Patients with rheumatoid arthritis
Katherine Liao, MD, MPH, Chair; Jonathon S. Coblyn, MD; Jeffrey Curtis, MD, MS, MPH; Jorge Plutzky, MD, FNLA;
Daniel Solomon, MD, MPH
Patients with residual risk despite statin and lifestyle therapy
Peter Jones, MD, FNLA, Co-Chair; James McKenney, PharmD, FNLA, Co-Chair
V. Improving patient outcomes section
Patient adherence
Joyce Ross, MSN, CRNP, FNLA, Co-Chair; Lynne Braun, PhD, CNP, FNLA, Co-Chair
Team-based collaborative care
Lynne Braun, PhD, CNP, FNLA, Co-Chair; Matthew Ito, PharmD, FNLA, Co-Chair; Joyce Ross, MSN, CRNP, FNLA, Co-Chair
VI. Additional general panel members
Harold Bays, MD, FNLA; W. Virgil Brown, MD, FNLA
HIV, human immunodeficiency virus; NLA, National Lipid Association.
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mittee (Table 2). After an initial draft of the consensus rec-
ommendations was compiled, this was made available to
the public for an open comment period. Input was solicited
from stakeholders, including the general public, NLAmembers, other professional societies, and governmental
agencies. Comments and suggestions were then collated
for adjudication by the NLA Expert Panel members, and
final recommendations were presented to the NLA Board
for approval.
Table 3 Grading of the strength of recommendations and quality of evidence
Evidence grading: strength of recommendation*
Grade Strength of recommendation
A Strong recommendation
There is high certainty based on the evidence that the net benefit† is substantial
B Moderate recommendation
There is moderate certainty based on the evidence that the net benefit is moderate to substantial, or there is high certainty
that the net benefit is moderate
C Weak recommendation
There is at least moderate certainty based on the evidence that there is a small net benefit
D Recommend against
There is at least moderate certainty based on the evidence that it has no net benefit or that the risks/harms
outweigh benefits
E Expert opinion
There is insufficient evidence or evidence is unclear or conflicting, but this is what the expert panel recommends
N No recommendation for or against
There is insufficient evidence or evidence is unclear or conflicting
Evidence grading: quality of evidence
Type of evidence Quality rating‡
Well-designed, well-executed RCTs that adequately represent populations to which the results are
applied and directly assess effects on health outcomes
Well-conducted meta-analyses of such studies
Highly certain about the estimate of effect; further research is unlikely to change our confidence in
the estimate of effect
High
RCTs with minor limitations affecting confidence in, or applicability of, the results
Well-designed, well-executed nonrandomized controlled studies and well-designed, well-executed
observational studies
Well-conducted meta-analyses of such studies
Moderately certain about the estimate of effect; further research may have an impact on our
confidence in the estimate of effect and may change the estimate
Moderate
RCTs with major limitations
Nonrandomized controlled studies and observational studies with major limitations affecting
confidence in, or applicability of, the results
Uncontrolled clinical observations without an appropriate comparison group (eg, case series, case reports)
Physiological studies in humans
Meta-analyses of such studies
Low certainty about the estimate of effect; further research is likely to have an impact on our confidence
in the estimate of effect and is likely to change the estimate
Low
RCT, randomized controlled trial.
This was the system used in the new American Heart Association/American College of Cardiology cholesterol guidelines3 that were published in the
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report from the Panel members appointed to the Eighth Joint Na-
tional Committee.3
*The system was adapted as a hybrid of the National Heart Lung and Blood Institutes (NHLBI) rating System (NHLBI cardiovascular-based method-
ology) used in the new American Heart Association/American College of Cardiology cholesterol guidelines3 and adapted from the original GRADE system of
evidence rating.4
†Net benefit is defined as benefits minus risks/harms of the service/intervention.
‡The evidence quality rating system used in this guideline was developed by the National Heart Lung, and Blood Institute’s (NHLBI’s) Evidence-Based
Methodology Lead (with input from NHLBI staff, external methodology team, and guideline panels and work groups) for use by all the NHLBI cardiovas-
cular disease guideline panels and work groups during this project. As a result, it includes the evidence quality rating for many types of studies, including
studies that were not used in this guideline.
Permission to reuse table granted from the American Medical Association.3
Taken from Jacobson TA, et al. J Clin Lipidol. 2015;9:129–169.1 Originally published in James PA, et al. JAMA. 2014;311:507–520 and Stone NJ, et al. J Am
Coll Cardiol. 2014;63(25 Pt B):2889–2934.2,3
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using an adapted grading system from both the National
Heart, Lung, and Blood Institute’s Evidence-BasedMethodology Team2,3 and the Grading of Recommenda-
tions Assessment, Development and Evaluation system of
evidence rating (Table 3).4 For each recommendation, the
S6 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015strength of the recommendation was assigned, with consid-
eration given to the ‘‘net benefit’’ after taking into account
potential benefits and risks or harms associated with the
service or intervention. The quality of the evidence rating
was determined using the rating system developed by the
National Heart, Lung, and Blood Institute’s Evidence-
Based Methodology Panel, as published in the 2013
American College of Cardiology (ACC)/American Heart
Association (AHA) Guideline on the Treatment of Blood
Cholesterol to Reduce Atherosclerotic Cardiovascular
Risk in Adults.3Lifestyle therapies
Lifestyle therapies are central to dyslipidemia manage-
ment and should be advised for all patients, whether or not
drug therapy is also prescribed. As outlined in Part 1 of the
NLA Recommendations for Patient-Centered Management
of Dyslipidemia,1 a trial of lifestyle therapies should be
attempted prior to use of drug therapy for most patients.
Exceptions include patients at very high or high risk for
whom clinicians may wish to simultaneously begin lifestyle
and drug therapies.
Targets of lifestyle therapies and rationale for
their use
The targets of lifestyle therapies will principally be
levels of atherogenic cholesterol, which include LDL-C and
non-HDL-C. The non-HDL-C concentration is comprised
mainly of LDL-C and very low-density lipoprotein choles-
terol (VLDL-C) levels. VLDL-C concentration is highly
correlated with the circulating level of triglycerides (TG).
The TG level per se is not a recommended target of therapy,
except when very high ($500 mg/dL). In these patients,
lowering the TG concentration to ,500 mg/dL is the
primary objective of therapy to reduce the risk of acute
pancreatitis. When the TG level is , 500 mg/dL, attaining
goal levels of atherogenic cholesterol is the main objective
of therapy. High-density lipoprotein cholesterol (HDL-C) is
not a target of therapy, although low HDL-C is a strong
predictor of ASCVD event risk. Lifestyle changes that
lower levels of atherogenic cholesterol often alter HDL-C,
but the clinical relevance of these changes is uncertain at
present. Additional targets of lifestyle interventions include
excess adiposity for those who are overweight or obese, and
other ASCVD risk factors, such as elevated blood pressure,
hyperglycemia (and diabetes), and smoking. The focus of
the evidence summarized below is on the influence of
lifestyle interventions on lipoprotein lipid levels, but
clinicians should be aware that changes in other risk factors
contribute to ASCVD risk.1
Limited evidence is available from randomized clinical
trials to assess the impacts of lifestyle therapies on ASCVD
event risk. However, evidence from epidemiologic studies
consistently supports a strong relationship betweencirculating levels of atherogenic cholesterol and ASCVD
event risk.1,5,6 In particular, studies of genetic variants that
influence LDL-C and VLDL-C levels show that even rela-
tively small differences in these lipoprotein lipid levels are
associated with changes in ASCVD event risk.7–9 More-
over, the differences in ASCVD risk for a given difference
in atherogenic cholesterol level produced by genetic vari-
ants is larger than would be predicted from RCTs of
lipid-altering drug therapies.7,8,10,11 In RCTs, each reduc-
tion of 1% in LDL-C or non-HDL-C is associated with a
1% reduction in coronary heart disease (CHD) event risk
over a period of w5 years.12,13 Genetic variants that alter
LDL-C have a stronger association with CHD event risk
than would be predicted based on RCT results, generally
showing that each 1% difference in LDL-C induced by ge-
netic variants is associated with a 2–3% difference in CHD
risk.10,11 These findings are consistent with the hypothesis
that relatively small differences in levels of atherogenic
cholesterol have important impacts on ASCVD risk if
maintained over an extended period. They also suggest
that results from intervention studies lasting only
w5 years likely underestimate the potential benefit of
decades-long exposure to lower levels of atherogenic lipo-
protein cholesterol levels.
Genetic variants that alter VLDL-C, without affecting
LDL-C, are also associated with differences in ASCVD
event risk. The magnitude of the differences observed with
genetically induced differences in VLDL-C are at least as
large as those associated with differences in LDL-C for a
given mg/dL difference.9,14 For example, in the Copenha-
gen Heart Studies, each 38.7 mg/dL (1 mmol/L) difference
in LDL-C was associated with a 47% difference in CHD
event risk. However, each 38.7 mg/dL (1 mmol/L) differ-
ence in VLDL-C (referred to as remnant cholesterol by
the investigators) was associated with a CHD risk differ-
ence of 182%.9 These findings are consistent with a causal
role for VLDL-C (or some variable closely correlated with
VLDL-C) in ASCVD event risk, and support the impor-
tance of both LDL-C and non-HDL-C (the sum of
LDL-C and VLDL-C) as targets of therapy.
In addition to strong and consistent associations in
observational studies between levels of atherogenic choles-
terol and ASCVD event risk, the diet and lifestyle patterns
recommended based on their ability to lower levels of
atherogenic cholesterol in RCTs have also been associated
with lower ASCVD risk in observational studies.15–17 These
findings are almost certainly explained in part by associations
with major ASCVD risk factors, such as lipoprotein lipid and
blood pressure levels. However, the recommended lifestyle
patterns have also been linked with potentially favorable
differences in emerging and non-traditional ASCVD risk
factors, including markers of insulin resistance, inflamma-
tion, thrombogenicity, and oxidative stress.18 Therefore,
clinicians should be aware that effective lifestyle therapies
elicit changes in biochemical parameters with potential clin-
ical relevance beyond those that are typically measured in
clinical practice.
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changes
Patients with dyslipidemia, metabolic syndrome,
overweight or obesity should be referred for lifestyle
modification counseling whenever possible. A registered
dietitian nutritionist plays an important role in counseling
the patient to develop and implement an individualized
cardioprotective eating plan (i.e., medical nutrition therapy
[MNT] for dyslipidemia). Other health professionals, such
as an exercise specialist, behavioral health specialist, social
worker and/or psychologist, also are important in achieving
physical activity/exercise goals, stress management, iden-
tification and management of triggers for unhealthy eating
patterns, and tobacco cessation.
General principles for a healthy lifestyle
The 2010 Dietary Guidelines for Americans (DGA)
present general principles for a healthy lifestyle.19 They
emphasize a balance between energy intake and expenditure
to maintain a healthy body weight. This includes controlling
energy intake to avoidweight gain and assist withweight loss
in overweight/obese persons, maintaining adequate physical
activity, andminimizing time spent in sedentary behaviors as
also recommended by the American College of Sports
Medicine20 and the American Council on Exercise.21 The
DGA also emphasize avoiding excessive sodium intake,
limiting consumption of energy from saturated fats, trans
fats, added sugars, refined grains, and for adults who choose
to consume alcohol, to do so in moderation. The DGA
emphasize consuming fruits and vegetables; nuts, peas and
legumes; whole grains; lean sources of protein; low-fat or
fat-free dairy products; seafood; and liquid vegetable oils.
Recommended macronutrient ranges for adults are 45–65%
of energy from carbohydrate, 10–35% from protein, and
20–35% of energy from fat. As of this writing, the 2015
DGA had not yet been released, but the 2015 Dietary Guide-
lines Advisory Committee’s (DGAC) Scientific Report
recommended removal of the upper limit for dietary fat to
allow greater flexibility, particularly with regard to reducing
intakes of cholesterol-raising (12–16 carbon saturated and
trans unsaturated) fatty acids and refined grains and sugars.22
In place of these dietary components, greater emphasis is
placed on increasing consumption of foods containing unsat-
urated fatty acids, such as nuts and liquid vegetable oils.22
Lifestyle therapies for dyslipidemia
management
The NLA Expert Panel recommends lifestyle therapies
as an integral component of treatment plans for manage-
ment of dyslipidemia and ASCVD event risk reduction at
all levels of risk. For lowering levels of atherogenic
cholesterol, the main features include a cardioprotective
dietary pattern low in cholesterol-raising fatty acids (,7%
of energy from saturated fatty acids and minimal intake oftrans unsaturated fatty acids) and dietary cholesterol
(,200 mg/day), as well as regular physical activity (at least
150 min per week of moderate or higher intensity activity).
Dietary adjuncts, including plant sterols/stanols and viscous
fibers, may be used to enhance the reductions in athero-
genic cholesterol. Energy restriction and further increases
in physical activity are recommended for overweight or
obese patients for whom weight loss and additional reduc-
tions in atherogenic cholesterol levels are desired. These
lifestyle interventions should be implemented within the
general principles outlined above from the 2010 DGA.
Reviews of the evidence in support of specific recommen-
dations and additional details about their implementation
are outlined below.
Nutrition
Dietary patterns to reduce risk of ASCVD
The focus of much contemporary nutrition research is on
dietary patterns because they represent the totality of the
diet, including the myriad of combinations and quantities of
foods and nutrients that are consumed.23 There is evidence
that particular dietary patterns, as well as specific nutrients
(and also physical activity), play significant roles in the pre-
vention and treatment of ASCVD by beneficially modifying
major ASCVD risk factors, particularly lipoprotein lipids
and blood pressure.24
Recommended dietary patterns share many characteris-
tics. For example, the 2013 AHA/ACC Guideline on
Lifestyle Management to Reduce Cardiovascular Risk24
made the following recommendation, which is similar to
other recommended diets (described below):
Advise adults who would benefit from LDL-C lowering
to consume a dietary pattern that emphasizes intake of
vegetables, fruits and whole grains; includes low-fat
dairy products, poultry, fish, legumes, non-tropical
vegetable oils and nuts; and limits intakes of sweets,
sugar-sweetened beverages and red meats. The dietary
patterns that are recommended and representative of
these foods/food groups are the DASH dietary pattern,
the USDA Food Pattern, or the AHA diet. These
recommended dietary patterns provide 5–6% of calories
from saturated fat and are low in trans fats.
Dietary Approaches to Stop Hypertension (DASH) dietary
patterns
The DASH dietary pattern emphasizes consumption of
vegetables, fruits, and low-fat milk and dairy products;
includes whole grains, poultry, seafood, and nuts; and is
lower in sodium, red and processed meats, sweets, and
sugar-containing beverages (e.g., soda, juice drinks). The
DASH dietary pattern assessed in the initial DASH RCTs
provides approximately 27% of calories from total fat (6%
saturated fatty acids, 13% monounsaturated fatty acids
[MUFA], 8% polyunsaturated fatty acids [PUFA]), 58% of
calories from carbohydrate, and 15% of calories from
S8 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015protein.25,26 Two DASH dietary pattern variations include
replacing 10% of total energy from carbohydrate with
either protein or unsaturated fat.27
United States Department of Agriculture (USDA) food
patterns
The USDA food patterns recommend daily amounts of
foods from the 5 major food groups (vegetables, fruits,
grains, dairy products, and protein foods).19 The patterns
include an allowance for liquid vegetable oils (and spreads
made from liquid vegetable oils) and limitations on the
quantity of calories consumed from solid fats and added
sugars.
AHA diet patterns
The AHA diet patterns24,28 recommend balancing en-
ergy intake and physical activity to achieve and maintain
a healthy body weight; consuming a diet rich in vegetables
and fruits; choosing whole-grain, high-fiber foods;
consuming fish, especially oily fish, at least twice a week;
and limiting intake of saturated fat, trans (partially hydro-
genated) fat, and cholesterol by choosing lean meats and
non-meat alternatives and fat-free (skim) or low-fat (1%
fat) dairy products. The AHA diet patterns further recom-
mend minimizing intake of beverages and foods with added
sugars and salt, and suggest that, if alcohol is consumed,
this should be done in moderation (and only by adults of
legal drinking age).
The 2015 DGAC Scientific Report
The 2015 DGAC23 evaluated 3 dietary patterns, all of
which have been associated with health benefits. These
are the healthy US.-style pattern, the healthy
Mediterranean-style pattern, and the healthy vegetarian
pattern. These have similar food-based characteristics to
those defined by the 2013 AHA/ACC Guideline on Life-
style Management and, compared to the average American
diet, are higher in vegetables, fruits, and whole grains; low-
or non-fat dairy; seafood, legumes, and nuts; moderate in
alcohol (for adults); lower in red and processed meats;
and low in sugar-sweetened foods/drinks and refined grains.
The Committee specified that: ‘‘A healthy diet can be
achieved in multiple ways and preferably with a wide
variety of foods and beverages. Optimal nutrition can be
attained with many dietary patterns and a single dietary
pattern or approach or prescription is unnecessary.’’
In addition, food-based recommendations for a tradi-
tional Mediterranean diet (from both Greece and Spain)
were presented, which underscores the fact that this dietary
pattern encompasses a wide range in cultures and food
production practices in countries that border the Mediter-
ranean Sea. Thus, the ‘‘Mediterranean diet’’ is not one
‘‘standard’’ eating pattern. Nonetheless, as is the case for
the dietary patterns summarized previously, it emphasizes
consumption of vegetables, fruits and nuts, and whole
grains. A unique attribute is a focus on olive oil. Small
amounts of meats and cheese are included routinely.It should also be noted that there are several Asian
dietary patterns, such as the traditional Japanese and
Okinawan diets that have been associated with a low risk
of CHD. However, there is limited information available
about the composition of Asian diets, and evidence of their
health benefits compared with other recommended dietary
patterns also is limited. Despite this, the recommended
food-based dietary patterns can be applied to a healthy
Asian eating pattern.
Vegetarian and semi-vegetarian dietary patterns
There are various vegetarian dietary patterns including:
an ovo-vegetarian diet that includes eggs; a lacto-vegetarian
diet, which includes dairy products; a vegan diet, which is
free of all meats, eggs and dairy products; a raw vegan diet,
which includes only fresh and uncooked foods; a macro-
biotic diet (pesco-vegetarian) that includes fish, but no
other meats; and a semi-vegetarian diet, which occasionally
includes meats; as well as combinations of the above. The
therapeutic vegetarian dietary patterns most studied are the
portfolio diet29; a very-low-fat vegetarian diet, such as the
Ornish Plan with ,10% of energy from fat30,31; and low-
fat vegan diet plans.32,33Associations of dietary patterns with ASCVD risk
DASH dietary pattern and USDA food pattern
The recommended dietary patterns were based on the
precept of reducing chronic disease risk (including ASCVD
risk) and promoting health. Two papers reported the health
benefits associated with different dietary patterns in several
large cohorts (Multiethnic Cohort, National Institutes of
Health-American Association of Retired Persons Diet and
Health Study, and the Women’s Health Initiative Observa-
tional Study).34–36 In both reports, the dietary patterns eval-
uated were the Healthy Eating Index 2010 (representative
of the USDA dietary pattern), the Alternative Healthy
Eating Index 2010 (representative of the AHA dietary
pattern), the Mediterranean-style dietary pattern, and the
DASH dietary pattern. The healthy eating indexes used in
these studies were based on the 2010 DGA, with adapta-
tions made based on dietary patterns consistently associated
with lower risk of chronic diseases. The Mediterranean-
style dietary pattern is an adaptation of the traditional
Mediterranean diet defined by Trichopoulou et al.37
Harmon et al.35 found that higher diet quality scores on
each of the indexes were associated with 11 to 26% lower
risks of mortality from all causes, as well as cardiovascular
and cancer mortality for both men and women. In the report
by Liese et al.,36 in women, high diet quality was associated
with an 18 to 26% lower risk of all-cause mortality, a 19 to
28% lower risk of cardiovascular mortality, and an 11 to
23% lower risk of cancer mortality. In men, the risk reduc-
tions associated with high diet quality were 17 to 25% for
all-cause mortality, 14 to 26% for cardiovascular mortality,
and 19 to 24% for cancer mortality. Similar findings have
been reported recently in the Southern Community Cohort
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the healthiest diets (in the top one-fifth of the Healthy
Eating Index 2010 score) had approximately 20% lower
risk of total mortality, and death from cancer and CVD
were lower compared with individuals consuming the
unhealthiest (bottom-fifth) diets. These studies provide
evidence that a variety of healthy dietary patterns (albeit
patterns that share many common foods and nutrient pro-
files) confer health benefits in diverse cohorts.
In other analyses of the health effects of the DASH-style
dietary pattern, results have consistently shown associations
with lower risks for CVD. For example, in the Nurses’
Health Study, Fung et al.39 reported that, in the highest
quintile of the DASH dietary score, there was a significant
decrease in relative risk (RR) of CHD by 24% and stroke
by 18%. In the Third National Health and Nutrition Exam-
ination Survey (NHANES), Parikh et al.40 reported that
consumption of a DASH-like diet was associated with a
significantly lower mortality from all causes (31%)
and decreased risk of stroke (89%) in adults with
hypertension.
In an analysis of NHANES 2007–2010 data of 11,296
men and women using the 2005 Healthy Eating Index
scores, consumption of AHA Heart-Check Food Certifica-
tion Program-certifiable foods was positively associated
with diet quality, and inversely associated with cardiome-
tabolic risk factors.41 Compared to the lowest quartile of
diet quality score, the highest quartile score was associated
with lower frequencies of obesity (26%), elevated waist
circumference (24%), and metabolic syndrome (24%).
Mediterranean-style dietary pattern
Several meta-analyses of epidemiologic studies have
reported that consumption of a Mediterranean-style diet is
associated with reduced risk for total and cardiovascular
mortality.42–45 In a very large meta-analysis of 18 cohorts
with greater than 4 million subjects, a 2-point increase in
the Mediterranean diet adherence score (score range was
from 0 [minimal adherence] to 18 [maximal adherence])
was associated with an 8% reduction in overall mortality,
a 10% reduction in CVD events, and a 4% reduction in
neoplastic disease.44 In an analysis of 81,722 women in
the Nurses’ Health Study, Chiuve et al.46 reported that
women in the highest quintile for the Mediterranean diet
score had a 40% reduction in sudden cardiac death
compared to women in the lowest quintile.
In a meta-analysis of 15 prospective and cross-sectional
studies and 35 clinical trials with 534,906 participants, the
Mediterranean diet was highly inversely associated with the
metabolic syndrome (log-hazard ratio 20.69, 95% confi-
dence interval [CI]: 21.24 to 21.16).47 Also, there were
favorable associations of the Mediterranean diet on criteria
for the metabolic syndrome, including a smaller waist
circumference (20.42 cm), higher HDL-C (1.17 mg/dL),
lower TG (26.14 mg/dL), lower systolic (22.35 mm Hg)
and diastolic (21.58 mm Hg) blood pressures, and lower
fasting glucose (23.89 mg/dL).PREvencion con DIeta MEDiterranea (PREDIMED)
was a multicenter RCT conducted in Spain that evaluated
the efficacy of advice to follow a Mediterranean diet on the
primary prevention of CVD.48 A total 7447 participants, 55
to 80 years of age, with type 2 diabetes or with 3 or more
CVD risk factors (hypertension, hypercholesterolemia,
family history of heart disease, tobacco use, or over-
weight/obesity) were randomized to: (1) advice to follow
a low(er)-fat diet; (2) a Mediterranean diet supplemented
with extra-virgin olive oil (1 L/week/family; 50 g/day per
participant); or (3) a Mediterranean diet supplemented
with tree nuts (30 g/day: 15 g walnuts, 7.5 g almonds,
7.5 g hazelnuts). After 4.8 years, there was a 30% reduction
in the primary endpoint, which was rate of major cardiovas-
cular events (myocardial infarction [MI] stroke, or death
from cardiovascular causes) in each of the Mediterranean
diet groups.
The Lyon Diet Heart Study,49 an RCT conducted in
France, evaluated the effects of a Mediterranean-style diet
vs a ‘‘prudent Western-style diet’’ on secondary prevention
of MI over 104 weeks. The Mediterranean-style diet was
lower in saturated fat and higher in a-linolenic acid
(ALA) from a canola oil–based margarine. Subjects in
the Mediterranean-style diet group were advised to
consume more bread, root vegetables, green vegetables,
and fish; less meat; to eat fruit every day; and to replace
butter and cream in the diet, which was facilitated by
provision of a canola oil-based margarine. The
Mediterranean-style diet treatment group had 50% to 70%
lower risk of recurrent cardiac events, major secondary
events, and hospitalizations, despite no changes in blood
lipids/lipoproteins and similar body mass index (BMI)
and blood pressure compared to the control group.
Vegetarian diet
In a systematic review and meta-analysis of 8 observa-
tional studies (183,321 participants) that evaluated clinical
outcomes associated with a vegetarian diet compared to a
non-vegetarian diet, Kwok et al.50 reported that, for
ischemic heart disease, the associations of a vegetarian
diet with lower risk for ischemic heart disease compared
to non-vegetarian controls, or the general population, in
the Seventh Day Adventist studies was RR 0.60, 95% CI
0.43–0.80 and in the non-Seventh Day Adventist studies
was RR 0.84, 95% CI 0.74–0.96. Key et al.51 reported
that, compared with regular meat eaters, mortality from
ischemic heart disease was 20% lower in occasional meat
eaters, 34% lower in individuals who ate fish but did not
eat meat, 34% lower in lacto-ovo-vegetarians, and 26%
lower in vegans.
Limitations of observational evidence
Several dietary patterns have been associated with
reduced risk for ASCVD. These dietary patterns share
many attributes because of an emphasis on plant foods and
lean proteins, as well as low intakes of saturated and trans
fatty acids compared with the average American diet.
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has changed over time (data below for 1971–1974 from:
Centers for Disease Control and Prevention [CDC]
200452 and data from 2011–2012 from: USDA 201453). Re-
sults from the NHANES surveys show that mean dietary
protein intake has remained relatively stable at w15–16%
of energy. Mean energy from dietary fat has declined
from 36–37% of energy in 1971–1974 to 33.8% of energy
in 2011–2012, with saturated fatty acid intake declining
from 13–14% of energy to 10.9% over that time. Trans fatty
acid consumption has also declined, particularly after 2006
when trans fatty acid content was required to be on the
Nutrition Facts label. A report from the US. Food and
Drug Administration (FDA) estimated that average US con-
sumption of industrially produced trans fatty acids
decreased from about 2.0% of energy in the late 1990s to
about 0.6% of energy in 2010.54 The decline in the energy
contribution of dietary fats has been accompanied by an in-
crease in the percentage of energy from carbohydrate from
42–45% (1971–1974) to 48.6% (2011–2012). However,
because mean energy intake has increased, the total average
daily consumption of dietary fat per person has been rela-
tively stable (69.0 g/day for women and 96.2 g/day for
men), while carbohydrate intake has increased from
175 g/day in 1971–1974 to 228 g/day in 2011–2012 for
women. Corresponding values for men are 260 and
305 g/day, respectively.
With some exceptions, such as the results from the
PREDIMED and Lyon-Diet Heart studies, little clinical
trial evidence from cardiovascular outcomes trials is avail-
able from, which to fully evaluate the possible risks and
benefits of these dietary patterns. It is also difficult to
determine the potential for bias and confounding because
dietary patterns are often associated with other lifestyle
factors.55 Nevertheless, the results from observational
studies are reasonably consistent across studies, and biolog-
ically plausible, given what is known about the effects of
such dietary patterns on major ASCVD risk factors from
RCTs that have compared them with dietary patterns
more similar to the average American diet, particularly
for serum lipids and blood pressure.15–17Table 4 Predicted effects of macronutrient replacement of dietary s
lipoprotein lipids based on results from controlled feeding trials*
Dietary
component
Predicted effects* on lipoprotein lipids of replacing





HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
fatty acid; TG, triglyceride.
*Results are summarized from controlled feeding trials of subjects with ave
may be more pronounced in those with higher baseline values.
Source: Adapted from Eckel RH, et al. J Am Coll Cardiol. 2014;63(25 Pt B):296NLA Expert Panel recommendations–dietary patterns
Several dietary patterns have been associated with
reduced risk for ASCVD. These dietary patterns share
many attributes, with an emphasis on plant foods and lean
sources of protein. Compared with an average American/
Western diet, these dietary patterns are lower in saturated
fats, trans fats, and cholesterol. The NLA Expert Panel rec-
ommends any of these healthy dietary patterns for lowering
elevated levels of atherogenic cholesterol (LDL-C and non-
HDL-C). However, the dietary pattern recommended
should be individualized based on the patient’s specific
dyslipidemia. Also, patient preferences and cultural consid-
erations are important for guiding decisions about recom-
mendations to maximize dietary adherence. Nutritional
counseling and follow-up/monitoring by a registered dieti-
tian nutritionist are recommended whenever possible to
individualize patients’ cardioprotective dietary patterns
and to promote long-term dietary adherence.
Replacements for saturated and trans fatty acids
in the diet
The dietary patterns reviewed previously are lower in
saturated and trans fatty acids compared to the average
American diet. This is important for dyslipidemia manage-
ment because these are the dietary components that have
the greatest adverse effect on atherogenic cholesterol levels.
Table 4 shows the predicted effects of replacing 5% of
energy from saturated fatty acids with a matched quantity
of energy from PUFA, MUFA, and carbohydrates, based
on results from controlled feeding trials.24 Values are
shown for LDL-C, TG, and HDL-C. Effects on VLDL-C
are estimated by dividing the predicted change in TG by
5. Accordingly, based on the data shown in Table 4, the pre-
dicted changes in non-HDL-C, approximated as the sum of
changes in LDL-C and estimated VLDL-C (TG/5), associ-
ated with substitution of 5% of energy from saturated fatty
acids with PUFA, MUFA and carbohydrate are 29.4, 26.0,
and 24.1 mg/dL, respectively.
Like saturated fats, trans fatty acid consumption in-
creases levels of atherogenic cholesterol, with each 1% ofaturated fatty acids with PUFA, MUFA, and carbohydrate on





cholesterol; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated
rage-to-mildly dyslipidemic baseline levels of lipoprotein lipids. Effects
0–2984.24
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dL compared with carbohydrate and, to a somewhat greater
extent, compared with MUFA and PUFA.24 As previously
discussed, intake of trans fatty acids in the average Amer-
ican diet has declined in recent years from w2.0% of
energy to 0.6% of energy.54 Further reductions are expected
due to recent actions by the FDA to remove industrially
produced trans fatty acids from the list of foods Generally
Recognized as Safe. For patients who consume greater than
average quantities of foods that may contain trans fatty
acids, such as some cookies, pastries, biscuits, crackers,
deep-fried foods, microwaved popcorn, and frozen dinners,
dietary advice that emphasizes the recommended food
categories and food patterns discussed previously will mini-
mize trans fatty acid consumption.
Selected results from randomized controlled feeding
trials
OmniHeart was a randomized, controlled feeding trial
that evaluated the effects of 3 variants of the DASH dietary
pattern on lipoprotein lipids and blood pressure in subjects
with pre-hypertension and stage I hypertension.27 After
baseline measurements were collected with subjects
consuming their habitual diets (similar to the average
American diet), 3 experimental diets were compared in a
randomized order: 1) a high-carbohydrate, low-saturated
fat DASH diet with 58% of energy from carbohydrate,
27% from fat (6% from saturated fatty acids) and 15%
from protein; 2) a higher protein diet where 10% of the en-
ergy from carbohydrate was replaced with mixed-source
protein; and 3) an unsaturated fat diet where 10% of energy
from carbohydrate was replaced with unsaturated fats (8%
from MUFA and 2% from PUFA). Baseline values and
changes in lipoprotein lipids are shown in Table 5.27
Atherogenic cholesterol levels were reduced on all 3
DASH diet variants compared with habitual intake.
Changes in LDL-C and non-HDL-C levels were signifi-
cantly greater during the higher protein (214.2 and
217.3 mg/dL, respectively) and higher unsaturated fat
(213.1 and 215.1 mg/dL, respectively) diets than during
the higher carbohydrate diet (211.6 and 211.0 mg/dL,Table 5 Changes from baseline lipoprotein lipid levels by diet in O
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HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
Different letters in a row denote statistically significant differences in resp
Source: Adapted from Appel LJ, et al. JAMA. 2005;294:2455–2464.27respectively). These results suggest that a diet low in satu-
rated fatty acids that emphasizes carbohydrates, proteins, or
unsaturated fats will improve the lipid profile, but that
emphasis on proteins and unsaturated fats may elicit the
most favorable effects on levels of LDL-C and non-HDL-C.
Liquid vegetable oils are a major dietary source of
unsaturated fatty acids. However, some vegetable oils are
higher in MUFA, such as canola, high-oleic safflower, and
olive oils, while others are higher in PUFA, such as corn
and safflower oils. Consequently, consumers and clinicians
should understand the effects of different vegetable oils on
lipoprotein lipid levels. A controlled feeding study
conducted by Maki et al.56 evaluated the effects of a
PUFA-rich corn oil and a MUFA-rich extra-virgin olive
oil (4 tablespoons/day were incorporated into foods) as
part of a weight maintenance diet (34% of energy from
fat,w8% from saturated fatty acids) on lipids and lipopro-
teins in men and women with elevated LDL-C. Consump-
tion of the corn oil diet reduced LDL-C by 10.9%
compared to subjects’ baseline (average American) diets,
which was significantly greater than the reduction of
3.5% with extra-virgin olive oil. Results were similar for
non-HDL-C, with a significantly greater mean reduction
of 9.3% with corn oil vs 1.6% with extra-virgin olive oil.
The HDL-C responses were similar between treatments;
however, there was a smaller increase in TG on the corn
oil (3.5%) vs the extra-virgin olive oil (13.0%) diet. These
results are generally consistent with those from other
studies,57,58 and support the view that greater reductions
in atherogenic cholesterol levels should be expected
when saturated fatty acids are replaced with PUFA
(omega-6) compared to MUFA (omega-9).59 However, it
should be noted that other factors, such as the higher plant
sterol content of the corn oil, may have also contributed to
the lipoprotein lipid changes observed in the study by Maki
et al.56
Summary–replacements for saturated fatty acids
The NLA Expert Panel recommends consuming a diet
that is low in saturated fatty acids (,7% of energy) for














onse, P , .05.
S12 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015Replacing saturated fats with unsaturated fats, proteins, or
carbohydrates lowers levels of atherogenic cholesterol,
although replacement with unsaturated fats and proteins
elicit greater reductions than carbohydrate. Unsaturated fat
intake can be increased by incorporating liquid vegetable
oils and oil-rich foods, such as nuts and liquid vegetable oil
spreads, into the diet. PUFA (mainly omega-6) produce
greater reductions in atherogenic cholesterol levels than
MUFA (omega-9).
Dietary cholesterol
The 2010 US Dietary Guidelines recommended that
dietary cholesterol be ,300 mg per day for healthy
individuals ages 2 years and older.19 In the 2006 Diet
and Lifestyle Revision,28 the AHA recommended
,300 mg per day and, in 2011, the AHA recommended
,150 mg per day for the prevention of CVD in women.60
The National Cholesterol Education Program (NCEP)
Adult Treatment Panel (ATP) III recommended
,200 mg/day of cholesterol as part of the Therapeutic
Lifestyle Changes diet.12 More recently, the 2013 AHA/
ACC Guideline on Lifestyle Management to Reduce Car-
diovascular Risk did not make a recommendation for die-
tary cholesterol because the panel concluded that there
was ‘‘insufficient evidence to determine whether lowering
dietary cholesterol reduces LDL-C’’.24 The 2015 DGAC
did not recommend continuation of the recommended limit
of dietary cholesterol to ,300 mg per day because ‘‘avail-
able evidence shows no appreciable relationship between
consumption of dietary cholesterol and serum choles-
terol’’.23 Thus, the usefulness of limiting dietary choles-
terol intake for the US population, and for those with
elevated levels of atherogenic cholesterol, has become
controversial. The available evidence was reviewed care-
fully by the NLA Expert Panel.
Effects of dietary cholesterol on total cholesterol
(total-C) and LDL-C levels
The effects of dietary cholesterol on circulating levels of
LDL-C and total-C (and to a lesser extent, non-HDL-C)
have been evaluated in a large number of studies. Results of
the effects of dietary cholesterol on serum total-C and
LDL-C have been evaluated in 6 meta-analyses.61-66 In
aggregate, these included data from 438 studies; 424 in
subjects with normolipidemia and 14 in participants with
dyslipidemia. An increase of 100 mg/day in dietary choles-
terol was reported to increase total-C approximately 2 to 3
mg/dL.63,64,66 Hopkins61 evaluated results from 27 studies
in which controlled diets were supplied by a metabolic
kitchen, and reported that the increase in serum total-C pro-
duced by a given change in dietary cholesterol is non-linear
and dependent on the baseline level of dietary cholesterol.
Accordingly, the increase in serum total-C predicted for an
increment of 100 mg/day in dietary cholesterol would be
progressively less with higher baseline levels of cholesterol
intake.Weggemans et al.66 completed a meta-analysis of results
from 17 studies involving 556 subjects in which diets
differed only in the amount of dietary cholesterol or num-
ber of eggs (with yolks) fed over periods of at least
14 days and for which lipoprotein lipid values were
reported. They reported that an addition of 100 mg/day of
dietary cholesterol would be predicted to increase total-C
by 2.17 mg/dL, LDL-C by 1.93 mg/dL, and HDL-C by
0.31 mg/dL, resulting in a small increment in the total-
C:HDL-C ratio of 0.02. These values align closely with
those reported by Clarke et al.63 from an analysis of data
reported in 395 dietary solid food experiments. It should
be noted that the clinical importance of the increase in
HDL-C observed with increasing dietary cholesterol is
uncertain.
A more recent systematic review and meta-analysis of
40 studies (17 cohort studies with 19 publications and 19
trials with 21 publications) was published by Berger et al.67
In the review of 17 of the 19 trials, dietary cholesterol
(intervention cholesterol intake was 501 to 1415 mg/day
and 0 to 415 mg/day in the control conditions) significantly
increased both serum total-C (11.2 mg/dL) and LDL-C
(6.7 mg/dL). When the intervention intake levels were
greater than 900 mg/day, there were no longer statistically
significant increases in LDL-C. In this review, dietary
cholesterol also increased HDL-C (3.2 mg/dL). Similar to
the Hopkins results,61 the increases in total-C and LDL-C
were greatest when the baseline dietary cholesterol intake
was the lowest.
Ginsberg et al.68 conducted a controlled feeding study in
which 4 dietary conditions were evaluated, each for 8 weeks
with washouts between treatments, in 20 young, healthy
men. This trial was chosen as an illustrative example of
the effects of dietary cholesterol because it was a well-
designed dietary intervention with controlled feeding that
allowed evaluation of dose-response, and included
measurements of lipoprotein lipids by ultracentrifugation,
the reference standard. In this trial, average total-C and
LDL-C increased by 1.47 mg/dL and 1.38 mg/dL, respec-
tively, for each 100 mg/day increase in dietary cholesterol.
HDL-C also increased by 0.29 mg/dL per 100 mg/day of
dietary cholesterol, while VLDL-C and TG levels did not
change. The apo B concentration rose by 1.19 mg per
100 mg/day increase in dietary cholesterol, and the change
in apo B correlated significantly with the change in LDL-C.
While these results are consistent with the view that an in-
crease in dietary cholesterol modestly raises levels of
atherogenic cholesterol (and lipoprotein particles), it should
be noted that the responses varied widely, with 3 subjects
showing a decrease in total-C with increasing cholesterol
intake and some subjects displaying more than twice the
mean response.Variation in responses to dietary cholesterol
Griffin and Lichtenstein reviewed results from studies on
the effects of dietary cholesterol and lipoprotein lipids
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following:
Within the context of current levels of dietary choles-
terol intake, the effect on plasma lipid concentrations,
with primary interest in LDL-C cholesterol concentra-
tions, is modest and appears to be limited to population
subgroups. In these cases, restrictions in dietary choles-
terol intake are likely warranted. The biological
determinants of inter-individual variability remain a
relatively understudied area.
The interpretation of the NLA Expert Panel is that the
available data are consistent with the conclusion that dietary
cholesterol has modest effects to increase total-C and LDL-C
levels on average, although there are hypo- and hyper-
responders in the population. Unfortunately, at present, there
is no widely available and inexpensive method for clinical
use to predict who is likely to experience a change in
atherogenic cholesterol (or not) in response to changes in
dietary cholesterol intake. The effects of other dietary
constituents, particularly saturated and unsaturated fatty
acids, on circulating levels of atherogenic cholesterol are
generally larger and more predictable than that of dietary
cholesterol. For most individuals, restricting saturated fat
intake to ,7% of energy, while following any of the
recommended dietary patterns, will result in lower dietary
cholesterol consumption, because saturated fats and choles-
terol are both present in many foods (e.g., fatty cuts of meats,
processed meats, full-fat dairy foods). However, some pop-
ular foods are particularly high in cholesterol, but not in
saturated fatty acids, including eggs, shrimp and other
shellfish, and some organ meats (which are commonly
consumed in some regions of the United States).70
Observational evidence for dietary cholesterol or egg
consumption and ASCVD risk
The authors of a meta-analysis of 16 prospective cohort
studies with follow-up times ranging from 5.8 to 20.0 years
reported that, in comparison with those who ate egg less
than once per week, individuals who ate egg once per day
or more did not have significantly higher risks of overall
CVD, ischemic heart disease, or stroke.71 The pooled haz-
ard ratios (HRs) (95% CI) were 0.96 (0.88, 1.05) for overall
CVD, 0.97 (0.86, 1.09) for ischemic heart disease, and 0.93
(0.81, 1.07) for stroke. The HR for ischemic heart disease
mortality was 0.98 (0.77, 1.24) and for stroke mortality
was 0.92 (0.56, 1.50). Thus, egg consumption was not asso-
ciated with the risk of CVD and cardiac mortality in the
general population. A more recent systematic review and
meta-analysis of 17 cohort studies with 361,923 subjects re-
ported that dietary cholesterol intake was not significantly
associated with incidence of coronary artery disease,
ischemic stroke, or hemorrhagic stroke.67 The authors
noted, however that the cohort studies reviewed were het-
erogeneous and lacked methodological rigor, which limited
definitive conclusions being made about dietary cholesterol
and ASCVD outcomes.The authors of a review of 8 large prospective cohort
studies (17 reports, including 9 for CHD and 8 for stroke)
and a meta-analysis (3,081,269 person years and 5847 cases
of incident CHD) reported an increased risk of CHD in a
subgroup analysis of individuals with diabetes comparing
the highest with the lowest categories of egg consumption
of 1.54 (1.14 to 2.09; P 5 .01).72 The association of egg
consumption with increased CHD risk in those with dia-
betes may be a reflection of the cholesterol content of
eggs (approximately 186 mg per single large egg yolk).
Among 5672 women with type 2 diabetes in the Nurses’
Health Study, higher consumption of dietary cholesterol
was associated with increased risk of CVD.73 Each increase
of 200 mg cholesterol/1000 kcal was associated with a 37%
increased risk of CVD, which was a composite of fatal
CHD, nonfatal MI, and stroke (Tanasescu 2014). In a
prospective cohort study of 37,851 men and 80,842 women
in the Health Professionals Follow-up Study, higher egg
consumption was associated with an increased risk of
CHD only among those subjects with diabetes.74 Men
with diabetes consuming 1 egg or more daily had double
the risk of CHD compared to those consuming 1 egg or
less each week; women with diabetes consuming 1 egg or
more daily had 1.49 times the risk of CHD than those
consuming 1 egg or less per week.74
In summary, the observational evidence suggests that
egg and dietary cholesterol consumption are not consis-
tently associated with increased ASCVD risk, with the
possible exception of increased risk in those with diabetes
mellitus. Mechanisms to potentially explain differences in
risk among those with and without diabetes are uncertain.
Observational studies are subject to various types of bias
and confounding,55 including intercorrelations between
types of foods consumed (e.g., a correlation between con-
sumption of eggs and processed breakfast meats) and
displacement effects (higher egg consumption may be asso-
ciated with lower consumption of other foods), thus such
evidence must be interpreted with caution. Accordingly,
the conclusions of the NLA Expert Panel regarding dietary
cholesterol intake for dyslipidemia management are based
mainly on the results from well-controlled RCTs designed
to evaluate the effects of dietary cholesterol on levels of
atherogenic cholesterol.
Conclusions from review of evidence on dietary
cholesterol and ASCVD risk
Results from well-controlled RCTs indicate that dietary
cholesterol has modest effects to raise levels of total-C,
LDL-C, and HDL-C. The increase in HDL-C associated
with increased dietary cholesterol is of uncertain clinical
importance. Hyper- and hypo-responders to dietary choles-
terol exist, with some individuals showing little or no
increases in atherogenic cholesterol levels in response to
greater intake of dietary cholesterol and others showing
responses well above the average. The biological determi-
nants of inter-individual variability are understudied, and
presently no inexpensive and widely available methods are
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or hypo-responders. In controlled feeding RCTs, each
100 mg/day of dietary cholesterol raises LDL-C by an
average of w1.9 mg/dL. Observational data have consis-
tently reported no association between dietary cholesterol
or egg consumption (a large contributor to dietary choles-
terol intake) and ASCVD risk in the general population, but
suggest that there may be increased ASCVD risk associated
with greater cholesterol and egg consumption in those with
diabetes mellitus. The NLA Expert Panel recommendations
are, therefore, based mainly on results from controlled-
feeding RCTs showing modest effects of dietary cholesterol
to raise total-C and LDL-C, while recognizing that other
dietary factors (saturated fatty acids, trans fatty acids,
MUFA and PUFA) more reliably and predictably influence
levels of atherogenic cholesterol.
Weight loss
Effects of weight loss on lipoprotein lipids
Results from systematic reviews of RCTs indicate that
clinically meaningful changes in CVD risk indicators are
associated with a loss of at least 2.5 kg or 3% of body
weight.75,76 A weight loss of 5 to 8 kg that is sustained re-
sults in a mean LDL-C reduction of approximately 5 mg/dL
and a mean increase in HDL-C of between 2 and 3
mg/dL.76 In addition, a 3 kg weight loss is expected to
decrease TG by at least 15 mg/dL.76 However, clinicians
should be aware that there is marked variation in the
lipid/lipoprotein responses to weight loss. In addition, all
of the major lipoprotein lipid variables (LDL-C, VLDL-
C, TG, and HDL-C) typically decrease during active weight
loss.75,76 The values above reflect the effects observed after
lower and stable levels of body weight and adiposity have
been established.76 Favorable changes in lipoprotein lipids
are unlikely to be sustained unless a reduced weight is
maintained. Therefore, the critically important consider-
ation for all lipoprotein changes is weight loss mainte-
nance. Behaviors associated with successful maintenance
of a reduced body weight include high levels of physical
activity (discussed in detail in the section on exercise/phys-
ical activity); eating breakfast regularly; self-monitoring of
weight; and maintaining consistent, calorie controlled
eating patterns across weekdays and weekends.77
LDL-C values decline with weight loss on average, but
the response tends to be larger in younger subjects, and may
be blunted in older individuals.78,79 However, the TG and
VLDL-C reductions appear to be similar among younger
and older individuals. The relationship between age and li-
poprotein lipid responses to weight loss is understudied and
should be pursued in future research. Among lipoprotein
lipid parameters, TG levels (and VLDL-C, which is highly
correlated with the TG concentration) appear to respond
most readily to weight loss.75 Higher baseline values and
larger weight loss are associated with greater TG
lowering.75 In addition, lower carbohydrate diets duringweight loss and weight maintenance have been shown to
lower TG more than higher carbohydrate diets.75 Loss of
at least 3% of body weight also produces favorable changes
in other ASCVD risk indicators, including blood pressure,
glycemia, and insulin resistance.75
Effects of macronutrient distribution on weight loss
and metabolic parameters
Many studies have been conducted to identify which
dietary approach is most successful in promoting long-term
weight loss and weight loss maintenance. It is clear that
losses of body weight and fat will occur with a variety of
macronutrient distributions, as long as they reduce energy
intake below energy expenditure.80 Several dietary patterns,
such as Mediterranean-style, DASH, USDA, and vegetarian
diets can be tailored to personal and cultural food prefer-
ences and appropriate calorie needs for weight control.23,24
The ideal macronutrient composition for weight
reducing diets and weight loss maintenance is the source
of much controversy and may differ among individuals for
a variety of physiological and behavioral reasons. The
consensus view of the NLA Expert Panel is that there is
suggestive evidence that partially replacing carbohydrate
(especially refined starches and sugars, thus, also reducing
dietary glycemic load) with higher protein foods may be
beneficial to enhance weight loss and weight loss mainte-
nance. This may be due, in part, to the effects of protein,
compared with carbohydrate, to enhance satiety, induce a
greater thermic effect of food, and to favor maintenance of
fat-free mass.81–84
In a review of the influence of protein intake on weight
loss and weight maintenance, Westerterp-Plantenga and
colleagues82 concluded:
.evidence shows that a relatively high protein intake
sustains weight maintenance by (a) favoring regain of fat
free mass at the cost of fat at a similar physical activity
level, (b) reducing the energy efficiency with respect to
the body mass regained, and (c) increasing satiety.
Wycherley et al.84 evaluated the effects of energy-
restricted high-protein, low-fat diets (25–35% energy
from protein, #30% of energy from fat) with standard-
protein, low-fat diets (12–18% of energy from protein,
#30% of energy from fat). Twenty-four trials that included
1063 individuals satisfied the search criteria. The higher
protein diets elicited greater decreases in body weight
(0.79 kg), fat mass (0.87 kg), and TG (20.4 mg/dL), and
smaller reductions in resting energy expenditure (596 kJ/
day [142.4 kcal/day]) and fat-free mass (0.43 kg). The
authors concluded that a higher protein weight loss diet
provides modest benefits for reducing body weight, as
well as TG, by attenuating reductions in fat-free mass
and resting energy expenditure. The degree to which these
differences can be attributed to increased protein vs lower
carbohydrate intake (and hence reduced glycemic load) is
uncertain, and both may be important contributors.
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diet composition on weight loss maintenance, Larsen
et al.85 randomly assigned a group of 773 adults who had
lost at least 8% of body weight to 5 diet groups to assess
effects of protein intake and glycemic index on weight
loss maintenance. The groups included a control diet with
intermediate levels of protein and glycemic index with
the remaining subjects assigned to lower and higher protein
and lower or higher glycemic index in a 2 x 2 factorial
manner. Targeted differences were 12% of energy between
the lower and higher protein groups, and 15 glycemic index
units for the lower and higher glycemic index groups. In an
intention-to-treat analysis, the weight regain over 26 weeks
was 0.93 kg less in the groups assigned to a high-protein
diet than in those assigned to a low-protein diet, and
0.95 kg less in the groups assigned to a low-glycemic-
index diet than in those assigned to a high-glycemic-
index diet. The group that received the combination of a
higher protein and lower glycemic index diet had the least
weight regain (showing a small mean additional weight
loss) of the 5 treatment arms, and also had the highest
rate of study completion. The authors concluded that a
diet with a moderately higher protein content (average
intake 22–23% of energy during the intervention) and
reduced glycemic index (56–57 units) improved the main-
tenance of weight loss, and may thus have advantages for
weight regain prevention.
The NLA Expert Panel acknowledges that additional
research is needed to more clearly define effective dietary
strategies for enhancing adherence to hypocaloric diets, and
preventing weight regain after weight loss interven-
tions.80,86 However, based on the evidence discussed here-
in, the NLA Expert Panel consensus view is that eating
patterns that contain a moderate quantity of carbohydrate,
lower glycemic index and load, and higher protein, have
been associated with modest benefits regarding weight
loss and maintenance.82,84,85 Furthermore, the Expert Panel
also strongly believes that additional research is needed to
more clearly define effective dietary strategies for
enhancing adherence to hypocaloric diets and preventing
weight regain after weight loss interventions.80,86
Importance of lifestyle counseling and ongoing
support
The Preventing Overweight Using Novel Dietary Stra-
tegies trial randomly assigned 811 overweight or obese
subjects to 1 of 4 dietary conditions that emphasized
different macronutrient distributions.80 Participants were
offered regular individual and group counseling sessions.
After 6 months and 2 years of the intervention, the groups
did not differ with regard to changes from baseline body
weight. However, the number of sessions attended was a
strong predictor of weight loss at the 2-year timepoint in
all groups, with each additional session attended associated
with a 0.2 kg greater loss of body weight. This illustrates
the importance of lifestyle counseling and ongoing support
to maximize success with weight loss interventions.Dietary adjuncts for lowering atherogenic
cholesterol
If a diet based on a cardioprotective dietary pattern that
is low in cholesterol-raising fatty acids and cholesterol
plus regular physical activity and weight loss, if over-
weight or obese is insufficient to attain atherogenic
cholesterol goals, clinicians may consider the use of
dietary adjuncts to enhance the effects of other lifestyle
interventions. The NLA Expert Panel consensus view is
that there was sufficient evidence to recommend consid-
eration of the use of supplemental plant sterols/stanols
(w2 g/day) and viscous fibers (5–10 g/day from foods
and/or supplemental sources) to enhance reductions in
levels of atherogenic cholesterol. Consumption of greater
quantities of viscous fiber (10 to 25 g/day) as was
recommended by the NCEP ATP III12 will generally result
in greater atherogenic cholesterol lowering; however, at-
taining this level of consumption is challenging. As is
the case for other lifestyle interventions, recommendations
are based primarily on results from RCTs demonstrating
reductions in atherogenic cholesterol levels. ASCVD event
trials are not available for these interventions, which pre-
vents a full evaluation of the potential benefits and risks
with their use.
Effects of plant (phyto) sterols/stanols on
lipoprotein lipids
Phytosterols (PS), a term used to refer to both plant
sterols and plant stanols, are compounds that naturally
occur in foods of plant origin, particularly vegetable oils,
nuts, seeds, and grain products. The typical diet consumed
in the United States provides approximately 200–400 mg/
day and the amount of PS consumed daily in a vegan diet is
roughly twice that amount. There is a large evidence base
supporting the LDL-C-lowering effect of PS, which has
been summarized in multiple meta-analyses. The meta-
analyses conducted by Law et al.87 and Katan et al.88 were
the first to examine the effects of PS on cholesterol levels.
Both showed that consumption of 2 g/day of stanols or ste-
rols lowered LDL-C by 5–10%. Follow-up meta-analyses
by Demonty et al.89 and AbuMweis et al.90 confirmed these
findings and concluded that, with an increasing dose of PS,
the LDL-C-lowering effect increases, but this plateaus at
doses above w3 g/day.
More recently Musa-Veloso et al.91 conducted the
largest meta-analysis on PS consumption, which included
114 trials representing 182 trial arms and evaluating
LDL-C lowering dose-response effects separately for plant
sterols and plant stanols. The range of PS intake was 0.2–
9.0 g/day; however, there were only 4 studies with a PS
intake .4.0 g/day. The authors concluded that at a dosage
,3 g/day, effects of plant sterols and stanols are
comparable.
The lipid-lowering efficacy of PS-fortified products
(both free plant sterols and stanols and their esterified
forms) has been demonstrated in different population
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metabolic syndrome, and familial hypercholesterolemia
(FH).92–94 Atherogenic cholesterol lowering with plant ste-
rols and stanols has been demonstrated in children with
FH,95 although an insufficient body of evidence is
available from which to draw firm conclusions about the ef-
ficacy of PS for reducing atherogenic cholesterol levels in
those with FH.
The efficacy of PS for lowering atherogenic cholesterol
levels in various food and beverage formulations was
examined by Demonty et al.89 who reviewed studies that
compared fat vs non-fat foods, dairy vs nondairy, liquid
vs solid foods, and free or esterified PS. There were no sig-
nificant differences in response to plant sterols vs stanols,
fat-based vs non-fat-based food formats, and dairy vs
nondairy foods at intake levels #2 g/day. It is possible
(and theoretically likely) consumption of PS multiple times
per day results in greater efficacy than a single intake.89 If
taken in a single dose, the efficacy of PS appears to be
greatest when consumed during or shortly after a meal,
preferably a large enough meal that bile flow is triggered.
There also appears to be an effect of baseline LDL-C con-
centration on the magnitude of the absolute decrease in
LDL-C concentration, with larger reductions in LDL-C
among individuals with higher baseline levels.89 However,
when expressed as a percentage of the baseline value,
LDL-C reductions are similar across a wide range of base-
line LDL-C values.88
In addition to the well-established effects of PS to
produce LDL-C-lowering, there also is some evidence that
PS reduce TG concentrations. In a meta-analysis of 12
RCTs, PS intake in the range of 1.6 to 2.5 g/day produced a
modest TG-lowering effect of about 6%.96 More recent data
reviewed by Rideout et al.97 indicate that PS supplementa-
tion results in a variable TG-lowering response ranging
from 0.8 to 28%. The evidence supports the view that indi-
viduals with elevated TG ($150 mg/dL) have a greater
TG-lowering response to PS (11–28%) than subjects with
normal plasma TG concentrations (0.8–7%).97
Mechanisms of action of PS
One mechanism by which PS lowers LDL-C is reducing
intestinal cholesterol absorption by competing with choles-
terol for limited space in mixed micelles.98 This makes less
cholesterol available to the enterocytes for transport via
Niemann-Pick C1-Like 1 transporters. A second mecha-
nism is that an increase in the intracellular level of PS in
the enterocytes triggers an up-regulation of adenosine
triphosphate-binding cassette transporter (ABC) G5 and
ABCG8 that move sterols (including cholesterol) out of
the enterocytes and into the intestinal lumen.98 The net
result of these actions is to reduce hepatic cholesterol con-
tent, which then results in an up-regulation of hepatic LDL
receptors that remove apo B-containing lipoproteins from
the blood, thus lowering the blood cholesterol concentra-
tion, particularly LDL-C.98Safety of supplemental PS consumption
The safety of PS has been reviewed by several
regulatory agencies. The US FDA classifies PS as having
Generally Recognized as Safe status. Furthermore, the FDA
has authorized a health claim stating that consuming foods
that include plant sterols/stanols (at least 0.75 g/serving)
may reduce the risk of CHD. Potential health concerns have
been raised related to elevated PS concentrations following
the intake of PS-enriched foods in those with homozygous
phytosterolemia (also known as sitosterolemia), a rare
autosomal recessive genetic disorder.99 Average PS concen-
trations in individuals consuming PS-fortified margarine-
type spreads range from 0.6 to 2.0 mg/dL.88 However,
patients with phytosterolemia are unable to effectively clear
absorbed PS from the blood and tissues due to defects in the
ABCG5 and/or ABCG8 sterol transporters. This causes PS
concentrations to increase to levels that are often 20–45
times typical values.100,101 The disorder occurs in about 1
in 5 million people and CVD risk is severe in these patients
due to premature atherosclerosis.88 Heterozygous phytos-
terolemia is much more common, occurring in w1 in 500
people. Individuals with heterozygous phytosterolemia
appear clinically and biochemically normal, with normal
to only a slight increase in plasma PS concentrations and
moderate hypercholesterolemia.102 Although few studies
have examined the effects of PS consumption in this sub-
group, individuals with heterozygosity for an ABCG8 mu-
tation appear to respond to a PS challenge similarly to
individuals without phytosterolemia.103,104
The connection between high circulating PS concentra-
tions and premature CHD has led to investigations of the
association between lower circulating PS concentrations and
CHD risk. To date, the findings have not supported a clear
link between circulating PS concentrations in the normal
range and the development of CVD.105 Genser et al.106 con-
ducted a meta-analysis specifically examining the impact of
increased serum concentrations of PS onCVD risk. The anal-
ysis included 17 studies involving 11,182 participants report-
ing either risk ratios of CVD in relation to PS concentrations
(8 studies) or standardizedmean differences in PS concentra-
tions between CVD cases and controls (15 studies). The
authors concluded that there is no relationship between
serum concentrations of PS and CVD risk over a 3-fold
difference in serum plant sterol concentrations.106 Measure-
ment of circulating PS concentrations in clinical practice is
generally limited to the diagnosis of phytosterolemia.107
Another concern that has been raised about plant sterols is
that they reduce the absorption of some fat-soluble vitamins.
Randomized trials have demonstrated that PS consumption
lowers blood concentrations of b-carotene by about 25%,
concentrations of a-carotene by 10%, and concentrations of
vitamin E by 8%.87 In part, this is likely due to reduced ab-
sorption of carotenoids; lower concentrations of vitamin E
are most likely due to reduced concentrations of its main li-
poprotein carrier, LDL. After the decrease in total-C induced
by PS was corrected for, a statistically significant reduction
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more fruits and vegetables would likely counter the
decreased carotenoid absorption. The blood concentrations
of vitamin D and vitamin A are unaffected by PS.108–111
There also does not appear to be any influence on vitamin
K-dependent clotting factors or prothrombin time.
Effects of viscous dietary fibers on lipoprotein lipids
Dietary fibers are plant substances that are resistant to
digestion in the small intestine.112 Fibers are classified in
various ways, including solubility in water, viscosity, and
fermentability by colonic microbiota. Viscous fibers,
including pectins, gums, mucilages and some hemicellu-
loses, have gelling properties in the gastrointestinal tract,
and their consumption has been associated with reductions
in total-C, LDL-C, and non-HDL-C.113–115 Commonly
consumed food sources of viscous fibers include oats,
barley and legumes (e.g., lentils, lima beans, kidney beans),
as well as fruits, including apples, pears, plums and citrus
fruits,70 and vegetables, including broccoli, Brussels
sprouts, carrots, and green peas. Supplemental forms of
viscous fibers are also available as fiber laxative products
(e.g., those that contain psyllium seed husk and
methylcellulose).
Well-controlled RCTs evaluating the effects of
consuming viscous fibers on lipoprotein lipids have consis-
tently shown reductions in total-C and LDL-C. Brown
et al.116 completed a meta-analysis of 66 RCTs to evaluate
the lipoprotein lipid effects of viscous fibers from oat prod-
ucts (beta-glucan), psyllium, pectin, and guar gum. Statisti-
cally significant reductions in total-C and LDL-C were
observed for each of the 4 fiber types, with no significant
changes observed for TG or HDL-C concentrations. The
pooled effects for all fibers per gram of daily consumption
for all studies were reductions of 1.1 mg/dL for both
total-C and LDL-C. Accordingly, intakes in the range of
5–10 g/day would be expected to lower mean total-C and
LDL-C levels by 5.5 to 11.0 mg/dL. A more recent meta-
analysis of 28 RCTs evaluating the effects of oat beta-
glucan on lipoprotein lipids found that, in studies where
3.0–12.4 g/day were provided, mean total-C and LDL-C
levels were reduced relative to control by 9.7 and 11.6 mg/
dL, respectively.117 TG and HDL-C levels were not signifi-
cantly altered.
Few data exist from which to evaluate determinants of
the atherogenic cholesterol responses to viscous dietary
fiber consumption. Fibers that create greater viscosity in
the intestinal lumen will tend to have a greater
cholesterol-lowering effect.115,118 Some forms of
processing that may occur during the production of dietary
fiber concentrates and extracts will lower the molecular
weight of the fiber, which will reduce their viscosity and
potentially interfere with the hypocholesterolemic
effects.117 Therefore, if a fiber supplement is to be used,
it is ideal to confirm that when mixed with water and
allowed to sit for several minutes a viscous gel-like solution
is formed.Mechanisms of action of viscous dietary fibers
Viscous dietary fibers may act through several
mechanisms to affect lipoprotein metabolism.119 The
main proposed mechanisms relate to trapping of cholesterol
and bile acids in the small intestine, resulting in reduced
absorption/reabsorption.119 The net result of these actions
is to reduce hepatic cholesterol content, which triggers an
up-regulation of hepatic LDL receptors that remove
apo B-containing lipoproteins from the blood, thus
lowering the blood cholesterol concentration, particularly
LDL-C.119
Safety of viscous fiber consumption
Few safety concerns are associatedwith increased viscous
fiber consumption. If viscous fiber supplements such as
fiber laxatives are used, it is critical to consume adequate
fluid as directed on the product label to avoid intestinal
blockage (a rare occurrence). The supplement should be
mixed and consumed immediately, before significant
thickening has occurred, to avoid choking. There is a
theoretical concern that viscous fiber supplements may
reduce carotenoid absorption. Regular consumption of fruits
and vegetables should help to counteract this potential
effect.120
Summary of the anticipated effects of
recommended dietary interventions on LDL-C
and non-HDL-C
A rule of thumb for clinicians to use in predicting the
effects of the recommended dietary interventions is that
each should be expected to reduce LDL-C (and non-
HDL-C) by 3–7%, or w5% on average. Expected results
based on RCTs of practical dietary interventions in
free-living individuals suggest that the LDL-C lowering
would be:
 Diet low in saturated and trans fatty acids and choles-
terol: 5 to 10%
 Loss of 5% of body weight: 3 to 5%
 2 g/day PS or 7.5 g/day viscous fiber: 4 to 10%
 Total: 12 to 25%
Combining any 2 of the interventions recommended
would be expected to reduce LDL-C by 6 to 19%. The
portfolio diet approach, which combines PS, viscous fibers,
soy, and almonds has been shown to reduce LDL-C by
w30% with controlled feeding, but the reduction was less
(w15%) when subjects were free-living.121,122 If main-
tained over an extended period, each 1% reduction in
LDL-C is expected to reduce CHD risk by 2–3%, based
on results from genetic variants that alter atherogenic
cholesterol levels.7,11 Thus, a modest reduction of as little
as 6% in LDL-C, maintained over an extended period,
could reduce CHD risk by 12–18%, whereas a reduction
of 15% by combining dietary interventions could poten-
tially reduce CHD risk by 30–45%.
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there are few studies that have administered them together
to investigate their combined influences on atherogenic
cholesterol. Both PS and viscous fibers reduce atherogenic
cholesterol, in part, by reducing cholesterol absorp-
tion.98,119 Viscous fibers also lower bile acid re-absorp-
tion.119 Therefore, there is uncertainty regarding whether
their effects are fully additive. PS products should not be
used in combination with a cholesterol absorption inhibitor
drug (ezetimibe) because both work through interference
with cholesterol absorption and the addition of PS to ezeti-
mibe therapy did not have an incremental effect on the
LDL-C response.123
Long-chain omega-3 fatty acids
The long-chain polyunsaturated fatty acids eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA), both
derived from marine sources, as well as the essential fatty
acid, ALA, derived from plant sources, have been of
scientific interest for decades. The history of the
marine-derived omega-3 fatty acids dates back to the first
studies conducted with Greenland Eskimos that reported
that a low death rate from CHD was associated with a
very high intake of seafood (around 400 g/day).124,125
Recommendations for EPA and DHA are based on
epidemiological and RCTs of both primary and secondary
prevention of CVD and have evaluated both fish/seafood
and omega-3 fatty acid supplements/fortified foods. The
recommendation for ALA is based on the precept of
meeting nutrient adequacy.
Evidence from prospective observational studies and
some randomized clinical trials suggests that, compared
with little or no intake, consumption of 250 to 550 mg/day
of EPA and DHA is associated with a 36% lower risk of
CHD death and reduced total mortality by 17% (summa-
rized by Mozaffarian and Rimm126). Harris et al.127 con-
ducted a pooled analysis of observational studies and
reported that the highest (approximately 566 mg/day) vs
lowest intake of EPA 1 DHA was associated with approx-
imately a 37% reduction in CHD mortality. These collec-
tive analyses formed the basis for the current dietary
recommendations for EPA and DHA for the primary pre-
vention of coronary disease.
The 2010 DGA recommended 250 mg/day of
EPA and DHA19 and the Academy of Nutrition and
Dietetics recommends 500 mg/day.128 The DGAC 2010
concluded:19
‘‘Moderate evidence shows that consumption of two
servings of seafood per week (4 oz per serving),
which provide an average of 250 mg per day of long-
chain n-3 fatty acids, is associated with reduced
cardiac mortality from CHD or sudden death in
persons with and without CVD. An increase in
seafood intake to two servings per week at 4 oz per
serving is advised for high-risk (those with CVD)
and average-risk persons, especially as the firstpresentation of CVD (MI, stroke) is frequently fatal
or disabling. The quantity and frequency of seafood
consumption is important, but the type of seafood
(those providing at least 250 mg of long-chain n-3
fatty acids per day) also is critical.’’19
The recommendation for increased seafood intake can
be met by consuming both farm-raised and wild-caught
seafood, because, as a result of current aquaculture
practices, they now contain approximately the same
amounts of omega-3 fatty acids.23
The AHA issued 2020 Impact Goals to improve the
cardiovascular health of all Americans, which included a
primary dietary recommendation for fish: $ two 3.5-oz.
servings per week (preferably oily fish).129
Secondary prevention
For secondary prevention of CHD, Harris et al.130 noted
that there have been 9 large randomized trials with omega-3
fatty acid supplements, of which 4 reported positive (favor-
able) results,131–134 4 were neutral,135–138 and 1 study was
negative (i.e., suggested an adverse effect).139 The positive
trials were conducted between the 1980s through the early
2000s and showed that EPA and DHA intakes between 0.85
and 1.8 g/day were associated with reduced risk for CVD
events. The trials with neutral results were reported be-
tween 2010 and 2012 and provided 376 to 840 mg/day of
EPA and DHA. Five systematic reviews and meta-
analyses have been conducted evaluating omega-3 long-
chain PUFA intake for the secondary prevention of CHD.
Two of these meta-analyses were published before
2010140,141 and reported evidence of benefits in patients
with existing CHD; however, the 3 meta-analyses published
after 2010 did not report benefits.142–144 The Rizos et al.144
meta-analysis has been criticized because the authors used
a critical value for declaring statistical significance of 0.006
to account for multiple comparisons instead of the tradi-
tional P value of 0.05. As noted by Harris,145 ‘‘Without
this statistical maneuver, their data led to the conclusion
that fish oil supplementation significantly reduced risk for
cardiac death by 9% [RR of 0.91; 95% CI 0.85–0.98;
P 5 .01].’’
Several possible reasons for the lack of an effect in the
most recent trials have been put forth.145 First, it may be
that EPA and DHA are not effective, although there is
considerable evidence that argues against this possibility.
Second, increased consumer awareness of the benefits of
fish and fish oil have increased background intakes and
an additional 1 g of supplemental omega-3 fatty acids daily
may not confer any further benefit. Notably, no measures of
omega-3 status, such as plasma or red blood cell levels of
omega-3, were included in most of the large-scale trials.
Thus, it is not possible to determine whether a subset of pa-
tients with low omega-3 status might have benefitted.
Third, in more recent clinical trials of higher risk subjects,
standards of medical care were different from those in
earlier decades, resulting in large percentages of study
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platelet agents, beta-blockers, and drugs that influence the
renin-angiotensin axis. As discussed by Rizos et al.,144
demonstrating benefits with a low dosage of EPA 1
DHA (median intake of 1.0 g/day omega-3 acid ethyl es-
ters) when added to these cardioprotective therapies may
not be possible.
Mechanisms for ASCVD benefits of long-chain
omega-3 fatty acids
Long-chain omega-3 fatty acids may influence ASCVD
event risk through a number of mechanisms, including
altering susceptibility to ventricular arrhythmia, lowering
heart rate and blood pressure, and reducing platelet activation
and inflammation.126 The dose-response characteristics for
these various effects have not been fully explored, and the
relative importance of these mechanisms in different popula-
tion subgroups may vary. At higher levels of intake, omega-3
fatty acids lower levels of TG and VLDL-C.
Heart failure
Nestel et al.146 noted that there may be a benefit for use
of omega-3 fatty acid supplements as an adjunct to heart
failure therapy. Results of the Gruppo Italiano per lo Studio
della Sopravvivenza (GISSI)-Prevenzione Trial147 showed
that there was a substantially larger benefit for sudden car-
diac death reductions with EPA and DHA supplementation
in patients with ejection fractions ,40% compared with
those .50% (58% reduction vs 11% reduction,
P 5 .0003). In the GISSI-Heart Failure Trial, patients
with functional Class II to IV heart failure who were ran-
domized to 1 g/day of EPA and DHA ethyl esters for
3.9 years had an absolute 9% reduction in mortality or hos-
pital admission (P5 .04). In a subsequent review, Marchioli
and Levantesi148 reported that in 100 heart failure patients,
treatment with 1 g/day omega-3 fatty acid supplements was
associated with prevention of 1.8 deaths and 1.7 cardiovas-
cular hospitalizations. Moreover, in the GISSI-Heart Failure
Trial, baseline plasma phospholipid EPA levels were
inversely related to total mortality.149 The National Heart
Foundation of Australia concluded that there is modest sup-
port for 1 g/day of omega-3 PUFA in addition to standard
therapy for patients with heart failure.146ALA
In a systematic review and meta-analysis of 27 studies,
Pan et al.150 reported an inverse association between ALA
intake and total CVD risk. They found a 14% higher inci-
dence in total events in the lowest vs highest tertile of die-
tary ALA intake and biomarker levels (combined). In the
dietary ALA studies, there was a 10% reduction in risk
when comparing those with the highest vs those with the
lowest tertiles of intake. Each 1 g/day increment of ALA
intake is associated with a 10% lower risk of CHD death.
This epidemiologic evidence needs to be corroborated
with clinical studies that evaluate the effects of ALA onprimary prevention of CVD events. The 2010 DGA recom-
mendation for ALA intake was 0.6 to 1.2% of energy,
which may lower CVD risk; however, evidence was insuf-
ficient to warrant a greater intake.19
Dietary considerations for management of
hypertriglyceridemia
Part 1 of the NLA Recommendations for Patient-
Centered Management of Dyslipidemia endorses non-
HDL-C and LDL-C as targets of therapy.1 Currently, TG
is not a specific target for therapy except when levels are
$500 mg/dL. When the TG concentration is $500
mg/dL—and especially if $1000 mg/dL—reducing risk
of pancreatitis by lowering of TG to ,500 mg/dL becomes
the primary goal of therapy. For patients with hypertrigly-
ceridemia who have borderline high to high TG (range:
150 to 499 mg/dL), the primary objective of therapy is to
reduce risk for an ASCVD event by lowering levels of
atherogenic cholesterol (non-HDL-C and LDL-C). The pre-
dominant lipoprotein transporter of TG in the blood is
VLDL, and the circulating level of TG is highly correlated
with VLDL-C, a component of non-HDL-C (non-HDL-C is
mainly comprised of LDL-C and VLDL-C).
Non-dietary secondary causes of hypertriglyceridemia,
such as medications and disease conditions, including un-
controlled diabetes, hypothyroidism, and renal disease,
should be identified and treated where applicable (Refer to
Part 1 of the NLA recommendations1). Elevated TG (and
VLDL-C) reflect multifactorial metabolic imbalances
derived from the interaction of genetic and environmental
factors and are highly responsive to lifestyle practices.151–154
The 2011 AHA Scientific Statement on TG and CVD152
provides a comprehensive review of the epidemiology,
pathophysiology, etiology, special populations and treat-
ment for hypertriglyceridemia, and proposes a practical al-
gorithm for screening and management of elevated TG
levels (Fig. 1 adapted152). This evidence-based analysis
yielded the following conclusion on nutrition and TG
management:
Overall, optimization of nutrition–related practices can
result in a marked triglyceride-lowering effect that
ranges between 20% and 50%. These practices include
weight loss, reducing simple carbohydrates at the
expense of increasing dietary fiber, eliminating
industrial-produced trans fatty acids, restricting
fructose and saturated fatty acids, implementing a
Mediterranean-style diet, and consuming marine derived
omega-3 PUFA. Dietary practices or factors that are
associated with elevated triglycerides levels include
excess body weight, especially visceral adiposity; simple
carbohydrates, including added sugars and fructose; a
high glycemic load; and alcohol.
The NLA has provided practical information for physi-
cians to give patients regarding approaches to reduce TG
(Supplemental Figure 1).155
Figure 1 Clinical algorithm for screening and management of elevated TG. Adapted from Miller M, et al. Circulation. 2011;123:2292–
2333.152 aSpecial consideration for patients with initial TG $1000 mg/dL and chylomicronemia: recheck lipids in 2 weeks. When
TG ,500 mg/dL, diet may gradually be liberalized with monitoring. bIn addition to added sugars, some foods and beverages that
are high in naturally occurring sugars, for example, honey and fruit juices, should be limited. EPA, eicosapentaenoic acid; DHA,
docosahexaenoic acid; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-
density lipoprotein cholesterol; SFA, saturated fatty acids; TG, triglyceride.
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The magnitude of reduction in TG is related to
magnitude of weight loss, but even a small (3–5%)
reduction in body weight can lower TG.152,156 As noted
by Miller et al.,152 a 5–10% weight loss would be expected
to lower TG by approximately 20%. A strong association
has been demonstrated between TG and weight, elevated
BMI, and visceral fat.
Mediterranean-style dietary pattern
While the optimal macronutrient distribution for lowering
TG is not established and likely depends on the individual, the
Mediterranean-style dietary pattern has been shown to consis-
tently produce aTG-loweringeffect.152Thevariousdefinitions
of the Mediterranean diet used in studies limits comparisons,
but in general, a Mediterranean-style dietary pattern includes
an emphasis on plant-based foods, including fruits, vegetables,whole grain cereals, legumes, nuts and seeds, alongwith small
amounts of dairy, fish and seafood, animal protein and eggs;
wine inmoderation andmainlywithmeals; and often a greater
proportion of total fat, typically from olive oil. Red meat, pro-
cessed meats, and simple and refined carbohydrates are
limited.157 The 2011 AHA Scientific Statement on TG and
CVD152 concluded that a Mediterranean-style dietary pattern
is associated with an approximate 10–15% reduction in TG
compared with a low-fat diet.
Macronutrient distribution
A high-carbohydrate/low-fat diet that is high in refined
starches and simple carbohydrates is not beneficial for the
management of elevated TG (200–500 mg/dL) and, thus, is
not recommended. The Institute of Medicine’s Panel on
Macronutrients reported that for every 5% decrease in total
fat, TG level is predicted to increase by 6%, which may be
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diets.158 Partial replacement of refined grains and added
sugars with fiber-rich whole grains and other complex car-
bohydrate foods, such as legumes, will often lower the TG
concentration. The preferred dietary substitutes for refined
grains and added sugars are foods high in unsaturated
fats, protein, and fiber-rich whole grains, nuts, seeds and le-
gumes. It is important, however, to understand that carbo-
hydrates from less refined sources, such as brown rice
and whole-grain bread, can also raise the TG concentration.
Alcohol
There is a J-shaped relationship between alcohol
intake and TG level. In some individuals, low alcohol
consumption may be associated with decreased TG.159–161
High alcohol intake is associated with TG elevation, espe-
cially in the presence of obesity.162 Patients with hypertri-
glyceridemia that is affected by alcohol should be advised
to reduce or eliminate alcohol. In those with very high
TG ($500 mg/dL), complete abstinence of alcohol is
generally recommended to reduce the likelihood of
pancreatitis.152,159,162
Long-chain omega-3 fatty acids
The lipid-altering effects of EPA 1 DHA are very
similar to those observed with fibrate medications. RCTs of
the effects of fibrates on ASCVD event risk have shown
mixed results, but subgroups with elevated TG, especially if
accompanied by low HDL-C, have consistently shown risk
reduction.163,164 Thus, it is possible that therapeutic dos-
ages of long-chain omega-3 fatty acids (2.0 to 4.0 g/day)
might lower ASCVD event risk in patients with elevated
TG or elevated TG plus low HDL-C. A subgroup analysis
of participants in the Japan EPA Lipid Intervention Study
(JELIS) with TG $150 mg/dL plus HDL-C ,40 mg/dL
suggested that the reduction in CVD event risk with EPA
ethyl esters (1.8 g/day) was larger in this subset (53%)
than in the overall study sample (19%).165 Two ASCVD
outcomes trials are currently underway to assess the influ-
ence of prescription omega-3 products on CVD outcomes
in patients with hypertriglyceridemia despite statin therapy
(Reduce Cardiovascular Events in High Risk Patients With
Hypertriglyceridemia and on Statin [REDUCE-IT] is regis-
tered at ClinicalTrials.gov as NCT01492361 and STatin
Residual Risk Reduction With EpaNova in HiGh CV
Risk PatienTs With Hypertriglyceridemia [STRENGTH]
is registered as NCT02104817).166,167
Intakes of 2.0 to 4.0 g/day of long-chain omega-3 fatty
acids are generally required to achieve significant (.15%)
TG-lowering effects.153 As noted by Pirillo and Cata-
pano,168 there is little evidence of clinically relevant effi-
cacy at dosages ,1 g/day. The TG-lowering effect
observed at recommended intakes (200 to 500 mg/day)
for primary prevention of coronary disease ranges from
3.1% to 7.2%.168 With higher intakes of EPA and DHA
(2.0 to 4.0 g/day), the TG-lowering effect ranges from
20% to 35% and even up to 45% in individuals with veryhigh TG ($500 mg/dL).168 The percentage reduction in
TG with therapeutic dosages of EPA 1 DHA increases in
a non-linear fashion with higher baseline TG concentra-
tions.169–172
Omega-3 fatty acid preparations containing EPA and
DHA may increase LDL-C by up to 49% in patients with
very high TG (the range is 117% to 149%), although little
or no increase is typically observed in patients with mixed
dyslipidemia. Wei et al.173 conducted a meta-analysis to
evaluate and compare the effects of EPA and DHA on lipo-
protein lipids. Randomized placebo-controlled trials of
monotherapy with EPA (n 5 10), DHA (n 5 17), or EPA
vs DHA (n 5 6) were identified. Compared with placebo,
DHA raised LDL-C 7.23 mg/dL (95% CI 3.98–10.5),
whereas EPA non-significantly reduced LDL-C. In direct
comparison studies, DHA raised LDL-C 4.63 mg/dL
(95% CI 2.15–7.10) more than EPA. Both EPA and DHA
reduced TG, with a slightly greater reduction by DHA in
direct comparison studies. DHA also raised HDL-C
(4.49 mg/dL; 95% CI 3.50–5.48) compared with placebo,
whereas EPA did not. The authors concluded that both
EPA and DHA lower TG, but that the two fatty acids
have divergent effects on LDL-C and HDL-C. This conclu-
sion is consistent with that from a review of 22 studies pub-
lished by Jacobson et al.,174 6 of which directly compared
EPA with DHA, 12 studied DHA alone, and 4 studied
EPA alone.
Prescription EPA and EPA 1 DHA concentrates have
been approved in ethyl ester and carboxylic acid forms
(discussed in Harris et al.130 and Ballantyne et al.175).
Presently, these are indicated for the treatment of very
high TG ($500 mg/dL). A cautionary note is that the
EPA and DHA ethyl esters may not be absorbed well on
an empty stomach or when consumed with a low-fat
meal.176 Omega-3 fatty acid preparations in other forms
(e.g., fish oil, algae oil, krill oil) are sold as dietary supple-
ments (reviewed by Skulas-Ray et al.177). The National
Heart Foundation of Australia has affirmed that omega-3
fatty acids are a means for TG lowering with the caveat
that they may augment the anti-platelet effects of combi-
nation therapy with aspirin and other anti-platelet drugs.146
Use of supplemental long-chain omega-3 fatty acids at
therapeutic dosages (2.0 to 4.0 g/day), whether taken as
prescription drugs or dietary supplements, should be
done under the supervision of a qualified clinician.
Dietary recommendations for management of
patients with very high TG ($500 mg/dL)
For individuals with very high TG ($500 mg/dL),
nutrition therapy will differ from the management of
TG ,500 mg/dL (Fig. 1).152 Plasma TG are mainly trans-
ported in plasma by 2 distinct classes of lipoproteins: 1)
chylomicrons produced and absorbed in the gastrointestinal
tract; and 2) VLDL synthesized in the liver. In healthy in-
dividuals, chylomicron particles quickly transfer TG to
the peripheral tissues and are removed from plasma within
Table 6 Nutrition therapy for very high TG ($500 mg/dL)/chylomicron clearing12
Temporarily limit total fat to 10%–15% calories (typically 20–40 g/day) during chylomicron clearing
Avoid alcohol
Avoid refined starches and partially replace with high fiber, whole grain foods
Avoid added sugars, limit fruit; no fruit juice or sugary beverages
Spread calories and carbohydrates evenly through the day
Limit calories if weight loss is indicated
If extra calories are needed, add medium chain TG oil and increase gradually
Exercise 30–60 min most days
Adjust diabetes medications as appropriate to maintain glycemic control
Once chylomicron particles have been cleared and TGs are ,500 mg/dL, gradually advance dietary fat to tolerance
TG, triglyceride.
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the TG in fasting plasma is carried by lipoproteins other
than chylomicron particles. When fasting TG are
$500 mg/dL, and particularly when $750 mg/dL, fasting
chylomicronemia is often present. At very high fasting
TG levels, especially if$1000 mg/dL, restriction of dietary
fat to less than 15% total energy intake (usually ,20–40 g
daily; 40 g is 15% of energy for a 2400 kcal diet) is recom-
mended to reduce the formation of chylomicron particles.
This restriction is temporary while chylomicron particles
are cleared, except for patients with lipoprotein lipase defi-
ciency. Table 6 summarizes recommendations for lifestyle
therapies in patients with very high TG ($500 mg/dL).12
Patients with very high TG should also adhere to other
dietary and lifestyle recommendations to reduce endoge-
nous TG synthesis, including reducing consumption of
sugars, refined grains, and alcohol (complete alcohol
abstinence is recommended for those with very high TG),
and engaging in moderate or higher intensity aerobic
activity $5 days per week. Medium chain TG oil may
provide additional calories during the initial chylomicron-
clearing phase because medium chain TG are directly
absorbed into portal circulation, and, thus, do not induce
chylomicron synthesis.178,179 Patients on very-low fat diets
(,15% of energy) over an extended period may benefit
from consuming a source of essential fatty acids (walnut
or sunflower oil), as well as fat-soluble vitamin
supplements.154
When TG have decreased to ,500 mg/dL, for most
individuals without lipoprotein lipase deficiency, dietary fat
intake may be liberalized with monitoring of the TG
response.Monitoring TG responses to changes in food intake
helps patients to learn their particular dietary sensitivities.
Additional dietary considerations for lowering
ASCVD risk
In addition to the core considerations for management of
dyslipidemia and associated ASCVD risk described above,
the NLA Expert Panel concluded that additional topics
warranted comment and consideration by clinicians. These
are described below.Whole grains and dietary fibers
Consumption of whole grains, including rye, oats,
barley, and whole wheat, is associated with a reduced risk
of ASCVD events including CHD and stroke, as well as
reduced risk for the development of type 2 diabetes
mellitus.17 There is no standard definition of whole grains;
however, whole grains generally include the bran, germ,
and endosperm.17 The bran component contains soluble
and insoluble dietary fibers, B vitamins, minerals, flavo-
noids, and tocopherols, whereas the germ fraction contains
fatty acids, antioxidants, and phytochemicals, and the endo-
sperm is comprised primarily of starch (carbohydrate poly-
saccharides) and storage proteins. The AHA issued 2020
Impact Goals to improve the cardiovascular health of all
Americans and included a recommendation to consume
$3 1-oz.-equivalent servings of fiber-rich whole grains
per day.129 The NLA Expert Panel endorses this
recommendation.Nuts, seeds, and legumes
Since the early 1990s, numerous observational studies
and controlled clinical trials have shown consistent associ-
ations between consumption of nuts, seeds, and legumes
with lower ASCVD event risk and an improved ASCVD
risk factor profile (reviewed by Griel and Kris-Etherton180
and Ros et al.181). The AHA’s 2020 Impact Goals to
improve the cardiovascular health of all Americans
included a recommendation to consume $4 servings per
week of nuts, seeds, and legumes.129 The NLA Expert
Panel endorses this recommendation, with particular
emphasis on nut consumption.
The NLA Expert Panel consensus view was that the
evidence was particularly strong and consistent for nut
consumption as a predictor of favorable cardiovascular
health outcomes. In a pooled analysis of 4 early prospective
studies (Adventist Health Study,182 Nurses’ Health
Study,183 Iowa Women’s Health Study,184 Physicians’
Health Study185) that evaluated nut consumption and
CHD incidence, there was a 37% reduction in
multivariable-adjusted risk of fatal CHD186 when the high-
est ($4 servings/week) vs the lowest frequency of nut
intake was compared (0.63; 95% CI 0.51 to 0.83). All
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consumption and reduced CHD mortality rates.
More recently, in a systematic review and meta-analysis
of 25 observational studies and 2 clinical trial reports with
501,791 individuals,187 nut consumption was inversely
associated with incidence of fatal ischemic heart disease
(6 studies; 6749 events; RR per 4 weekly 28.4-g servings:
0.76; 95% CI 0.69–0.84; I2 5 28%), nonfatal ischemic
heart disease (4 studies; 2101 events; RR: 0.78; 0.67–
0.92; I2 5 0%), and diabetes (6 studies; 13,308 events;
RR: 0.87; 0.81–0.94; I2 5 22%), but not stroke (4 studies;
5544 events). In this study, individuals from the United
States, Spain, Finland, China, Greece, Costa Rica and Japan
were studied. Thus, the favorable associations between nut
consumption and risk for fatal and nonfatal ischemic heart
disease are present in many countries with a wide range of
risk profiles and background diets.
As mentioned previously, the PREDIMED RCT48 ran-
domized participants to receive: (1) a low(er)-fat diet
(37% calories from fat); (2) a Mediterranean diet with
extra-virgin olive oil (EVOO) (1 L/week/family; 50 g/day
per participant); or (3) a Mediterranean diet with tree
nuts (30 g/day: 15 g walnuts, 7.5 g almonds, 7.5 g hazel-
nuts). After 4.8 years, there was a 30% reduction in the
primary endpoint, which was rate of major cardiovascular
events (MI, stroke, or death from cardiovascular causes)
in both Mediterranean diet groups. These results are, there-
fore, concordant with those from observational studies and
suggest that a Mediterranean-style dietary pattern rich in
nuts is associated with lower ASCVD event risk.
The NLA Expert Panel consensus includes a recom-
mendation to consume$4 servings/week of nuts (including
the legume, peanuts) to reduce risk of ASCVD. One serving
of nuts is 1 oz. Nuts should be incorporated as part of a
cardioprotective dietary pattern that also ideally includes
seeds and legumes. For diet planning purposes, nuts may be
considered a plant protein food as well as a source of
unsaturated fatty acids.
Soy protein
Many RCTs have assessed the effects of soy protein on
serum lipoprotein lipids, with emphasis on LDL-C. In the
early clinical studies, in which animal protein was almost
entirely replaced with soy protein, significantly reduced
plasma cholesterol levels were observed in both healthy
young women188 and hypercholesterolemic patients.189
Subsequent investigations of the cholesterol-lowering ef-
fects of soy protein were examined in a 1995 review that
showed consumption of 47 g soy protein/day reduced
serum total-C by 9.3%, LDL-C by 12.9%, and TG by
10.5%, while increasing HDL-C by 2.4%.190 This analysis
provided the basis for the FDA health claim for soy, which
states: ‘‘Diets low in saturated fat and cholesterol that
include 25 g of soy protein a day may reduce the risk of
heart disease.’’
Despite the evidence in support of this health claim,
more recent meta-analyses have reexamined the effects ofsoy on the lipid profile and reported substantially smaller
effects.191,192 The AHA Soy Science Advisory Panel re-
ported results from a meta-analysis that showed a mean
LDL-C reduction of 3% with soy protein interventions
from results in 22 randomized trials.193 This panel also
concluded that soy had no effect on HDL-C, TG, lipopro-
tein (a) [Lp(a)], or blood pressure.
The evidently smaller LDL-C-lowering effect of soy in
recent studies prompted concern regarding the heart-health
claim previously allowed for soy products. In response,
Jenkins et al.194 reviewed the evidence in an attempt to es-
timate the intrinsic and extrinsic (displacement) potential of
soy for reducing LDL-C to assess whether the heart health
claim for soy continues to be justified. The intrinsic effect
of soy was derived from a meta-analysis using soy studies
(20–133 g/day soy protein). The extrinsic effect of soy in
displacing foods higher in saturated fat and cholesterol
was estimated using predictive equations for LDL-C and
NHANES III population survey data with the substitution
of 13 to 58 g/day soy protein for animal protein foods.
Their results suggested that soy protein consumption of
approximately 30 g/day may have an intrinsic effect of
reducing serum LDL-C by approximately 4% to 5% and
may displace animal products rich in saturated fat and
cholesterol to reduce LDL-C values by an additional 4%
to 5%. Taken together, the estimated LDL-C reduction
attributable to both the intrinsic and extrinsic effects of
soy protein foods range from 7.9% to 10.3%.
The conclusions of Jenkins and colleagues194 were
confirmed in the 2011 meta-analysis by Anderson
et al.195, which also sought to reexamine the effects of
soy protein on lipids and lipoproteins. This analysis
included 20 parallel-design studies (981 control and 954
soy-treated subjects) and 23 crossover studies (970 control
and 970 soy-treated subjects). Soy protein intake ranged
from 15 to 50 g/day, with a mean intake of w30 g/day.
Soy protein intake was associated with an LDL-C reduction
of 5.5% in parallel studies and 4.2% in crossover studies. In
studies that presented baseline data, hypercholesterolemic
individuals experienced significantly greater reductions in
LDL-C compared to individuals with normal cholesterol
levels. In parallel studies, HDL-C values were 3.2% higher
with soy vs control, and fasting TG levels were 10.7%
lower for soy vs control. The duration of treatment neces-
sary to produce maximal effects on LDL-C was 8 weeks.
The authors also examined whether the delivery form influ-
enced the lipoprotein lipid response to soy protein con-
sumption from studies where soy protein was consumed
in water or another beverage (n5 27), in soy milk or yogurt
(n 5 9), or in other food forms (n 5 11), such as soy nuts,
tofu, or muffins. No association between food form and
reduction in LDL-C was reported.
The mechanisms responsible for the effects of soy
protein consumption on LDL-C remain unclear. Maki
et al.196 evaluated the effects of 25 g/day of a very low
isoflavone soy protein preparation (1 mg aglycone
equivalent/g protein) on lipoprotein lipids in men and
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w134 mg/dL) who had a demonstrated response to a bile
acid sequestrant drug (colesevelam) to assess the possible
roles of binding with bile acids and cholesterol on the
cholesterol-lowering effect. Compared to a milk protein
control, significant reductions were observed for non-
HDL-C (6.9%), TG (13.7%), and apo B (7.3%) with the
soy protein preparation. A near-significant reduction of
5.0% was observed for LDL-C (P 5 .08). No significant
differences between the treatments were observed for fecal
excretion of bile acids or cholesterol. Therefore, these
results suggest that the lipid-altering effects of soy are
not attributable to trapping of bile acids or cholesterol, or
to effects of isoflavones (because this study used a very
low isoflavone preparation). Additional research is needed
to more clearly define the mechanisms by which soy pro-
tein influences lipoprotein metabolism.
The existing FDA-approved health claim for soy and
heart disease requires that each food with the health claim
on its label contain at least 6.25 g of soy protein, based on
the need for 25 g of soy protein to show significant
lowering of serum total-C and LDL-C levels. Soy foods
that meet the 6.25 g level include 4 oz. of whole soybeans,
8 oz. of soy milk, 3.5 oz. soy flour, 8 oz. textured soy
protein, 4 oz. tofu, and 4 oz. tempeh.
In summary, soy protein lowers LDL-C via intrinsic and
extrinsic effects. When incorporated in a cardioprotective
diet as a substitute for foods high in saturated fat, there is an
LDL-C-lowering effect that is due to both decreasing
saturated fat and increasing soy protein. Soy protein foods
are one source of plant protein among others (e.g., nuts,
legumes) that can be included in a cardioprotective eating
pattern.
Probiotics
Probiotics are live microorganisms that can confer
beneficial effects on the host.197 There is emerging evi-
dence that certain bacterial strains reduce blood cholesterol
levels (reviewed in DiRienzo198 and Ettinger et al.199). The
genera Lactobacillus and Bifidobacterium are a significant
proportion of probiotic cultures in functional foods; howev-
er, certain Bacillus and Enterococcus strains may also be
incorporated into probiotic products.200
In a meta-analysis of 13 controlled trials of 485
participants with normal or high cholesterol levels who
were treated with probiotics, total-C decreased 6.40 mg/dL,
LDL-C decreased 4.90 mg/dL, and TG decreased 3.95
mg/dL.201 An earlier meta-analysis of 6 intervention studies
reported similar lipid and lipoprotein effects.202 In a more
recent review of 26 clinical studies,198 a significant
LDL-C-lowering effect was reported for 4 probiotic strains:
Lactobacillus reuteri NCIMB 30242 (8.9–11.6%), Entero-
coccus faecium (5%), and the combination of Lactobacillus
acidophilus La5 and Bifidobacterium lactis Bb12 (0–7.5%).
There are several proposed LDL-C-lowering mecha-
nisms of probiotics: 1) sequestering of cholesterol in the gut
by incorporation into cellular membranes203,204; 2)conversion of cholesterol to coprostanol, which is excreted
in the feces204; and 3) production of bile salt hyrolases that
deconjugate bile acids, interfering with incorporation of
cholesterol into mixed micelles; and possibly through an ef-
fect of deconjugated bile acids to stabilize ABC sterol
transporters that move cholesterol and other sterols out of
enterocytes.205,206
At present, the evidence base is too limited to make a
recommendation regarding the use of probiotic products as
dietary adjuncts to lower atherogenic cholesterol levels.
However, the available data appear promising and suggest
that additional research is warranted to further evaluate this
class of products.
Effects of coconut oil on lipoprotein lipids
Despite being comprised of approximately 65%
cholesterol-raising (12–16 carbon saturated) fatty
acids,207,208 coconut oil, and particularly ‘‘virgin’’ coconut
oil, has gained popularity among some consumers because
of purported health benefits. However, the claims made for
virgin coconut oil, or coconut oil in general, are not sup-
ported by a robust scientific evidence base. There are few
published studies in humans that have examined the effect
of coconut oil or virgin coconut oil on lipids/lipoproteins,
and all were conducted outside the United States.
One RCTwas a well-controlled feeding study conducted
in Malaysia with a group of 45 healthy subjects who
consumed diets in a crossover fashion with 30% of energy
from fat, two-thirds of which was provided by 1 of 3 test
fats: palm oil, olive oil, or coconut oil.209 The 3 diets
differed only in the type of test fat incorporated, and intakes
of cholesterol-raising saturated fatty acids (12 to 16 carbon)
during the 3 diets were 10.7% (palm oil), 5.2% (olive oil),
and 17.0% (coconut oil). Compared to the olive oil diet, the
coconut oil diet increased mean levels of total-C (6.5%) and
LDL-C (7.8%), while also raising HDL-C to a similar de-
gree (7.0%). Values were intermediate between the olive
and coconut oil conditions during the palm oil diet, with
levels of total-C, LDL-C, and HDL-C raised by 3.4%,
4.6%, and 2.3%, respectively, compared with the olive oil
diet. These findings are similar to the effects predicted
based on the differences in the fatty acid compositions of
the 3 test fats. Therefore, the results of this study illustrate
that the saturated fatty acids in coconut oil increase total-C,
LDL-C, and HDL-C. The increase in HDL-C is of uncer-
tain clinical relevance, but the increase in LDL-C would
be expected to have an adverse effect on ASCVD risk.
After reviewing the limited available evidence, the NLA
Expert Panel consensus view is that, if coconut oil is used
as part of a daily eating plan and/or in food preparation, it is
recommended that it be used within the context of a
healthy dietary pattern. One tablespoon of coconut oil
contains 11.7 g of saturated fat and 1 tablespoon of
virgin coconut oil contains 13.6 g of saturated fat.70 Either
would, therefore, contribute a significant portion of the
recommended total daily saturated fat limit of ,7% of
energy (15.5 g/day of saturated fat would constitute 7%
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and virgin coconut oil are incorporated into a healthy
dietary pattern, this must be done sparingly by patients
who would benefit from reductions in atherogenic
cholesterol (LDL-C and non-HDL-C).
Role of the registered dietitian nutritionist in the
management of dyslipidemia
Four systematic reviews210–213 conducted from 1995 to
2014 and 7 research trials214–220 conducted from 2011 to
2014 have been completed to assess the effectiveness of
MNT guided by dietitian(s) for ASCVD risk factor modifica-
tion. The results support the conclusion that multiple visits
with a dietitian (nutritionist) can result in improvements in
LDL-C, TG, and metabolic syndrome criteria.221–231 Five
studies conducted abroad (inChina,Greece,Korea,Malaysia,
Japan) refer to nutrition professionals as ‘‘dietitians’’ rather
than as ‘‘registered dietitian nutritionists’’ or ‘‘registered
dietitians’’.216–220 Of note, is that the studies conducted in
the United States used the ‘‘registered dietitian’’ credential
because it was only recently replaced by the ‘‘registered
dietitian nutritionist’’ credential in 2014 by the Academy of
Nutrition and Dietetics. In this document, ‘‘registered
dietitian nutritionist’’ is used synonymously for ‘‘registered
dietitian’’ as well as ‘‘dietitian.’’
McCoin et al.213 systematically reviewed the lipid pro-
file changes in 8 studies conducted between 1991 and
2006 that met the criteria for MNT interventions provided
by a registered dietitian nutritionist, with the MNT pro-
vided for 6 weeks to 6 months. Interventions resulted in sig-
nificant decreases in total-C (6–13%) and LDL-C (7–15%).
TG and HDL-C changes were mixed.213 Authors of a sys-
tematic Cochrane review of 9 studies212 concluded that
MNT by a registered dietitian nutritionist is recommended
for treating patients with disorders of lipid metabolism and
other CHD risk factors. On the basis of this review, the
Academy of Nutrition and Dietetics Expert Panel on Disor-
ders of Lipid Metabolism recommended that the registered
dietitian nutritionist should provide multiple visits for MNT
(3 to 6 visits) over 8 to 12 weeks to improve a patient’s lipid
profile. Two studies reported that the magnitude of LDL-C
reduction was greater with additional visits or time spent
with the registered dietitian nutritionist.212 There is no ev-
idence to support an adverse effect of MNT for dyslipide-
mia management on quality of life, and some evidence is
suggestive of a favorable effect of MNT on patients’ sense
of well being.232,233
Taken together, these data strongly indicate that MNT
provided by a registered dietitian nutritionist is effective for
improving lipid/lipoprotein profiles and cardiometabolic
risk factors and may favorably affect quality of life.
Overall, MNT provided by a registered dietitian nutritionist
resulted in improved LDL-C, TG, HDL-C, glycemia, and
body weight status. Several studies212–220 also reported re-
ductions in waist circumference, BMI, body fat, and
improved dietary intakes (energy, saturated fat, and fiber).See Chart 1 for the Nutrition Recommendations.Exercise/physical activity
Considerable evidence from population studies links
higher levels of physical activity and cardiorespiratory
fitness with reduced risk for ASCVD events. Physical
activity has a number of beneficial effects on risk factors
for ASCVD. In addition to effects on lipids and lipoproteins
summarized below, increasing physical activity and cardio-
respiratory fitness in previously sedentary people has been
associated with improvements in blood pressure, insulin
resistance, and hemostasis.234–237
Exercise training in the absence of a change in adiposity
has effects to reduce the circulating TG concentration and
modestly raise the level of HDL-C.238 If the volume of ex-
ercise is sufficient to lower body fat, this will typically
enhance these changes, while also resulting in a modest
to moderate reduction in the LDL-C concentration.238,239
The magnitudes of changes in lipid and lipoprotein
levels depend on a number of variables (see below) beyond
the type, frequency, intensity, and duration of physical
activity. These factors are important for clinicians to be
aware of because they may influence, or interact with, the
effects of exercise and contribute to variability in responses.
 Gender and menopausal status
 Race/ethnicity
 Nature and severity of the lipid/lipoprotein disorder
 Accompanying changes in diet (including alcohol intake)
 Changes in body fat
 Plasma volume changes
 Genetic factors (e.g., apo E and C isoforms)
 Seasonal and diurnal changes in lipoprotein lipid levels
Quality and quantity of physical activity
required to generate favorable lipid and
lipoprotein changes
In order to reduce LDL-C, the quantity of physical
activity needed is consistent with recommendations for
long-term weight control (200–300 min/week of moderate
intensity physical activity or$2000 kcal/week), which may
be accumulated in repeated bouts of exercise of at least
10 min each.20 Use of well-engineered pedometers for
recording walking step counts has been successfully em-
ployed in outpatient clinic settings as a means of tracking
activity for managing dyslipidemia and promoting weight
loss. In general, the amount of walking required to produce
weight loss is $40,000 steps/week (beyond steps/activities
of daily living), which is approximately equivalent to
2000 kcal/week energy expenditure (based on w2000
steps/mile and w100 kcal gross energy cost/mile).21,240
The recommendations for accumulating sufficient physical
activity to lower body fat and LDL-C differ from the more
general public health guidelines.241 The CDC public health
guidelines recommend that all healthy adults aged 18 to
65 years should engage inmoderate intensity aerobic (cardiore-
spiratory endurance) physical activity for aminimumof 30min
Chart 1 Nutrition recommendations
Recommendations Strength Quality
The NLA Expert Panel supports a cardioprotective eating pattern for the management of dyslipidemia and
overall cardiovascular health that includes ,7% of energy from saturated fat, with minimal intake of trans
fatty acids to lower levels of atherogenic cholesterol (LDL-C and non-HDL-C).
A Moderate
The cardioprotective eating pattern should limit cholesterol intake to ,200 mg/day to lower levels of
atherogenic cholesterol (LDL-C and non-HDL-C).
B Moderate
There are individuals who are hyper-responders to dietary cholesterol because of genetic or other reasons. For
known or suspected hyper-responders, further reduction in dietary cholesterol beyond the ,200 mg/day
that is recommended as part of the cardioprotective eating pattern for the management of dyslipidemia
may be considered. Consumption of very low intakes of dietary cholesterol (near 0 mg/day) may be helpful
for such individuals.
B Low
The NLA Expert Panel recommends any of the following healthy dietary patterns, including an emphasis on a
variety of plant foods and lean sources of protein for managing dyslipidemia: DASH, USDA (healthy
US-style), AHA, Mediterranean-style, and vegetarian/vegan. However, the dietary pattern should be
individualized based on the patient’s specific dyslipidemia. Also, patients’ cultural and food preferences are
important for guiding food selection to maximize dietary adherence. Nutritional counseling and follow-up/
monitoring by a registered dietitian nutritionist is recommended whenever possible to individualize a
patient’s dietary pattern. Nutrition therapy should be included in those with other medical conditions,
including diabetes.
A Moderate
If alcohol is consumed as part of a healthy dietary pattern, this should be in moderation (#7 drinks per week
for women and #14 drinks per week for men; consumed in a non-binge pattern). One drink is equivalent to
12 oz. beer, 5 oz. wine, or 1.5 oz. distilled spirits.
A Moderate
Dietary saturated fat may be partially replaced with unsaturated fats (mono- and polyunsaturated fats), as
well as proteins, to reach a goal of ,7% of energy from saturated fats. This can be achieved, in part, by
incorporating foods high in unsaturated fats, such as liquid vegetable oils and vegetable oil spreads, nuts
and seeds, as well as lean protein foods, such as legumes, seafood, lean meats, and non- or low-fat dairy
products, into the diet as replacements for foods high in saturated fats.
A Moderate
Weight loss of 5-10% body weight is generally recommended for overweight or obese individuals to lower
atherogenic lipoprotein lipids and improve other ASCVD risk factors. A variety of dietary approaches can be
implemented for weight loss. Any dietary approach will result in weight loss if energy intake is reduced. An
energy-reduced healthy dietary pattern that meets nutrient needs is recommended for patients who are
overweight or obese. Several healthy dietary patterns, such as the Mediterranean-style, DASH, USDA, and
vegetarian diets, can be tailored to personal and cultural food preferences and appropriate calorie needs for
weight control.
A Moderate
Eating patterns that contain a moderate quantity of carbohydrate, lower glycemic index and load, and higher
protein, have been associated with modest benefits for weight loss and maintenance.
C Low
Plant sterols and stanols (w2 g/day) are recommended for cholesterol lowering, as well as viscous fibers (5 to
10 g/day or even greater, if acceptable to the patient), as adjuncts to other lifestyle changes. However,
individuals with phytosterolemia (sitosterolemia) should avoid foods that are fortified with stanols and
sterols.
B Moderate
For patients with TG levels$150 mg/dL, lifestyle therapy is indicated, including weight loss, if overweight or
obese, physical activity, and restriction of alcohol, and sugars and refined starches. Partial replacement of
sugars and refined starches with a combination of unsaturated fats, proteins, and high-fiber foods may help
to reduce TG and non-HDL-C concentrations.
A Moderate
For patients with TG levels $1000 mg/dL (and selected patients with TG 500-999 mg/dL), a low-fat diet
(,15% of energy) and alcohol abstinence are recommended initially to minimize chylomicronemia. In
patients with hypertriglyceridemia and diabetes, dietary carbohydrate should not be substantially
increased to avoid worsening glycemia when reducing fat intake. Medium chain TG oil may be used as a
source of energy that will not induce chylomicron production. For patients without lipoprotein lipase
deficiency, dietary fat may be liberalized with monitoring of the TG response once the TG concentration is
,500 mg/dL.
B Moderate
Therapeutic dosages of EPA + DHA for TG reduction are 2.0 to 4.0 g/day. Use of these dosages of long-chain
omega-3 fatty acids for TG-lowering should be done only under the supervision of a qualified clinician.
Clinicians are encouraged to educate patients on the importance of the amount of EPA + DHA in each
capsule of dietary supplement or prescription products, and to take the appropriate number of capsules
daily to achieve therapeutic levels. At present, prescription forms of EPA and EPA + DHA concentrates are
only indicated for treatment of very high TG ($500 mg/dL) to reduce the risk of pancreatitis.
B Moderate
(continued on next page)
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Chart 1 (continued )
Recommendations Strength Quality
For primary and secondary prevention of ASCVD, consuming $2 servings/week of fish/seafood (preferably
oily) is recommended. One serving is equal to 3.5 to 4 oz. and should ideally not be prepared using deep-
frying.
A Moderate
For patients with known ASCVD, suggestive, but not conclusive, evidence from RCTs is available for a benefit
of long-chain omega-3 fatty acid supplementation at w1 g/day EPA + DHA on cardiac mortality, but not
non-fatal ASCVD events. EPA + DHA supplements may be considered for such patients, especially those who
do not consume the recommended intakes of EPA + DHA from dietary sources.
C Low
For patients with heart failure, 1 g/day of EPA + DHA is recommended as an adjunct to heart failure therapy. A Moderate
An ALA intake of 0.6 to 1.2% of energy is recommended. A Moderate
Consumption of at least three 1-oz. equivalent servings per day of fiber-rich whole grains is recommended. A Moderate
Consumption of $4 servings/week (1 oz. per serving) of nuts (including the legume, peanuts) is
recommended, because nut consumption has been consistently associated with reduced ASCVD risk. Nuts
may be included in the diet as a protein food and as a source of healthy fat (predominantly unsaturated
fatty acids).
A Moderate
Soy protein foods are one source of plant protein, among others (e.g., nuts, legumes), that may be used as a
substitute for protein foods high in saturated fat as part of a cardioprotective eating pattern.
B Moderate
Nutrition education/MNT by a registered dietitian nutritionist with follow-up and monitoring are
recommended to promote long-term dietary adherence. Clinicians should, when feasible, refer patients to a
registered dietitian nutritionist for MNT to individualize a cardioprotective dietary pattern and promote
successful lifestyle modifications.
A Moderate
Jacobson et al NLA Dyslipidemia Recommendations - Part 2 S27on 5 days each week (i.e.,$150min per week), or vigorous in-
tensity aerobic physical activity for a minimum of 20 min on
3 days each week. Combinations of moderate and vigorous in-
tensity activity may be performed to meet this recommenda-
tion. The weekly volume of physical activity required to
lower LDL-C and body weight is greater, i.e., $2000 kcal/
week, which generally requires 200–300 min/week of moder-
ate or higher intensity physical activity.6,20 This greater amount
of physical activity necessary for reducingLDL-Cwas also rec-
ommended by the 2008 Physical Activity Guidelines Advisory
Committee.242 Thus, for management of body weight and
LDL-C, the recommendations are as follow:
 Primary activity: aerobic exercise
 Intensity: 40–75% aerobic capacity (oxygen uptake
reserve)
 Frequency: 5 or more days a week
 Duration: 30–60 min per session
 200–300 min/week of moderate or higher intensity phys-
ical activity ($2000 kcal/week).Type of physical activity
Aerobic exercise is the preferred mode of physical activity
in nearly all consensus guidelines that cover exercise and
dyslipidemia. This is because there is significantly greater
energy expenditure in dynamic aerobic exercise, compared
with resistance exercise training, and this appears to be a
necessary component of the lipid-altering effects of exercise
training, andmore likely to produce reductions in adiposity.236
However, resistance exercise can, and should, play a support-
ive role to helpmaintain strength, balance, and bone health.236
There is a dose-response effect of physical activity requiredfor significant weight loss, with 250–300 min or more per
week of moderate aerobic exercise being near optimum.20,243
Exercise and TG
The circulating TG level frequently declines with exercise
training to a degree that depends upon several factors,
including baseline value, exercise energy expenditure, and
how soon TG values are measured after the last exercise
session. Higher baseline values, greater energy expenditure
andmeasurement closer to the time of the last exercise bout are
all associated with larger reductions. In intervention trials,
fasting TG have been lowered by 4 to 37% (approximate
median reduction of 24%).244 TG generally decline immedi-
ately after a session of high-volume endurance exercise, and
remain lower for up to 48 hours after the session. The magni-
tudes of the decreases in plasma TG concentration after a sin-
gle exercise session before and after training are similar, i.e.,
15 to 50%. These observations suggest that chronic exercise,
if not accompanied by reduced adiposity, does not have a sus-
tained effect on the plasma TG concentration beyond that
attributed to the repeated effects of acute exercise; hence exer-
cise should be performed on a regular and uninterrupted basis
to maintain a lower TG concentration.245 Changes in TG are
highly correlatedwith changes inVLDL-C concentration.9,151
Thus, exercise training can help to lower the atherogenic
cholesterol level by reducing VLDL-C, one of the two main
components of non-HDL-C (non-HDL-C ismainly comprised
of LDL-C and VLDL-C).
Elevated postprandial TG levels are associated with
reduced HDL-C; an increase in the generation of small,
dense LDL particles246; impaired endothelial function247;
and is postulated to increase atherosclerotic plaque
Chart 2 Exercise/physical activity recommendations
Recommendations Strength Quality
The recommended minimal quantity of
exercise for supporting
cardiovascular health and improving
the lipid profile (lowering TG and
sometimes raising HDL-C) is 150 min
per week of moderate to higher
intensity aerobic activity. This level
of physical activity is consistent with
public health recommendations.
A High
To enhance the effects on TG and
HDL-C, and produce reductions in
LDL-C, as well as loss of body fat
and weight, $2000 kcal per week of
energy expenditure (generally 200 to
300 min per week) of moderate or
higher intensity physical activity is
recommended.
B Moderate
Resistance exercise is also
recommended to play a supportive
role in maintaining strength,
balance, and bone density.
B Moderate
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sive research supporting the finding that sufficient exercise
completed 1 to 12 hours before a fat-rich meal will reduce
postprandial lipemia by 25 to 40%.249–251 The suppression
of postprandial TG can last up to 36 hours after a significant
bout of exercise, e.g.,$400 kcal of exercise orw4 miles of
walking. Some investigators report that women may be
more responsive to reducing postprandial TG with exercise
than men.252 Higher intensity exercise (.60% of maximum
aerobic capacity) appears to be more effective for reducing
postprandial TG than moderate intensity exercise, even
when matched for the same total energy expenditure.253
Exercise and HDL-C
There is a marked variability of HDL-C response
between individuals, with a small 3 to 5% increase in
HDL-C on average having been observed after training,
albeit with a range of results from 25 to 125%.254,255 The
HDL-C response appears to be influenced by baseline
HDL-C, gender, training volume, and, to a lesser degree,
training intensity.255 In general, there are greater HDL-C
responses to exercise training in those who have relatively
low HDL-C and high TG levels.254 Average TG levels are
higher and HDL-C levels lower in men compared to
women,256, which may help to explain the larger mean
HDL-C response to exercise training in men.255
The amount of aerobic exercise needed to produce signif-
icant HDL-C changes is estimated at w1000 to 1500 kcal/
week (i.e.,w7 to 14miles/week ofwalking or jogging).257,258
Resistance training may also generate increases in HDL-C.
There are reports that 6 to 9 weeks of resistance training (8
to 10 exercises, 3 times/week) can significantly increase
HDL-C 4 to 9% in men and women.259,260 Moreover, the
HDL-C response to exercise training is under considerable
genetic influence, with underlying genetic polymorphisms
(e.g., lipoprotein lipase and hepatic lipase) explaining up to
50% of the variation in HDL-C.261,262
LDL-C response to physical activity
Exercise programs have the best chance of reducing LDL-
C when there is associated body fat reduction.24,238,263,264
Most studies evaluating the total-C and/or LDL-C response
to exercise training have found minimal to moderate de-
creases with sufficient exercise volume. Many studies have
used an insufficient volume of exercise or energy expendi-
ture, or failed to account for the effects of other variables
such as changes in fat mass, plasma volume, dietary habits,
or seasonal variation in cholesterol and lipoproteins. When
changes in LDL-C and total-C have been reported, they are
often associated with exercise training programs in which
participants expended considerable more than 1200 kcal/
week.263 Endurance exercise programs producing this level
of caloric expenditure most effective at lowering total-C
and LDL-C in previously untrained individuals, since trained
individuals do not seem to respond, even with extremeincreases in training volume.263 On average, the volume of
exercise training associated with body fat loss (200–
300 min per week of moderate intensity activity) will reduce
LDL-C by 4 to 7%.263,264 The LDL-C response to exercise
training appears to be greatest with higher baseline LDL-
C, greater total energy expenditure of the exercise program,
and more loss of fat mass.242,263,265,266
Few controlled exercise trials have been conducted in
subjects with dyslipidemia, with most evaluating individ-
uals with normal or modestly elevated TG and/or LDL-C.
An often-quoted meta-analysis (of 13 studies) found a non-
significant decrease of ,1% in LDL-C, independent of
changes in body weight.267 This analysis included a wide
range of training modalities (running, swimming, stationary
cycling, dance) and an average training stimulus of
w40 min/session, 3.9 times a week at the higher end of
the range of what is considered moderate intensity exercise.
This volume of exercise, w1600 to 1800 kcal/week,
is insufficient by current recommendations ($2000 kcal/
week) to demonstrate meaningful reductions in LDL-C.See Chart 2 for the Exercise/physical activity
Recommendations.The lifespan–children to seniors
Children and adolescents
Lipid abnormalities and increased lifetime risk of
ASCVD
Although ASCVD events rarely occur in children, the
risk factors and risk behaviors that accelerate development
of ASCVD are present in childhood.268–270 In pathology
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extent of atherosclerosis as age and the number of risk fac-
tors increase.271 The presence and intensity of risk factors
are highly correlated with the extent and severity of athero-
sclerosis. The combined impact of multiple risk factors is
exponentially greater than individual factors alone.271
Furthermore, risk factors measured in childhood and
adolescence are better predictors of the severity of athero-
sclerosis than risk factors measured in young adults.272
Observational data from individuals with genetic muta-
tions that alter atherogenic cholesterol (LDL-C and non-
HDL-C) over a lifetime provide the best evidence relating
dyslipidemia to future probability of ASCVD. Genetic traits
characterized by lifelong elevation of atherogenic choles-
terol are associated with increased age-adjusted rates of
ASCVD related events,273 while those with genetically low
levels of atherogenic cholesterol are associated with few
events and longer life expectancy.11,274 What is not known
is whether achieving the same level of lipid lowering with
medications over decades will offer the same protective
effects as observed in individuals with lifelong lower
cholesterol levels secondary to a genetic mutation.275
Expected lipid values in children and adolescents
Cholesterol levels, including LDL-C and non-HDL-C,
are low at birth, increase in the first two years of life, peak
prior to adolescence and decline during adolescence.276
The expected values for LDL-C, non-HDL-C and apo B
in children ,19 years of age are lower than those in
adults.277,278 Table 7 lists acceptable, borderline-high and
high values for children and adolescents.279
Genetic and acquired conditions associated with
abnormal lipid levels
Present from birth, FH is associated with accelerated
atherosclerosis and early ASCVD events.280 Despite itsTable 7 Acceptable, borderline-high, and high plasma lipoprotein l
adolescents
Category Low, mg/dL* Acceptable, m
TC — ,170
LDL cholesterol — ,110
Non–HDL cholesterol — ,120
Apolipoprotein B — ,90
Triglycerides
0–9 y — ,75
10–19 y — ,90
HDL cholesterol ,40 .45
Apolipoprotein A-1 ,115 .120
Values far plasma lipid and lipoprotein levels are from the NCEP Expert Pane
Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cut points for L
are from the National Health and Nutrition Examination Survey III. Note that va
LDL cholesterol, HDL cholesterol, and non-HDL cholesterol by 38.6; for triglyc
*Low cut points for HDL cholesterol and apolipoprotein A-1 represent appro
represent approximately the 95th and 75th percentiles, respectively.
Taken from: Expert Panel on Integrated Guidelines for Cardiovascular Health an
Blood Institute. Pediatrics. 2011;128(Suppl 5):S213–256.279 Permission to repprevalence and the availability of effective treatment
options, FH is underdiagnosed and undertreated in
both children and adults in the United States and
worldwide.281,282
Youth with FH and other genetic forms of dyslipidemia
often have severe alterations in blood lipids and incur the
highest risk for CVD in early adulthood, yet rarely have
signs or symptoms. This highlights the need for lipid
screening. Affected children can be detected in families
with premature ASCVD when a reliable family history is
available. Often, however, the family history is unavailable,
incomplete or inaccurate.283
In addition to genetic forms of dyslipidemia, acquired
forms commonly occur in children who are overweight or
obese, insulin resistant, and those with moderate to high
risk conditions (Table 8).
Clustering of risk factors in youth greatly accelerates
atherosclerosis.271 Among the most prevalent risk combina-
tions are the use of cigarettes with one other risk factor,
obesity associated with insulin resistance, elevated TG
levels, reduced HDL-C levels, and elevated blood pressure.
The increasing prevalence of obesity in childhood, which is
often continued into adult life, is associated with the same
obesity-related risk factor clustering seen in adults. In 2007,
the International Diabetes Federation launched a new
definition to identify children and adolescents with the
metabolic syndrome (Table 9).284
Risk factor tracking from childhood to adulthood
Elevated levels of cholesterol present during childhood
track moderately well as children mature into adults.285
Correlation is strongest for the highest and lowest levels
of LDL-C. The strongest association of elevated LDL-C
levels with ASCVD risk is evident in children with FH.
Some genetic dyslipidemias require additional risk factors,
such as obesity and insulin resistance, for full expression.ipids and apolipoprotein concentrations for children and









l on Cholesterol Levels in Children. Non-HDL cholesterol values from the
DL cholesterol. Values for plasma apolipoprotein B and apolipoprotein A-1
lues shown are in mg/dL; to convert to SI units, divide the results for TC,
erides, divide by 88.6.
ximately the 10th percentile. The cut points for high and borderline-high
d Risk Reduction in Children and Adolescents; National Heart, Lung, and
rint was obtained.
Table 8 Major risk factors and conditions in children and adolescents
Criteria Moderate risk High risk
Body mass index $95th percentile–96th percentile $97th percentile
Hypertension High blood pressure without medication High blood pressure with medication
Cigarette smoking — Current smoker
HDL-C ,40 mg/dL —
Predisposing medical conditions Kawasaki disease with regressed coronary
aneurysms
Kawasaki disease with current coronary aneurysms
Chronic inflammatory disease* Type I and II diabetes mellitus
HIV infection Postorthotopic heart transplant
Nephrotic syndrome Chronic kidney disease/end-stage renal disease/
postrenal transplant
HDL-C, high-density lipoprotein cholesterol; HIV, human immunodeficiency virus.
*Systemic lupus erythematous, rheumatoid arthritis.
S30 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015Therefore, complete phenotypic expression may be delayed
until adulthood.
Lowering LDL-C and diminished lifetime risk of
ASCVD
Although there is ample evidence that the lesions of
atherosclerosis may begin in childhood, ASCVD is rarely
symptomatic during the first 4–5 decades of life.286 In
adults, efforts to lower atherogenic cholesterol and other
risk factors have resulted in substantial reduction in
ASCVD-related morbidity and mortality.287 Despite thisTable 9 International Diabetes Federation’s definition of the at risk
Age group
(years) Obesity (WC) Triglycerides HDL-C
6–,10† $90th percentile









WC $94 cm for
Europid males

















BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; FPG, fastin
diabetes mellitus; WC, waist circumference.
Diagnosing the metabolic syndrome requires the presence of central obesit
*For those of South and South-East Asian, Japanese, and ethnic South an
$80 cm for women. The IDF Consensus group recognise that there are ethni
to establish risk.
†Metabolic syndrome cannot be diagnosed, but further measurements shoul
lipidemia, cardiovascular disease, hypertension and/or obesity.
‡For clinical purposes, but not for diagnosing the MetS, if FPG 5.6–6.9 mm
tolerance test should be performed.
Taken from: Zimmet P, et al.; IDF Consensus Group. Pediatr Diabetes. 2007;8:2success, ASCVD remains a leading cause of morbidity
and mortality in the adult population. Reducing risk factors
with a healthy diet and lifestyle is the primary intervention
in youth. However, for those at high risk due either to
genetics and/or lifestyle, many have advocated for earlier
identification and treatment with the aim of providing
more effective primary prevention,288–290 including reduc-
tion of all risk factors.291
Recent publications using genome-wide analysis have
demonstrated many alleles that profoundly affect ASCVD




























g plasma glucose; IDF, International Diabetes Federation; T2DM, type 2
y plus any two of the other four factors.
d Central American origin, the cutoffs should be $90 cm for men, and
c, gender and age differences but research is still needed on outcomes
d be made if there is a family history of metabolic syndrome, T2DM, dys-
ol/L (100–125 mg/dL) and not known to have diabetes, an oral glucose
99–306.284 Permission to reprint was obtained.
Jacobson et al NLA Dyslipidemia Recommendations - Part 2 S31cholesterol levels that are higher or lower than the general
population.274,292–294 Individuals with hypobetalipoprotei-
nemia, whose lifelong LDL-C levels may be as low as
10–15 mg/dL, have normal growth, development and
increased longevity.295 Proprotein convertase subtilisin
kexin type 9 (PCSK9) variants resulting in more subtle
LDL-C lifetime lowering to approximately 100 mg/dL
have shown substantial reduction in ASCVD risk as
well.11 Polymorphisms in Niemann-Pick C1-like 1 protein
also result in lower lifetime levels of LDL-C and reduced
ASCVD risk.7,8 Genetic mutations that result in altered
concentrations of TG and TG-rich lipoproteins, such as var-
iants in lipoprotein lipase, apo C3, and apo A5, are also
associated with increased or reduced ASCVD risk, depend-
ing on the direction of the lipid changes.9,294,296–298
Importantly, there is no evidence to suggest that
moderately lower LDL-C levels, such as those that occur
in some genetic mutations, are harmful. Lowering plasma
cholesterol does not decrease intracellular cholesterol
levels, which are maintained by an efficient LDL receptor
homeostatic mechanism.299 In healthy newborns when
brain growth is most rapid, umbilical cord LDL-C levels
are ,40 mg/dL, only rising to levels of approximately
100 mg/dL by 2 years of age.300 Long-term safety data in
youth receiving lipid-lowering medication, however, are
lacking, and evidence from RCTs is based on relatively
small sample sizes.Lipid screening
Who to screen
Screening should be performed in children 2–18 years of
age: 1) in whom one or both biological parents are known
to have hypercholesterolemia or are receiving lipid-
lowering medications; 2) who have a family history of
premature ASCVD in an expanded first-degree pedigree in
men,55 or women ,65 years of age; and 3) whose family
history is unknown (e.g., children who were adopted)
(Table 8). In addition, universal screening of all children,
regardless of general health or the presence or absence of
CVD risk factors, is recommended once between 9 and
11 years of age, with repeat lipid screening at 20 years of
age, or earlier if dyslipidemia is present. The NLA Recom-
mendations for the Patient-Centered Management of Dysli-
pidemia–Part 1 defined adults as individuals $20 years of
age.1
Age of screening
Targeted screening based on family history and presen-
tation should begin at 2 years of age. For universal
screening, 10 years of age (9–11) is the optimal time for
initial lipid testing, with repeat screening at 20 years of age,
or earlier if dyslipidemia is present. Lipid testing during
scheduled clinic visits, such as with childhood immuniza-
tions and well child visits as recommended by the current
American Academy of Pediatrics (AAP) well childschedule (Bright Futures), present other opportunities for
screening.301
Role of family history and risk factors in ASCVD risk
assessment
Risk evaluation should include a family history of early
ASCVD in all first-degree relatives. A family history of
premature ASCVD represents the net effect of genetic,
biochemical, behavioral, and environmental components.
However, reliance on family history alone as a basis for
lipid screening fails to identify as many as 30–60% of
children and adolescents with elevated levels of choles-
terol.302–304 Despite its limitations, the presence of a posi-
tive family history (i.e., a parent, sibling, aunt, uncle or
grandparent with a history of treated angina, MI, percuta-
neous coronary artery catheter intervention procedure,
coronary artery bypass grafting, stroke, or sudden cardiac
death before 55 years of age in a male or 65 years of age
in a female) has been consistently found to increase base-
line risk for ASCVD. Detection of a positive family history
and/or risk factors should lead to evaluation of all family
members, especially the biologic parents, for ASCVD
risk factors. The family history should be updated regularly
as a part of routine pediatric care.
Risk factors and conditions
Children should be regularly screened for major risk
factors and conditions associated with increased ASCVD
risk. Validated methods for risk factor scoring are not
available for patients ,20 years of age.
Normal and abnormal lipid values and children
The AAP305 and AHA306 have established cut points for
plasma lipids, lipoproteins, and apolipoproteins
(Table 7).279 These population-derived values in children
vary from the values defined by the NLA for adults,1 the
latter derived from observational studies and ASCVD out-
comes of RCTs as levels that provide optimum cardiovas-
cular health. Although comparable outcome data are not
available for children, studies are needed to help determine
whether such levels might provide optimum cardiovascular
health for children .2 years of age.
The use of age-appropriate lipid percentiles during
childhood and adolescent growth and development is
supported by the tracking of lipids from youth to adulthood.
Evidence from adult studies that non-HDL-C is a better
independent predictor of ASCVD than LDL-C, is supported
by pediatric data as well.307,308
LDL-C and/or non-HDL-C goals for children
Although long-term outcome data are lacking, the
case for managing children and adolescents based on
their percentiles is strengthened by Mendelian random-
ization studies showing that lower levels of LDL-C and
non-HDL-C may be more advantageous for cardiovas-
cular health, especially if maintained over a life-
time.11,275 Use of percentile-based norms is consistent
S32 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015with cut points for the metabolic syndrome adopted by
the International Diabetes Federation (Table 9).284
Consequently, percentile-based cut points are recommen-
ded and should be considered as the upper limits for
valid therapeutic goal ranges for managing children
and adolescents.279
Testing methods
Use of measured fasting total-C, HDL-C, and TG
allows calculation of LDL-C, which equals the total-C –
[HDL-C 1 TG/5]. Non-HDL-C, an estimate of the
cholesterol content of all atherogenic lipoprotein particles,
is simply total-C minus HDL-C in fasting or non-fasting
blood. A non-fasting blood sample is often more practical
and efficient for calculation of non-HDL-C. If the non-
HDL-C level is $145 mg/dL (95th percentile), then
additional follow-up is recommended. Two fasting lipid
profiles should be obtained and the results averaged for
evaluation of the risk related to apo B-containing
lipoproteins.
Blood samples can be drawn by venipuncture or finger
stick, the latter often preferred by children. If available,
point of care lipid testing has proven reliable and correlates
well with standard laboratory results.309–311
Routine measurement of Lp(a), apo B, apo A1, and
lipoprotein subclasses and their sizes by advanced lipo-
protein analysis is not recommended at this time, but may
be helpful in selected cases. Lp(a) may be useful in the
assessment of children with a strong family history of
vascular disease as well as stroke, both hemorrhagic and
ischemic.312 In individuals with FH, Lp(a) has increasingly
been recognized as a risk accelerator and can be useful in
assessing risk in addition to non-HDL-C and LDL-C
levels.
Selective screening and cascade screening
Prior guidelines focused on selective screening of
children with a family history of hypercholesterolemia
and/or premature CHD.313,314 A 2007 United States
Preventive Services Task Force Report concluded that
‘‘inaccurate and incomplete family history reporting makes
it neither sensitive nor specific enough to use as a predictive
screening tool for childhood dyslipidemia’’.283 Therefore,
although a detailed family history should always be per-
formed, a family history alone is inadequate as an indica-
tion for screening.
Screening the family of an affected FH patient by
systematically identifying first-degree relatives, i.e.,
cascade screening, is recommended to enhance detection
of individuals at risk for FH. Reverse cascade screening,
i.e., screening all first-degree relatives of a child identified
with FH, is also recommended. The adults are at greater
short term risk than the child. Although less evidence exists
for cascade (and reverse cascade) screening in other
dyslipidemias with strong genetic components such as
elevated levels of Lp(a) and familial combinedhyperlipidemia, it is a reasonable consideration when these
conditions are identified in a first-degree relative.
Adverse effects of screening
Recommendations for any screening program should
depend on assessment of benefits and harms, and whether
there are overall health gains.315 The case for screening
children for dyslipidemia appears justified by the benefits
of early education of families with respect to adoption of
healthy lifestyles and the potential of offsetting early
atherosclerosis.316,317 The prevention of premature cardio-
vascular death in youth is best established in FH; the
LDL-C lowering efficacy and safety of treatment with
statins has been demonstrated in children after age 8 for
pravastatin but after age 10 for other approved statins.318
The benefit of lipid-lowering therapy is less clear for other
lipid disorders.
Although the cost of universal screening is unknown, the
current and projected human and fiscal costs of premature
ASCVD are substantial.319 The cost-effectiveness of FH
screening based on targeted screening has been estimated
in Holland.320 Screening family members of a proband
was shown to be effective in the United Kingdom by
increasing the detection rate and cost savings on long-
term health321 and in Australia.322 The cost effectiveness
of reverse cholesterol screening has also been shown.323
There is no evidence of harm from a child being labeled
as a result of disclosure of inherited ASCVD risk factors,324
although there are potential hazards of unsupervised and
overly restrictive diets.279,325 There have been no adverse
psychosocial effects identified during dietary treatment
for hypercholesterolemia.326 With recent health insurance
reforms, the potential issues related to future insurability
have hopefully been negated.
Lifestyle interventions
Diet and other lifestyle interventions have been shown to
be modestly effective in lowering LDL-C in children and
adolescents. A diet that has a total fat content of 25–30% of
calories, saturated fat content of #7% of calories and
dietary cholesterol ,200 mg/day is beneficial in lowering
LDL-C and non-HDL-C. This diet has no adverse effects,
including no adverse effects on growth and development.279
Dietary adjuncts, such as plant stanols or sterol esters
and viscous fibers can enhance LDL-C lowering, particu-
larly in children with FH.95,327 Long-term data are lacking
on the safety and efficacy of plant stanols and sterol esters
in children and adolescents.
In children with elevated TGs, a diet that includes
reduction of refined carbohydrates and sugars, along with a
reduction of saturated fat is recommended.279 When over-
weight/obesity is present, a decrease of total calories is
recommended as part of weight management using multi-
component interventions.328 Increased physical activity,
including increased moderate or higher intensity physical
activity of at least 60 minutes per day is also important.
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tegies should, when feasible, be guided by a registered
dietitian nutritionist. There is limited evidence on the
effectiveness of diet and lifestyle interventions in
improving intermediate or surrogate markers of atheroscle-
rosis, such as carotid intima-media thickness or endothelial
function, although obesity is associated with higher carotid
intima-media thickness in children.329
Pharmacotherapy
There is evidence from clinical trials on children age 10
and above that pharmacologic treatment to lower athero-
genic cholesterol is safe, effective and improves carotid
intima-media thickness. Most of the available evidence
focuses on the relatively short-term use of statins.316 There
is some evidence to support the use of bile acid seques-
tering agents for lowering LDL-C in children and adoles-
cents.330,331 There is limited evidence on the safety and
efficacy of cholesterol absorption inhibitor in children and
adolescents.332
The risks of pharmacologic treatment for elevated
LDL-C or non HDL-C in children appear to be low and
quite similar to the short-term risks in adults. In general,
high intensity statin therapy has not been studied in
children and adolescents and the longest duration studies
have only been 2 years. Thus, the long-term safety of
cholesterol-lowering agents is not specifically known for
children and adolescents.
The major adverse event for statins is the risk of
myositis and potentially for rhabdomyolysis.333,334 The
extent of these side effects in the pediatric population is un-
known, given the limited frequency and duration of statin
use in children, the lack of concomitant or underlying dis-
eases, and the use of multiple drug therapies. Muscle symp-
toms should be monitored in pediatric patients who are
treated with a statin, following a baseline (pretreatment)
fasting glucose or glycated hemoglobin measurement for
those with diabetes risk factors, as well as measurement
of liver enzymes and creatine kinase.279 The NLA updated
its statin safety recommendations in 2014, which offer use-
ful guidance for management of adult and pediatric patients
with statins.334 The primary adverse events for bile acid
sequestering agents are gastrointestinal. These side effects
can often be managed with increased dietary fiber and fluid
consumption. There has been increasing risk for type 2 dia-
betes mellitus in adolescents indicating that adult risk for
statin-associated diabetes should also be considered in chil-
dren, especially in those with diabetes risk factors.335
Target level of lipids for lifestyle intervention and
pharmacologic treatment
The evidence supports that children age 8 years and
above are potential candidates for pharmacologic treatment
for lipid lowering. There is not a strong evidence base to
determine at what level of LDL-C or non-HDL-C treatment
with a pharmacologic agent should be considered. There is
also inadequate evidence regarding target levels fortreatment goals. Those with LDL-C $190 mg/dL are quite
likely to have heterozygous FH with an elevated lifetime
risk for ASCVD.
The National Heart, Lung, and Blood Institute’s Expert
Panel considered the evidence regarding risk for increased
progression of atherosclerotic lesions associated with mul-
tiple risk factors. This led to an algorithm based on additional
risk factors for children and adolescents age 10 and olderwith
LDL-C $160 but ,190 mg/dL and with LDL-C $130 but
,160 mg/dL. This algorithm is presented in Figure 2.279
Decisions on target levels during treatment are a matter of
clinical judgment and can be based on the percentiles for
LDL-C and non-HDL-C presented in Table 7.279
This NLA Expert Panel recommends upper limits for
therapeutic atherogenic cholesterol goal ranges for manag-
ing children and adolescents of 144 mg/dL for non-HDL-C
and 129 mg/dL for LDL-C. However, in patients with FH
for whom these targets are unachievable, an atherogenic
cholesterol reduction of 50% should be the target.286 The
NLA has also endorsed the FH guidance from the Interna-
tional FH Foundation.337
When pharmacologic treatment is initiated, it is impor-
tant to continue lifestyle-based treatment because this
combination is probably more effective than medication
alone and may allow for use of a lower dosage of medication.
At present, there are no clinically useful tests with,
which to monitor the effectiveness of statin therapy, other
than following the LDL-C and/or non-HDL-C levels.
Surrogate testing for atherosclerosis progression, such as
carotid intima media thickness or coronary artery calcium
(CAC), is not recommended at this time, because they are
regarded as investigational modalities.See Chart 3 for the Recommendations for Children and
Adolescents.
Women’s health
Management of dyslipidemia in women
Management of dyslipidemia in women requires consid-
eration of gender-specific differences in cardiovascular
risk, strengths and weaknesses of the available scientific
evidence base, and the potential risks and benefits of lipid-
lowering therapies. The most recent data available indicate
that while the gap is narrowing, more women than men
continue to die annually from CVD.256 Heart disease
remains the leading killer of women. After MI, women
are more likely than men to develop heart failure or die
within 5 years of the event. Women have a higher risk for
stroke than men, with a lifetime risk for initial stroke at
55–75 years of age of 20–21% for women vs 14–17% for
men.338 Women account for nearly 60% of deaths due to
stroke in the United States. Before the age of 75 years,
men experience a higher proportion of events attributable
to CHD, while women experience a higher proportion of
events attributable to stroke.339
Despite the importance of ASCVD as a health concern
for women, they have historically been under-represented
Chart 3 Recommendations for children and adolescents
Recommendations Strength Quality
Universal lipid screening of all children, regardless of general health or the presence or absence of ASCVD risk
factors, is recommended between 9-11 years of age, with repeat lipid screening at 20 years of age, or
earlier if dyslipidemia is present.
E Low
If a child or adolescent patient is screened and has a fasting or non-fasting non-HDL-C level $145 mg/dL,
then additional follow-up is recommended. Two fasting lipid profiles should be obtained and the results
averaged for evaluation of the most appropriate course of action.
E Low
Children at least 2 years of age with the following characteristics should be screened for dyslipidemia:
 One or both biological parents are known to have hypercholesterolemia, or are receiving lipid-lowering
medications
 Have a family history of premature ASCVD in an expanded first degree pedigree (i.e., to include not only
parents and siblings, but also aunts, uncles, and grandparents) in men ,55 or women ,65 years of age
 Consideration should also be given to screening for those in whom family history is unknown (e.g.,
adopted)
B Moderate
Children should be regularly screened for major risk factors and conditions associated with increased ASCVD
risk, but there are no validated methods for risk factor scoring in patients ,20 years of age.
B Moderate
Decisions on target levels during treatment are a matter of clinical judgment, but age-appropriate,
percentile-based cutpoints from the 2011 Expert Panel on Integrated Guidelines for Cardiovascular Health
and Risk Reduction in Children and Adolescents: National Heart, Lung, and Blood Institute should be
considered as the upper limits for therapeutic atherogenic cholesterol goal ranges for managing children
and adolescents:
 Non-HDL-C: 144 mg/dL
 LDL-C: 129 mg/dL
E Low
Cascade screening and reverse cascade screening are recommended to enhance detection of individuals at risk
for FH.
B Moderate
An alternate treatment goal for pediatric FH patients in whom it may not be possible to achieve an LDL-C level
of ,130 mg/dL, is a 50% reduction in LDL-C.
E Low
Diet and other lifestyle interventions, including increased physical activity and weight management when
overweight/obesity is present, are recommended for lowering elevated LDL-C, non-HDL-C, and TG in
children and adolescents. Dietary management strategies should be guided by a registered dietitian
nutritionist whenever feasible.
A High
Children $8 years of age are potential candidates for pharmacologic treatment for lipid lowering. The
following treatment plans can be considered:
 Administer pharmacologic agents, primarily statins, when LDL-C level is $190 mg/dL and/or non-HDL-C is
$220 mg/dL.
 Consider additional risk factors in addition to elevated LDL-C and/or non-HDL-C and follow the treatment
algorithm from the 2011 Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk
Reduction in Children and Adolescents: National Heart, Lung, and Blood Institute.
B Moderate
Statins and bile acid sequestrants are pharmacologic agents with evidence for efficacy and safety in children
and adolescents. There is limited evidence on the safety and efficacy of cholesterol absorption inhibitors in
children and adolescents.
B Moderate
Consideration should be given to measurement of pretreatment fasting glucose or glycated hemoglobin
levels, liver enzymes, and creatine kinase in pediatric patients for whom a statin is prescribed.
E Low
Potential side effects with lipid-altering pharmacotherapy should be monitored in pediatric patients
according to the recommendations from the respective 2014 NLA statin safety task force.
B Moderate
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that have included women, there have been no gender-
specific differences in the observed lipid responses to
statin therapy, with similar reductions in total-C, LDL-C,
and TG, and increases in HDL-C among men and
women.340,341 In studies of primary prevention of ASCVD
there has not been adequate statistical power to draw firm
conclusions from subgroup analyses by gender. Similarly,
no individual secondary prevention trials of lipid-
lowering therapies have been adequately powered to reli-
ably detect gender-specific differences in effect. A recentreview, however, demonstrated that there has been signifi-
cant improvement in the recruitment of women for statin
RCTs from 1990 to 2010.342 In the 1990’s, statin RCTs
of .500 participants included only 18.6% women (95%
CI 16.31–21.13%). By the first decade of the 2000’s
similar-sized trials included, on average, 31.46% women
(95% CI 29.45–32.52%). Although the available data are
limited, the prevalence, morbidity, and mortality of
ASCVD in women make it imperative to consider ap-
proaches to lipid management while the evidence base
expands.
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Although women without previous ASCVD are at lower
absolute short- to intermediate-term event risk compared to
men for a given age, lifetime risk is higher among women,
in part due to longer life expectancy.256 Approximately
70% of MIs in the United States are first events, and
approximately 15% of these will be fatal during hospitali-
zation.343 However, nearly 50% of sudden cardiac deaths
occur outside a hospital and these patients will not have
an opportunity for prevention of recurrent events. Clearly,
primary prevention strategies are critical to reduce mortal-
ity and morbidity for both at-risk women and men.
The lower age-adjusted incidence of ASCVD events in
women compared to men requires that lipid-lowering RCTs
include a large sample size of women to make valid gender-
specific comparisons, and to extend age limits through the
ninth decade of life. The Justification for the Use of Statins
in Prevention: An Intervention Trial Evaluating Rosuvas-
tatin (JUPITER) primary prevention trial included 6801
women and 11,001 men with high-sensitivity C-reactive
protein (hs-CRP) $2.0 mg/dL and LDL-C #130 mg/dL
randomized to rosuvastatin 20 mg vs placebo.344,345 The
primary endpoint was a composite of MI, stroke, hospital-
ization for unstable angina, arterial revascularization, or
ASCVD death. The absolute rates of the primary endpoint
in the rosuvastatin and placebo groups were lower in
women compared to men, even though women tended to
be older and had more ASCVD risk factors than men. How-
ever, the proportional reduction in the primary endpoint
with rosuvastatin was similar and statistically significant
in both women (HR 0.54; 95% CI 0.37–0.80; P 5 .002)
and men (HR 0.58; 95% CI 0.45–0.73; P , .001).
In an accompanying meta-analysis, authors of the
JUPITER gender-specific analysis also considered data
from earlier primary prevention trials with subgroup
analyses in women, including the Air Force/Texas Coro-
nary Atherosclerosis Prevention Study (AFCAPS/Tex-
CAPS), the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial–Lipid Lowering
Trial (ALLHAT-LLT), the Anglo-Scandinavian Cardiac
Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA),
and the Management of Elevated Cholesterol in the
Primary Prevention Group of Adult Japanese (MEGA)
trial, as well as data from the primary prevention patients
in the Prospective Study of Pravastatin in the Elderly at
Risk (PROSPER) and the Heart Protection Study
(HPS).345–351 Compared with placebo, statin therapy
significantly reduced CVD events in women by about
one-third (summary RR 0.63; 95% CI 0.49–0.82;
P , .001; P for heterogeneity 5 0.56) in exclusively pri-
mary prevention trials (AFCAPS/TexCAPS, MEGA, and
JUPITER). When trials that included predominantly pri-
mary prevention (ASCOT-LLA and ALLHAT-LLT) were
analyzed together with the exclusively primary prevention
trials, the summary RR for CVD events was higher and
not statistically significant (0.79; 95% CI 0.59–1.05;P 5 .11; P for heterogeneity 5 0.053). The summary
RR was not materially altered by the inclusion of data
from HPS and PROSPER, although it was significantly
different from unity (0.82; 95% CI 0.69–0.98; P 5 .03).
The summary RR for total mortality was similar when
the 3 exclusively primary prevention trials (n 5 13,154
women, 216 deaths) were considered (0.78; 95% CI
0.53–1.15; P 5 .21) and with the inclusion of data from
predominantly primary prevention trials, but did not
achieve statistical significance. HPS and PROSPER did
not report sex-specific mortality data in the primary pre-
vention arms.
In view of the relatively small numbers of women
previously participating in primary prevention trials,
several other meta-analyses have also been conducted to
examine a possible interaction between gender and the
effects of lipid-lowering therapies on ASCVD outcomes,
and have reported similar results.352–359 The first meta-
analysis conducted by the Cholesterol Treatment Trialists’
(CTT) Collaboration included individual participant data
from 14 statin RCTs with 21,575 women (24%).352 None
of the trials included in the analysis were exclusively pri-
mary prevention trials, although 46% of patients had no es-
tablished ASCVD. The number of events in women was
smaller (1441) compared to the number in men (6316),
but there was a statistically significant reduction in major
coronary events in both women (RR 0.82; 95% CI 0.73–
0.93) and men (RR 0.76; 95% CI 0.72–0.80) without het-
erogeneity of effect by gender (c21 5 2.6; P 5 .1). There
was also a statistically significant reduction in major
vascular events that was similar in women and men. The
relative reductions in the incidence rates for major coronary
and vascular events were similar among participants with
previous history of MI or other CHD and those without
pre-existing CHD. A separate gender-specific analysis of
primary prevention patients was not provided.
Another analysis from the CTT Collaboration examined
26 statin RCTs that included 45,495 women in primary and
secondary prevention trials.355 Women had a lower baseline
ASCVD event rate compared to men, but experienced a
17% (99% CI 10–24%, P , .0001) reduction in major
vascular events per 1 mmol (39 mg/dL) reduction in
LDL-C compared to a 23% (99% CI 20–26%) reduction
per 1 mmol in men. A separate gender-specific analysis
in exclusively primary prevention trials was not reported,
however, the benefit of statin therapy was similar in both
primary and secondary prevention patients in all partici-
pants. In both of these CTT meta-analyses, the point esti-
mates for men and women have been similar, suggesting
that any gender-related differences in event reduction
with statin therapy, if present, are small.
Most recently, the CTT Collaborators conducted a meta-
analysis of 27 primary and secondary prevention RCTs
with 174,249 participants (46,675 [27%] women) to
examine gender differences in the efficacy and safety of
statin therapy.357 The risk of major vascular events in the
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compared with men (4.4% per year) in these trials. Howev-
er, after adjusting for non-gender-related differences in
baseline characteristics, there was no heterogeneity by
gender in the proportional effects of statin therapy in
women (RR 0.84; 99% CI 0.78–0.91; P , .0001) and
men (RR 0.78; 99% CI 0.75–0.81; P , .0001; heterogene-
ity unadjusted P 5 .021, adjusted for baseline characteris-
tics, P for interaction 5 .331) (Fig. 3).357 The
proportional reductions in major vascular events (CHD,
stroke and revascularization) in individuals with no known
history of vascular disease was somewhat greater in men
(RR 0.72; 99% CI 0.66–0.80) than in women (RR 0.85;
99% CI 0.72–1.00; heterogeneity unadjusted P 5 .033,
adjusted P 5 .023) (Fig. 3).357 However, it is difficult to
interpret this finding because there is a relatively large
element of clinical judgment and regional variation in
revascularization procedures.
Another recent study examined gender differences in the
effect of atorvastatin on lipids and cardiovascular outcomes
from the Incremental Decrease in End Points ThroughFigure 2 Dyslipidemia algorithm targeting LDL-C from the 2011 E
Reduction in Children and Adolescents. Dyslipidemia algorithm: target L
results for TC, LDL-C, HDL-C, and non–HDL-C by 38.6; for triglycerid
3 months apart. bPer Table 9-9 (in the original publication from which
aged 10 years and older with defined risk profiles. cIn a child with an
CHILD-2-LDL may be abbreviated. CVD, cardiovascular disease; FHx
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
Integrated Guidelines for Cardiovascular Health and Risk Reduction
Institute. Pediatrics. 2011;128 Suppl 5:S213–S256.279 Permission to reAggressive Lipid Lowering trial, the Treating to New
Targets (TNT) trial, the Stroke and Prevention by Aggres-
sive Reduction in Cholesterol Levels trial, the Collaborative
Atorvastatin Diabetes Study (CARDS), ASCOT, and the
Atorvastatin Study for Prevention of Coronary Heart Dis-
ease Endpoints in Non-Insulin-Dependent Diabetes Melli-
tus (ASPEN).360 In all studies combined, there were 30,000
men and 9173 women. Major cardiovascular events
occurred in 3083 (10.3%) men and 823 (9.0%) women.
Lipid changes were similar between genders, and major
cardiovascular events were associated with quintiles of
on-treatment LDL-C in both men and women. LDL-C
was also a significant predictor of risk for stroke in women,
but not in men.
Thus, the available primary prevention data support the
conclusion that women and men of comparable ASCVD
risk experience similar reductions in events and all-cause
mortality when treated with statin therapy, particularly
when adjusted for age and comorbidities. Therefore,
women without ASCVD should undergo ASCVD risk
assessment and the intensity of lipid-lowering therapyxpert Integrated Guidelines for Cardiovascular Health and Risk
DL cholesterol. Values are in mg/dL. To convert to SI unit, divide
es, divide by 88.6. aObtain FLPs at least 2 weeks but no more than
this figure was taken), use of drug therapy is limited to children
LDL-C level of .190 mg/dL and other risk factors, a trial of the
, family history; FLP, fasting lipid profile; HDL-C, high-density
RF, risk factor; TG, triglyceride. Taken from: Expert Panel on
in Children and Adolescents; National Heart, Lung, and Blood
print was obtained.
Figure 3 Meta-analysis of effects of statin on cardiovascular disease in primary and secondary prevention of women and men. Effects on
major vascular events per 1-0 mmol/L reduction in LDL cholesterol, subdivided by history of vascular disease and sex. *Adjusted hetero-
geneity test calculated from a Cox model that corrects for nonsex differences between women and men (appendix pp 12–14; this appendix
is in the original publication from which this figure was taken). †Results for men with no known history of vascular disease included 189 vs
264 first major vascular events from participants recruited into WOSCOPS in which information on previous stroke was not available. CI,
confidence interval; RR, rate ratio. Taken from Cholesterol Treatment Trialists’ (CTT) Collaboration, et al. Lancet. 2015;385:1397–
1405.357 Permission to reprint was obtained.
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and treatment of men, as described in the NLA Recom-
mendations for the Patient-Centered Management of
Dyslipidemia–Part 1.1
Use of risk calculators in primary prevention in
women
The Expert Panel of the NLA Recommendations for the
Patient-Centered Management of Dyslipidemia–Part 1
recommended quantitative risk scoring as an option for
patients with 2 major ASCVD risk factors, in the absence
of any high or very high risk conditions, to facilitate
treatment decisions.1 Thresholds recommended for high
risk categorization were $10-year risk for a hard CHD
event using NCEP ATP III Framingham, $15% 10-year
risk for a hard ASCVD event using the 2013 ACC/AHA
Pooled Cohort Equations, and $45% risk for CVD using
Framingham long-term, 30-year risk. An examination by
Cavanaugh-Hussey et al.361 of the online ATP III risk
calculator, in which the investigators entered data into
the online tool for men and women in 5-year intervals
from ages 30 to 75 years with varying risk factors, demon-
strated that few women exceeded the treatment thresholds
set by the ATP III guidelines and thus few qualified forintensive ASCVD prevention, regardless of risk factor
burden. The 2013 ACC/AHA Pooled Cohort Equations
differ from the earlier ATP III Risk Calculator because
they include 1) diabetes as a risk indicator, 2) fatal and
nonfatal stroke as endpoints, and 3) sex- and race-
specific equations for non-Hispanic white (NHW) and
AA women and men.362,363 These changes have important
implications for risk assessment for women, because
stroke constitutes a greater proportion of ASCVD events
in women, and often occurs earlier in life than for men.
However, clinicians should be aware that the Pooled
Cohort Equations have been shown to overestimate risk
in some analyses.364–367 Additional studies in which these
equations are applied to different, more contemporary co-
horts, are needed to further examine the potential for over-
estimation of risk.
The Reynolds Risk Score has been found, in some
analyses, to improve the accuracy of ASCVD risk
assessment in women.368 It incorporates family history,
hs-CRP, and glycated hemoglobin, as well traditional
risk factors.368 However, in a recent analysis of calibration
and discrimination among multiple cardiovascular risk
scores in the Multi-Ethnic Study of Atherosclerosis
(MESA) population, the Framingham Risk Score and
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events in women by 8 to 67%, while the Reynolds Risk
Score underestimated risk by 21%.367 Due to these
challenges in ASCVD risk assessment, some experts
have recommended calculation of a patient’s risk by
multiple algorithms when considering initiation of statin
therapy in both women and men.369
Secondary ASCVD prevention in women
The CTT Collaborators’ 2015 meta-analysis evaluating
gender-specific effects of statin therapy observed no het-
erogeneity by gender in the proportional effects of statin
therapy overall in women and men after adjusting for non-
gender related differences in baseline characteristics.357
The proportional reductions in major vascular events in par-
ticipants with a definite history of ASCVD were similar
among women compared to men (heterogeneity unadjusted
P 5 .098, adjusted P 5 .431) (Fig. 3).357 Results demon-
strated that, for each 1 mmol/L reduction in LDL-C, statin
therapy reduced major vascular events by about 20%, major
coronary events by 25%, coronary revascularizations by
25%, and ischemic stroke by just under 20%, and that these
proportional reductions were similar in men and women,
even though women had lower absolute cardiovascular
risk. Non-gender related differences in baseline characteris-
tics (e.g., differences in average age between men and
women) accounted for any apparent differences between
women and men in the magnitude of proportional reduc-
tions achieved with statin therapy.
In a meta-analysis by Kostis et al.358 that included
40,275 women from 18 primary and secondary prevention
RCTs with gender-specific outcomes, a statistically signif-
icant decrease in the primary endpoint was observed among
women in both primary and secondary prevention.
Although the benefit was more pronounced in secondary
prevention trials (odds ratio [OR] 0.78; 95% CI 0.72–
0.91; P , .0001) than in primary prevention trials (OR
0.85; 95% CI 0.75–0.98; P 5 .0209), the difference was
not statistically significant (P for interaction 5 .3397).
Consistent with findings from the most recent CTT meta-
analysis,357 there was a statistically significant benefit of
statin therapy at all levels of risk in women, with a more
pronounced benefit in low-risk groups (Fig. 4).358 Statisti-
cally significant reductions in stroke (OR 0.74; 95% CI
0.55–0.99; P 5 .0396) and CHD events (OR 0.78; 95%
CI 0.67–0.94; P 5 .0090) were also observed for women
(Fig. 5).358 All-cause mortality was lower with statin ther-
apy in both men and women without significant interaction
by gender (P for interaction 5 .4457).
The results summarized above support the conclusion
that women with manifest ASCVD benefit from statin
therapy. As outlined in the NLA Recommendations for the
Patient-Centered Management of Dyslipidemia–Part 1,1
statin therapy should be a consideration for patients at
very high risk of either gender, even if the pre-treatment
levels of atherogenic cholesterol are below the treatmentgoals. Results from recent trials in which additional benefit
has been observed when atherogenic cholesterol levels have
been lowered to values well below treatment goal thresh-
olds further support this conclusion.370–372
Lipid-altering therapy in women with diabetes
Diabetes type 1 and type 2 increase the risk for ASCVD
in both men and women compared to individuals without
diabetes.373 A meta-analysis of 37 prospective, multina-
tional studies demonstrated that the RR for fatal CHD
associated with diabetes is nearly 50% higher in women
(RR 3.5; 95% CI 2.7–4.5) than it is in men (RR 2.06;
95% CI 1.81–2.34) after adjustment for major coronary
risk factors, although the absolute ASCVD risk may remain
lower in women with diabetes compared to men with dia-
betes.374 Clinical trials in patients with diabetes375–377
and subgroup analyses of patients with diabetes in larger
trials378–381 have demonstrated significant effects of
lipid-lowering therapy (primarily statins) on CVD out-
comes. The 3 statin outcome trials exclusively in patients
with diabetes (CARDS, the German Diabetes and Dialysis
Study, and ASPEN) included a total of 1898 women
(32–46% of total participants) but no gender-specific
outcomes analyses were reported. The CTT meta-analysis
of 14 statin RCTs with 18,686 patients with diabetes
(6165 women) demonstrated a 9% proportional reduction
in all-cause mortality (RR 0.91; 99% CI 0.82–1.01;
P 5 .02) and a 13% reduction in vascular mortality (RR
0.87; 99% CI 0.76–1.00; P 5 .008) for each 1 mmol/L
reduction in LDL-C.382 Although the number of events
was lower in women (833) than in men (2414), the
proportionate reduction in risk was similar (women:
RR 0.81; 95% CI 0.67–0.97 vs men: RR 0.78; 95% CI
0.71–0.86) and there was no heterogeneity by gender
(c2 5 0.1; P for interaction 5 .7).
Women with diabetes type 1 or type 2 are considered to
be at high to very high risk for an ASCVD event, depending
on the presence of ASCVD or the presence of additional
major risk factors. Moderate to high intensity statin therapy
should be considered for these at-risk women matching
intensity of therapy to the level of ASCVD risk.
Non-statin lipid-lowering therapy in women
There is limited gender-specific evidence for the benefit
of non-statin drugs in the prevention of ASCVD events.
The available clinical trial outcomes evidence for use of
non-statins in women, and gaps in the evidence, are
summarized below.
Bile acid sequestrants
The only outcomes trial of bile acid sequestrants
has been the Lipid Research Clinics Coronary Primary
Prevention Trial.383,384 The Lipid Research Clinics
Coronary Primary Prevention Trial was a multicenter,
randomized double-blind study that examined the efficacy
of the bile acid sequestrant, cholestyramine, for reducing
Figure 4 Meta-analysis of benefit of statin therapy in primary prevention according to level of risk in women. Forest plot for the primary
event by level of risk participants in each study in women. Solid squares represent the odds ratios in individual trials and have a size
proportional to the inverse of variance. Horizontal lines, diamonds, and squares denote the 95% confidence intervals (CIs) for individual
trials and summary statistics. Pooled estimates were computed from a random effects model. Taken from: Kostis WJ, et al. J Am Coll
Cardiol. 2012;59:572–582.358 Permission to reprint was obtained.
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men, and did not enroll any women.
Cholesterol absorption inhibitor
The Study of Heart and Renal Protection evaluated
simvastatin 20 mg and ezetimibe 10 mg vs placebo in
9270 patients (3470 women, 37%) with chronic kidney
disease (3023 on dialysis and 6247 non-dialysis
dependent).385 Treatment with simvastatin and ezetimibe
produced a 17% proportional reduction in major athero-
sclerotic events compared to placebo (RR 0.83; 95% CI
0.74–0.94; log-rank P 5 .0021). Although the point
estimates were nearly identical in men and women, there
were a smaller number of events in women (324)
compared to men (821) with wider CIs for women that
crossed the line of unity.
In the Improved Reduction of Outcomes: Vytorin
Efficacy International Trial (IMPROVE-IT), 18,144 pa-
tients (approximately 24% women) with acute coronary
syndrome ,10 days were randomized to simvastatin
40 mg daily plus ezetimibe 10 mg or placebo.370 The pri-
mary outcome endpoint was a composite of cardiovascular
death, MI, hospital admission for unstable angina,
coronary revascularization ($30 days after randomiza-
tion), or stroke. Combination therapy with simvastatinand ezetimibe was associated with a statistically signifi-
cant 10% relative reduction in the primary endpoint (HR
0.90; 95% CI 0.84–0.97; P 5 .003) compared to simva-
statin alone. Gender was pre-specified for subgroup
analysis. Women trended toward greater benefit compared
to men, and although CIs were wider than in men, they did
not cross the line of unity. For men, the CIs were tighter,
but crossed unity. However, this gender difference (i.e.,
treatment by gender interaction) did not achieve statistical
significance.
Niacin
The earliest large RCT of niacin, the Coronary Drug
Project, included 1119 patients (men only) with prior
history of electrocardiogram-documented MI randomized
to niacin and 2789 randomized to placebo.386 With a mean
follow-up of 15 years, nearly 9 years after termination of
the trial, mortality in the niacin group was 11% lower
than in the placebo group (52.0 vs 58.2%; P 5 .0004).
The HDL-Atherosclerosis Treatment Study was an angio-
graphic trial of 160 patients (21 women) with known
CHD who were randomized to 1 of 4 treatment groups:
simvastatin plus niacin, antioxidants, simvastatin–niacin
plus antioxidants, or placebo.387 Endpoints included angio-
graphic evidence of a change in coronary stenosis and the
Figure 5 Meta-analysis of sex-specific coronary heart disease (CHD) and stroke outcomes. Forest plots for CHD event and for stroke in
women and men. Solid squares represent the odds ratios in individual trials and have a size proportional to the inverse of variance. Hor-
izontal lines, diamonds, and squares denote the 95% confidence intervals (CIs) for individual trials and summary statistics. Pooled estimates
were computed from a random effects model. Taken from: Kostis WJ, et al. J Am Coll Cardiol. 2012;59:572–582.358 Permission to reprint
was obtained.
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stroke, or revascularization), but the trial was not powered
to detect a significant difference in clinical outcomes. The
average stenosis progressed by 3.9% with placebo, 1.8%
with antioxidants (P 5 .16 for the comparison with the
placebo group), and 0.7% with simvastatin–niacin plus
antioxidants (P 5 .004) and regressed by 0.4% with simva-
statin–niacin alone (P , .001). The frequency of the clin-
ical end point was 24% with placebo, 3% with
simvastatin–niacin alone, 21% in the antioxidant therapy
group, and 14% in the group given simvastatin–niacin
plus antioxidants. The number of women included in this
study was small and no gender-specific analysis of out-
comes was reported.
In the Atherothrombosis Intervention in Metabolic Syn-
drome with Low HDL/High Triglycerides: Impact on
Global Health Outcomes (AIM-HIGH) study, 3414 patients
(14.8% women) with established ASCVD were randomized
to extended-release niacin 1500 to 2000 mg per day or
matching placebo.388 All patients received simvastatin, 40
to 80 mg per day plus ezetimibe 10 mg per day, if needed,
to maintain an LDL-C level of 40 to 80 mg/dL. The
primary end point was the first event of the composite of
death from CHD, nonfatal MI, ischemic stroke, hospitaliza-
tion for an acute coronary syndrome, or symptom-driven
coronary or cerebral revascularization. Following a
36-month follow-up, the trial was terminated due to lack
of clinical benefit from the addition of extended-release
niacin to statin therapy. There was no heterogeneity by
gender (P 5 .75) but the small number of women resulted
in wider CIs.
The Heart Protection Study 2–Treatment of HDL to
Reduce the Incidence of Vascular Events (HPS2-THRIVE)
was a large trial conducted in 25,763 patients with
established vascular disease (4444 women, 17.3%).389 Par-
ticipants were randomly assigned to receive 2 g of
extended-release niacin and 40 mg of laropiprant or a
matching placebo daily. The primary outcome was the first
major vascular event (nonfatal MI, CHD death, stroke, or
arterial revascularization). Women randomized to niacin
and laropiprant had an excess of events compared to those
randomized to placebo with a trend toward harm compared
to a trend toward benefit in men, but this gender difference
was not statistically significant (c2 3.21, P 5 .07).
Fibrates
Gemfibrozil has shown benefits in both primary and
secondary prevention of CHD events when administered as
monotherapy in patients with dyslipidemia, but RCTs have
included only men. The Helsinki Heart Study was a
primary prevention trial with gemfibrozil in 4081 asymp-
tomatic middle-aged men with elevated levels of non-HDL-
C.390 Cardiac endpoints were reduced by 34% (95% CI
8.2–52.6; P , .02) in patients randomized to gemfibrozil
compared to placebo. In the Veterans Affairs High-
Density Lipoprotein Intervention Trial, 2531 men with a
history of CHD, low HDL-C levels, and low LDL-C levelswere randomly assigned to gemfibrozil 1200 mg/day or
matching placebo.391 CHD events were reduced with gem-
fibrozil by 11% for every 5 mg/dL (0.13-mmol/L) increase
in HDL-C (P 5 .02). There are no available trials of gem-
fibrozil as monotherapy or in combination with statins that
have included women. However, because current guidelines
recommend fenofibrate as the preferred fibrate for patients
with hypertriglyceridemia or mixed dyslipidemia due to the
potential for adverse effects when statins are combined
with gemfibrozil, the lack of evidence in women is likely
of little consequence.
Two large RCTs of fenofibrate have included women as
well as men. The Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) study included 9795
participants 50–75 years of age with type 2 diabetes
mellitus and not taking statin therapy at study entry.392
Approximately 22% of patients had pre-existing ASCVD
and 3657 (37.3%) of study participants were women. Pa-
tients were randomly assigned to micronized fenofibrate
200 mg daily or matching placebo; however, over the
follow-up period of 5 years, more patients allocated to
placebo (17%) than fenofibrate (8%; P , .0001) initiated
combination therapy, primarily with statins. The primary
outcome was CHD events (CHD death or non-fatal MI);
the outcome for pre-specified subgroup analyses including
gender was total cardiovascular events (composite endpoint
of cardiovascular death, MI, stroke, and coronary and
carotid revascularization). The reductions in total-C and
LDL-C with fenofibrate therapy were greater in women
than in men (P , .001). Men and women experienced
similar increases in HDL-C and reductions in TGs. There
was an 11% relative reduction in the primary endpoint of
coronary events in all participants (men and women) allo-
cated to fenofibrate, but this difference did not achieve
statistical significance (HR 0.89; 95% CI 0.75–1.05;
P 5 .16). Women had a statistically significant 18.9% rela-
tive reduction in the pre-specified secondary endpoint of
total cardiovascular events (9.5% for placebo vs 7.7% for
fenofibrate; P 5 .04), but the study was not adequately
powered for gender-specific analysis and CIs were
wide.392 There was no significant treatment by gender inter-
action (P for interaction 5 .3). When analyses were
adjusted for on-trial statin uptake (drop-in) and covariates
(including ethnicity, age, diabetes duration, BMI, waist-
to-hip ratio, systolic and diastolic blood pressures, smok-
ing, prior CVD, prior coronary revascularization, hyperten-
sion, microvascular disease, baseline total-C, LDL-C,
HDL-C, creatinine, homocysteine, dyslipidemia, microal-
buminuria, macroalbuminuria, use of metformin, and use
of sulfonylurea), allocation to fenofibrate reduced total
CVD events in women by 30% (95% CI 8–46%;
P 5 .008). There was no statistical evidence of heterogene-
ity of effect by gender (P for interaction 5 .17). There were
no significant gender-specific differences in adverse effects
of treatment with fenofibrate, including cancer incidence,
rhabdomyolysis, pancreatitis, pulmonary embolism, or pro-
gression to end stage renal disease requiring dialysis.393
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(ACCORD) trial included both primary and secondary
prevention patients (women 1694, men 3824) with type 2
diabetes (glycated hemoglobin $7.5%), LDL-C 60–
180 mg/dL, HDL-C ,55 mg/dL for women and blacks,
HDL-C ,50 mg/dL for all other groups, and TG ,750 mg/
dL if patients were not on lipid-lowering therapy or
,400 mg/dL if they were on therapy.394 Participants were
randomized to simvastatin plus fenofibrate 160 mg or pla-
cebo and followed for a period of 4.7 years for the primary
outcome, and 5.0 years for all-cause death. The primary
outcome was the first occurrence of a major ASCVD event
(nonfatal MI, nonfatal stroke, or death from cardiovascular
causes). Secondary outcomes included the combination of
the primary outcome plus revascularization or hospitaliza-
tion for congestive heart failure; a combination of a fatal
coronary event, nonfatal MI, or unstable angina; nonfatal
MI; fatal or nonfatal stroke; nonfatal stroke; death from
any cause; death from cardiovascular causes; and hospital-
ization or death due to heart failure. There was no statistical
difference between study groups in the primary endpoint of
major ASCVD event (P 5 .32) or with respect to any sec-
ondary outcome. There was a possible interaction accord-
ing to lipid subgroup, with a possible benefit for patients
with both a high baseline TG level and a low baseline level
of HDL-C (P for interaction 5 .057). Of concern, gender-
specific analyses suggested heterogeneity in treatment ef-
fect according to sex, with a benefit for men and possible
harm for women (P for interaction 5 .01).393 However,
no heterogeneity by gender was observed in the subset
with high TG and low HDL-C. As noted above, no
gender-specific safety signal was observed in the larger
FIELD trial of fenofibrate in patients with diabetes, so the
significance of the treatment by gender interaction in
ACCORD is of uncertain clinical relevance.
Omega-3 fatty acids/fish oil
JELIS evaluated the effects of statin plus highly purified
EPA ethyl ester 1800 mg daily (600 mg three times a day
after meals) or usual care (no EPA) in 18,645 Japanese
primary and secondary prevention patients.134 The study
sample was predominantly women (n 5 12,789, approxi-
mately 68%) and the trial examined the incremental benefit
of EPA added to low-dose statin therapy (dosage was due to
ethnic differences in the susceptibility to statin effects). The
primary endpoint was CHD events, including sudden car-
diac death, fatal and non-fatal MI, and other non-fatal
events including unstable angina pectoris, angioplasty,
stenting, or coronary artery bypass grafting. At the mean
follow-up of 4.6 years, 262 (2.8%) patients in the EPA
group experienced the primary endpoint compared to 324
(3.5%) patients who did not receive EPA—a 19% relative
reduction in major coronary events (P 5 .011). Unstable
angina and non-fatal coronary events were also signifi-
cantly reduced in the EPA group, but sudden cardiac death
and CHD death did not differ between groups. In primary
prevention patients with no history of coronary arterydisease, EPA treatment reduced major coronary events by
18%, but this difference did not achieve statistical signifi-
cance (P 5 .132). There was no heterogeneity by gender
for the relative reduction in the occurrence of CHD event,
although women had a lower absolute risk of events
compared to men.
Non-statin recommendations
In general, the recommendations for the use of non-
statin drug therapy for the management of dyslipidemia in
women are the same as those outlined in the NLA
Recommendations for the Patient-Centered Management
of Dyslipidemia–Part 11: ‘‘Nonstatin drug therapy (choles-
terol absorption inhibitors, bile acid sequestrants, fibric
acids, long-chain omega-3 fatty acid concentrates, and
nicotinic acid) may be considered for patients with contra-
indications for, or intolerance to, statin therapy’’ with the
following special considerations for women. Although clin-
ical outcomes data for the use of bile acid sequestrants in
women are lacking, results from RCTs enrolling both
men and women report that bile acid sequestrants reduce
atherogenic cholesterol levels in both men and women to
a similar degree. Furthermore there has been no evidence
of gender-specific harm associated with the use of this class
of medication.
Women treated with niacin and laropiprant in HPS2-
THRIVE had an excess of events and a trend toward harm,
compared with men.389 However, clinicians might consider
niacin when other agents are not options for women with
elevated levels of atherogenic cholesterol, based on the
hypothesis that niacin might lower risk in those with
residual elevation in non-HDL-C with or without
concomitant statin therapy. Because levels of atherogenic
cholesterol were low in the AIM-HIGH and HPS2-
THRIVE trials prior to initiation of niacin therapy, the
hypothesis that adding niacin to statin therapy in those
with residual elevation in atherogenic cholesterol levels
has not been adequately tested.
Fenofibrate is the preferred fibrate for use in women
with severe hypertriglyceridemia for prevention of pancre-
atitis, although gender-specific evidence is limited and the
benefit for cardiovascular risk reduction is uncertain.393
Fenofibrate might also be considered for those with
elevated TG and non-HDL-C, particularly in patients with
low HDL-C and/or diabetes mellitus (because of microvas-
cular benefits392,395). Prescription dosages of omega-3 fatty
acids may be used in women for management of severe
hypertriglyceridemia for prevention of pancreatitis.134 The
benefit of omega-3 fatty acid therapy for ASCVD preven-
tion in a US population has not yet been established.
Gender differences in adverse events of lipid-
lowering therapy
Adverse events of lipid-lowering therapy are commonly
reported and often lead to discontinuation in health care
settings,396,397 but as with RCT evidence for benefits of
lipid-lowering therapy in women, there is a paucity of
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in adverse events. Meta-analyses have shown no evidence
for an increase in non-cardiovascular mortality, specifically
no increase in cancer, associated with statin therapy in
women.340,351,352,355,357
In the TNT trial, 23.5% (n 5 1902) of the 8099 patients
enrolled were women.398 Significant gender differences in
the baseline patient characteristics were noted. Women
were older, had a higher BMI, had more hypertension and
diabetes, were more symptomatic with angina, had a lower
estimated glomerular filtration rate, and had higher levels of
total-C, TG, and HDL-C. Rates of myalgia were slightly
higher among women than men in TNT, but similar be-
tween treatment groups for both women and men. Discon-
tinuations due to statin-related adverse events in both the
high and low intensity groups were higher in women than
in men, but the overall rates were low. Persistent elevations
in hepatic transaminases were more frequent in women
than men assigned to atorvastatin 80 mg (2.6% women,
0.9% men).
In JUPITER, women (n 5 6801) were significantly
older, more likely to have hypertension and the metabolic
syndrome, and had a higher BMI and lower estimated
glomerular filtration rate compared to men (n 5 11,001)
(all differences P , .001).345 Gender-specific comparisons
were provided for a number of adverse events in rosuvasta-
tin and placebo groups. The rates of muscle-related adverse
events were similar among women and men regardless of
assignment to statin or placebo. Both women and men
experienced a small but statistically significant increase in
glycated hemoglobin (P , .0001). There was a higher inci-
dence of physician-reported diabetes in women treated with
rosuvastatin vs placebo (HR 1.49; 95% CI 1.11–2.01;
P 5 .008). There was, however, no heterogeneity by gender
for new diabetes (P for interaction 5 .16). There were no
gender-specific differences in any serious adverse event,
rhabdomyolysis, cancer, transaminase elevation .3 times
the upper limit of normal on consecutive visits, or hemor-
rhagic stroke. The Pravastatin or Atorvastatin Evaluation
and Infection Therapy–Thrombolysis in Myocardial Infarc-
tion 22 (PROVE IT-TIMI 22) trial that included 21.9%
(n 5 911) women demonstrated no statistically significant
gender differences in premature discontinuation of statin
therapy, increases in hepatic transaminases, elevated crea-
tine kinase levels, or myalgias/myositis.399 Compared to
men (n 5 3251), women were older, more likely to have
diabetes or hypertension, and had a higher incidence of his-
tory of congestive heart failure. In the CTT analysis of the
safety and efficacy of statins by gender, women were older
compared to men (mean age 65.1 vs 61.8 years) and had a
higher prevalence of hypertension (60.0 vs 47.5%) and of
diabetes (23.6 vs 17.8%).357
In the study of atorvastatin by Hsue et al.,360, which
examined results from the Incremental Decrease in End
Points Through Aggressive Lipid Lowering trial, TNT,
the Stroke and Prevention by Aggressive Reduction in
Cholesterol Levels trial, CARDS, ASCOT, and ASPEN,in 4 of the 6 trials, discontinuation rates due to adverse
events were higher in women than in men, but only 1 trial
reported a significant treatment by gender interaction. Rates
of myalgia were higher in women than men in both the
statin and placebo groups.
It has been estimated that women tend to be at 1.5–1.7
times greater risk for clinically significant adverse drug
reactions compared to men.400,401 Gender differences in
body fat, muscle mass, quantities of cytochrome P450
(CYP450) metabolic enzymes, coenzyme Q10 levels, pain
perception and reporting of adverse reactions, and underly-
ing genetic factors (polymorphisms associated with
CYP450 isoenzymes, drug transporters, or myocyte meta-
bolism) may all play a role in the increased frequencies
of adverse drug effects reported by women.401 Women
with ASCVD or at high ASCVD risk are likely to be older
with more comorbidities, which may play a role in slowing
statin metabolism and clearance. Polypharmacy in elderly
women, particularly with drugs known to be metabolized
via the CYP450 enzyme system, can lead to drug-drug in-
teractions and increased systemic exposure to statins with
resulting adverse events.
In summary, clinicians should be particularly aware of
the potential for elevated adverse events with taking statins
in women, particularly glucose elevations and myalgia,
which may be due to differences in age, comorbidities,
BMI and body fat, muscle mass, and polypharmacy. Further
study of genetic polymorphisms will provide insight into
gender-specific differences in statin-related drug reactions.See Chart 4 for the Recommendations for Women’s
Health.
From pregnancy to menopause
In general, preventing ASCVD requires the practice of
universal principles common to both genders, however the
diagnosis and treatment of lipid disorders in women poses
some unique challenges. The clinical lipidologist needs to
view lipids from the perspective of ASCVD prevention
throughout awoman’s lifespan. The fact that clinical ASCVD
(particularly CHD) events occur an average of 10 years later
in women compared to men has created an unfortunate
misconception that prevention is less of a concern forwomen.
The clinical lipidologist must have a working knowledge of
issues important in managing primary and secondary
dyslipidemias in women. Of particular concern are women
with genetic dyslipidemias, lipids during pregnancy, women
with polycystic ovarian syndrome (PCOS), the use of
contraception, and lipid changes during menopause with
and without the use of sex hormone therapy (HT).
Pregnancy
Detection, management, and treatment of dyslipidemia in
pregnancy
Average values of total-C, LDL-C, HDL-C, and TG
measured in 8700 women (mean 6 standard deviation age
Chart 4 Recommendations for women’s health
Recommendations Strength Quality
In general, women should be treated according to the NLA Recommendations for Patient-Centered
Management of Dyslipidemia – Part 11 with the following special considerations.
A High
First-line cholesterol-lowering drug therapy, unless contraindicated, is moderate- to high-intensity statin.
The statin dosage may be increased or the patient switched to a more efficacious agent, if goal levels of
atherogenic cholesterol are not achieved. Statin therapy should be a consideration for patients at very high
risk (i.e., ASCVD or diabetes mellitus with $2 major ASCVD risk factors), even if the pre-treatment levels of
atherogenic cholesterol are below the treatment goals.
A High
Non-statin drug therapy with cholesterol absorption inhibitor, bile acid sequestrant, fibric acid, nicotinic
acid, or long-chain omega-3 fatty acid concentrates (the latter currently indicated only for very high TG)
may be considered for women with contraindications for, or intolerance to, statin therapy, or in
combination with statin therapy for patients who need additional lowering of atherogenic cholesterol to
achieve treatment goals.
A High
Women taking statins may be at increased risk for certain adverse events, particularly myalgia. Variations
between men and women observed in clinical studies of statin-related myalgia incidence may have been
related to differences in age, comorbidities, body composition, and polypharmacy.
B Low
S44 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015of 29.5 6 5.8 years) without cardiovascular co-morbidities,
and who did not develop gestational diabetes or preeclamp-
sia as they were followed before, during, and after
pregnancy are shown in Figure 6.402 A steady rise
throughout pregnancy occurs in the major lipoprotein
lipids, and these levels peak near term. The lipid changes
favor the availability of fuel for fetal development and
also reflect increasing insulin resistance for the mother as
pregnancy progresses through term. In uncomplicated or
‘‘normal’’ pregnancies, neither total-C nor TG exceeds
250 mg/dL at any time during pregnancy.
The cholesterol and TG responses shown in Figure 7 are
from a population that also included women with compli-
cated pregnancies, such as hypertension and preeclamp-
sia.403 As in the normal pregnancy population, the values
for total-C and TG rose to term. However average values
were near or exceeded 300 mg/dL in this analysis.403 TGFigure 6 Lipid values in normal pregnancies (n 5 8700). HDL,
high-density lipoprotein; LDL, low-density lipoprotein; TC, total
cholesterol; TG, triglyceride. Taken from Wiznitzer A, et al. Am
J Obstet Gynecol. 2009;201:482.e1–e8.402 Permission to reprint
was obtained.levels exceeding 250 mg/dL are associated with pregnancy
complications, including pregnancy-induced-hypertension,
preeclampsia, gestational diabetes, and large for gestational
age babies.404 When values exceed 250 mg/dL, this should
alert that an obstetrical complication is more likely and the
woman may have had pre-pregnancy dyslipidemia.
Optimum strategies for detection and treatment of dyslipi-
demia in pregnancy
Many women have significant undiscovered dyslipide-
mia before pregnancy, and this is often associated with
conditions that put them at risk for obstetrical and fetal
complications. The AAP/American College of Obstetri-
cians and Gynecologists Guidelines for Perinatal Care has
no set lipid screening recommendations, however they do
suggest that lipid assessment should be performed at the
annual visit for all age groups.405 By current guidelines,Figure 7 Pregnancy lipids and lipoproteins in normal and
complicated pregnancies. TG, triglyceride. Taken from Potter
JM, Nestel PJ. Am J Obstet Gynecol. 1979;133:165.403 Permission
to reprint was obtained.
Table 10 Evaluation of hypertriglyceridemia
Medical history
 Personal and family history of high TG, diabetes,
pancreatitis, thyroid issues
 Medicinal history, prescription, supplements
- Antipsychotics, alpha interferon, beta-blockers, bile
acid sequestrants, hormones, protease inhibitors,
retinoids, thiazides, steroids
Lifestyle issues: alcohol use, smoking, activity status
 Laboratory testing
- Renal function including urine protein
- Thyroid function
- Liver enzymes
- Fasting glucose, glycated hemoglobin
Physical examination
 BMI and waist size
 Blood pressure
 Skin examination (xanthomata, acanthosis nigricans)
BMI, body mass index; TG, triglyceride.
Table 11 Lipid-lowering agents and pregnancy categories*







Omega-3 fatty acids C
Colesevelam B
Mipomersen B
*These categories were removed from drug labeling per the new
Food and Drug Administration labeling guidance effective June 30,
2015, and instead drug labeling will include a summary of the risks
of using a drug during pregnancy and lactation, discussion of data sup-
porting that summary, and relevant information to assist health care
providers in treatment decisions for pregnancy (8.1), lactation (8.2),
and females and males of reproductive potential.411
†Categories previously established by the Food and Drug Adminis-
tration to indicate the potential of a drug to cause birth defects if used
during pregnancy: B, animal reproduction studies have failed to
demonstrate a risk to the fetus and there are no adequate and well-
controlled studies in pregnant women; C, animal reproduction studies
have shown an adverse effect on the fetus and there are no adequate
and well-controlled studies in humans, but potential benefits may war-
rant use of the drug in pregnant women despite potential risks; and X,
studies in animals or humans have demonstrated fetal abnormalities
and/or there is positive evidence of human fetal risk based on adverse
reaction data from investigational or marketing experience, and the
risks involved in use of the drug in pregnant women clearly outweigh
potential benefits.
Jacobson et al NLA Dyslipidemia Recommendations - Part 2 S45patients with the following risk factors should be screened
for gestational diabetes at the first prenatal visit: 1) BMI
$30 kg/m2, 2) personal history of gestational diabetes, or
3) known impaired glucose metabolism (e.g.,
prediabetes).405
The best time to screen for dyslipidemia is prior to
pregnancy. When that has not occurred, lipid values may be
collected with other routine laboratory tests once pregnancy
is diagnosed, and monitored during the pregnancy if values
are elevated. Follow-up should be performed routinely after
the pregnancy is over, usually by the 6-week postpartum
visit. Women who experience complications of pregnancy,
or who gain excessive weight before or during pregnancy
are more likely to have abnormal lipid profiles.406 These
risk factors should be queried in the diagnosis and manage-
ment of dyslipidemia.
Evaluation of hypertriglyceridemia in pregnancy
Evaluation and classification of hypertriglyceridemia in
a woman preparing for pregnancy, or when she is pregnant,
are not different from such evaluation in the non-pregnant
woman (Table 10). As noted previously, a TG elevation by
the third trimester of pregnancy is to be expected.
Women with gestational diabetes and/or preeclampsia
during pregnancy often have abnormal TG levels before
they become pregnant. TG values in women with gestational
diabetes may exceed 300 mg/dL and levels become higher
as pregnancy progresses. A common reason for hyper-
triglyceridemia is poorly controlled or undiscovered
diabetes mellitus. Most women with gestational diabetes
have glucose intolerance that begins early in pregnancy.
Some have type 2 diabetes mellitus that was unrecognized
prior to pregnancy, and about 10% have circulating islet cell
antibodies and/or HLA DR3 or DR4 and are at increased
risk for type 1 diabetes mellitus post-delivery.407,408
Treatment and monitoring of dyslipidemia associated with
pregnancy
Appropriate diet, weight management, and exercise
always apply with regard to health management during
pregnancy. For women on lipid-lowering medication prior
to pregnancy, all, except bile acid sequestrants, are
currently recommended to be stopped in preparation for
pregnancy.409,410 Table 11 provides the classification of
approved lipid-lowering agents that had previously been
used by the FDA.411 The FDA has classified statins as cate-
gory X; however, as of June 30, 2015, the FDA mandated
new labeling changes (see below).411 These changes should
provide better guidance for clinicians as to the risk/benefit
for use in pregnant women, lactating women, and women
with reproductive potential. The new labeling changes
will be used immediately for all new submissions for pre-
scription drugs and biological agents. Previously approved
drugs will switch to the new labeling gradually.
Controlling glycemia is central to managing TG eleva-
tions in women with gestational diabetes or diabetes
present prior to pregnancy. Very high TG ($500 mg/dL,with risk for pancreatitis) may be treated with diet/
lifestyle management plus omega-3-fatty acids and/or
with fenofibrate or gemfibrozil early in the second trimester
based on clinical judgment (class C medication).412 It is
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tored every trimester, or within 6 weeks of an intervention
to evaluate for compliance, response, and drug/dose adjust-
ment. Women who have high TG, pregnancy-induced-
hypertension, preeclampsia, gestational diabetes, and/or
albuminuria during their pregnancy need to be evaluated
for residual cardiometabolic risk post-pregnancy. Hyper-
cholesterolemia during pregnancy, especially in women
with FH, may be treated with bile acid sequestrants. Cole-
sevelam is preferred because it is category B. Women with
FH may also be treated with LDL apheresis.
Pregnancy and FH
Patients with FH have elevated levels of total-C, non-
HDL-C and LDL-C, and an increased risk of premature
atherosclerosis.413 The increase in atherogenic lipoproteins
that occurs during pregnancy may exacerbate this risk.
Total-C and LDL-C have been observed to progressively
rise during pregnancy in individuals with and without
FH.414 Women with FH exhibit a greater rise in LDL-C
during pregnancy than those without FH.409
Despite high circulating levels of atherogenic lipopro-
teins in FH patients, data from several studies do not
support an association between maternal lipid levels and
maternal or perinatal outcomes.404 In addition, FH preg-
nancy outcome studies have not shown an increased risk
of preterm delivery, infant low birth weight, or congenital
malformations as compared to women without FH.415
There is a theoretical risk related to repetitive discontinua-
tions of statin therapy in FH patients who have multiple
pregnancies. However, results from registry analyses do
not support this hypothesis.415 There is no consistent
evidence indicating that the incidence of adverse cardiovas-
cular outcomes in those with FH is related to the gender of
their FH parent.416
The United Kingdom National Institute of Care
Excellence, the NLA Expert Panel on Familial Hypercho-
lesterolemia, and the International Familial Hypercholes-
terolemia Foundation have provided recommendations that
emphasize several principles.337,413,417 Women with FH
who wish to conceive should generally stop statin and other
systemically absorbed lipid drug therapy a minimum of one
month, and possibly as long as 3 months, prior to attempted
conception337,413,417 (opinion only). Theoretically water
soluble statins have less risk. Women who conceive while
on a systemically absorbed lipid drug should be advised
to immediately stop the medication, although the likelihood
of fetal complications in such patients is low. These patients
should undergo an appropriate fetal assessment, and typi-
cally not re-start lipid drug therapy until they have
completed lactation. LDL apheresis may be considered
during pregnancy in homozygous FH patients, or in those
heterozygous FH patients with ASCVD. Results from
several small cohort studies suggest that this procedure is
safe and effective in pregnant FH patients.418,419
Adolescent and adult female FH patients should be
counseled about the need for appropriate birth control whenstatins are prescribed. When contraception is advised for
female FH patients, low estrogen-containing oral agents,
intra-uterine devices and barrier techniques are the
preferred methods.337 Intra-uterine devices and barrier tech-
niques are preferable for those older than 35 years of age.337
Most women with FH should not be treated with drug
therapy during pregnancy. However, those with ASCVD or
homozygous FH may require pharmacotherapy. Among
currently available lipid drugs, only bile acid sequestrants
and mipomersen are considered to be reasonable therapeu-
tic options (pregnancy class B on the old FDA classification
system). Mipomersen is FDA-approved only for those with
homozygous FH. The efficacy and safety of PCSK9
inhibitors during pregnancy has not been determined.
Based upon the complexities of clinical decision-making
in pregnant FH patients, referral to a clinical lipidologist is
recommended.
Recommendations for women with dyslipidemia who are
breast feeding
Appropriate heart healthy diets and exercise should be
continued following pregnancy during breast feeding, and if
weight loss is needed, a nutrition consultation with a
registered dietitian nutritionist is advised. Patients with
FH can receive bile acid sequestrants (colesevelam), and
drug therapy for severe hypertriglyceridemia may be
continued (as described in the previous section for preg-
nancy). For women with high TG, it is advisable to avoid
estrogenic oral contraception, even with late breast feeding.
As a modifiable behavior, lactation may favorably affect
women’s future risk for cardiovascular and metabolic
diseases.420 In the Nurse’s Health Study there was a 23%
lower incidence of MI in women in their 60s if they had
breast fed.421 In the Women’s Health Initiative observa-
tional study, among postmenopausal women, increased
duration of lactation earlier in life was associated with
lower prevalence of hypertension, diabetes, hyperlipidemia,
and ASCVD.422 About 1 of 3 women will ovulate with pro-
longed breast feeding and therefore women should be
advised to use contraception throughout the breast feeding
period.
Long term ASCVD implications of complications in
pregnancy
Dyslipidemia, obesity, and/or presence of the metabolic
syndrome or diabetes mellitus before pregnancy, high risk
status such as PCOS,423 as well as hypertension during
pregnancy are important for future ASCVD risk. Pre-
eclampsia and pregnancy-induced-hypertension are not
only associated with post-pregnancy cardiovascular risk
factors such as hypertension, dyslipidemia, and obesity
for the mother, but have also been linked to epigenetic
factors influencing subsequent infant health.424 Much evi-
dence exists to suggest that developmental programming
by pathologies during pregnancy influences both fetal
development and future cardiometabolic risk of the fetus
and the mother.425,426
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PCOS affects 7–22% of reproductive-age women. Un-
derstanding how to diagnose and treat PCOS is important
to the clinical lipidologist.427 Women with PCOS are at
increased risk for metabolic syndrome, diabetes mellitus,
and complications of pregnancy,423 as well as endometrial
cancer.428 Nearly all women with PCOS have insulin resis-
tance and this is aggravated by obesity and pregnancy.
They are also at greater risk for obstetrical complications
even if they have not developed overt metabolic
syndrome.423Criteria for diagnosis of PCOS
The term PCOS emanates from the characteristic
morphology of the ovary (polycystic ovary), which is
referred to as a string of pearl sign. This occurs because
many follicles are ‘suspended’ in similar stages of devel-
opment usually, although not always, arranged around the
perimeter of the ovary. The follicles surround an endocri-
nologically active inner stroma that secretes androgens.
There are several standard sets of criteria for diagnosis of
PCOS—the most widely used are the Rotterdam criteria
(Table 12427).429 The Rotterdam PCOS criteria are based
upon the presence of at least 2 of the following: androgen
excess (measured in the blood or clinically in the form of
hirsutism, acne, and/or androgenic alopecia), ovulatory
dysfunction, and/or the presence of polycystic ovaries as-
sessed by vaginal probe ultrasound.429 The Androgen
Excess Society insists that some form of androgen excess
is necessary for the diagnosis of PCOS.427 The spectrum
of the condition can include persons mildly to severely
affected with androgen excess, sometimes bordering on se-
vere virilization. Women with PCOS frequently have dysli-















AE-PCOS, Androgen Excess and PCOS society; NIH, National In-
stitutes of Health; PCOS, polycystic ovarian syndrome.
NIH, both oligomenorrhea and clinical/biochemical hyperandro-
genism; Rotterdam, any 2 of the previously mentioned criteria; AE-
PCOS, presence of clinical and/or biochemical hyperandrogenism and 1
other criterion.
*8 or fewer menses per year.
†Acne, or hirsutism, or androgenic alopecia.
‡Ovarian volume .10 mL and/or .12 follicles ,9 mm in at least 1
ovary.
Adapted from: Wild RA, et al. J Clin Endocrinol Metab. 2010;95:2038–
2049.427 Permission to reprint was obtained.including at the onset of menses and throughout the adoles-
cent years.
Screening for associated dyslipidemia in PCOS
This NLA Expert Panel recommends that all patients
with PCOS, regardless of age should undergo initial lipid
and diabetes screening, typically with fasting glucose or
glycated hemoglobin.430 The panel also recommends more
frequent follow-up screening (at least every 2 years) if
initial values are normal, because women with PCOS are
at increased risk for dyslipidemia as they age. For those
with dyslipidemia, we recommend that the lipid targets
should be both non-HDL-C and LDL-C, as discussed in
Part 1 of the NLA Recommendations for the Patient-
Centered Management of Dyslipidemia.1 As is the case
for other conditions associated with increased risk for
ASCVD, the accuracy of risk assessment using prediction
equations is uncertain for women with PCOS, but, in gen-
eral, the approach to risk stratification and atherogenic
cholesterol treatment goals for women with PCOS should
be the same as described for all patients with dyslipidemia
in the NLA Part 1 Recommendations.1
Treatment of dyslipidemia in PCOS
Therapeutic management of dyslipidemia in PCOS
should be focused on reversing all components of the
metabolic syndrome through diet, exercise, and medication,
if needed.431 Metformin is frequently used to improve insu-
lin sensitivity and is low cost, and relatively safe. However,
metformin is not first line therapy for ovulation induction in
PCOS women who desire pregnancy.432 First-line therapy
for ovulation induction through reducing insulin resistance
is lifestyle modification. Weight loss should be targeted in
all overweight/obese women with PCOS.432,433 All lipid-
lowering medications, including statins, have been used
in women with PCOS, to treat the demonstrated lipid dis-
turbances. However, it is necessary to educate women on
the importance of pregnancy avoidance with some lipid
lowering agents (Table 11).411
Unique challenges for women with PCOS
Therapy for PCOS is complicated because of several
patient concerns, including: cosmetic–to reduce unwanted
hair growth that, for some, is debilitating; menstrual
control–to improve fertility and to reduce endometrial
cancer risk; and metabolic–to control or prevent diabetes
and to lower ASCVD risk.
The standard medication used to control menses, reduce
endometrial and ovarian cancer risk, and reduce hirsutism
is the combined oral contraceptive (COC). The more
estrogenic oral contraceptives are effective for hirsutism
control. Spironolactone may be used concomitantly
because of its ability to reduce 5-alpha reductase, which
is responsible for converting circulating testosterone into
the more potent locally active dihydrotestosterone. The
major risk associated with COC use is thrombotic, and
therefore these agents should not be used in women
S48 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015$35 years of age who smoke because of additive stroke and
MI risk. Persons with a family history positive for
thrombotic disorder should be evaluated for genetic risk
factors prior to using oral contraceptives.
In general, the dyslipidemia of PCOS is a result of
insulin resistance. The HDL-C level is often reduced,
hepatic TG production is increased, and there is often a
predominance of small, dense LDL particles, particularly
when a woman with PCOS is obese. Depending upon,
which COC is used, the TG level may increase (sometimes
to more than 500 mg/dL), HDL-C may increase, and
calculated LDL-C may decrease.432
Lipid changes with different forms of contraception
COC can have estrogenic, progestational, androgenic,
anti-estrogenic, and anti-androgenic effects. All formulations
reduce risk for endometrial and ovarian cancer.435 The major
risk associated with their use is thrombotic, including venous
and arterial events. Women with comorbidities, older age,
and, most importantly, current smokers, are at greater risk
for cardiovascular events.434 There are 2 types of estrogen
(ethinyl-estradiol and mestranol) used in the United States.
Different doses of estrogen within the COC are available
and a higher dose carries greater risk.435 Most contain
#35 mg of ethinyl-estradiol and there are multiple types of
progestin in the COCs available today.
The estrogen contained in COC will frequently increase
TG and HDL-C, and lower LDL-C.436 Androgenic proges-
tins (such as norgestrel and levonorgestrel) can raise
LDL-C and lower HDL-C. The other progestational agents
are usually lipid neutral. COCs with low dose norethindrone
can lower LDL-C and raise HDL-C. Desogestrel (third
generation) raises HDL-C and lowers LDL-C. The more es-
trogen a COC contains, the greater TG raising-effect it will
generally have; these agents may cause severe hypertrigly-
ceridemia in women with high baseline TG.437 Transdermal
or vaginal contraceptives (estrogen plus progestin) do not
have a lower thrombotic risk in comparison to COC, but
transdermal contraceptives are less prone to producing
clinically important elevations in TG concentration.438,439
Implantable and injectable progestin forms of contra-
ception are very efficacious for preventing pregnancy and
are used especially for women at risk of noncompliance.440
Progestin only-containing oral contraceptives are available
and may be used if estrogenic preparations are contraindi-
cated. They are, however, associated with greater risk for
breakthrough bleeding and are not as effective for contra-
ceptive purposes.
Lipid changes during menopause
The natural changes in lipids and apolipoproteins in
women transitioning through the menopause years are
shown in Figure 8.441 Both LDL-C and apo B increase in
the few years prior to menopausal symptoms, peak, and
then plateau. HDL-C tends to decrease after menopause.
The changes that occur are presumed to be related in part
to declining ovarian estradiol production, although shiftsin body composition, body fat distribution and other age-
related physiologic changes are also likely contribu-
tors.441,442 It is important to note that the absolute risk
for ASCVD increases substantially during the menopause
transition for women. Women with abnormal risk factors
prior to menopause are more likely to have these factors
worsen. In particular, the prevalence of metabolic
syndrome increases and changes in body fat distribution
occur, shifting toward a pattern of greater central and
intra-abdominal adipose storage.443,444
Current recommendations for menopausal sex HT
Menopausal sex HT is primarily indicated to control
menopause-related quality of life issues. It should not be
prescribed for prevention or treatment of vascular diseases.
Because sex HT increases risk for thrombosis, there is a
black box warning on oral estrogen preparations for women
with known coronary artery disease, thromboembolic
disorders, or who have had a cerebrovascular accident.
When a woman is identified as a potential candidate for sex
HT for quality of life improvement due to moderate-to-
severe menopausal symptoms, appropriate risk stratification
is an important tool for minimizing future risk.445
Results from the Women’s Health Initiative Trial suggest
that women at higher risk for ASCVD events (e.g.,
dyslipidemia or presence of the metabolic syndrome) are
more likely to have even higher risk when they take oral
menopausal sex HT (Table 13).445 This appears to be due to
increased intravascular thrombotic activity and is evident in
the first year of therapy. In general, prescribing the lowest
effective dose of sex HT is recommended, but doses lower
than 0.3 mg of oral conjugated estrogen given at night will
not control hot flashes for most women. This dose is, how-
ever, protective against bone loss.446 Transdermal or
vaginal delivery may be associated with fewer adverse
events than the oral route.447 Vaginal and transdermal prep-
arations also have smaller effects on clotting factors, lipid
metabolism, inflammatory biomarkers, and sex hormone-
binding globulin synthesis. Results from observational
studies, although limited in number, suggest that trans-
dermal delivery may be associated with less risk of venous
thromboembolism and stroke than oral estrogen.448
See Chart 5 for the Recommendations for Pregnancy to
Menopause.
Older patients
According to the World Health Organization, most
developed countries have accepted the chronological age
of 65 years as the definition of ‘‘elderly’’.449 Statistical data
from the AHA and American Stroke Association indicate
that about 80% of people who die from CVD are
$65 years of age. Among those who are 60–79 years of
age, 69.1% and 67.9% of men and women, respectively,
have CVD (CHD, heart failure, stroke or hypertension,
and some with a combination of these). Among those
$80 years of age, the figures are 84.7% and 85.9% of
Chart 5 Recommendations for pregnancy to menopause
Recommendations Strength Quality
Women should be screened for dyslipidemia before pregnancy or as part of the routine obstetrical laboratory
examination.
E Low
For women taking lipid-lowering medications prior to pregnancy, all, except bile acid sequestrants, should be
stopped when the woman becomes pregnant, or is trying to become pregnant.
B Moderate
Women should be educated on the importance of pregnancy avoidance when lipid-altering therapies other
than bile acid sequestrants are used.
A Moderate
Total-C and TG levels in women with normal pregnancies should not exceed 250 mg/dL. If they do, the
clinician should consider and evaluate preexisting or acquired medical or obstetrical conditions, including
hypothyroidism, chronic kidney disease, liver disease, uncontrolled diabetes mellitus, or preeclampsia.
A Moderate
Hypercholesterolemia during pregnancy and breast feeding, especially in women with FH, may be treated with
bile acid sequestrants.
B Low
Women with FH may be treated with LDL apheresis during pregnancy and breast feeding. A Low
Very high TG ($500 mg/dL) may be treated during pregnancy with diet/lifestyle management plus
prescription omega-3 fatty acids; fenofibrate or gemfibrozil may be administered beginning early in the
second trimester, based on clinical judgment. These agents may be used during breast feeding.
B Low
PCOS is a high-risk condition for dyslipidemia, metabolic syndrome, and obstetrical complications of
preeclampsia, hypertension, diabetes, and premature delivery. All patients with PCOS, regardless of age,
should undergo initial lipid and diabetes screening and more frequent follow-up screening is
recommended, even if initial values are normal.
A Moderate
The approach to risk stratification and atherogenic cholesterol treatment goals for women with PCOS should
be the same as described for all patients with dyslipidemia in the NLA Recommendations for Patient-
Centered Management of Dyslipidemia – Part 1 (Jacobson 2015).
A Moderate
Therapeutic management of dyslipidemia in PCOS should focus on diet, exercise, and lipid-lowering
medication, if needed. Use of metformin should also be considered to lower TG and reduce insulin
resistance.
A Moderate
Contraceptive choice impacts dyslipidemia. COC should generally not be used by women$35 years of age who
smoke because of additive stroke and MI risk.
A High
Sex HT should not be used for prevention or treatment of ASCVD. A High
Menopausal sex HT is an option for treatment of significant menopause symptoms during menopause
transition for women at minimal risk for ASCVD.
A Moderate
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and stroke w16.4% of deaths attributable to CVD. The
average age of first heart attack is 65.0 years in men and
71.8 years in women, and nearly 70% of first strokes are
in patients $65 years of age.256
ASCVD risk assessment in older patients
All current scoring systems that assess ASCVD risk
reflect the progressive increase in absolute risk that occurs
with advancing age, likely reflecting an age-related increase
in atherosclerotic plaque burden.However, population norms
often do not apply to individual patients. Application of
average risk scores for age to specific patients may lead to
miscalculation of risk and inappropriate consideration of
drug therapy.450 The ACC/AHA Pooled Cohort Risk Equa-
tion3was applied forASCVD risk assessment to 4854Rotter-
damStudy participants with amean age of 65 years.366 Using
$7.5% 10-year risk as the threshold for consideration of
initiation of moderate or high intensity statin therapy,
96.4% of men and 65.8% of women were potential candi-
dates for such therapy. In this population the average pre-
dicted vs observed cumulative incidence of ASCVD events
was 21.5% vs 12.7% for men and 11.6% vs 7.9% in women,
reflecting poor calibration of risk in this European sample.366A 1999 AHA Scientific Statement on ASCVD Risk Assess-
ment suggested that when risk scoring is used to adjust the in-
tensity of risk factor management in elderly patients, RR
estimates, which eliminate the age factor and focus on the
major risk factors, might bemore useful than absolute risk es-
timates.450 This approach allows providers to risk stratify and
compare patients of the same age and select those at highest
RR for the most aggressive treatment strategies.450 Results
from some studies suggest that serum lipids partially lose
their predictive power for relative ASCVD risk prediction
in the elderly.451 Avariety of reasons exist for this, including
the increased number of co-morbidities among patients of
advanced age.
In another study of Rotterdam study participants, 2028
patients underwent electron beam tomographic imaging of the
epicardial coronary arteries and CAC scores were reported
using Agatston’s method.452 During a mean follow-up of
9.2 years there were 135 hard coronary events. Subjects
were classified into low (,10%), intermediate (10–20%)
and high (.20%) 10-year coronary risk using a Framingham
refitted risk model. The model was extended by CAC and re-
classification percentages were calculated. Reclassification
into high or low risk categories was greatest in those classified
as intermediate risk. A total of 52% of men and women were
Figure 8 Patterns of LDL-C (A), apo B (B), HDL-C (C), and apo A1 (D) among women in menopausal transition in the Study of
Women’s Health Across the Nation. apo, apolipoprotein; CI, confidence interval; FMP, final menstrual period; HDL-C, high-density lipo-
protein cholesterol; LDL-C, low-density lipoprotein cholesterol. Taken from Matthews KA, et al. J Am Coll Cardiol. 2009;54:2366–
2373.441 Permission to reprint was obtained.
S50 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015reclassified into either higher or lower risk categories based
upon their CAC score. Empirically derived CAC cutoffs at,
which subjects were reclassified into either high or low risk
categories were 615 and 50 Agatston units, respectively.452
CAC is reported to be present in .50% of middle-aged
US residents, and the probability of CAC is .90% by age
70 years.453–456 Although measurement of CAC provides a
more accurate means of CHD risk assessment than the use
of traditional risk factor-based algorithms, the cost of the
test, lack of widespread availability, and absence of studies
linking results with outcomes is a limiting factor in its im-
plementation in older patients. Nevertheless, when such
testing is available it may be a valuable addition to CHD
risk assessment, particularly in older patients.
Value of statin therapy in older patients
The CTT Collaboration meta-analysis of data from 26
randomized controlled primary and secondary prevention
trials of statin therapy in 170,000 subjects examined the RRof fatal or non-fatal MI, percutaneous coronary intervention
or bypass grafting, stroke and new cancer diagnosis, and
included subgroup analyses of those#65,.65 to#75, and
.75 years of age.355 The latter two groups included 4032
and 885 subjects respectively, comparing either statin ther-
apy or more intensive statin therapy vs control or less inten-
sive statin therapy. The RR for those .65 to #75 years of
age was 0.78 (95% CI 0.74–0.83) and for those .75 years
of age was 0.84 (95% CI 0.73–0.97). No significant effects
on cancer incidence or cancer death were observed.355
Secondary prevention studies
Lipid-lowering therapy in older patients is a valuable
adjunct to secondary prevention of ASCVD. Few studies
have specifically addressed the use of lipid-lowering therapy
in older patients, although many statin studies have included
subjects between the ages of 65 and 75, and have demon-
strated similar relative risk reduction (RRR) in older and
younger individuals. One study that specifically focused on
Table 13 CHD risk in the Women Health Initiative hormone
therapy trials (estrogen plus progestin and estrogen alone)









,130 0.66 (0.34–1.27) .03
$130 1.46 (1.02–2.10)
LDL-C/HDL-C ratio
,2.5 0.60 (0.34–1.06) .002
$2.5 1.73 (1.18–2.53)
hs-CRP (mg/dL)
,2.0 1.01 (0.63–1.62) .16
$2.0 1.58 (1.05–2.39)
Metabolic syndrome 2.26 (1.26–4.07) .03
No metabolic syndrome 0.97 (0.58–1.61)
CI, confidence interval; HDL-C, high-density lipoprotein choles-
terol; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density
lipoprotein cholesterol.
Adapted from: Wild RA, Manson JE. Semin Reprod Med. 2014;32:433–
437.445 Permission to reprint was obtained.
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70–82 years of age with a history of, or risk factors for,
vascular disease. A meta-analysis of 19,569 subjects aged
65–82 years from9 secondary statin RCTs showedRRRs and
absolute risk reductions (ARRs) of 22% and 3.1%, respec-
tively, in all-cause mortality, 30% and 2.6% in CHD mortal-
ity, 26% and 2.3% in non-fatalMIs, and 30%RRR in need for
revascularization (ARR was not reported).457,458
A 25%/1.7% RRR/ARR in stroke risk was also reported
in this meta-analysis (Table 14).458 However, in studies that
reported stroke risk, it was favorable only in the Long-Term
Intervention with Pravastatin and the Cholesterol and
Recurrent Events studies. It was not reported separately
in the Scandinavian Simvastatin Survival Study, HPS,
PROVE IT study, and the Study Assessing Goals in the
Elderly. The RRR for stroke was not significantly different
with statin vs placebo in the TNT study and PROSPER.458
Primary prevention studies
Results from a meta-analysis of 8 statin primary preven-
tion trials in individuals $65 years of age including
AFCAPS/TexCAPS; ALLHAT; ASCOT-LLA; CARDS;
JUPITER; MEGA; and PROSPER are shown in
Figure 9.459 This analysis included 24,674 subjects (42.7%
female; mean 6 standard deviation age 73 6 2.9 years
and follow up 3.5 6 1.5 years), treated with statin therapy
vs placebo, and examined the incidence of all cause death,
cardiovascular death, MI, stroke, and new cancer onset.
Statin therapy was associated with an RR for MI of 0.61
(95% CI 0.43–0.85; P 5 .003). Stroke incidence
in ASCOT-LLA, CARDS, JUPITER, MEGA and
PROSPER had an RR favoring statin therapy of 0.76(95% CI 0.63–0.93; P 5 .006). PROSPER did not
demonstrate RRR (1.03; 95% CI 0.73–1.45), and the Forest
plots showed that the RRR crossed the line of identity in
ASCOT-LLA (0.80; 0.58–1.11) and CARDS (0.60; 0.30–
1.19), indicating that stroke benefit was limited to JUPITER
and MEGA. The RRR was similar for most studies, but not
all of the original trials were powered to evaluate stroke
alone. There was no difference in the risk of all cause death,
cardiovascular death, or cancer incidence.459
Statin safety in older patients
Biases in reporting side effects
Although there have been no definite signals in RCTs to
suggest a higher incidence of side effects in older vs
younger populations treated with statins, the use of RCTs
for this purpose has limitations. Observational studies often
report a higher incidence of side effects than RCTs. Patients
entering RCTs and experiencing side effects during run-in
periods, or exhibiting conditions that predispose to side
effects are often excluded. Validated inquiry instruments
that assess for harm may not be employed. Other issues
including definition of adverse events, selective reporting of
outcomes, and publication bias may affect the reported
incidence of side effects.335
Myalgia
It is generally reported that older individuals have a
higher incidence of statin-associated myalgia than younger
patients.460–463 It is unclear whether this is related to
decreasing muscle mass that occurs during aging; polyphar-
macy, common among older patients that increases the risk
for drug-drug interaction; a loss in the function of drug
metabolizing enzymes; or a combination of these fac-
tors.463 Results from a study based on the Understanding
Statin Use in America and Gaps in Education Internet sur-
vey showed more muscle side effects in older patients, and
that older patients were more likely to discontinue a statin
due to muscle side effects.464
Diabetes
As reviewed in the NLA Task Force on Statin Safety –
2014 Update, clinical trial data, including meta-analyses,
suggest a modest, but statistically significant increase in the
incidence of new-onset type 2 diabetes with statin vs no
statin use and with use of higher vs lower intensity statin
use.356 However, because of the well-established benefits
for ASCVD risk reduction with statin use, there have
been no recommendations to change clinical practice with
regard to statin use other than recommending the measure-
ment of glycated hemoglobin or fasting glucose in patients
at elevated risk for diabetes. In JUPITER, which included
patients with a median (interquartile range) age of 66.0
(60.0–71.0) years, patients with at least 1 major diabetes
risk factor were at higher risk for developing diabetes
than patients without a major diabetes risk factor. However,
the cardiovascular and mortality benefits exceeded the







RRR%/ARR% CHD Events RRR%/ARR%
Stroke
RRR%/ARR% Comment
4S53 S20–40 vs PL 65–70 (1021) 34/6.2* 43/6.0 34/13.3 NR YCV admissions by 21%
33/7.1†
LIPID54 P40 vs PL 65–75 (3514) 21/4.5 24/2.9* 26/3.3 12/1.3
CARE55 P40 vs PL 65–75 (1283) NR 45/4.5 32/9*
39/6.7‡
40/2.9 32% RRR/5.2% ARR for
PCI/CABG
HPS56 S40 vs PL 70–80 (5806) NR NR 18/5.1‡ NR 9.2% ARR in primary end
point in patients
75–80 y (n 5 1263)
PROSPER57 P40 vs PL 70–82 (5804) NS 24/0.9 19/2.1‡ NS 25% [ cancer risk with P40
PROVE-IT
TIMI 2258
A80 vs P40 $70 (634) NR NR 40/8 LDL-C ,70 vs
LDL-C $70 mg/dL
(in death/MI/UAP*)
NR AE rate similar to young
TNT59 A80 vs A10 65–75 (3809) NS NS 19/2.3* (A80 vs A10) 21/0.9-NS [LFTs w A80 vs A10
SAGE60 A80 vs P40 65–85 (893) 67/2.7 67/0.9 based
on 8 deaths
29/3.1‡ (P 5 .11) Too few to
compare
[LFTs w A80 vs P40
Meta-
analysis61
65–82 (19,569) 22/3.1* 30/2.6 17/2.1‡ 26/2.3 NFMI 25/1.7 30%YPCI/CABG
A, atorvastatin; AE, adverse events; ARR, absolute risk reduction; CABG, coronary artery bypass grafting; CARE, The Cholesterol and Recurrent Events; CHD, coronary heart disease; CV, cardiovascular; HPS,
Heart Protection Study; LDL-C, low-density lipoprotein cholesterol; LIPID, Long-Term Intervention with Pravastatin in Ischaemic Disease; LFTs, liver function tests; Ml, myocardial infarction; NFMI, nonfatal
myocardial infarction; NR, not reported; NS, not significant; P, pravastatin; PCI, percutaneous coronary intervention; PL, placebo; PROSPER, PROspective Study of Pravastatin in the Elderly at Risk; PROVE IT-
TIMI 22, Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22; S, simvastatin; w, with; RRR, relative risk reduction; SAGE, Study Assessing Goals in the Elderly;






































Figure 9 Relative risk (RR) for myocardial infarction and stroke from randomized trials comparing statins vs placebo in older subjects
without established cardiovascular disease. Gray squares represent RRs in trials. The 95% confidence intervals (CIs) for individual trials are
denoted by lines and those for the pooled RRs by open diamonds. Meta-analysis is performed by fixed effects model. AFCAPS/TexCAPS,
Air Force/Texas Coronary Atherosclerosis Prevention Study; ALLHAT-LLT, Antihypertensive and Lipid-lowering Treatment to Prevent
Heart Attack Trial; ASCOT-LLA, Angio-Scandinavian Cardiac Outcomes Trial Lipid-lowering Arm; CARDS, Collaborative Atrovastatin
Diabetes Study; JUPITER, Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; MEGA,
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; PROSPER, Prospective Study of Pravastatin
in the Elderly at Risk. Taken from Savarese G, et al. J Am Coll Cardiol. 2013;62:2090–2099.459 Permission to reprint was obtained.
Jacobson et al NLA Dyslipidemia Recommendations - Part 2 S53diabetes hazard in all patients, including those at high risk
for developing diabetes.344,465 Because the incidence of
diabetes increases with age, periodic glucose monitoring,
and when appropriate, glycated hemoglobin measurement,
should be performed when administering statins to older
patients.
Cognitive dysfunction
There have been case reports of patients noting cognitive
dysfunction during the course of statin therapy. The NLA
Task Force on Statin Safety – 2014 Update defined
cognitive dysfunction as impairment in any of 4 domains,
including executive function, memory, language and visuo-
spatial ability.466 Mild cognitive impairment was defined as
a state of cognitive dysfunction between normal cognition
and dementia, the latter of which is defined as cognitive
dysfunction involving 2 domains and is sufficiently severe
to interfere with activities of daily living associated with
progressive loss of independence. Clinically, it is especially
important to differentiate a potential medication side effect
causing cognitive impairment from other causes of demen-
tia in older patients, including Alzheimer’s disease; fronto-
parietal dementia; Parkinson’s disease; Lewy body
dementia; infectious processes; inflammatory, vascular or
metabolic disorders; and depression.The following perspective on statins and cognition was
put forth by the NLA Task Force on Statin Safety: 1) a
baseline cognitive assessment does not need to be per-
formed prior to initiation of statin therapy (strength of
recommendation: expert opinion; quality of evidence: low);
2) statins as a class are not associated with adverse effects
on cognition (strength of recommendation: strong; quality
of evidence: low to moderate); and 3) in patients who report
cognitive symptoms after beginning a statin, cognitive
testing should be performed, other potential contributors
should be ruled out, and the risk of stopping the statin
should be assessed.466 The provider may consider stopping
the statin to assess the reversibility of symptoms, lowering
the dose, or switching to an alternative statin. If the statin is
switched, consideration may be given to starting a statin
that is less likely to penetrate the brain, including pravasta-
tin or rosuvastatin (strength of recommendation: expert
opinion; quality of evidence: low).466
Polypharmacy and drug-drug interactions
Polypharmacy, defined as the concurrent use of 5 or
more medications, is common in older patients, and is
likely contributed to by changes in absorption, bioavail-
ability, and volume of distribution. Multiple pathways of
altered metabolism have been described in statin drug-drug
S54 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015interactions; the CYP3A4 and CYP2C9 pathways are most
commonly implicated. In addition, single-nucleotide poly-
morphisms in organic anion transporter 1B1, encoded by
the soluble carrier organic anion transporter 1B1 gene; in
breast cancer-related protein, encoded by the ABC sub-
family G2 gene; and in the p-glycoprotein transporter, alter
the movement of statins in and out of cells and may be an
additional cause of statin-related drug interactions.
Reduced muscle mass in older patients may also predispose
to muscle-related side effects. It has been suggested that
older patients on polypharmacy regimens be regularly
evaluated for drug-drug-interactions and that medication
reconciliation be carefully performed at each clinic visit.
Providers should have access to references that provide a
comprehensive listing of statin therapies and common drug-
drug interactions.463
Recommendations for lipid management in older
patients in other major guideline documents
The 2013 ACC/AHA Guideline for the Treatment of
Blood Cholesterol includes different treatment regimens for
individuals .75 years of age compared to those who are
younger. Moderate intensity statin therapy is recommended
for secondary prevention in those .75 years of age vs high
intensity in those who are younger. In primary prevention,
the ACC/AHA guidelines recommend the use of the Pooled
Cohort Risk Equations to inform statin treatment decisions
and the use of provider-patient discussion in which the pros
and cons of statin therapy are discussed.3 No specific
recommendation is made for the intensity of statin therapy
in primary prevention for those .75 years of age.
The International Atherosclerosis Society Guidelines
recommend for persons .65 years of age the use of
short-term (10-year) Framingham risk scoring (recalibrated
for country) to estimate CHD risk, and then elevation of the
estimated value by 1/3 to estimate total ASCVD risk. The
guideline suggests that statin therapy should be used in
those whose risk is estimated to be moderately-high or
high, but that decisions about the use of drug therapy
should be made while considering the pros and cons of
polypharmacy, drug-drug interactions, and cost.6
The European Atherosclerosis Society/European Society
of Cardiology Guidelines advocate for elderly patients that
statin therapy generally be given for secondary prevention in
the same manner as in younger patients (class 1, level of
evidence B). However, because of co-morbidities and altered
pharmacokinetics, therapy should be started at a low dosage
and the dosage should be titrated to achieve target lipid levels
that are the same as for younger patients (class 1, level of
evidenceC). They also recommend statin therapy for primary
prevention in those with 1 or more additional risk factors,
aside from age (class IIb, level of evidence B).467
The Canadian Cardiovascular Society Guidelines
recommend statin therapy without specific upper age cut-
offs for secondary prevention of ASCVD. For primary
prevention, 10-year Framingham risk scoring is advocated
for men ages 40–75 years and for women ages 50–75 years.Because the Framingham model is not well validated in
those .75 years of age, clinical judgment regarding the use
of drug therapy should be used.468
In secondary prevention, the National Institute of Care
and Health Excellence Clinical Guideline from the United
Kingdom recommends the use of high intensity statin (i.e.,
atorvastatin 80 mg), but a lower dosage may be considered
in those with potential drug interactions, high risk of
adverse effects, or patient preference. For primary preven-
tion in those individuals up to age 84 years, the provider
should discuss the benefits of lifestyle modification and
optimize the management of all other modifiable ASCVD
risk factors, followed by a repeat assessment of risk factors.
If lifestyle modification is ineffective or inappropriate, a
moderate intensity statin (i.e., atorvastatin 20 mg) is
advised for those with a $10% 10-year ASCVD risk using
the QRISK2 assessment tool.469 In the QRISK2 tool,
ASCVD includes CHD (angina and MI), stroke, and tran-
sient ischemic attack, but not peripheral arterial disease.
It has been validated in populations ranging from 30–
84 years of age.469
Summary of recommendations for lipid management
from the 2015 NLA Expert Panel on older patients
Secondary and very high risk prevention (ASCVD or type 1
or 2 diabetes mellitus with $2 major ASCVD risk factors
or evidence of end organ damage)
Consistent with the NLA Recommendations for the
Patient-Centered Management of Dyslipidemia–Part 1,1 the
Expert Panel recommends consideration of moderate or
high intensity statin therapy for those individuals age
$65 to#75 years of age with ASCVD or diabetes mellitus.
Secondary prevention patients who are .75 to ,80 years
of age may be treated with similar regimens after a careful
consideration of the risk-benefit ratio of such therapy. In
those $80 years of age, moderate intensity statin therapy
should be considered based upon a provider-patient discus-
sion of the risks and benefits of such therapy, consideration
of drug-drug interactions, polypharmacy, concomitant med-
ical conditions including frailty, cost considerations and pa-
tient preference. With regard to the use of combination
therapy, IMPROVE-IT identified individuals (mean age
64 years) who suffered an acute coronary syndrome as be-
ing more likely to benefit from simvastatin-ezetimibe com-
bination therapy than from simvastatin monotherapy.370 In
those older than age 65 years, the ASCVD event rate with
combination simvastatin-ezetimibe therapy was 36.4% vs
39.9% on simvastatin monotherapy, for an absolute risk
reduction of 3.5%.
Primary prevention
Primary prevention strategies in those 65–79 years of
age should be managed in accordance with the NLA
Recommendations for the Patient-Centered Management
of Dyslipidemia–Part 1.1 An individualized approach
should be taken to lifestyle change recommendations in
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weight has been shown to protect against mortality in
some elderly individuals.470 Therefore, promoting weight
loss in the elderly is not broadly recommended. However,
recent RCTs have shown that supervised, moderate calorie
restriction in combination with regular physical exercise in
obese older adults did not increase mortality risk and may
be beneficial for reducing metabolic complications.470 An
approach that takes into consideration the older patient’s
life expectancy, chronic comorbidities, functional status,
personal motivation, and social support is recommended.
In patients age 80 or older, recommendations about the
advisability of weight loss should be individualized based
upon clinical judgment.
Although the NLA Recommendations state that risk
calculators such as the ACC/AHA Pooled Cohort Risk
Calculator or the ATP III Framingham Risk Calculator can
be used in select individuals with 2 risk factors, this approach
in older patients has significant limitations. As most men
.60 years of age andwomen.70 years of age are candidates
for a risk-benefit discussion about statin therapy, using the
ACC/AHA recommended cutpoints for the Pooled Cohort
Risk Equations, there is a risk for over-treatment in this
population. An application of the 2013 ACC/AHA Risk
Assessment Working Group Guidelines to NHANES data
from 2005 to 2010 indicated that the number of adults
who would be eligible for statin therapy would increase by
12.8 million, due mostly to an increase among older adults
without CVD.471 Among adults between the ages of 60 and
75 years without CVD and not receiving statin therapy, the
percentage that would be eligible for statin therapy would
increase from 30.4% to 87.4% among men and from 21.2%
to 53.6% among women.
The threshold recommended by the NLA for classifica-
tion of high risk using the Pooled Cohort Equations
is $15% 10-year risk for a hard ASCVD event (MI, stroke,
or death from CHD or stroke), and using the ATP III
Framingham Risk Calculator, a high risk cutpoint of $10%
10-year risk for a hard CHD event (MI or CHD death) is
recommended.1 Providing the older, statin-eligible patient
with easy to understand concepts such as the number
needed to treat to prevent an ASCVD event vs the number
needed to harm for a statin-related side effect may allow
patients to make more informed decisions about taking
long-term statin therapy.472
For lipid management in primary prevention, non-HDL-
C and LDL-C goals of ,130 mg/L and ,100 mg/dL are
appropriate targets. Those who are unable to achieve these
atherogenic cholesterol goals after a minimum 3–6 month
trial on lifestyle modification should engage in a patient-
provider discussion about the pros and cons of drug therapy
and be recommended, whenever feasible, moderate in-
tensity statin therapy. In those patients $65 years of age in
whom the decision regarding the use of drug therapy
remains in question, it is reasonable to recommend mod-
erate intensity statin therapy in those with 1 or more major
ASCVD risk factor aside from age, those with additionalrisk factors whose risk exceeds 15% on the Pooled Risk
Calculator or 10% on the ATP III Framingham Risk
Calculator. In those situations in which additional objective
information is deemed necessary, CAC scoring may be
considered for those willing to incur the cost of the test, as a
score of zero in asymptomatic patients may suggest that
non-pharmacologic approaches to atherogenic cholesterol
reduction are a reasonable option.473,474
For those $80 years of age with atherogenic lipopro-
teins above the stated goals, a provider-patient discussion
of the risks and benefits of statin therapy, consideration of
drug-drug interactions, polypharmacy, concomitant medical
conditions including frailty, cost considerations, and patient
preference should be undertaken. If statin intolerance is the
primary issue, consideration should be given to the use of
alternate statin regimens such as low intensity statin
therapy or non-daily moderate intensity statin therapy,
low dose statin combination therapy with ezetimibe, bile
acid sequestrants, or niacin, or non-statin monotherapy (i.e.,
ezetimibe or bile acid sequestrant) or their combination. Of
note, these recommendations are less evidence based than
using moderate to high intensity statin daily therapy. In
general, we recommend that providers try to achieve at
least a 30% LDL-C reduction.
ASCVD prevention using appropriate lifestyle and lipid-
related pharmacological therapy should remain an impor-
tant health care priority in our older population, a group
that carries the largest proportional burden of these
diseases. Evidence-based, empathetic shared decision-
making will help to facilitate the optimal preventive
strategy for the care of these patients.See Chart 6 for the Recommendations for Older
Patients.
Ethnic and racial groups
Hispanics/Latinos
Hispanics/Latinos are the largest and one of the fastest
growing minority populations in the United States, and
represent diverse cultures, backgrounds, and exposures.
ASCVD is one of the leading causes of mortality among
Hispanics/Latinos,256 and similar associations of major
ASCVD risk factors with adverse ASCVD outcomes have
been reported among Hispanic/Latino adults compared to
NHWs.475
Prevalence of hypercholesterolemia among diverse
US Hispanics/Latinos
NHANES 2009–2012 data show that prevalence of total-
C $200 mg/dL and of LDL-C $130 mg/dL are higher
among Hispanic men compared to NHW men, and slightly
lower for Hispanic women vs NHW women (Table 15).256
As shown in Table 16, the mean level of LDL-C was higher
among Hispanic men vs NHW men, and the mean level of
HDL-C was lower and mean TG was higher for both
Chart 6 Recommendations for older patients
Recommendations Strength Quality
Primary prevention strategies in patients 65-79 years of age should be managed in accordance with the NLA
Recommendations for the Patient-Centered Management of Dyslipidemia-Part 1.1
A High
For patients age $65 to ,80 years of age with ASCVD or diabetes mellitus, moderate or high intensity statin
therapy should be considered after a careful consideration of the risk-benefit ratio.
A High
For secondary prevention in patients $80 years of age, moderate intensity statin therapy should be
considered based upon a provider-patient discussion of the risks and benefits of such therapy,
consideration of drug-drug interactions, polypharmacy, concomitant medical conditions including frailty,
cost considerations, and patient preference.
B Moderate
Risk calculators such as the ACC/AHA Pooled Cohort Risk calculator or the ATP III Framingham Risk Calculator
can be used in select older individuals with one additional risk factor to further assess risk, using the
thresholds for high risk of $15% 10-year risk for a hard ASCVD event (MI, stroke, or death from CHD or
stroke) with the Pooled Cohort Equations, and $10% 10-year risk for a hard CHD event (MI or CHD death)
using the ATP III Framingham risk calculator. However, these risk calculators have several limitations for
use in older patients, since advanced age is often the predominate driver of increased ASCVD risk, and this
may result in overtreatment of lower risk older individuals.
E Low
Older, primary prevention patients who are statin-eligible should undergo a patient-centered discussion with
their provider about the risks and benefits of statin therapy so that they can make a more informed
decision about taking statins over the long term.
E Low
If the older primary prevention patient is unable to achieve atherogenic cholesterol goals after a minimum 3-
6 month trial on lifestyle modification, the provider should discuss the pros and cons of drug therapy and,
if feasible, prescribe moderate intensity statin therapy, particularly for patients with one or more ASCVD
risk factor aside from age, with risk exceeding the high risk threshold using the Pooled Risk Equation or
ATP III Framingham Risk Calculator.
E Moderate
CAC scoring may be useful to further assess risk in older patients for whom questions remain about whether to
prescribe drug therapy.
E Low
If statin intolerance is an issue, consideration should be given to the use of alternate statin regimens such as
low intensity statin therapy or non-daily moderate intensity statin therapy, low dose statin combination
therapy with ezetimibe, bile acid sequestrants, or niacin, or non-statin monotherapy (i.e., ezetimibe or bile
acid sequestrant) or their combination, with a goal of at least a 30% reduction in LDL-C.
B Moderate
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women (Table 16).256
The Hispanic Community Health Study/Study of
Latinos (HCHS/SOL), the largest study of diverse
Hispanic/Latino individuals to date, has yielded compre-
hensive data on the prevalence of hypercholesterolemia
and dyslipidemia among Hispanic/Latino groups in
the United States.476 Among HCHS/SOL participants,
51.7% of men and 36.9% of women, respectively, had
hypercholesterolemia (defined comprehensively as total-C
$240 mg/dL, HDL-C ,40 mg/dL, LDL-C $160 mg/dL,
or receiving lipid-lowering treatment). Prevalence of
hypercholesterolemia ranged from 47.6% among men of
Dominican background to 54.9% among men of Central
American background. Mean total-C and LDL-C levels
were 195.8 mg/dL and 122.0 mg/dL among men overall,
and were highest among men of Central American
background (201.5 mg/dL and 125.3 mg/dL, respec-
tively).476 Among women, hypercholesterolemia preva-
lence ranged from 31.4% (South American background)
to 41.0% (Puerto Rican background). Overall mean total-
C and LDL-C levels among women were 195.1 mg/dL
and 119.0 mg/dL, respectively, and were both highest
among those of Cuban background (199.4 mg/dL and
124.2 mg/dL).476A subsequent report by Rodriguez et al.477 found that
among HCHS/SOL participants, the prevalence of any dys-
lipidemia was 65% overall and ranged from 57.7% among
participants of Dominican background to 69.8% among
those of Cuban background. Lower educational attainment
and Spanish language preference were associated with
higher prevalence of any dyslipidemia.477 Overall, 14.1%,
36.0%, and 14.8% of HCHS/SOL participants had high
levels of total-C ($240 mg/dL), LDL-C ($130 mg/dL),
and TG ($200 mg/dL), respectively, and 41.4% had low
HDL-C levels (defined as ,40 mg/dL for men and
,50 mg/dL for women). Prevalence of mixed dyslipidemia
(defined as presence of both elevated TG and low-HDL-C)
was 10.7% overall, and ranged from 5.4% among Domin-
ican participants to 12.7% among Central American
participants. Studies have suggested that this mixed
pattern–indicating higher CVD risk regardless of LDL-C
level–may be more common among Hispanics compared
to NHWs.478 Among participants of the Northern Manhat-
tan Study, Hispanics had lower mean HDL-C (43.9 mg/dL),
and higher mean TG (146.5 mg/dL) and TG:HDL-C ratio
(3.9) compared to non-Hispanic blacks (NHBs) and
NHWs.479 A recent study based on electronic health data
for 169,430 racially diverse patients from California re-
ported that among men, age-standardized rates of low





2012 Age $20 y
Prevalence of Total
Cholesterol $240 mg/dL,
2012 Age $20 y
Prevalence of LDL
Cholesterol $130 mg/dL,
2012 Age $20 y
Prevalence of HDL
Cholesterol ,40 mg/dL,
2012 Age $20 y
Both sexes, n (%)* 100,100,000 (42.8) 30,900,000 (13.1) 73,500,000 (31.7) 44,600,000 (19.9)
Males, n (%)* 45,300,000 (40.4) 13,000,000 (11.6) 34,900,000 (31.0) 32,400,000 (28.9)
Females, n (%)* 54,830,000 (44.9) 17,900,000 (14.4) 38,600,000 (32.0) 12,200,000 (10.4)
NH white males, % 39.9 11.5 29.4 28.7
NH white females, % 45.9 15.3 32.0 10.2
NH black males, % 37.4 8.8 30.7 20.0
NH black females, % 40.7 10.9 33.6 10.3
Hispanic males, % 46.2 14.8 38.8 33.8
Hispanic females, % 43.4 13.7 31.8 12.8
HDL, high-density lipoprotein; LDL, low-density lipoprotein; NH, non-Hispanic.
Prevalence of total cholesterol $200 mg/dL includes people with total cholesterol $240 mg/dL. In adults, levels of 200 to 239 mg/dL are considered
borderline high. Levels of $240 mg/dL are considered high.
*Total data for total cholesterol are for Americans $20 years of age. Data for LDL cholesterol, HDL cholesterol, and all racial/ethnic groups are age
adjusted for age $20 years.
Source for total cholesterol $200 mg/dL, $240 mg/dL, LDL, and HDL: National Health and Nutrition Examination Survey (2009–2012), National Center
for Health Statistics, and National Heart, Lung, and Blood Institute. Estimates from National Health and Nutrition Examination Survey 2009 to 2012
(National Center for Health Statistics) were applied to 2012 population estimates.
Taken from: Mozaffarian D, et al. Circulation. 2015;131:e29–e322.256 Permission to reprint was obtained.
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highest among Mexican patients (47.8%), who also had
among the highest prevalence (55.9%) of elevated TG
levels ($150 mg/dL).480 Among women, prevalence of
high TG levels was greatest among Mexicans (45.4%),
and prevalence of low HDL-C (50.9%) was higher in Mex-
icans than in all other groups except Asian Indians.480
Furthermore, in MESA, compared to whites, Hispanic
participants had higher age-sex adjusted odds of having
combined hyperlipidemia (defined as age-sex specific
LDL-C and TG levels in the 75th percentile or higher based
on a mostly white reference population) (OR 1.48; 95% CI
1.04–2.11).481 This association was no longer significant
after adjustment for BMI, suggesting that obesity may at
least partly explain the increased risk for dyslipidemia
among Hispanic participants.481 Taken together these
studies suggest the need to screen Hispanic/Latino individ-
uals for mixed dyslipidemia subtypes, particularly to iden-
tify those without elevated LDL-C levels who nonetheless
may be at high ASCVD risk.Table 16 Mean levels of LDL-C, HDL-C, and TG for adults aged $20




LDL-C, mg/dL 113.8 116
HDL-C, mg/dL 47.7 58
TG, mg/dL 117.7 104
AHA, American Heart Association; HDL-C, high-density lipoprotein cholesteAn examination of the prevalence of non-HDL-C by
Gardner et al.482 found that among NHANES III (1988–
1994) participants, mean non-HDL-C levels were lower
among Mexican American women $25 years of age
compared to NHWs in this age bracket (150 mg/dL vs
155 mg/dL); non-HDL-C levels among Mexican American
and NHW men were similar (160 mg/dL vs
162 mg/dL).482 However, an analysis of data from
NHANES 2005–2010 showed that after adjustment for
age and sex, Hispanic participants were more likely than
other racial/ethnic groups to have normal LDL-C and
high non-HDL-C levels (defined according to the NCEP
ATP III guidelines12).483 The discordance between LDL-
C and non-HDL-C concentrations is particularly important
in assessing residual risk for ASCVD, and clinicians
should be aware of the increased possibility of this discor-
dance in Hispanic/Latino patients. More recently, in the
HCHS/SOL study, 38.2% of men and 31.5% of women
were reported to have high non-HDL-C (i.e., $160 mg/






rol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride.
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women combined).477
Hypercholesterolemia awareness, treatment, and
control among US Hispanics/Latinos
According to NHANES 2011–2012 data,256 rates of
cholesterol screening are lower among Hispanic/Latino
adults compared to all other major racial/ethnic groups in
the United States. About 55% of Hispanic men and 64%
of Hispanic women reported having been told by a doctor
that their cholesterol was high and having had their choles-
terol levels checked in the past 5 years (compared to about
71% and 73% of NHW men and women, respectively).256
In NHANES 2009–2010, prevalence frequencies for aware-
ness, treatment, and control of high LDL-C were 46.4%,
77.8%, and, 63.5%, respectively, among Hispanic partici-
pants (vs. 65.3%, 70.2%, and 67.2%, respectively among
NHWs).484 In MESA, rates of treatment and control of dys-
lipidemia were lower among Hispanic men and women
compared to NHWs, although the prevalence of dyslipide-
mia was similar. Dyslipidemia treatment rates were 39.4%
and 50% among Hispanic men and women, respectively. Of
those treated, 68.5% and 74.5% of Hispanic men and
women, respectively, had met treatment goals.485 Another
report from MESA found that compared to NHWs, Hispan-
ic participants with similar levels of CVD risk factors were
less likely to receive lipid-lowering treatment (prevalence
ratio 0.75; 95% CI 0.61–0.91) although findings were atten-
uated and lost statistical significance with adjustment for
socioeconomic status, particularly health insurance.486
Use of Framingham Risk Score and other
cardiovascular risk assessment criteria in
Hispanic/Latino adults
A report from the San Antonio Heart Study found that
CVD risk scores derived from Framingham Study risk
equations were higher among Mexican American men and
women compared to NHWs.487 A subsequent study by
D’Agostino et al.488 examined the validity of the Framing-
ham coronary disease risk prediction scores among 6
racially/ethnically diverse cohorts, including 8713 Hispanic
men from the Puerto Rico Heart Health Program. The au-
thors concluded that among Hispanic men, the Framingham
Risk Score systematically overestimated 5-year CHD risk
compared to observed CHD event rates (c-statistics: 0.69
vs 0.79 for white men from the Framingham Heart Study);
however, this was improved by recalibration of the model
using data on mean CVD risk factor levels and CHD inci-
dence from the Puerto Rico Heart Health Program cohort
(c-statistic: 0.72).488 More recently, Hurley et al.489 exam-
ined the ability of Framingham risk factors to predict
CVD death in Mexican Americans compared to NHWs us-
ing data from NHANES III (1988–1994) linked with the
National Death Index. They reported that survival models
based on Framingham risk factors were similarly calibrated
when models were developed separately within each racial/
ethnic group, and the ability of these models to discriminatebetween individuals who experienced CVD death from
those who did not was also similar (c-statistic was 0.8126
for NHWs and 0.7854 for Mexican Americans).489 DeFilip-
pis et al.490 examined the association of the Framingham
Risk Score and the Reynolds Risk Score with incidence
and progression of CAC using data from MESA. They re-
ported that the Framingham Risk Score and Reynolds
Risk Score predicted incident CAC similarly across
racial/ethnic groups; both scores predicted significantly
greater progression of CAC among white participants
compared to Hispanic, AA, and Chinese participants.490
Further research is required to validate existing risk predic-
tion scores and/or develop new prediction tools for use
among Hispanics/Latinos residing in the United States us-
ing current data on risk factor prevalence and CVD inci-
dence among diverse Hispanic/Latino groups. Globorisk
is a novel CVD risk prediction tool that can be recalibrated
for application in different countries, including Mexico,
with routinely available information.491
Association of lipid measures with ASCVD outcomes
among Hispanic/Latino individuals
High cholesterol was associated with increased risk of
both CVD mortality and all-cause mortality among
Mexican American adults who participated in the San
Antonio Heart Study.475 In analyses adjusted for age, sex,
socioeconomic status, and other CVD risk factors, the RR
of CVD mortality and all-cause mortality associated with
total-C levels .240 mg/dL (vs 160–240 mg/dL) were 2.1
(95% CI 1.0–4.6) and 1.6 (95% CI 1.0–2.6), respectively,
among Mexican American participants (corresponding
RRs among NHWs were 2.4 [95% CI 0.8–6.8] and 1.4
[95% CI 0.7–2.8]).475 The authors concluded that choles-
terol and other major CVD risk factors were important pre-
dictors of mortality among Mexican Americans.475
However, in a multiethnic cohort of Medicare recipients
ages 65 and older residing in Northern Manhattan
(including 1054 Hispanic adults primarily of Dominican
origin), plasma total-C, LDL-C, and HDL-C were not asso-
ciated with all-cause mortality or with self-reported heart
disease among Hispanic adults.492 An analysis from the
Northern Manhattan study also found no associations of
HDL-C and TG levels with risk of MI among Hispanic par-
ticipants over an average 8.9 years of follow-up.479 Howev-
er, each 1-unit increase in the TG:HDL-C ratio (examined
as a continuous variable) was associated with 8% increased
risk of MI in Hispanics, although no association was found
in analyses with TG:HDL-C as a categorical variable (using
the cut-point of TG:HDL-C .2).479 The authors suggested
that this cut-point may be unsuitable for use in Hispanics/
Latinos, but cautioned that further research is required.479
Several studies have examined associations of lipid
levels with measures of subclinical atherosclerosis. Sacco
et al.493 reported that in the Northern Manhattan Stroke
Study, increasing LDL-C levels were associated with
higher maximum internal carotid artery plaque thickness
among Hispanic participants free of stroke (but not among
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found that despite lower prevalence of carotid plaque
among Hispanic participants compared to NHWs and
NHBs, there was no evidence that the effect of lipid levels
(total-C, LDL-C, non-HDL-C, apo B, and total-C:HDL-C
and LDL-C:HDL-C ratios) on carotid plaque differed
among Hispanics compared to other racial/ethnic groups
(i.e., no significant interactions were found).494 Among
MESA participants, those who had combined hyperlipid-
emia (LDL-C $160 mg/dL and TG $150 mg/dL) or
hypercholesterolemia (LDL-C $160 mg/dL and
TG ,150 mg/dL) had increased risk of prevalent CAC
compared to participants with normal lipid levels (RRs
for combined hyperlipidemia and hypercholesterolemia
were 1.22 [95% CI 1.08–1.38] and 1.22 [95% CI 1.11–
1.34], respectively).495 Combined hyperlipidemia or hyper-
cholesterolemia was also associated with increased
common carotid intima media thickness and internal
carotid intima media thickness, compared to normal lipid
levels.495 No significant interactions between lipid levels
and race were seen for any of the outcomes, which the
authors suggested could possibly be due to inadequate
power.495 These findings underscore the need for further
research to examine whether the impact of specific lipid pa-
rameters on the atherosclerotic process differs by race/
ethnicity, given the increasing diversification of the US
population.
It should be noted that most of the abovementioned
studies have involved limited Hispanic/Latino background
groups and thus, these findings may not be generalizable to
the diverse, heterogeneous US Hispanic/Latino population.
In the HCHS/SOL study, high cholesterol level (serum
total-C $240 mg/dL or use of cholesterol-lowering medi-
cation) was associated with higher age-adjusted odds of
prevalent self-reported CHD (among both men and
women) and stroke (women only).476 However, these asso-
ciations were attenuated and lost significance with addi-
tional adjustment for other CVD risk factors,
socioeconomic status, Hispanic background group, and
acculturation-related factors (with the exception of the as-
sociation of high cholesterol with CHD among women).476
At this time there is no evidence to indicate that there is a
substantial difference between Hispanics/Latinos and
NHWs for the associations of atherogenic cholesterol
with risk. Thus, at present, no differences in LDL-C and
non-HDL-C treatment goals for Hispanics/Latinos are
recommended.
Use of cholesterol-lowering medications among US
Hispanic/Latino adults
Clinical trial research on effectiveness and safety of
statins has largely focused on white populations, with little
data on diverse Hispanic/Latino individuals. To address the
scarce data in this population group, the Study Assessing
Rosuvastatin in Hispanic Population investigated the effects
of rosuvastatin and atorvastatin among 696 Hispanic
individuals $18 years of age (mean age 57.9 years) whohad an LDL-C level in the range of 130–300 mg/dL,
TG ,400 mg/dL, and a 10-year CHD risk $10% based on
criteria described by the NCEP.496 Both statins were asso-
ciated with reductions in total-C, non-HDL-C, LDL-C,
and apo B concentrations. The adverse events were mild/
moderate in nature, and there were no cases of clinically
relevant increases in serum creatine kinase, myopathy, or
rhabdomyolysis.496
JUPITER, a randomized double-blind placebo-
controlled trial, investigated the effectiveness of rosuvasta-
tin in the primary prevention of MI, stroke, hospitalization
for unstable angina, arterial revascularization, and CVD
death among persons with LDL-C ,130 mg/dL and hs-
CRP $2.0 mg/L.497 Among Hispanic participants
(n 5 2261) rosuvastatin therapy was associated with 42%
lower risk of the primary endpoint (non-fatal or fatal
CVD), which was similar to the reduction observed in
NHWs (HRs were 0.58 [95% CI 0.25–1.39] among His-
panics and 0.55 [95% CI 0.43–0.69] among NHWs).497
Rates of adverse events were, in general, lower among His-
panic participants compared to NHWs.497 Despite a higher
prevalence of type 2 diabetes mellitus among Hispanics,256
there was no significant difference in cases of new-onset
diabetes with statin treatment for Hispanics compared
with NHWs in JUPITER (P 5 .41), and tests for heteroge-
neity between diabetes mellitus by race/ethnicity and statin
treatment were not significant.
ALLHAT-LLT examined the effect of pravastatin vs
usual care on reducing all-cause mortality in 10,355
individuals $55 years of age (23% Hispanic, 38% black)
who had LDL-C levels of 120–189 mg/dL (100–129 mg/dL
among those with history of CHD), TG ,350 mg/dL, and
who had hypertension and at least 1 other CVD risk
factor.347 Although pravastatin therapy was associated
with lower total-C and LDL-C levels at 4 years of follow-
up compared to usual care, all-cause mortality and CHD
event rates did not differ significantly between the pravas-
tatin and usual care groups (all-cause mortality: RR 0.99
[95% CI 0.89–1.11]; fatal/non-fatal CHD events: RR 0.91
[95% CI 0.79–1.04]). Analyses examining whether these
findings varied by race were limited to blacks vs non-
blacks and outcomes among Hispanic participants were
not reported separately.347 Thus, rigorous primary and sec-
ondary prevention clinical trials and post-marketing studies
of new and existing lipid-lowering agents inclusive of suf-
ficient numbers of diverse Hispanic/Latino adults are
required to generate convincing evidence on the effective-
ness and safety of such medications in this population
group. However, the results to date indicate that there are
no clear differences in responsiveness among Hispanics/
Latinos with regard to the lipid effects of statins or the
risk reduction associated with statin therapy.
Novel lipid measures among US Hispanic/Latino
individuals
Although Lp(a) levels have been shown to vary by race/
ethnicity, studies that have included Hispanic/Latino
S60 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015participants have yielded conflicting results. In the San
Antonio Heart Study, Mexican American men and women
had significantly lower Lp(a) levels compared to NHW men
and women (men: 10.4 vs 16.3 mg/dL; women: 11.5 vs
16.4 mg/dL).498 A report based on data from NHANES III
also found that mean Lp(a) levels were lower among
Mexican American participants compared to NHWs and
NHBs (14.9 vs 20.3 and 43.4 mg/dL, respectively).499
Conversely, Kamboh et al.500 reported that in the San Luis
Valley Diabetes Study, Lp(a) levels were significantly higher
in Hispanic men free of diabetes compared to NHWs (men:
13.2 vs 8.7 mg/dL, P , .003; women: 11.1 vs 10.3 mg/dL).
Both JUPITER and MESA demonstrated no meaningful dif-
ferences in Lp(a) levels between Hispanic and NHW partic-Chart 7 Recommendations for Hispanics/Latinos
Recommendations Strength Quality
In general, patients of Hispanic/Latino ethnicity should be treated according to the NLA Recommendations
for Patient-Centered Management of Dyslipidemia – Part 11 with the following special considerations.
A High
Clinicians should be aware that Hispanics/Latinos in the United States are a diverse population group tracing
their ancestry to Mexico, the Caribbean (Puerto Rico, Cuba, and the Dominican Republic), Central America
(El Salvador and Guatemala), and South America. ASCVD risk factor burden varies widely among individuals
of Hispanic/Latino descent, depending on their country of origin.
A High
Hispanics/Latinos tend to have a greater prevalence of high TG and low HDL-C than NHWs, leading to higher
levels of non-HDL-C, and an increased likelihood for discordance between LDL-C and non-HDL-C
concentrations. LDL-C levels tend to be higher in Hispanic men compared with NHW men.
A Moderate
Hispanics/Latinos have higher prevalence of type 2 diabetes mellitus, obesity, and metabolic syndrome
compared to NHWs, particularly among women.
A Moderate
Some cardiovascular risk equations (e.g., Framingham equations) may overestimate risk in Hispanic/Latino
individuals.
B Moderateipants.501,502 Findings from MESA suggested that a Lp(a)
cut-point of 50 mg/dL, which is consistent with the NLA
Recommendations for the Patient-Centered Management of
Dyslipidemia–Part 1,1 rather than the commonly used
30 mg/dL, was better at identifying Hispanic individuals at
high CHD risk. Among Hispanics, the HR for incident
CHD associated with Lp(a) $50 mg/dL was 2.37 (95% CI
1.17–4.78), whereas HR associated with Lp(a) $30 mg/dL
was 1.46 (95% CI 0.78–2.75).502
Further research on prevalence of adverse levels of
various novel lipid measures among diverse Hispanic/
Latino groups, mean levels by age, sex, and Hispanic
background, and associations with CVD endpoints is
required for valid evidence-based statements to be made
about which of these measures (and cut-points) can be used
to identify high risk Hispanic/Latino individuals.Conclusions
ASCVD is one of the leading causes of mortality among
Hispanics/Latinos.256 Similar associations of major ASCVD
risk factors with adverse ASCVD outcomes have been re-
ported among Hispanic/Latino adults compared to NHWs.
However, it should be recognized that, as a group, the lipid
profile in Hispanic Americans is characterized by higherTG and lower HDL-C levels, resulting in higher non-HDL-
C concentration and more frequent discordance between
LDL-C and non-HDL-C levels. At this time, there is no evi-
dence to suggest a need for different treatment goals, or a dif-
ference in responsiveness to lipid-lowering therapy, among
Hispanics/Latinos compared to other ethnic groups. There-
fore the recommendations put forth by the NLA’s Patient-
CenteredManagement ofDyslipidemia–Part 11 are generally
recommended for patients ofHispanic/Latino ethnicity. Cali-
brated equations are needed to more accurately predict risk
among Hispanics/Latinos, because some equations such as
Framingham, appear to overestimate risk.See Chart 7 for the Recommendations for Hispanics/
Latinos.African Americans (AAs)
ASCVD in AAs: a high risk population
Since the 1980’s, the United States has made substan-
tial progress in improving overall health and reducing
ASCVD, but racial/ethnic and socioeconomic disparities in
health still persist.503 AAs, also referred to as NHBs or
blacks in the present document, have higher rates of
CVD, including CHD and stroke, and CVD mortality
than do Caucasians (whites).504 These differences continue
to contribute significantly to AAs having a reduced life ex-
pectancy compared to whites.504 Moreover, AAs have
higher levels of several major risk factors, most notably
obesity (especially in females), arterial hypertension,
type 2 diabetes mellitus, chronic kidney disease (CKD),
and multiple risk factor status (Table 17).256 Unfortu-
nately, AAs often are underdiagnosed and undertreated
for CVD risks, and they may present to the health care
system late in their disease course, frequently at the time
of a CVD event.504 Hypertension is a powerful contributor
to the increased CVD risk in AAs, with earlier onset and
more severe blood pressure elevation, leading to increased
target organ damage including left ventricular hypertrophy,
heart failure, stroke, CKD and end stage renal disease,










Both SexesMales Females Males Females Males Females
Smoking
Prevalence, 2013* 43.4 M (17.9%) 21.7% 18.7% 21.1% 15.0% 16.6% 6.7% 9.5% 21.0%
PA†






159.2 M (68.5%) 72.7% 61.2% 69.4% 81.9% 80.1% 76.3% N/A N/A
Obesity, BMI
.30.0 kg/m2‡





100.1 M (42.8%) 39.9% 45.9% 37.4% 40.7% 46.2% 43.4% N/A N/A
Total cholesterol
.240 mg/dL‡
30.9 M (13.1%) 11.5% 15.3% 8.8% 10.9% 14.8% 13.7% N/A N/A
LDL cholesterol
.130 mg/dL‡
73.5 M (31.7%) 29.4% 32.0% 30.7% 33.6% 38.8% 31.8% N/A N/A
HDL cholesterol
,40 mg/dL‡
44.6 M (19.9%) 28.7% 10.2% 20.0% 10.3% 33.8% 12.8% N/A N/A
HBP
Prevalence, 2012† 80.0 M (32.6%) 32.9% 30.1% 44.9% 46.1% 29.6% 29.9% N/A 26.2%*





21.1 M (8.5%) 7.6% 6.1% 13.8% 14.6% 12.5% 11.8% N/A N/A
Undiagnosed DM‡ 8.1 M (3.3%) 4.0% 1.7% 4.8% 2.3% 6.8% 5.0% N/A N/A
Prediabetes‡ 80.8 M (35.3%) 43.0% 28.9% 36.3% 27.8% 43.0% 26.0% N/A N/A
Incidence, diagnosed
DM‡
1.7 M N/A N/A N/A N/A N/A N/A N/A N/A
Mortality, 2011x 73,831 30,783 27,191 6048 6847 jj jj 2035jj 927jj
Total CVD
Prevalence, 2012‡ 85.6 M (35.0%) 36.1% 31.9% 46.0% 48.3% 32.4% 32.5% N/A N/A
Mortality, 201lx,{ 786,641 331,751 340,803 46,081 47,130 jj jj 17,050jj 3826jj
Stroke
Prevalence, 2012‡ 6.6 M (2.6%) 2.2% 2.5% 4.2% 4.7% 2.8% 2.0% N/A 2.7%*,#
New and recurrent
strokesx
795.0 K 325.0 K 365.0 K 45.0 K 60.0 K N/A N/A N/A N/A
Mortality, 2011x 128,932 43,264 65,278 7039 8814 jj jj 3937jj 600jj
CHD
Prevalence, CHD; 2012
‡ 15.5 M (6.2%) 7.8% 4.6% 7.2% 7.0% 6.7% 5.9% N/A 4.5%*,#
Prevalence, MI, 2012‡ 7.6 M (2.8%) 4.1% 1.8% 3.4% 2.2% 3.5% 1.7% N/A N/A
Prevalence, AP, 2012‡ 8.2 M (3.3%) 3.4% 2.9% 3.3% 5.0% 3.2% 3.8% N/A N/A
New and recurrent
CHD**,††
935.0 K 475.0 K 330.0 K 70.0 K 60.0 K N/A N/A N/A N/A
Mortality, 2011,CHDx 375,295 180,658 145,443 20,693 18,760 jj jj 7828jj 1913jj
Mortality, 2011, MIx 119,905 58,447 45,576 6551 6228 jj jj 2476jj 627jj
(continued on next page)
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Both SexesMales Females Males Females Males Females
HF
Prevalence, 2012‡ 5.7 M (2.2%) 2.2% 2.2% 2.8% 3.2% 2.1% 2.1% N/A N/A
Incidence, 2010xx 870.0 K 365.0 K 395.0 K 50.0 K 60.0 K N/A N/A N/A N/A
Mortality, 2011x 58,309 21,802 30,036 2371 3143 jj jj 727jj 230jj
AP, angina pectoris (chest pain); BMI, body mass index; CHD, coronary heart disease (includes heart attack, angina pectoris chest pain, or both);
CVD, cardiovascular disease; DM, diabetes mellitus; HBP, high blood pressure; HDL, high-density lipoprotein; HF, heart failure; K, thousands; LDL, low-
density lipoprotein; M, millions; MI, myocardial infarction (heart attack); N/A, data not available; PA, physical activity.
*Age $18 years (National Health Interview Survey, 2013).
†Met 2008 full federal PA guidelines for adults.
‡Age $20 years.
xAll ages.
jjMortality data for the white, black, Asian or Pacific Islander, and American Indian/Alaska Native populations include deaths of people of Hispanic
and non-Hispanic origin. Death rates for Hispanic, American Indian or Alaska Native, and Asian and Pacific Islander people should be interpreted with
caution because of inconsistencies in reporting Hispanic origin or race on the death certificate compared with censuses, surveys, and birth certificates.
Studies have shown underreporting on death certificates of American Indian or Alaska Native, Asian and Pacific islander, and Hispanic decedents, as well
as undercounts of these groups in censuses.
{Total CVD mortality includes deaths from congenital heart disease.
#Figure not considered reliable.
**New and recurrent MI and fatal CHD.
††Age $35 years.
xxAge $55 years.
Taken from: Mozaffarian D, et al. Circulation. 2015;131:e29–e322.256 Permission to reprint was obtained.
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physical inactivity.
Furthermore, ASCVD (CHD plus stroke) is not only
the leading cause of death for AAs, but also accounts for
the largest proportion of inequality in life expectancy
between whites and AAs, despite the existence of low-
cost, highly effective preventive treatments.503,505 In the
Atherosclerosis Risk in Communities (ARIC) study, AA
men and women had a higher incidence of first heart
attack than did their white counterparts.256 Additionally,
the rate of premature CHD death among AAs surpasses
that of whites.506 AAs aged 45–74 years have a much
higher proportion of CHD deaths than whites: 37.9%
vs 19.4% in women and 61.5% vs 41.5% in men.505
Nevertheless, in the Coronary Artery Risk Development
in Young Adults (CARDIA) study, the prevalence of
CAC in US adults aged 33 to 45 years was higher in
white men and women than in their AA counterparts,
despite higher rates of first MI in AAs, suggesting that
CAC may be less reliable as an indicator of MI risk in
AAs.507,508
The NCEP ATP III report in 2002 provided a concise
description of unique non-lipid risk factors in AAs,
emphasizing the impact of hypertension and left ventric-
ular hypertrophy as more common and powerful
predictors of mortality, and reporting that obesity is twice
as common among AA women than white women.12 Dia-
betes mellitus and multiple risk factor status were 1.5
times more frequent in AAs. The ATP III noted a similarrelationship of total-C to CVD in both races, and slightly
lower mean LDL-C levels in AA men than in white men.
Also in the ATP III report, women were noted to have
similar LDL-C levels among AAs and whites. In both
sexes, HDL-C levels were noted to be higher among
AAs than whites, whereas TG were lower and Lp(a) levels
were higher in AAs.12 The ATP III guidelines also
suggested that the relatively high normal creatine kinase
concentrations in AAs should be recognized before initia-
tion of statin therapy.
Impact of race in ASCVD disparities
Increased ASCVD risk is associated with the social
determinants of health (low income, lack of access to, or
inadequate, health insurance, and low educational attain-
ment) and geographic region.503,509,510 Furthermore,
‘‘race’’ is a crude proxy for genetics and culture (shared
values, beliefs, customs, and learned behavior) that impact
disease burden.510,511 Broad policy areas for addressing
racial/ethnic health care disparities include raising public
and provider awareness of racial/ethnic disparities in care
and outcomes, expanding health insurance coverage,
improving capacity and number of providers in underserved
communities, and increasing the knowledge base on causes
and interventions to reduce disparities. Data-driven perfor-
mance improvement, provider education, cultural compe-
tency, team-based care, patient education, and increased
community resources are all approaches with the potential
Jacobson et al NLA Dyslipidemia Recommendations - Part 2 S63to reduce these disparities.512 Low health literacy is partic-
ularly detrimental, and patients with less knowledge often
miss essential health services.513
Recent advances in atherosclerotic risk assessment in
AAs
The recent 2013 ACC/AHA Guideline on the Assess-
ment of Cardiovascular Risk includes AA status in its
calculator to estimate 10-year ASCVD risk.362 In addition,
this new ASCVD risk calculator includes the prediction of
both CHD and stroke risk, as it is notable that stroke
disproportionately affects AAs.256 Developed and sup-
ported by the National Heart, Lung, and Blood Institute,
the 2013 ACC/AHA Risk Calculator utilized pooled
cohorts with participants from several large, racially and
geographically diverse populations with endpoint data
from recent periods (up to the early 1990’s) including the
ARIC study, the Cardiovascular Health Study, and the
CARDIA study, combined with applicable data from the
Framingham Original and Offspring populations.362 In a
clinical vignette provided for illustration, a higher 10-
year risk is calculated for AA vs white patients with the
following characteristics: 55 years of age, nonsmoker,
without diabetes, and with a total-C level of 213 mg/dL,
HDL-C level of 50 mg/dL, and untreated systolic blood
pressure of 120 mm Hg. With the 2013 ACC/AHA Risk
Calculator, the predicted 10-year ASCVD risks for patients
with this profile would be 2.1% and 3.0% for white and AA
women, respectively, and 5.3% and 6.1% for white and AA
men, respectively.
In view of the higher risk for ASCVD in AAs, there is a
greater opportunity for risk reduction. A 2014 analysis of
data from NHANES (1999–2000 to 2011–2012) examined
trends in predicted 10-year ASCVD risk using the 2013
ACC/AHA Pooled Cohort Equations and calculated poten-
tial improvement in ASCVD risk by optimizing levels of all
5 modifiable cardiovascular risk factors—eliminate smok-
ing, decrease systolic blood pressure to ,120 mm Hg,
decrease total-C to ,200 mg/dL, raise HDL-C to .40
mg/dL (men) or .50 mg/dL (women), and eliminate
diabetes.514 The absolute change in mean predicted
10-year ASCVD risk declined by 3.3% overall, but by
6.4% among NHB (AA) men, and by 4.5% among NHB
(AA) women.514Table 18 Mean levels of LDL-C, HDL-C, and triglycerides for adults ag




LDL-C, mg/dL 113.8 116.8
HDL-C, mg/dL 47.7 58.5
TG, mg/dL 117.7 92.7
AHA, American Heart Association; HDL-C, high-density lipoprotein cholesteDyslipidemia and CHD in AAs
In a sample of 14,812 asymptomatic subjects including
637 AAs, 1065 Asians, 13,345 Hispanics, and 11,776
NHWs, the prevalence of any CAC upon measurement in
NHWs and AAs was 66% and 58%, respectively
(P , .0001).515 Among all racial/ethnic groups, the lowest
survival during the 10-year follow-up was observed in AAs
(83% of AAs, P , .0001 between ethnic groups), despite
the lack of a difference between groups in the prevalence
of hypercholesterolemia.515
In the Genetic Epidemiology Network of Arteriopathy
Study (1286 NHB hypertensive subjects and 1070 NHW
hypertensive subjects), the prevalence of dyslipidemia was
significantly greater among NHWs than NHBs.516 At base-
line, mean LDL-C concentrations in NHB men and women
were 118 and 123 mg/dL, respectively, and in NHW men
and women were 123 and 119 mg/dL, respectively
(P 5 .06 for ethnic comparison in both men and women).
Among dyslipidemic subjects for whom treatment was
indicated, treatment with lipid-regulating drugs was signif-
icantly more common among NHWs than NHBs (women
25.4% vs 16.4% [P 5 .001]; men 32.6% vs 12.8%, respec-
tively [P 5 .001]).
The 2015 compilation of the National Heart Disease and
Stroke Statistics from the AHA also suggest that hyper-
cholesterolemia (elevated total-C and LDL-C) or dyslipi-
demia (elevated TG and low HDL-C) are not culpable for
the excess CVD risk in AAs/NHBs (see Tables 15 and
18).256 Mean levels and percentages of NHB (AA) adults
with high levels of total-C and LDL-C were similar to those
of NHWs. Mean levels of TG were lower and HDL-C
higher in NHB (AA) adults compared to NHWs and the
prevalence values for high TG and low HDL-C were also
lower.
Importantly, the annual age-adjusted rates per 1000
population of first MI (2005–2011) from the ARIC study
were 4.9 in black men, compared to 3.2 in white men, and
3.5 in black women, compared to 1.9 in white women
(Unpublished data from ARIC Surveillance 2005–2011,
NHLBI256) (Fig. 10). The 2015 AHA report also reinforces
the higher ASCVD mortality in AAs/NHBs. CHD
death rates per 100,000 were 146.5 for white males, but
161.5 for black males; for white females, the rate was
80.1, and for black females, it was 99.7. The decrease in






rol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride.
Figure 10 Incidence of myocardial infarction by age, race, and
sex from the Atherosclerosis Risk in Communities (ARIC) Study.
Incidence of myocardial infarction by age, sex, and race (ARIC
Surveillance: 2005–2011; source, unpublished data from ARIC
study, National Heart, Lung, and Blood Institute.) Taken from:
Mozaffarian D, et al. Circulation. 2015; 131:e29–e322.256 Permis-
sion to reprint was obtained.
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age.
Based on these results, it can be concluded that
dyslipidemia is not the primary driver of the increased
CVD mortality among AAs/NHBs compared to whites, but
instead this increased risk appears to be explained by a
higher prevalence of certain non-lipid risk factors such as
hypertension, obesity, type 2 diabetes mellitus, smoking,
and low physical activity (Table 17).256 In addition, even
when these risk factors are identified, their management
may be suboptimal in AAs compared to whites because
of issues related to socioeconomic status and reduced ac-
cess to health care, as well as a lack of compliance with
medication, in part due to the cost of medications.517
Dyslipidemia, insulin resistance and metabolic syn-
drome recognition in AAs
In Ford et al.’s514 examination of NHANES data, AAs
were found to have lower TG and higher HDL-C. Thus,
the prevalence of metabolic syndrome was lower in AAs
than whites, and this was more evident in men than
women.514
There are distinctive features of lipoprotein metabolism
in AAs, including increased post-heparin lipoprotein lipase
activity.518,519 AAs are more insulin-resistant than whites,
insulin concentrations are higher, and there is greater inhi-
bition of hormone sensitive lipase in adipose tissue, as well
as less release of free fatty acids from peripheral adipose
tissue. Activity of lipoprotein lipase to clear TG-rich lipid
particles is higher in AAs than whites and is less inhibited
by apo C3 and insulin resistance.519,520 Obese AA women
have a reduced whole-body adipose tissue lipolytic rate,
less visceral adipose tissue, and lower intrahepatic TG con-
tent than do obese white women.521 These differences in
free fatty acid kinetics and body fat distribution could
reduce substrate availability for TG-rich VLDL particleassembly and secretion from the liver in AA women.521
Data suggest that lower VLDL-TG secretion is primarily
responsible for the lower plasma TG concentration
observed in AA women. Post-absorptive plasma free fatty
acids and TG concentrations were lower in obese AA
women with type 2 diabetes than in obese white women
with type 2 diabetes mellitus who were matched for BMI,
percentage of body fat, and insulin sensitivity, likely due
to lower adipose tissue lipolytic activity and hepatic
VLDL-TG secretion rates.521 Thus, lower levels of TG
and higher levels of HDL-C result in AAs having a lower
prevalence of metabolic syndrome than whites, even though
AAs are more likely than whites to be insulin resistant.522
Lp(a), variations in PCSK9, and unique aspects of
lipids in AAs
Lp(a) consists of an LDL-like particle to which an apo
B100 lipoprotein is covalently linked to apo(a). Lp(a) levels
are nearly 2-fold higher in AAs than in whites. In the
Jackson Heart Study, a panel of ancestry informative
markers accurately estimated African ancestry and revealed
the amount of African, compared to European, ancestry at
the Lp(a) locus was strongly associated with Lp(a) level.523
Newer data from ARIC indicate that Lp(a) levels were posi-
tively associated with CVD events, at least as strongly and
with a larger range of Lp(a) concentrations, in AAs
compared with whites.524 This contradicts the previously
suggested paradox for Lp(a) in AAs. More recent data
from larger, long term studies provide further evidence
that elevated Lp(a) concentration in AAs, as in whites, is
associated with an elevated risk for ASCVD.525 In general,
elevated Lp(a) levels associate robustly and specifically
with increased CVD risk. The association is continuous
without a threshold and does not depend on high levels of
LDL-C or non-HDL-C, or on the levels or presence of other
cardiovascular risk factors. Therefore, if in an AA patient,
premature CVD or CHD is not explained by conventional
lipid levels and other risk factors, Lp(a) may be a factor.
PCSK9 is a serine protease that binds the LDL receptor,
thereby targeting it for lysosomal degradation.11 In the
Dallas Heart Study (3543 subjects), among AAs missense
mutations were associated with low plasma LDL-C levels
and substantial protection from CHD.526,527 Genetic vari-
ants of PCSK9 genes in AA men associated with lower
LDL-C were also associated with lower carotid intima-
media thickness and lower prevalence of measured CAC.
Some loss-of-function PCSK9 mutations are relatively
common in AAs (combined frequency, 2%) but rare in
Americans of European descent (,0.1%), and are associ-
ated with w40% lower plasma levels of LDL-C.528,529
Lipoprotein particle characteristics in AAs
The Studies of a Targeted Risk Reduction Intervention
through Defined Exercise demonstrated unique aspects in
lipoprotein subclass distributions among middle-aged
AAs as compared to whites, controlling for a number
of confounding risk factors and with no known history of
Jacobson et al NLA Dyslipidemia Recommendations - Part 2 S65active smoking, CHD, or diabetes.530 AAs of both sexes
had larger HDL and LDL particle sizes than whites.
Since TG elevation correlates strongly with reductions
in HDL and LDL particle size, this may reflect the lower
average TG level among AAs compared to whites. Group
differences in the amount of visceral fat, lipoprotein
lipase activity, and hepatic lipase activity may all be
key mechanistic contributors to lipoprotein differences
in AAs compared with whites. Despres et al.518 reported
that hepatic lipase levels were highest in white men,
lowest in AA women, and intermediate in white women
and AA men.
ApoL-I, the trypanosome lytic factor, has a pronounced
association of 2 independent genetic variants within the
APOL1 gene with focal segmental glomerulosclerosis and
with end-stage renal disease attributed to hypertension.
The described variants are very common in AAs, but absent
in chromosomes of European origin.531 ApoL-I is a serum
factor that lyses trypanosomes, but increased risk for CKD
is the downside of having variants of this parasite-slaying
protein and may thus contribute to the higher rates of renal
disease in AAs.532,533
Statin use and efficacy in AAs
Various factors may contribute to lower frequencies of
successful dyslipidemia management among AAs with
dyslipidemia, including reduced awareness of lipid levels
and poor long-term adherence. The frequency of LDL-C
testing has been shown to be significantly less in AAs. In
one study, less than 14% of those in urban settings recalled
their cholesterol levels.534 Even among hypertensive
patients, over 50% did not have cholesterol measured in
the prior year. ALLHAT-LLT was the first clinical outcome
trial of the efficacy of statin (pravastatin) with substantial
representation of black subjects.347 In the main study
results, there was no difference in all-cause mortality or
CHD events in those treated with pravastatin vs usual
care. However, AAs in the pravastatin group had signifi-
cantly reduced risk for CHD events, possibly driven by
underuse of statin in the usual care cohort. Nevertheless,
the AHA 2015 report of data on CVD in America reported
that screening now appears to be similar among NHWs
(71.8% screened; 70.6% of men and 72.9% of women)
and NHBs (71.9% screened; 66.8% of men and 75.9% of
women).256 In addition, the percentage of adults at least
40 years of age who used a prescription cholesterol-
lowering medication in the United States from 2011–2012
was similar in blacks (28.2%) and whites (28.3%).
However, data from a large Medicare Advantage plan
showed that elderly blacks were still less likely to have
their LDL-C controlled.535 Also, data from a recent
meta-analysis suggested that nonadherence to statins was
greater in nonwhites than whites.536
In an examination of ethnic differences in LDL-C goal
achievement in the NCEP Evaluation Utilizing Novel
E-Technology II survey of 4885 patients receiving
treatment for dyslipidemia, 79.7% were NHW and 8.4%were AA.517 Frequencies of treatment success (defined as
NCEP ATP III LDL-C goal attainment) were significantly
lower among AAs than NHWs: 53.7% vs 69.0%
(P , .001). Furthermore AAs were more likely to be in
the highest risk category, but less likely to be using lipid
drug therapy or taking high-efficacy statins. The gap in
goal achievement between AAs and NHWs remained
statistically significant after adjustment for these, as well
as other, predictors of treatment success. Additional
research is needed to examine the role that reduced
compliance may have in the reduced treatment success
reported among AAs.
A study on the phenotypic predictors of response to
simvastatin therapy among AAs and Caucasians, the
Cholesterol and Pharmacogenetics study, enrolled 944
AA and white men and women who completed an open-
label, 6-week pharmacogenetics trial of 40 mg simva-
statin.537 Overall, simvastatin lowered LDL-C by 54 mg/dL
or 41%. Compared with AAs, whites had a 3 mg/dL greater
LDL-C reduction and a 1 mg/dL higher HDL-C elevation.
These findings were independent of other variables,
including baseline lipoprotein levels. Participants were
required to demonstrate at least 90% compliance with pill
counts at each 2-week clinic visit throughout the study.
Therefore, reduced compliance was not likely the main
contributor to reduced LDL-C lowering with the statin
in AAs.
In JUPITER, subjects without hyperlipidemia but with
elevated hs-CRP levels were assigned to placebo or 20 mg
rosuvastatin daily. In JUPITER and other studies, black
participants have been shown to have higher hs-CRP
levels, particularly black women compared with women
of other races.344,497 Compared with placebo, blacks had
somewhat smaller reductions than whites in hs-CRP
(222.2% vs 236.4%), LDL-C (243.0% vs 251.4%),
and apo B (230.6% vs 238.7%) (P , .001 for all).497
Rosuvastatin reduced the incidence of major cardiovascular
events and first MI, stroke, arterial revascularization,
hospitalization for unstable angina, and cardiovascular
death in the overall study sample.497 Rosuvastatin resulted
in a 45% reduction in the primary end point among whites
(HR 0.55; 95% CI 0.43–0.69), and a 35% reduction
among blacks (0.65; 0.35–1.22). Rosuvastatin also
resulted in a 55% reduction in stroke among whites
(0.45; 0.27–0.77), and a 46% reduction among blacks
(0.54; 0.19–1.60). Although differences in benefits were
not statistically significant, the somewhat smaller responses
to treatment for LDL-C and apo B may have contributed to
the trend toward smaller benefits in blacks compared with
whites.
Creatine kinase levels in AAs
Baseline creatine kinase levels are generally higher in
AAs than in whites, SAs, and Hispanics/Latinos, and are
also higher in men than in women.538,539 The higher mean
level in AAs is thought to be due to a proportional leak
from normal tissues related to higher creatine kinase
S66 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015activity, and is not reflective of tissue damage.540 Clinicians
should not withhold statin therapy from hypercholesterol-
emic patients with asymptomatic baseline creatine kinase
levels that are .1.0 but ,5.0 times the upper limit of
normal. This would potentially deprive many AA men
from receiving statin treatment, adding to the well-
documented higher risk of cardiovascular problems caused
by statin undertreatment. Recognizing the importance of
promoting awareness of expected creatine kinase levels,
the NLA Muscle Expert Panel recommended using norma-
tive upper limits for creatine kinase that are adjusted for
age, race, and sex.334
Conclusions
Despite improvements in US health, life expectancy,
and care, the distribution of ASCVD benefits has not been
equitable, and there is a persistent mortality gap between
AAs and whites, driven in part by disparate ASCVD
outcomes. AAs are at higher risk for hypertension,
diabetes mellitus, obesity, first MI, stroke, CKD, and
cardiovascular mortality, especially premature cardiac
death. As a group, the lipid profile in AAs is characterized
by lower TG and higher HDL-C, leading to a lower
prevalence of the metabolic syndrome despite higher
prevalence of insulin resistance. Greater risk due to higher
concentrations of Lp(a) in AAs is now recognized as
important. In the past, AAs were under-represented in
many landmark lipid trials and assumptions of treatment
efficacy have been based on limited clinical data. Fortu-
nately, the appropriate use of lipid-lowering drugs has
become more equitable between AA and white popula-
tions in the United States in recent years. However, the
rates of LDL-C control and adherence to medication
regimens still differ materially, and therefore, increased
efforts should be directed toward improving the persistent
treatment gap between AAs and whites.Chart 8 Recommendations for African Americans
Recommendations
In general, AAs should be treated according to the NLA Recommendat
of Dyslipidemia – Part 11 with the following special considerations
Clinicians should be aware that AAs as a group are at increased risk f
Because attributable ASCVD risk in AAs is less driven by dyslipidemia
should be given to assessing non-lipid risk factors, such as hyperte
diabetes mellitus, and physical inactivity, when ascertaining ASCVD
AAs have a lower incidence of metabolic syndrome than NHWs, due t
HDL-C. However, the incidence of type 2 diabetes mellitus is highe
Because AA race/ethnicity is included in the 2013 ACC/AHA Pooled Co
ASCVD risk, this may be the preferable risk calculator to use in pat
Because Lp(a) levels tend to be higher in AA patients, measuring Lp(a)
in AA patients, particularly in those with a family history of premat
factors.
Clinicians should not withhold statin therapy from at risk AA patient
levels that exceed, but are ,5.0 times, the standard upper limits o
upper limits for creatine kinase that are adjusted for age, race, anSee Chart 8 for the Recommendations for African
Americans.
South Asians (SAs)
Asian/SA population in the United States
The 2010 Census showed that the US population on
April 1, 2010, was 308.7 million.541 Out of the total US
population, 14.7 million people (4.8%) were Asian alone
(Table 19).542 In addition, 2.6 million people, or another
0.8%, reported Asian ethnicity in combination with at
least 1 other race/ethnicity. Together, these 2 groups
totaled 17.3 million people. Thus, 5.6% of all people in
the United States identified as Asian, either alone or in
combination with 1 or more other races/ethnicities. The
Asian population in the United States increased more
than 4 times faster than the total US population from
the years 2000 to 2010. The total US population grew
by 9.7%, from 281.4 million in 2000 to 308.7 million
in 2010, whereas the Asian alone population in the
United States grew by 43%, from 10.2 million to 14.7
million.
Of the total Asian population in the United States, SAs
totaled 3.86 million.541 The SA community in the United
States includes individuals who trace their ancestry to
Bangladesh, Bhutan, India, the Maldives, Nepal, Pakistan,
and Sri Lanka. The community also includes members of
the SA diaspora–past generations of SAs who originally
settled in other parts of the world, including Africa, Can-
ada, the Caribbean, Europe, the Middle East, and other
parts of Asia and the Pacific Islands. The 5 US states
with the largest SA populations are California, New York,
New Jersey, Texas, and Illinois. Metropolitan areas with
the largest SA populations are New York City, Chicago,
Washington DC, Los Angeles, and the San Francisco Bay
area.541Strength Quality
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Table 19 Asian population by number of detailed groups from the US Census 2010
Detailed group
Asian alone Asian in combination with one or more other races Detailed Asian
group alone or in
any combination*1 Asian Group 2 or more groups 1 Asian group 2 or more groups
Total† 14,327,580 346,672 2,429,530 217,074 17,320,856
Asian Indian 2,843,391 75,416 240,547 23,709 3,183,063
Bangladeshi 128,792 13,288 4364 856 147,300
Bhutanese 15,290 3524 442 183 19,439
Burmese 91,085 4451 4077 587 100,200
Cambodian 231,616 23,881 18,229 2941 276,667
Chinese‡ 3,347,229 188,153 334,144 140,588 4,010,114
Chinese, except
Taiwanesex
3,137,061 185,289 317,344 140,038 3,779,732
Taiwanesex 196,691 2501 15,781 468 215,441
Filipino 2,555,923 94,050 645,970 120,897 3,416,840
Hmong 247,595 4728 7392 358 260,073
Indonesian 63,383 6713 22,425 2749 95,270
Iwo Jiman 1 1 7 3 12
Japanese 763,325 78,499 368,094 94,368 1,304,286
Korean 1,423,784 39,690 216,288 27,060 1,706,822
Laotian 191,200 18,446 19,733 2751 232,130
Malaysian 16,138 5730 3214 1097 26,179
Maldivian 98 4 25 — 127
Mongolian 14,366 772 2779 427 18,344
Nepalese 51,907 5302 1941 340 59,490
Okinawan 2753 2928 3093 2552 11,326
Pakistani 363,699 19,295 24,184 1985 409,163
Singaporean 3418 1151 645 133 5347
Sri Lankan 38,596 2860 3607 318 45,381
Thai 166,620 16,252 48,620 6091 237,583
Vietnamese 1,548,449 84,268 93,058 11,658 1,737,433
Other Asian, not
specifiedjj
218,922 19,410 366,652 18,777 623,761
For information on confidentiality protection, nonsampling error, and definitions, see www.census.gov/prod/cen2010/doc/sf1.pdf.
— represents 0.
Note: This table shows more detailed Asian groups and response types than tables in 2010 Census Summary File 1. As a result, some numbers do not
match those shown in 2010 Census Summary File 1.
*The numbers by detailed Asian group do not add to the total Asian population. This is because the detailed Asian groups are tallies of the number of
Asian ‘‘responses’’ rather than the number of Asian ‘‘respondents.’’ Respondents reporting several Asian groups are counted several times. For example, a
respondent reporting ‘‘Korean’’ and ‘‘Filipino’’ would be included in the Korean and the Filipino numbers.
†The total of 14,327,580 respondents categorized as reporting only one detailed Asian group in this table is higher than the total of 14,314,103
shown in Table PCT5 (US Census Bureau, 2010 Census Summary File 1). This is because the number shown here includes respondents who reported ‘‘Chi-
nese’’ and ‘‘Taiwanese’’ together as a single detailed group, ‘‘Chinese,’’ whereas PCT5 excludes respondents who reported ‘‘Chinese’’ and ‘‘Taiwanese’’
together.
‡Includes respondents who reported ‘‘Chinese’’ and ‘‘Taiwanese’’ together.
xExcludes respondents who reported ‘‘Chinese’’ and ‘‘Taiwanese’’ together.
jjIncludes respondents who checked the ‘‘other Asian’’ response category on the census questionnaire or wrote in a generic term such as ‘‘Asian’’ or
‘‘Asiatic.’’
Source: US Census Bureau, 2010 Census special tabulation. Accessed at: http://www.census.gov/prod/cen2010/doc/sf1.pdf on May 14, 2015.542
Jacobson et al NLA Dyslipidemia Recommendations - Part 2 S67The heterogeneity of cardiovascular risk factors such
as dyslipidemia, hypertension, obesity, and diabetes, as
well as differences in the prevalence of ASCVD and
cerebrovascular disease, among persons of Asian/SA
ethnicity suggest a need to consider risk assessment and
treatment strategies specific to these subgroups of the US
population.Prevalence of dyslipidemia, diabetes mellitus, and
metabolic syndrome among Asians/SAs in the United
States
The majority of studies of Asians have been conducted
in their countries of origin. Data from the 2011–2012
NHANES provide a glimpse of current rates of hyperten-
sion, abnormal cholesterol levels, and high BMI among
S68 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015non-Hispanic Asian Americans over 20 years of age.543
About 1 in 4 (25.6%) surveyed Asian adults had hyperten-
sion (blood pressure $140/90 mm Hg or were taking anti-
hypertensive medication), similar to the prevalence among
Hispanics or whites, but less than the prevalence among
blacks. About 1 in 10 Asian men and women had high
total-C ($240 mg/dL), similar to the prevalence in other
groups. However, among non-Hispanic Asian adults,
many more men than women—24.5% vs 5.1%—had low
levels of HDL-C (,40 mg/dL), which was a greater sex
difference than among other groups. In a 3-year cross-
sectional study of 169,430 active primary care patients
($35 years of age) from an outpatient healthcare organiza-
tion in northern California, Asian Indians, Filipino, and
Vietnamese women and Asian Indian men stood out as
the Asian subgroups with increased risk of having the com-
bination of high LDL-C ($130 mg/dL or taking LDL-C
lowering medication), low HDL-C (,40 mg/dL for men
and ,50 mg/dL for women), and elevated TG
($150 mg/dL) compared to NHWs.480 The Study of Health
Assessment and Risk in Ethnic Groups from Canada
showed greater prevalence of high LDL-C, increased small
dense LDL, low HDL-C and higher TG levels among SAs
compared to Chinese and European controls.544
Lipid abnormalities in SAs are closely intertwined with
the prevalence of insulin resistance and diabetes. The
prevalence of type 2 diabetes is growing worldwide with
a projected rise in the total number of individuals with
diabetes from 171 million in 2000 to 366 million in 2030
based on data from the World Health Organization Global
Burden of Disease Study, which also predicted a particu-
larly concerning 151% increase in prevalence of diabetes in
the Indian subcontinent (from 31.7 million to 79.4
million).545 The susceptibility towards developing insulin
resistance may be partially explained by the ‘‘fetal origins
hypothesis’’, which postulates that malnourished fetuses
adapt to impaired nutrition by becoming relatively insulin
resistant.546 This adaptation may persist into adult life
even when calories are abundant, thus leading to insulin
resistance and type 2 diabetes mellitus. SAs have approxi-
mately 2- to 4-fold increased prevalence of diabetes
compared to other native ethnic groups. Population-based
studies that sampled SAs from different countries have re-
ported an age-standardized adult diabetes prevalence of
15.7% in India, 21.0% in the United Kingdom, 12.8% in
Singapore, 15.3% in Mauritius, 13.1% in Fiji, 9.8% in
South Africa, 9.9% in Tanzania, and 15.3% in Can-
ada.547–555 Surveys in rural and urban India (including the
India - Jaipur Heart Watch, and Chennai Urban Population
studies) suggest that about one-third of the urban popula-
tion in large cities in India have metabolic syndrome.556–558
A few studies have estimated diabetes and metabolic
syndrome prevalence in SAs in the United States. In a
community-based survey of 1046 Asian Indian immi-
grants living in and around the Atlanta, Georgia metro-
politan area, 18.3% had diabetes based on self-report553;
17.4% of SA adults in a national US study were found tohave diabetes based on self-report and fasting glucose
levels554; and in a study from the Bay Area, California,
27% had diabetes based on an oral glucose tolerance
test.559 In a recent large population-based study from
New York City, it was noted that the prevalence of
diabetes among foreign-born SAs was nearly twice
that of foreign-born other Asians (13.6% vs 7.4%,
P 5 .001).555 In multivariate analyses, normal-BMI
foreign-born SAs had nearly 5 times the diabetes preva-
lence of comparable US-born NHWs (14.1% vs 2.9%,
P , .001) and 2.5 times higher prevalence than
foreign-born other Asians (P , .001).555 The Diabetes
in Indian American (DIA) Study of Asian Indian
immigrants in 7 cities in the United States revealed an
age-adjusted prevalence of metabolic syndrome of 33%
in men and 32% in women; this was driven mainly by
a high prevalence of low HDL-C (65%), high TG
(45%), and increased waist circumference (32%).554
Clinicians should be aware when evaluating patients of
Asian ethnicity of the need to interpret BMI values
differently than in Caucasian patients. In the 2011–2012
NHANES data, only 38.6% of Asian adults had BMI
$25 kg/m2—much lower than previously reported rates for
Caucasian (66.7%), NHB (76.7%), and Hispanic adults
(78.8%)—but at a given BMI, Asian adults may have
more body fat than white adults.543 A large study
(n 5 43,507) from the Palo Alto Medical Foundation
Research Institute examined the relationship between
BMI and metabolic syndrome for Asian Americans and
NHWs.560 Metabolic syndrome prevalence was signifi-
cantly higher in Asians compared to NHWs for every
BMI category. A comparable prevalence of metabolic syn-
drome to that seen among NHW women and men with BMI
of 25 kg/m2 was observed among Asians with a BMI of
19.6 kg/m2 for women and 19.9 kg/m2 for men.560 Because
of this, screening for type 2 diabetes should be considered
in all Asians and SAs with a BMI $23 kg/m2. Furthermore,
clinicians should be aware of the different waist
circumference thresholds for defining abdominal obesity
as a characteristic of metabolic syndrome in different
populations (and from different organizations) (Table 20).6
The SA diet may predispose towards developing dysli-
pidemia and thus increases CHD risk. Use of clarified
butter (ghee), deep frying, long cooking times, and reuse of
the same oil multiple times may contribute to fatty acid
oxidation and increased saturated and trans fat consump-
tion. Furthermore, regular physical exercise is rare in this
population, especially among women, and may also
contribute to dyslipidemia.561
Treatment of dyslipidemia in Asians/SAs
There are few data available from large clinical trials or
observational studies regarding the awareness, treatment,
and control of dyslipidemia among Asians/SAs in the
United States. However, available data suggest that similar
to the overall population with dyslipidemia, and particu-
larly those with metabolic syndrome, lifestyle modification
Table 20 Waist circumference thresholds for abdominal obesity by various international organizations
Recommended waist, cm
Population Organization (reference) Men Women
Caucasian WHO, 2000112 $94 (increased risk)
$102 (still greater risk)
$80 cm (increased risk)
$88 (still greater risk)
United States AHA/NHLBI (ATP III*) (NCEP 2002)26 $102 $88
Canada Health Canada (Health Canada 2003113;
Khan et al 2006)114
$102 $88
European European Cardiovascular Societies
(Graham et al 2007)115
$102 $88
Asian WHO (Hara et al 2006)116 $90 $80
Japanese Japanese Obesity Society (Oka et al 2008)117,118 $85 $90
China Cooperative Task Force (Zhou 2002)119 $85 $80
Middle Eastern,
Mediterranean
IDF (Alberti et al 2005)120 $94 $80
Sub-Saharan African IDF (Alberti et al 2005)120 $94 $80
Ethnic Central and
South American
IDF (Alberti et al 2005)120 $90 $80
Europid IDF (Alberti et al 2005)120 $94 $80
Asian (including Japanese) IDF (Alberti et al 2005)120 $90 $80
AHA, American Heart Association; ATP, Adult Treatment Panel; IDF, International Diabetes Federation; NCEP, National Cholesterol Education Program;
WHO, World Health Organization. The reference numbers in this table refer to the reference numbering from the original publication.
*Recent American Heart Association/NHLBI guidelines for metabolic syndrome recognize an increased risk for cardiovascular disease and diabetes at
waist-circumference thresholds of $94 cm in men and $80 in women and identify these as optional cut points for individuals or populations with
increased insulin resistance.112,121
Taken from Expert Dyslipidemia Panel, Grundy SM. J Clin Lipidol. 2013;7:561–565.6
Jacobson et al NLA Dyslipidemia Recommendations - Part 2 S69including a diet low in saturated and trans fats, with weight
loss if overweight/obese and increased physical activity
should be the first-line and mainstay of treatment for the
management of dyslipidemia in Asians/SAs.1 When
used, pharmacologic therapy should be directed at
non-HDL-C and LDL-C targets as described in the NLA
Recommendations for the Patient-Centered Management
of Dyslipidemia–Part 1.1 The higher prevalence of
hypertriglyceridemia and small, dense LDL particles
among some Asian subgroups (SAs) suggest that
non-HDL-C, which includes the cholesterol carried by all
atherogenic cholesterol particles, may be a particularly
important consideration.480,543,554
Statins should generally be first-line drug therapy for
patients of Asian/SA ethnicity, with consideration of the
potential for side effects as discussed later in this document.
The Investigation of Rosuvastatin in South Asians was a
large randomized trial of statin therapy in 740 patients of
SA origin and with hypercholesterolemia in the United
States and Canada.562 Subjects received 6 weeks of
treatment with rosuvastatin 10 or 20 mg or atorvastatin
10 or 20 mg. LDL-C decreased by 45% and 40% with
10 mg rosuvastatin and atorvastatin, respectively, and by
50% and 47% with 20 mg rosuvastatin and atorvastatin,
respectively. LDL-C goal (based on NCEP ATP III risk
categories) was achieved by 76% and 88% of patients
receiving rosuvastatin 10 and 20 mg, respectively, and
70% and 81% of patients receiving atorvastatin 10 and
20 mg, respectively.Prevalence and incidence of CHD and ASCVD among
Asians/SAs in the United States
The majority of studies of CHD and ASCVD risk in
Asians have been conducted in their countries of origin.
Compared to NHWs, Chinese generally have lower levels of
LDL-C and TG, and Japanese have higher levels of HDL-C,
which may help to explain the lower risk of CHD in these
Asian subgroups.563 Asian Indians and Filipinos have been
shown to have higher prevalence of low HDL-C and high
TG, and increased CHD risk.563 Prevalence of CHD in rural
South Asia is 3–4%, while the CHD prevalence among urban
SAs and SA immigrants to the west approaches 10%.564
An assessment of CVD risk in a large multi-ethnic
population study of 126,088 adults was performed in
Northern California and included 13,448 (10.6%) Asian
Americans with 5951 of them Chinese, 1676 Japanese,
4236 Filipino, 689 SA (mostly Asian Indian), and 896 other
Asian.563 The HRs and 95% CIs for CHD incidence among
ethnic groups are shown in Table 21.563 Increased risk
among SAs was present in multiple strata, with the largest
hazard in men, younger persons, heavy smokers, and
persons with CHD events in the first 10 years of follow-up.
A study by Jose et al.565 utilizing death records from 34
US states reported heart disease and stroke mortality rates
for the 6 largest Asian-American subgroups. More than
10 million death records were examined and population
data for 2003 to 2010 were derived. Standardized mortality
ratios, relative standardized mortality ratios, and propor-
tional mortality ratios for each sex and ethnic group
Table 21 Risk of coronary artery disease in a large multi-ethnic population study of 126,088 adults in Northern California
Group (Number With CAD) HR 95% Confidence Interval P Value
Adjusted* HR of various ethnic groups vs white
White (4478) 1.0 – –
African American (2055) 0.8 0.8–0.9 ,.001
Hispanic (282) 0.9 0.8–1.0 .2
All Asian 1.0 0.9–1.0 .2
Chinese (262) 0.8 0.7–0.9 ,.001
Japanese (95) 0.9 0.7–1.1 .18
Filipino (263) 1.2 1.0–1.3 .02
Other Asian (24) 0.8 0.5–1.1 .17
South Asian† (56) 2.4 1.9–3.2 ,.001
Additional models for South Asian people vs white as
referent
Age- and sex-adjusted model 2.3 1.7–2.9 ,.001
Added covariates‡ 2.3 1.8–3.0 ,.001
Adjusted* HR of CAD in South Asian people vs ethnicities
other than white as referent
African American 2.9 2.2–3.8 ,.001
Hispanic 2.8 2.1–3.8 ,.001
Chinese 3.3 1.4–3.3 ,.001
Japanese 3.2 2.3–4.6 ,.001
Filipino 2.3 1.7–3.1 ,.001
Other Asian 2.8 2.1–5.6 ,.001
CAD, coronary artery disease; HR, hazard ratio.
*Cox models in 7658 people with hospitalization for CAD vs 118,430 without hospitalization for CAD; controlled for age, sex, smoking, alcohol, body
mass index, educational level, marital status, and cardiorespiratory composite. The cardiorespiratory composite was based on 27 questions about present
or past history of possible diagnoses or symptoms including diabetes. It was a dichotomous (yes, no) marker considered positive if there was a ‘‘yes’’
response to any question.
†Mostly Asian Indian.
‡After correcting for age, sex, smoking, alcohol, body mass index, educational level, cardiorespiratory composite, and marital status, the following
covariates were added to the model: systolic pressure, total cholesterol level, blood glucose level, and leukocyte count.
Taken from Hajra A, et al. J Am Coll Cardiol. 2013;62:644–645.563 Permission to reprint was obtained.
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although NHW men and women had the highest overall
CVD mortality rates when examined over the study period,
standardized mortality ratios from all CVDs decreased each
year. Except for Vietnamese women, the category of all
other Asian women had an increased rate of hemorrhagic
stroke compared to NHW women. While there has been a
decrease in mortality rates for NHWs, the declines for
ischemic heart disease and stroke have been less pro-
nounced or absent in Asian populations.565 Chinese Amer-
icans appear to have higher prevalence of hypertension,
which may contribute to increased risk for stroke.565,566
ASCVD risk assessment in Asians/SAs
As described above, there are differences in the risk
profile and in cardiovascular and cerebrovascular event
rates among diverse groups of Asians. This heterogeneity of
risk factors such as dyslipidemia, hypertension, obesity, and
diabetes, as well as differences in the prevalence of
ASCVD and cerebrovascular disease in the Asian sub-
groups, make it vital to accurately assess their risk.
However, there is an absence of data from the United
States and Asia to definitively guide risk assessment in
these subgroups. Therefore, consensus recommendationsby the experts must be adapted from US, British, and
international recommendations and guidelines for the man-
agement of dyslipidemia for SAs. For the most part, both
the Framingham Risk Score and the ACC/AHA Pooled
Cohort Equations may be relevant in SAs with some
adjustments.3,362 As there are no outcome studies based
on targeted therapeutic intervention or an adjusted risk
scoring system in Asian and SA populations, the following
recommendations regarding risk assessment were made by
this NLA Expert Panel based on consensus:
1. The use of non-HDL-C concentrations in addition to
LDL-C for screening purposes and for on-treatment
assessment may be particularly important for SAs.
Non-HDL-C includes the cholesterol carried by all
atherogenic lipoproteins, including Lp(a) (which is
elevated in Asian Indians compared to NHWs567) and
VLDL (which is increased in SAs in association with
a higher prevalence of elevated TG480).
2. Clinicians should be aware that risk assessment methods
developed in other populations may underestimate
risk in SAs living in the United States and should take
this into account when making decisions about risk
stratification and treatment.
Jacobson et al NLA Dyslipidemia Recommendations - Part 2 S71The underestimation of CVD risk in SAs may be due to a
high prevalence of non-traditional risk factors, notably high
levels of Lp(a) and visceral adiposity with insulin resistance,
despite comparatively low BMI.543,560,567 Observed CHD
morbidity and mortality rates among SAs have been substan-
tially higher than those predicted by Framingham Risk Score
and European System for Cardiac Operative Risk Evaluation,
which led to the development of QRISK2 in the United
Kingdom, a calculator that incorporates social deprivation
and ethnicity.568 The Joint British Societies Guideline uses
QRISK2 lifetime risk, which uses amultiplier of 1.5 for Asian
Indian men and 1.42 for Asian Indian women.568 The calibra-
tion factors are even higher for Pakistanis (2.05 for men and
2.04 for women) and Bangladeshis (2.14 for men and 1.6
for women). Additional research is needed to establish appro-
priate risk scoring methods for Asians/SAs living in the
United States. Therefore, the panel does not endorse a specific
risk multiplier, but instead advises that clinicians should be
aware of the increased risk in SAs, which may warrant classi-
fying SAs into a higher risk category for a given number of
major ASCVD risk factors, as a matter of clinical judgment.
ASCVD risk reduction with statins in Asians/SAs
In a Canadian study from British Columbia, investiga-
tors explored the associations between statin prescriptions
and outcomes in a multiethnic population with diabetes
using administrative data from 1993 to 2006.569 Subjects
had newly diagnosed diabetes and included 143,630 white
persons, 9529 SAs, and 14,084 Chinese. White patients
were older and had more comorbidity than the other groups.
A statin prescription was associated with lower mortality
compared with no prescription within each ethnic group,
and to a similar degree: SA (HR 0.69; 95% CI 0.55–0.86;
P 5 .001), Chinese (HR 0.60; 95% CI 0.49–0.72;
P , .0001), and white (HR 0.65; 95% CI 0.63–0.67;
P , .0001). These findings suggest that statin use is associ-
ated with lower mortality in white, Chinese, and SA
patients with newly diagnosed diabetes, consistent with
benefits of statins observed in other ethnic groups.
Side effects of statins in Asians/SAs
Statins are generally considered to be safe for use among
Asians/SAs. Although not placebo-controlled, the Investiga-
tion of Rosuvastatin in South Asians, described previously,
which was a large randomized trial of rosuvastatin 10 and
20mg and atorvastatin 10 and 20mg in patients of SA origin,
showed that both statins were generally well tolerated.562
There were no clinically relevant differences between statins
in adverse events or the incidence of creatine kinase .10
times the upper limit of normal, alanine aminotransferase
.3 times the upper limit of normal on 2 consecutive occa-
sions, proteinuria, or hematuria. However, genetic variability
in drug metabolism and increased prevalence of certain risk
factors suggest the need for caution when prescribing statins
to patients with Asian/SA ethnicity.
HPS2-THRIVE examined the cardiovascular outcomes
of treatment with extended-release niacin/laropiprant orplacebo added to simvastatin (with or without ezetimibe) in
.25,000 patients with pre-existing CVD from the United
Kingdom, several Scandinavian countries, and China (40%
of patients).570 Safety data indicated significantly greater
incidence of myopathy in patients receiving the combina-
tion of niacin/laropiprant plus simvastatin compared to sim-
vastatin alone (0.34%/year vs 0.08%/year of any myopathy,
P , .0001). This appeared to be driven primarily by an in-
crease in myopathy among Chinese patients (0.66%/year vs
0.13%/year for niacin/laropiprant plus simvastatin
compared to simvastatin alone). Among patients in Europe,
the incidence was 0.07%/year vs 0.04%/year, respectively.
Therefore, the incidence of myopathy was elevated in Chi-
nese patients in both treatment arms compared to Euro-
peans. Although Chinese patients were the only Asians in
HPS2-THRIVE, these results have led to a warning
advising caution when prescribing simvastatin to Asian pa-
tients and instructions to use the lowest dose possible.
To date, the specific cause of the increased susceptibility
of Chinese patients to myopathy has not been identified.
Genetic variability in drug metabolism, especially with
statins, among Asians through the CYP450 pathway and
P-glycoprotein, as well as uptake via organic anion
transporting polypeptides may play a role. Even if phar-
macokinetics is not the explanation, a potential pharmaco-
dynamic sensitivity justifies utilization of lower doses of
statins during initiation in Asian patients with titration to
goal as tolerated.571
Clinical trial data suggest a modest, but statistically
significant, increase in the incidence of new-onset type 2
diabetes mellitus with statin use. In their review of the
published evidence relating statin use to the hazard for
diabetes mellitus or worsening glycemia, the Diabetes Sub-
panel of the NLA Expert Panel on Statin Safety concluded
that the well-established benefits of statin therapy in primary
and secondary prevention of cardiovascular events outweigh
the risk of new-onset diabetes.336 The Panel therefore did not
recommend changes to clinical practice other thanmeasuring
glycated hemoglobin or fasting glucose prior to and within
one year of statin initiation in thosewith diabetes risk factors.
The risk for diabetes with statin use seems to be greater for
intensive-dosage statin therapy, and to be most evident in
those with major risk factors for diabetes.572 Because SAs
have increased risk for developing diabetes at a younger
age, statin therapy and new-onset diabetes is a particular
concern for this population, and clinicians should be vigilant
in screening and monitoring for worsening glycemia in SA
patients given statin therapy.
Conclusions
Heterogeneity of risk factors such as dyslipidemia, hy-
pertension, obesity and diabetes, as well as disparities of
ASCVDand cerebrovascular disease risks, among persons of
Asian ethnicity make it important to address specific pre-
vention and treatment strategies for this portion of the US
population.563 Among Asian subgroups, Chinese seem to
have a higher prevalence of hypertension and stroke,565,566
S72 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015and SAs have high TG, low HDL-C, increased visceral
adiposity at lower BMI, and higher prevalence of type 2 dia-
betes and CHD.566 These differences may be the result of
both genetic and lifestyle factors. There are no prospective
ASCVD outcome data in a randomized controlled trial of
lipid-lowering therapy in an Asian population. A large inter-
ventional cohort study in SAs utilizing traditional and
emerging risk factors and implementing strategies to reduce
the burden of diabetes and ASCVD is needed.Chart 9 Recommendations for South Asians
Recommendations Strength Quality
In general, patients of SA ethnicity should be treated according to the NLA Recommendations for Patient-
Centered Management of Dyslipidemia – Part 11 with the following special considerations.
A High
Clinicians should be aware that SAs (including individuals who trace their ancestry to Bangladesh, Bhutan,
India, the Maldives, Nepal, Pakistan, and Sri Lanka; and also members of the SA diaspora–past generations
of SAs who originally settled in other parts of the world, including Africa, Canada, the Caribbean, Europe,
the Middle East, and other parts of Asia and the Pacific Islands) as a group are at increased risk for ASCVD.
A Moderate
Patients of SA descent in the United States have a greater prevalence of insulin resistance than NHWs, and
some of the metabolic disturbances that accompany this condition include high TG, low HDL-C, and
dysglycemia.
A Moderate
SAs have increased prevalence of metabolic syndrome compared to NHW Americans. Clinicians should be
aware that Asians have different waist circumference cut-points for defining overweight/obesity for the
definition of the metabolic syndrome than those recommended for Caucasian populations ($37 inches
[$94 cm] for men and $32 inches [$80 cm] for women).
A Moderate
Clinicians should be aware that risk assessment methods may under- or over-estimate ASCVD risk when used in
populations different from those in which they were developed. ASCVD risk equations may underestimate
risk for SAs in particular, although the degree of underestimation is uncertain. Clinicians should consider
this when making decisions about risk stratification and treatment.
B Moderate
Due to the possibility of genetic variation in drug metabolism (as demonstrated mainly in studies of Chinese
and Japanese patients), starting with a moderate intensity statin dosage and titrating upward to reach
atherogenic cholesterol goals, or downward if intolerance occurs, is recommended for patients of Asian
ethnicity.
B Moderate
Because SAs are at increased risk for diabetes, vigilant monitoring for the potential of new-onset diabetes
with statin treatment is warranted.
A ModerateAmerican Indians (AIs) and Alaska Natives
(ANs)
The US CDC defines AIs and ANs as people having
origins in any of the original peoples of North and South
America (including Central America), and who maintain
tribal affiliation or community attachment.573 According to
the US Census Bureau, in 2013 there were roughly
5.2 million AIs and ANs living in the US, representing
approximately 2% of the US total population.573
Relative to other US ethnic and racial groups, AIs/
ANs have higher prevalence and incidence rates for
certain medical conditions, including obesity, diabetes
mellitus, and ASCVD. Average life expectancy is
reduced by 5.2 years compared to the general US
population, which is likely to be explained in part by
elevated ASCVD risk.574
A number of ASCVD risk factors are clearly more
common among AI/AN populations in the US than inNHWs. These include, obesity, metabolic syndrome,
diabetes mellitus and cigarette smoking.256,575 Prevalence
values for hypertension and hypercholesterolemia appear to
be comparable or slightly elevated in AIs/ANs compared to
NHWs.575 Additional factors that may contribute to ASCVD
risk in AI/AN populations include low rates of achieving fed-
eral physical activity guidelines and high prevalence of low
socioeconomic status.256,576
See Chart 9 for the Recommendations for South Asians.Dyslipidemia screening and management in AI/AN
patients
In general, clinicians should screen for and manage
dyslipidemia in AI/AN patients using the approach
outlined in Part 1 of the NLA Expert Panel Recommen-
dations for Patient-Centered Management of Dyslipide-
mia.1 Because of the high prevalence and incidence rates
for obesity, metabolic syndrome and diabetes mellitus in
AI/AN populations, strong emphasis on lifestyle thera-
pies, starting at an early age, is warranted, especially
for patients who are overweight/obese or display meta-
bolic syndrome.
ASCVD risk assessment in AI/AN patients
The NLA Expert Panel recommends that clinicians
should be aware that ASCVD risk is elevated, on average,
in AI/AN populations, which emphasizes the importance of
controlling dyslipidemia and other modifiable risk factors.
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using the risk assessment approach outlined in Part 1 of the
NLA Expert Panel Recommendations for Patient-Centered
Management of Dyslipidemia.1
When compared with NHWs, estimated 10-year risk of
ASCVD is generally higher in AI/AN populations,
although the degree to which this is attributable to
differences in traditional ASCVD risk factors is uncertain.
In primary prevention, for patients at moderate risk with 2
major ASCVD risk factors, and no conditions that would
otherwise classify an AI or AN patient as high or very high
risk, quantitative risk scoring may be used for risk
refinement. The lack of specific risk assessment tools
validated for use in AI/AN populations is an important
gap, but development of such a tool would be a challenge
due to blood quantum and multiracial composition of a
significant portion of AI/AN patients. The ACC/AHA
Guideline on the Assessment of Cardiovascular Risk362 rec-
ommends that, although the development of algorithms
specific to these groups is encouraged, in the interim, pro-
viders may consider using the Pooled Cohort equations for
NHWs and for AI/AN patients. However, it is important to
note that internal validation cohorts did not include AI or
AN patients. Similarly, other quantitative risk assessment
tools such as the Framingham Risk Score and the long-
term Framingham Risk Score may be applied. However,
this should be done with recognition that such tools may
under estimate risk in groups, such as AI/AN populations
that have higher average risk than the groups for whom
the tools were validated.See Chart 10 for the Recommendations for American
Indians/Alaska Natives.Chart 10 Recommendations for American Indians/Alaska Natives
Recommendations Strength Quality
Clinicians should be aware that AIs/ANs have higher prevalence and incidence rates for ASCVD, and that
certain ASCVD risk factors (e.g., obesity, metabolic syndrome, diabetes mellitus, and cigarette smoking)
are more common among AIs/ANs than NHWs, whereas prevalence values for hypertension and
hypercholesterolemia are comparable or slightly elevated compared to NHWs.
A Moderate
In general, clinicians should screen for and manage dyslipidemia in AI/AN patients using the approach
outlined in the NLA Expert Panel Recommendations for Patient-Centered Management of Dyslipidemia –
Part 1.1 Because of the high prevalence of obesity, metabolic syndrome, and diabetes mellitus in AI/AN
populations, strong emphasis should be on lifestyle therapies.
A Moderate
Clinicians should generally assess risk in AI/AN patients using the risk assessment approach outlined in the
NLA Expert Panel Recommendations for Patient-Centered Management of Dyslipidemia – Part 1.1
B LowHigh risk conditions and residual risk
Human immunodeficiency virus (HIV)-infected
persons
The lifespan of patients with HIV infection and
suppressed viral replication now approaches that of the
general population. This prolonged survival is associated
with an increased prevalence of co-morbidities, includingCVD, presumably due in part to the inflammation,
immune activation, and immune senescence associated
with this viral infection. Results from observational
studies support an increased CVD risk in the HIV
population; however there is a paucity of data linking
cardiovascular outcomes with lipid goals and no vali-
dated risk stratification schemes for this patient popula-
tion. The NLA Expert Panel recognizes the paucity of
data from RCTs with cardiovascular outcomes in patients
with HIV infection to guide decisions on when to
intervene using lipid-altering drug therapy. There is
insufficient information available to make definitive
recommendations at this time. However, given the strong
data indicating that HIV infection is a risk factor for
ASCVD, the Expert Panel believes that clinicians should
have a frank discussion of risk with patients and consider
HIV as an independent risk factor that should influence
when to consider drug therapy for lowering atherogenic
cholesterol.
While some experts suggest that it may be more
difficult to achieve lipid goals in HIV-infected persons
with current therapies, data from lipid-lowering trials
suggest that the percent reductions in non-HDL-C, LDL-
C, and TG with statins and fibrates are comparable to
those achieved in the general population.577,578 Not
known is whether goals should be more aggressive in
these patients, similar to those with other high risk fea-
tures such as diabetes or known ASCVD. With no defin-
itive data regarding lipid goals in HIV, following the
NLA recommendations for the general population is a
reasonable approach,1 with the caveat that HIV infection
can be considered an additional major ASCVD risk fac-tor when counting risk factors for risk stratification. This
recommendation is based on results from observational
studies suggesting that the independent effect of HIV
infection is similar to that of major, established ASCVD
risk factors.579–583 A multi-disciplinary panel of HIV ex-
perts reviewed the literature and has provided additional
guidance on how the NLA recommendations on risk
assessment and treatment may be applied to the HIV-
infected population.
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HIV disease is associated with many of the risk factors
for CVD. In persons not receiving antiretroviral therapy
(ART), HIV infection clearly increases CVD risk.584
Whether HIV infection itself causes atherosclerosis due to
inflammation, immune activation, and/or another mecha-
nism is unclear (Fig. 1).585 Multiple cohort studies
have demonstrated excess CVD risk among untreated
HIV-infected patients and in ART-treated patients
compared to those without HIV infection.586,587 Patients in-
fected with HIV and on ART often had a constellation of
metabolic abnormalities including lipodystrophy (lipoatro-
phy and lipohypertrophy), insulin resistance, elevated TG,
and low HDL-C. However, newer ART medications do
not cause significant dyslipidemia and are associated with
less risk of MI compared to prior regimens.588 The impor-
tance of treating HIV infection with continuous ART
cannot be overstated.589
Even with treatment of HIV, having a lower CD4 count
is associated with increased risk of MI.588 ART-associated
lipodystrophy has been linked with cardiac and metabolic
complications in patients similar to those observed in obese
people.590 This is of particular importance because patients
with lipodystrophy often have normal body mass indices.
Furthermore, patients with lipodystrophy have a greater
prevalence of dyslipidemia and impaired glucose meta-
bolism than patients without lipodystrophy.591
It is unclear what accounts for the association of CD4
count with CVD risk. Silverberg and colleagues588 found
that HIV-infected patients with recent or nadir CD4 count
$500 cells/mm3 had similar rates of MI compared to
HIV-negative patients, whereas HIV-infected patients with
recent or nadir CD4 count ,200 cells/mm3 had an
increased risk. Viral load, prior ART use, and duration of
therapy with protease inhibitors and nonnucleoside reverse
transcriptase inhibitors were not associated with MI.
Unsuppressed HIV viremia has been associated with
MI580 and stroke592 in other studies. Both viral load and
CD4 count are included as variables in the Veterans Aging
Cohort Study,582,593 one of the commonly used risk esti-
mating equations in HIV (Table 22).1,3,6,12,362,368,583,
593–603 However neither viral load nor CD4 count are
included in another HIV-specific risk calculator developed
from the Data Collection on Adverse Events of Anti-HIV
Drugs (D:A:D) cohort.595
Special consideration of certain HIV subpopulations is
warranted. Observational cohort data suggest that HIV-
infected women have higher CVD risk than infected
men.582 Many patients with HIV infection are co-infected
with hepatitis C. Hepatitis C infection increases CVD
risk, but it is unclear whether the risks associated with
HIV and hepatitis C virus are additive.582 Other chronic
viral infections, including cytomegalovirus infection, are
more prevalent in HIV-infected persons and may also
increase CVD risk.604 Although the role of aging in HIV
disease remains unclear, aging is associated with greaterCVD risk. Increased attention to CVD risk in HIV-
infected persons with advancing age is warranted.
Traditional CVD risk factors should not be overlooked.
The prevalence of smoking is 2- to 3-fold higher among
HIV-infected Americans compared with the general popu-
lation.605 Smoking increases mortality even in the presence
of maximal viral suppression.606 Furthermore, among
HIV-infected individuals, the prevalence of dyslipidemia,
diabetes mellitus, and hypertension is higher than in the
general population.582 The lipid profiles of HIV-infected
patients are characterized by the ‘‘lipid triad’’ of hypertri-
glyceridemia, accompanied by an increase in small LDL
particles and lower HDL-C.607–609
Although hs-CRP is valuable to discriminate individuals
at higher risk of CVD events in the HIV seronegative
population, the data are not as clear in those with HIV
infection. Triant and colleagues610 studied 70,357 patients
in a single center database with hs-CRP measured. They
found an increased risk of acute MI with elevated hs-
CRP in HIV-infected individuals (OR 2.51). However, the
bias of which HIV-infected persons were tested for hs-
CRP (n 5 487) vs not tested (n 5 7099) and the lack of
an absolute cut-off make these data difficult to gener-
alize.610 In the Multicenter AIDS Cohort Study, elevated
CRP prior to initiation of ARTwas associated with a higher
risk of progression to acquired immunodeficiency syn-
drome (AIDS).611 The association between pre-ART eleva-
tion of CRP and HIV progression was also confirmed in a
case-cohort study within the multinational Prospective
Evaluation of Antiretrovirals in Resource-Limited Settings
clinical trial.612 Despite initiation of ART with efavirenz,
CRP levels did not decline after 96 weeks with viral sup-
pression.613 In a randomized trial of pravastatin and fenofi-
brate for persons with HIV and combined hyperlipidemia
there was no change in hs-CRP levels despite significant
declines in LDL-C and TG levels.614 Conversely, there
are a number of studies demonstrating that hs-CRP de-
clines with the use of statins in the general population.615
In JUPITER, the 44% risk reduction with the use of rosu-
vastatin was associated with a decline in hs-CRP.344 Thus,
the biology of CRP levels in HIV infection is complicated
and likely driven by multiple factors. It is possible that
future randomized clinical endpoint trials of statins in
persons with HIV may be able to address this question.
However, until such time, the use of hs-CRP to adjudicate
CVD risk in persons with HIV is not recommended.
Proposed mechanisms of atherosclerosis in HIV
infection
Although data remain limited, chronic HIV infection
appears to alter the morphologic characteristics and
progression of atherosclerotic plaque. Plaques tend to
have larger lipid pools with dystrophic calcification.616
Patients with well-controlled HIV infection have
modestly higher rates of subclinical vascular disease
compared to uninfected controls—including worsened
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function,618 increased arterial inflammation,619 higher prev-
alence of detectable CAC,620,621 and greater burden of cor-
onary plaque.621,622 Carotid intima-media thickness may
also progress more rapidly in HIV infection,623 although
this has not been confirmed in all studies.624,625 Despite
some attenuation in multivariable models, the HIV effect
persists after adjustment for traditional vascular risk
factors. HIV-infected persons are more likely to have
non-calcified626,627 and rupture-prone plaques that are
highly associated with non-traditional risk factors, such as
inflammation626 and monocyte activation.621,622 This sug-
gests that chronic inflammation and immune activation
are mediators of CVD risk in HIV (Fig. 11).585
Although antiretroviral drugs—particularly older prote-
ase inhibitors such as indinavir and lopinavir—were
implicated as a cause of CVD in older studies,627 newer
drugs in this class (i.e., atazanavir or darunavir) do not
appear to convey the same risk. Abacavir is a nonnucleo-
side reverse transcriptase inhibitor that has also been asso-
ciated with higher CVD risk in some studies, although the
association remains controversial.628,629 Platelet activation
may be worsened by abacavir630 and ameliorated by
switching to newer classes of drugs.631 Most importantly,
however, interruption of ART results in increased mortality
and acute CVD events when compared to continued ther-
apy.587 The take-home message for the practicing physician
and HIV-infected patient is that the benefits of ART greatly
outweigh potential CVD risks.632
Role of inflammation in the pathogenesis of athero-
sclerosis in HIV-infected patients
Atherosclerosis is a chronic inflammatory process in
which plaque formation is triggered by arterial wall injury,
lipoprotein deposition, endothelial activation, and pro-
inflammatory molecules.633 An atherosclerotic lesion de-
velops as focal thickening in the inner layers of the artery
composed of vascular endothelial cells, smooth muscle
cells, and immune cells (T cells, macrophages) that are
prone to rupture and manifest as acute MI. In the setting
of persistent systemic inflammation, the process of athero-
sclerosis is accelerated (Fig. 1).585 HIV infection rapidly
depletes CD4 cells, most notably from the gut, causing
marked immune dysfunction and a chronic inflammatory
state that accelerates end-organ diseases, and likely contrib-
utes to the development of atherosclerosis. Published data
highlight the numerous pathways involved in HIV-
associated atherosclerosis.634
Excess microbial translocation
Early depletion of CD4 cells from gastrointestinal-
associated lymphoid tissue (GALT) is a signature feature
of HIV infection.635–637 GALT constitutes the largest im-
mune compartment in the body. The profound depletion
of CD4 cells from the GALT during acute HIV infection
causes profound changes in the gut mucosal integrity, facil-
itating bacterial translocation, augmenting trafficking ofinflammatory cells to the gastrointestinal tract, and promot-
ing chronic systemic immune activation.638,639 Activation
of both the innate and adaptive arms of the immune system
ensues and a state of chronic inflammation and immune
activation is created.634,638 Elevated inflammatory bio-
markers can be measured, including markers of microbial
translocation (e.g., lipopolysaccharide, lycium barbarum
polysaccharide), pro-inflammatory biomarkers (e.g., inter-
leukin [IL]-6, IL1b), monocyte activation (e.g., soluble
CD14, soluble CD163), neutrophil activation (e.g., myelo-
peroxidase, neutrophil gelatinase-associated lipocalin),
adhesion molecules (e.g., soluble intercellular adhesion
molecule-1), coagulation markers, and fibrin degradation
products (e.g., D-dimer).638,640 Thus, changes in the
GALT have profound ramifications for end-organ disease
in the setting of HIV infection.
Cellular activation
With a massive depletion of CD4 cells, HIV-infected
persons are left with a state of immune dysregulation
manifested by low numbers of na€ıve T cells, an increase in
terminally differentiated effector T cells, the generation of
excessive pro-inflammatory cytokines, and altered T cell
functional and proliferative profiles.637,641,642 The chroni-
cally activated immune system generates excessive pro-
inflammatory cytokines associated with end-organ disease
such as atherosclerosis, diabetes, and renal injury.622,643,644
Even with suppressive ART, T cell activation remains
elevated above that seen in HIV-uninfected individuals.
Recent data assessing non-AIDS events in persons on sup-
pressive ART have suggested that the cells of the innate im-
mune system play a more important role in the process of
persistent inflammation and end-organ disease than the
adaptive immune system.645,646
In HIV-negative persons with ASCVD, a shift in the
monocyte phenotype has been demonstrated, consisting of
a greater proportion of pro-inflammatory monocytes that
target activated endothelial cells contributing to atheroma
formation and resulting in acute MI.617,647–649 In HIV
infection, even with ART and viral suppression, these
pro-inflammatory monocyte subsets are overrepresented
and similarly contribute to excess vascular inflammation
and hence atherosclerosis.622,650,651
Neutrophils, the most predominant immune cell popu-
lation, are specifically geared for the rapid detection of
invading pathogens. They have recently emerged as
important contributors to atherosclerosis.652–658 In the
setting of HIV, neutrophil activation and degranulation is
increased and remains elevated even with suppressive
ART. The dysregulated neutrophil population in HIV is
likely another immune mechanism driving accelerated
atherosclerosis.
Additionally, the processes of coagulation and platelet
function are dysregulated with HIV infection and likely
also contribute to atherosclerosis.659 Even with suppressive
ART, markers of coagulation (e.g., D-dimer) remain
elevated and are associated with end-organ disease,
Table 22 Risk scores and algorithms for assessing CV risk in the general population and among patients infected with HIV
Descriptor Framingham Risk Score SCORE PROCAM REYNOLDS
Population General population from 1
geographic area:
Framingham, MA, USA
European European men Men and women from USA, no
known CVD (men were
nondiabetic)
Age, y 30–74 19–80 35–65 Men, 57–80; women, $45
Data collection 1968–1971 Original Framingham
cohort, 1971–1975, and
1984–1987; offspring studies
1967–1992 Recruitment 1979–1985 d
followed for 10 y
Men, 1995–2008, followed for
median of 10.8 y; women,
1992–2004, followed for a
median of 10.2 y
Years risk
prediction
10-y risk of CHD events; 30-y risk
of CHD and stroke
10-y risk of CVD fatality 10-y fatal or nonfatal M r
sudden cardiac death
10-y risk for CVD
Variables Sex, age, total-C, HDL-C,
smoking status, systolic blood
pressure (treated or not
treated), diabetes
Sex, age, total-C or total-C/HDL-
C, systolic blood pressure,
smoking status
Age, LDL-C, HDL-C, TG, s oking
status, diabetes, fami
history of MI, systolic lood
pressure
Sex, age, smoking status, total-C,
HDL-C, hs-CRP, parental history










European (ESC/EAS)594 None None






0.77; O/E595–597: 1.18, 1.51
c-statistic597: 0.57; O/E597: 1.20 Unknown Unknown
Reference 598,599 600 673 368
Notes Different versions applied to
countries with low or high risk
Men were in the Physicians
Health Study and women in







































Pooled cohort equations D:A:D VACS
Population Population-based cohort studies
funded by NHLBI
D:A:D cohort of HIV 1 men in
Europe, Argentina, Australia,
USA
HIV 1 USA veterans, men
Age, y 16–85 $18
Data collection Varied 1999–2008; followed for a
median 4.8 y
2000–2007
Years risk prediction 10-y risk of ASCVD 5-y risk of CVD 5-y mortality
Variables Sex, age, race (white or black),
total-C, HDL-C, systolic blood
pressure, treatment for high
blood pressure (if systolic
.120 mm Hg), diabetes,
smoking status
Number of years on inidinavir,
lopinavir, currently on
indinavir, lipinavir, abacavir,
sex, age, current cigarette
smoker, previous cigarette
smoker, diabetes, family
history of CVD, systolic blood
pressure, total-C, HDL-C
Age, CD4 count, HIV-1 RNA (viral
load), hemoglobin, FIB-4,
estimated GFR, hepatitis C
infection status








Discrimination and calibration in
HIV1
c-statistic596,597: 0.65, 0.71;
O/E597: 1.20; may be better












Reference 362 595 602
Notes Risk scores account for white and
black race; eliminated targets
for LDL-C3
Predicts mortality and CHD death
for HIV 1 patients who have
been treated with ART for
at least 1 year583,593,601,603
ACC/AHA, American College of Cardiology/American Heart Association; ART, antiretroviral therapy; ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; D:A:D, Data Collection on
Adverse Events of Anti-HIV Drugs; eGFR, estimated glomerular filtration rate; ESC/EAS, European Society of Cardiology/European Atherosclerosis Society; FIB-4, (years of age ! aspartate transaminase)/
(platelets! Oalanine transaminase); HDL-C, high-density lipoprotein cholesterol; HIV, human immunodeficiency virus; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol;
MI, myocardial infarction; NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III; NHLBI, National Heart, Lung, and Blood Institute of the National Institutes of Health; O/E,
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been demonstrated to increase the production of procoagu-
lant factors and down-regulate anticoagulants, leaving indi-
viduals at increased risk for thrombotic events.664 Chronic
viral infections, including HIV, activate the coagulation
cascade by tissue injury and endothelial tissue damage
with subsequent expression of tissue factor, which serves
as a signaling molecule for activated T cells, monocytes,
and neutrophils inducing atheroma formation.665 Platelet
activation is increased with HIV infection, even with sup-
pressive ART, and the platelets express pro-inflammatory
cytokines and tissue factor.656,657
Measuring inflammation or immune activation
There are no reliable clinically available markers of
inflammation and immune activation to guide clinicians in
the management of persons with HIV. There are many
markers of inflammation and immune activation that
correlate with chronic HIV infection, such as IL-6,
D-dimer, and hs-CRP, but most are not measured routinely
in clinical practice. Whether any of these markers can be
altered in persons with HIV to reduce the risk for ASCVD
is not known. The National Institutes of Health randomized
trial Evaluating the Use of Pitavastatin to Reduce the Risk
of Cardiovascular Disease in HIV-Infected Adults
(REPRIEVE), which started in March 2015 and has an
estimated completion date of April 2020, may shed some
light on this issue by determining whether the use of statins
is beneficial in HIV-infected patients who do not meet
standard criteria for their use.666 REPRIEVE is a large
(N 5 6500) multi-center randomized trial investigating
the use of pitavastatin (4 mg) in HIV-infected patients on
ART that do not qualify for statin therapy according to
the 2013 ACC/AHA Guideline on the Treatment of Blood
Cholesterol to Reduce Atherosclerotic Cardiovascular
Risk in Adults.666
Statin use in HIV patients
Two mainstays of CVD prevention among HIV-infected
patients are 1) treatment with ART to reduce HIV immune
activation and inflammation, and 2) control of modifiable
risk factors, including lipids.653 Given that statins not only
reduce LDL-C but also have anti-inflammatory properties,
they may be beneficial in reducing the chronic inflamma-
tion associated with HIV infection.652,667,668 Statins have
been shown to be both safe and effective in HIV-infected
persons.669–671 However, the use of statins remains rela-
tively low in HIV-infected patients.580,672 The low use of
statins in the HIV-infected population may reflect the rela-
tively low prevalence of elevated LDL-C, their uncertain
efficacy for CVD prevention, and the potential for adverse
side effects and negative drug-drug interactions.
REPRIEVE described above has been designed to help
answer this question. Until these data are available, it is
not clear whether statins should be used more aggressively
in persons with HIV infection.Assessing cardiovascular risk in the HIV-infected
population
Risk scores and algorithms are used to determine
intensity of lipid-lowering therapy to prevent disease.
They have been used extensively for ASCVD, in particular
to establish an LDL-C goal or to determine the percentage
LDL-C reduction. Risk prediction in HIV-infected patients
is an evolving science, because potential drivers of risk are
present in HIV-infected patients that were not prevalent in
the populations from which risk prediction equations were
developed. Risk prediction schemes must also be easily
employed and discriminate correctly.
The most widely used algorithm in recent years has been
the Framingham Risk Score from the Framingham Heart
Study. This score predicts 10-year risk for MI and CHD
death.598 Other established risk scores for the general pop-
ulation include: Systematic Coronary Risk Estimation,600
Prospective Cardiovascular Munster (PROCAM),673 Rey-
nolds Risk Score,368 and the 2013 ACC/AHA Pooled
Cohort Equations.362 The last, newest set of equations has
been extensively debated. Some groups in the United States
have recommended further validation prior to its adop-
tion.674–676 The risk prediction tools used in the NCEP
ATP III guidelines (Framingham Risk Score) and the
2013 ACC/AHA Pooled Cohort Equations both underesti-
mate the risk of CVD among HIV-infected individ-
uals.654,655,658 Although the NCEP ATP III Framingham
equation and the 2015 NLA Recommendations risk stratifi-
cation system1 have not been validated in HIV-infected
patients, the NLA Expert Panel agreed that either risk
stratification scheme is acceptable for providing risk infor-
mation for this patient population.
At this time there is no validated, 10-year risk score
specifically for people infected with HIV. The D:A:D Study
investigators595 have published a risk equation for men that
includes several antiretroviral drugs as well as traditional
risk factors. Predictions were estimated for 5-year risk.67
The Veterans Aging Cohort Study also published a mortal-
ity risk index that includes CD4 count and viral load. It is
used for overall mortality prediction602 but has also been
used to assess cardiovascular mortality.593 The risk scores
noted above are summarized and compared in
Table 22.1,3,12,279,344,362,368,467,579,583,593–600,672
There are differing opinions and data on how well the
existing risk score tools predict risk among persons with
HIV infection. Friis-Moller et al.595 and Parra et al.655
found that the Framingham Risk Score underestimated
the presence of subclinical atherosclerosis and clinically
manifest disease in HIV-infected patients. Falcone
et al.678 showed that increased Framingham Risk Scores
predicted risk accurately and were associated with
abnormal early and late surrogate markers (carotid
intima-media thickness) in a group of 334 HIV-infected
adults. Law et al.679 compared the number of MIs observed
among participants infected with HIV in the D:A:D Study
with the number predicted by conventional risk factor
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over-predicted rates in patients who did not receive ART
and under-predicted rates in patients on ART. Nery and col-
leagues680 assessed the agreement between Framingham,
PROCAM, and D:A:D risk equations in HIV-infected
patients in Brazil. The authors also used an expanded
Framingham prediction tool for those with low or moderate
10-year Framingham risk by adding family history of CVD,
metabolic syndrome, serum creatinine $1.5 mg/dL, hs-
CRP .3.0 mg/L, or albuminuria .30 mg/mg. The
PROCAM score placed the lowest proportion of patients
into the high-risk group, while the Framingham with
expanded risk indicators tool placed the highest proportion
of patients into the high-risk group. Zanni and col-
leagues658 used computed tomography angiography to
assess the performance of the 2013 ACC/AHA Cholesterol
Guideline in 108 HIV-infected individuals without known
CVD. Thirty-nine participants had coronary atherosclerotic
plaque morphology classified as high risk; however, statin
therapy would not have been recommended for 74% of
these individuals by the 2013 ACC/AHA guideline.
Risk for ischemic stroke had not been considered in
most prior risk scores, although several, including the
recent ACC/AHA Pooled Cohort Equations for 10-year
risk, do include stroke risk. Fewer studies are available
providing data on stroke in HIV-infected patients, but
existing studies suggest an increase risk above what would
be predicted from traditional risk factors.592,681,682 Ovbia-
gele and colleagues683 reported a 67% increase in HIV-
infected patients hospitalized for stroke (hemorrhagic and
ischemic) from 1997 to 2006 in the United States.683 Ma-
teen et al.684 tested the accuracy of the Framingham Risk
Score for prediction of stroke of any type in HIV-infected
men compared to non-infected men in the Multicenter
AIDS Cohort Study, and found that Framingham underesti-
mated the long-term risk for stroke in HIV-infected men.
It does not appear that HIV itself directly increases risk
for hypertension although there may be an increased
prevalence of hypertension among older HIV-infected
persons compared to age-matched uninfected individ-
uals.685 The prevalence of hypertension was reported to
be 43% in one outpatient setting in New York City686 and
31% in two HIV Naval Clinics.687 Evidence for an associ-
ation between use of ART and hypertension is not consis-
tent; with some studies showing no association687,688 and
others showing that ARTwas associated with a higher prev-
alence of systolic hypertension.689
While it is clear that prolonged survival in HIV infection
is accompanied by an increased prevalence of non-HIV
related co-morbidities at all ages, it is less clear whether
this increased prevalence may be attributed to the actual
aging process or ‘‘accelerated aging’’.690,691 A Kaiser-
Permanente group reported that the overall incidence rates
for MI for the HIV-infected population has steadily
declined from 1996 to 2011 and this rate now approximates
that of the general population.692 An epidemiologic study
of HIV-associated CVD mortality 2001–2012 inNew York City showed that while the number of deaths
due to ASCVD increased as a cause of death among those
with HIV infection, the overall CVD mortality rate has
steadily declined. Furthermore, the CVD mortality rates
were significantly higher in the HIV-infected population
under age 65 whereas CVD mortality after the age of 65
was essentially the same as the general population.693
Nevertheless, it is likely that persistent underlying inflam-
mation is contributing to the increased CVD morbidity,
which is not captured in the current risk assessment tools
leading to an underestimation of actual risk.596,597
Recommendations for assessing cardiovascular risk
in the HIV-infected population
HIV-infected patients have a higher prevalence of CVD
compared to the general population, which persists even
after control of traditional risk factors.581 This population
also has higher rates of smoking and other behavioral and
social factors that increase ASCVD risk.677,686 HIV infec-
tion and its therapies may also produce a syndrome consist-
ing of insulin resistance, lipodystrophy (lipoatrophy and fat
accumulation including an increase in abdominal visceral
fat), and abnormal lipids (elevated TG and low
HDL-C).653,694,695 The role of inflammation in the patho-
genesis of atherosclerosis is well known in the general pop-
ulation and is believed to play a significant and unique role
in the increased ASCVD risk in patients infected with
HIV.619,660,696 Taken together, these factors provide evi-
dence that patients infected with HIV are at higher ASCVD
risk, both from traditional and unique risk factors. This
increased risk is not accurately assessed with existing risk
scoring systems. There is a clear need to develop specific
cardiovascular risk equations for people living with HIV.
Established risk scoring systems are for short-term predic-
tion, generally ten years. However, both the Framingham
Risk Score and the ACC/AHA Pooled Cohort Equations
provide lifetime risk estimates.362,599 Most HIV cohort
studies have followed patients for less than ten years;
hence, there are no lifetime risk scores for patients infected
with HIV.
At this time, the HIV Medicine Association of the
Infectious Disease Society of America697 and the European
AIDS Clinical Society698 both endorse use of the Framing-
ham Risk Score, although it is not validated in patients with
HIV.
This Expert Panel recommends estimating risk as out-
lined in the NLA Recommendations for the Patient-
Centered Management of Dyslipidemia–Part 1.1 This
includes determining the number of risk factors, the use
of risk prediction tools, such as the ATP III Framingham
Risk Score or the ACC/AHA Pooled Cohort Equations if
two risk factors are present, as well as clinical judgment.
The Expert Panel consensus view is that it is reasonable
to consider HIV a risk factor for ASCVD in risk factor
counting. In primary prevention patients, for those with
HIV infection plus 2 other major ASCVD risk factors,
atherogenic cholesterol levels for non-HDL-C and LDL-C
S80 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015goals are ,130 mg/dL and ,100 mg/dL, respectively. The
NLA Part 1 document also states that ‘‘risk indicators’’ can
be used for ‘‘risk refinement.’’ These include strong family
history of premature ASCVD and multipack per day smok-
ing. Metabolic syndrome is not specifically listed as a risk
criterion but can be considered for risk refinement, espe-
cially because this cluster of metabolic abnormalities
(high TG, low HDL-C, insulin resistance, elevated waist
circumference, and hypertension) is common in HIV-
infected patients.
Current evidence suggests that HIV-infected patients are
at higher risk for ASCVD, although whether it meets
criteria for classification as an ‘‘ASCVD risk equivalent’’
similar to diabetes plus 2 major ASCVD risk factors is
unknown. The importance of shared decision-making be-
tween the patient and provider about whether to initiate
statin therapy is also a central principle of the NLA Part 11
and these Part 2 recommendations.
Treatment of dyslipidemia in HIV infection
HIV-infected patients should be treated similarly to the
general population, with atherogenic cholesterol goals
according to the NLA Part 1 Recommendations1 with the
caveat of considering the presence of HIV infection an
additional major ASCVD risk factor. Challenges include
understanding the risks attributable to HIV itself vs those
induced by ART, as well as the complexities of selecting
the specific lipid-lowering agents and adjusting their doses
to reach maximal effectiveness without compromising
safety. The current Department of Health and Human Ser-
vices Panel on Antiretroviral Guidelines for Adults and
Adolescents and the International Antiviral Society-USA
HIV treatment guidelines recommend that everyone in-
fected with HIV should be offered ART, regardless of their
absolute CD4 cell count, to reduce all-cause mortality,
including that from CVD events, and to reduce transmis-
sion.589,699 Although previous antiretroviral agents were
associated with significant metabolic side effects, the
more commonly prescribed and recommended regimens
of today are not. It is also important to consider how
many of these side effects are likely due to the current
ART as opposed to traditional risk factors or HIV itself.
In a patient who is otherwise tolerating ART with full viro-
logic suppression, one must weigh the risks and benefits of
switching ART. Many experts prefer treating with the
appropriate lipid-lowering therapies rather than switching
the ART regimen.
As with all patients with dyslipidemia, lifestyle in-
terventions remain the cornerstone of therapy. Patients
should be referred for nutritional counseling, smoking
cessation, and weight management. Patients who are not
virologically suppressed on ART should be referred for
adherence counseling and managed with a goal of
achieving full suppression. If dyslipidemia persists after
maximizing HIV control and lifestyle interventions, pa-
tients should be treated according to the lipid abnormality
present.As in the general population, statins are the first-line
drug class for treatment of dyslipidemia. The choice of
statin is largely based on its drug interaction potential with
the patient’s ART as well as the intensity of the statin. The
FDA recently issued updated recommendations concerning
drug-drug interactions between drugs for HIV and statins
and provided the statin dose limitations.700 The reader is
also referred to Kellick et al.463 for a thorough review of
statin drug-drug interactions by the NLA’s Safety Task
Force, as well as a systematic review of the use of statin
therapy in patients with HIV by Feinstein et al.701 The
Expert Panel has provided a summary of the interactions
between protease inhibitors (including cobicistat) and
non-nucleoside reverse transcriptase inhibitors and statins
(Table 23).578 Nucleoside reverse transcriptase inhibitors
and integrase inhibitors, except when boosted with cobici-
stat, do not have any significant drug-drug interactions with
statins. In previous years, pravastatin was the preferred
agent for patients with HIV, due to its limited interactions
with most antiretroviral agents. However, in more recent
years, atorvastatin and rosuvastatin have been prescribed
more often because of their greater efficacy. Given the in-
crease in certain statin blood concentrations due to HIV
drug interactions, concerns exist for increased statin side ef-
fects such as myalgia or myopathy. As a result, it is gener-
ally recommended that lovastatin and simvastatin not be
used in HIV patients despite being generic and inexpensive.
In addition, some of the interactions are associated with a
decrease in statin concentrations; caution should be used
when prescribing statins so as not to under- or overdose.
It should be noted that pharmacokinetic studies of ART
and statins have been primarily conducted in HIV-
uninfected subjects who may not adequately represent the
metabolism of these medications in those with HIV infec-
tion, given the differences in gastric acidity and host-
genomics-disease mechanisms. To date, pitavastatin is the
only statin not known to have significant interactions with
ART and does not require dose adjustments. Atorvastatin
and rosuvastatin can also be used, but with dose adjust-
ments depending on the type of HIV therapy used.
Monitoring of statin side effects in the HIV-infected
patients is similar to monitoring in the general population.
Questions about statin safety have been largely addressed
by understanding the drug-drug interactions and relative
plasma concentration of the statin compared to the dose
prescribed. Routine monitoring of creatine kinase is not
recommended. Some clinicians do order liver function tests
approximately 1 month after prescribing statins, although
the FDA does not recommend monitoring, suggesting that
liver function be monitored only in patients with pre-
existing conditions that increase the risk of liver toxicity.
The most common lipid abnormality reported in persons
with HIV is high TG with low HDL-C, presumably due to
underlying inflammation and insulin resistance. Infections
are known to increase TG by decreasing the clearance of
circulating lipoproteins or by stimulating hepatic lipid
synthesis or reesterification of fatty acids derived from
Table 23 Interactions between ART and statins*
Statin
Antiretroviral therapy drug class
Protease inhibitor, including cobicistat Nonnucleoside reverse transcriptase inhibitor
Atorvastatin  AUC [[.
 Use lowest starting dose and titrate carefully.
 Do not exceed 20 mg daily with DRV/r, FPV/r, SQV/r.
 AUC [[ 488% with LPV/r.
 [[[ 836% with TPV/r and should not be
coadministered.
 Start with the lowest recommended dose and titrate
while monitoring for safety with all cobicistat containing
regimens.
 AUC Y 43% with efavirenz.
 4but Cmax Y 37% with etravirine.
 No data for nevirapine.
 May need higher starting dose with efavirenz and
etravirine.
 No dose adjustments for rilpivirine.
Fluvastatin  Use not recommended with nelfinavir.  AUC [ with etravirine.
 May require higher starting dose with etravirine.
Lovastatin  Contraindicated with all PIs and cobicistat (AUC [[[).  AUC YY with efavirenz. May require higher starting dose.
 No adjustment needed for rilpivirine.
Pitavastatin  Modest AUC [ with ATV/r (31%).
 Modest Y AUC with DRV/r (20–26%) and LPV/r (20%). No
dose adjustment required.
 No dose adjustment with cobicistat.
 4 with efavirenz and no dose adjustment needed.
 No dose adjustment needed for rilpivirine.
Pravastatin  Y AUC of except with DRV/r and LPV/r which [ AUC by
81% and 33%, respectively. Use lowest possible starting
dose.
 AUC Y 40% with efavirenz.
 4 with etravirine. May need higher starting dose.
Rosuvastatin  AUC [[ 213% and Cmax [[[ 600% with LPV/r.
 AUC [[ 108% and Cmax [[[ 366% with ATV/r.
 AUC [ 48% and Cmax [ 139% with DRV/r. Do not exceed
10 mg daily. With DRV/r, use lowest necessary dose.
 AUC4 and Cmax [ 123% with TPV/r.
 4 with FPV/r. Titrate dose carefully with LPV/r or ATV/r.
 AUC [ 38% and Cmax [ 89% with cobicistat.
 Allowed.4. No reported interactions.
Simvastatin  Contraindicated with PIs and cobicistat (AUC [[[).  AUC Y 58% with efavirenz and Y with etravirine.
 No data for nevirapine. May require higher starting dose.
[, some increase; [[, moderate increase; [[[, large increase; Y, some decrease; 4, no significant change; ART, antiretroviral therapy; ATV/r,
atazanavir/ritonavir; AUC, area under the concentration–time curve; Cmax, maximum drug concentration; DRV/r, darunavir/ritonavir; FPV/r, fosamprena-
vir/ritonavir; LPV/r, lopinavir/ritonavir; PI, protease inhibitor; SQV/r, saquinavir/ritonavir.
*Nucleoside reverse transcriptase inhibitors and integrase inhibitors, except when boosted with cobicistat, do not have any significant drug–drug
interactions with statins.
Table modified from Myerson M, Malvestutto C, Aberg JA. J Clin Pharmacol. 2015;55:957–974.578 Permission to use adaptation was obtained.
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ported in inflammatory conditions are thought to be second-
ary to cytokine responses. In HIV, circulating interferon
alpha may induce increased TG in part by decreasing lipase
activity and slowing the clearance of TG.704 Furthermore,
there are complex lipid metabolism pharmacogenomic in-
teractions with ART as evidenced by differences in race
and gender while on ART.705,706
TG must be determined in a fasting state. Repeated
values $500 mg/dL that are unresponsive to lifestyle
interventions should be treated with medications (see
NLA Recommendations for the Patient-Centered Manage-
ment of Dyslipidemia–Part 11). Secondary causes of hyper-
triglyceridemia such as dietary characteristics (e.g., excess
alcohol, high glycemic load) and other conditions (e.g., dia-
betes mellitus, hypothyroidism, CKD) that may elevate TG
should also be considered, as described in the NLA Part 1
Recommendations.1 Statins have a moderate effect on TG;fibrates, prescription omega-3 fatty acids, and niacin are
frequently used pharmacologic therapies for very high
TG.153 In patients with hypertriglyceridemia $500
mg/dL, fibrates and certain omega-3 fatty acid preparations
(those that contain DHA) may raise LDL-C. Niacin is
generally the least well tolerated of the drugs that primarily
lower TG and TG-rich lipoproteins, and high doses are
necessary to achieve significant TG-lowering. Niacin also
has the potential to induce insulin resistance and new-
onset diabetes mellitus, thus it is generally reserved for pa-
tients that do not tolerate a fibrate or prescription omega-3
fatty acid agent.
Summary of treatment recommendations
All HIV-infected patients should be assessed for cardio-
vascular risk, including measurement of a fasting lipid
panel with total-C, HDL-C, TG, LDL-C, and non-HDL-C,
and should be counseled about lifestyle interventions,
Chart 11 Recommendations for HIV-infected persons
Recommendations Strength Quality
Clinicians should be aware that patients with HIV are at increased risk for ASCVD. The association between
HIV infection and ASCVD risk is independent of the risk associated with major established ASCVD risk
factors.
A High
A fasting lipid panel should be obtained in all newly identified HIV-infected patients before and after starting
ART.
A Moderate
For primary prevention of ASCVD, HIV infection may be counted as an additional ASCVD risk factor for risk
stratification.
B Moderate
Risk stratification is based on the NLA Recommendations for the Patient-Centered Management of
Dyslipidemia – Part 11 with initial risk stratification based on the number of major ASCVD risk factors (with
the caveat that the presence of HIV infection may be counted as an additional risk factor), the use of risk
prediction tools, such as the ATP III Framingham Risk Score or the ACC/AHA Pooled Cohort Equations if two
risk factors are present, and the use of other clinical indicators to help inform clinical judgment, if needed.
B Moderate
The non-HDL-C and LDL-C goals described in the NLA Part 1 Recommendations should be followed for HIV-
infected patients.1 Atherogenic cholesterol goals may not be attainable in all patients, but there is
incremental benefit to lowering non-HDL-C and LDL-C to approach these goal levels.
B Moderate
Elevated TG $500 mg/dL that is refractory to lifestyle modification or changes in ART (if an option) should
generally be treated with either a fibrate (fenofibrate preferred) or prescription omega-3 fatty acids. After
TG is lowered (,500 mg/dL), non-HDL-C and LDL-C should be reassessed for appropriate management.
B Moderate
Statin therapy is first-line for elevated LDL-C and non-HDL-C; however, interactions between statins and
antiretroviral agents and other medications must be considered prior to initiating lipid-lowering therapy.
The NLA Expert Panel recommends using atorvastatin, rosuvastatin, or pitavastatin as the generally
preferred agents in HIV-infected patients.
A Moderate
S82 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015including smoking cessation, diet, and exercise. At this
time there has not been sufficient research to formulate
comprehensive, evidence-based guidelines and validated
risk stratification schemes for HIV-infected patients. Based
on guidelines and recommendations for the general popu-
lation with modification for this patient population, the
NLA Expert Panel recommends the following.See Chart 11 for the Recommendations for HIV-infected
Persons.
Patients with rheumatoid arthritis (RA)
Heart disease is a leading cause of death in patients with
RA.707 Although RA is typically considered a disease of the
joints, the systemic inflammation in RA has effects
throughout the body, particularly in the vasculature. As a
result, a leading cause of death in RA is CVD. CVD risk is
1.5- to 2-fold higher in RA compared to individuals from
the general population with the same age and gender.708,709
This elevated CVD risk in RA is attributed to chronic inflam-
mation leading to accelerated atherosclerosis.707,710
Currently no validated strategy exists for those in the United
States that can integrate the burden of chronic inflammation
with traditional risk factors to quantify cardiovascular risk in
RA patients. Thus, a major challenge for physicians treating
patients with RA and other inflammatory diseases is esti-
mating their cardiovascular risk and identifying interventions
to lower risk beyondmanaging traditional risk factors. In this
section, we focus on topics surrounding the management of
cardiovascular risk and dyslipidemia where adequate data
exist for recommendations based on expert opinion. Our dis-
cussion focuses on RA because it is the most commoninflammatory disease among the rheumatic diseases with
the most data available on cardiovascular risk. CVD has
been found to be elevated across the spectrum of inflamma-
tory diseases including temporal arteritis711 andwith perhaps
the highest risk among young women with systemic lupus
erythematosus.712,713
Estimating cardiovascular risk in RA
No risk calculator has been validated for RA or other
inflammatory diseases in the United States. A study that
applied the 2013 ACC/AHA guidelines for the treatment of
blood cholesterol,3 to a cohort of RA patients with CAC
scores found that a substantial proportion of RA patients
with low CAC scores were classified as high risk and
vice versa, i.e., RA patients with high CAC scores were
classified as low risk.714 The observed cardiovascular risk
among RA patients was 2-fold higher than the calculated
Framingham Risk Score488 in women and 65% higher in
men.715 The Reynolds Risk Score368 also underestimated
cardiovascular risk in RA. The United Kingdom based
QRISK2716 is the only cardiovascular risk calculator that
incorporates RA as a variable. While QRISK2 is a validated
risk calculator for the general UK population, one study
that examined its performance in RA showed that it overes-
timated cardiovascular risk.717
The European League Against Rheumatism published
recommendations in 2009 for cardiovascular risk manage-
ment in RA and other inflammatory diseases relying heavily
on expert opinion.718 These recommendations have not been
adopted into clinical practice in the United States. They rec-
ommended multiplying a patient’s Framingham Risk Score
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by 1.5 in RA patients who meet 2 of the following criteria:
(1) RA disease duration .10 years, (2) rheumatoid factor
or antibodies to cyclic citrullinated peptide positivity, or
(3) presence of extra-articular manifestations such as
bone erosions. Studies in the US population have found
that multiplying the Framingham Risk Score by 1.5
does not improve how well the cardiovascular risk is
estimated.715
There is evidence that assessment of cardiovascular risk
factors may occur at a lower rate in RA patients than the
general population.719 Thus, this NLA Expert Panel recom-
mends particular vigilance in ensuring that RA patients are
routinely assessed for cardiovascular risk factors, e.g., hy-
pertension, dyslipidemia, diabetes, family history of
early-onset CVD, and smoking. In the NLA Recommenda-
tions for Patient-Centered Management of Dyslipidemia–
Part 1, high-risk thresholds based on 3 commonly used
risk calculators are $10% 10-year risk for a hard CHD
event (MI or CHD death) using the ATP III Framingham
Risk Calculator, $15% 10-year risk for a hard ASCVD
event (MI, stroke, or death from CHD or stroke) using
the ACC/AHA 2013 Pooled Cohort Equations, and $45%
risk for CVD (MI, CHD death, or stroke) using the Fra-
mingham long-term (30-year) Risk Calculator.1 For clini-
cians who routinely measure CRP, the Reynolds Risk
Score, which incorporates CRP, was also identified as a
reasonable option for estimating cardiovascular risk.368
We note that despite the inclusion of CRP, the Reynolds
Risk Score also significantly underestimates cardiovascular
risk in RA similar to Framingham.715 Statins are the first-
line treatment for dyslipidemia in RA, but insufficient
data are available to determine whether different treatment
goals are warranted for patients with RA and other inflam-
matory diseases.720
Relationship between inflammation, treatment, and
lipids
As in the general population, elevated non-HDL-C and
LDL-C levels are associated with higher cardiovascular risk
in RA. However, chronic inflammation adds to the
complexity of this relationship.721,722 RA patients have
lower total-C and LDL-C levels than individuals of similar
age and gender from the general population,723,724 despite
an overall higher risk of CVD. In addition, LDL-C levels
may correlate with levels of inflammation. In a study ofTable 24 RA treatments with manufacturer package inserts recomm
RA treatment Rates of dyslipidemia (%) Recommendation
Tofacitinib730 .10 4–8 wk after init
Tocilizumab731 .10 4–8 wk after init
then at w24-
HDL, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol.RA patients who experienced a reduction in inflammation,
patients experienced an increase in their LDL-C levels.725
Similarly, RA patients who received a tumor necrosis factor
inhibitor as part of a clinical trial had a mean increase in
their LDL-C level of up to 30%.726,727 These data suggest
that in an individual RA patient, LDL-C levels may in-
crease when RA disease activity is controlled.728,729
Although the overall reduction in inflammation is likely
associated with reduced cardiovascular risk, the clinical
significance of these lipid elevations with regards to cardio-
vascular risk has not been established.
Frequency of lipid assessments
Lipid levels, inflammation, and use of RA treatments are
tightly linked. RA patients routinely experience a decreased
response to their disease-modifying anti-rheumatic drugs
over time, which requires treatment adjustments. If a
patient has had lipid levels checked during an RA flare
(e.g., swollen joints, high CRP), it is recommended that the
lipids be re-checked when their disease is controlled,
because the LDL-C level may have been artificially lower
during the flare.
Of the RA treatments, only tofacitinib and tocilizumab
have package inserts recommending a specific frequency of
lipid measurements (Table 24).730,731 Generally, patients
should be referred to a preventive cardiologist or lipid clinic
for issues such as high atherogenic cholesterol levels
despite statin therapy (e.g., LDL-C $190 mg/dL and/or
non-HDL-C $220 mg/dL), or for very high TG. Due to
the higher cardiovascular risk in RA, it is reasonable to
also consider referrals to a specialist for assessment of pa-
tients with lower LDL-C levels (e.g., 160 mg/dL).
RA treatments with known drug interactions with
statins
Methotrexate (MTX), a folate antimetabolite, is the first-
line agent for treatment of RA. In drug interaction
databases, the recommendation is to monitor therapy with
atorvastatin (Lexicomp Risk Rating C), because it can
increase the serum concentration of MTX. The effects of
this interaction have not been linked to increased side
effects at the levels of MTX used for RA (maximum dosage
of 25 mg once a week). In a trial of 30 subjects randomized
to MTX plus prednisone vs MTX plus prednisone plus
atorvastatin, there was no increase in adverse events in the
atorvastatin arm. Specifically, no significant increases inending frequency of lipid measurements
s Comments
iation Increases in total-C, LDL-C, and HDL-C




Increases in total-C, LDL-C, HDL-C, and TG
cholesterol; RA, rheumatoid arthritis; TG, triglyceride; total-C, total
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observed.732
Tocilizumab, an IL-6 receptor blocker, also has a
recommendation to monitor therapy (Lexicomp Risk
Rating C) for atorvastatin, lovastatin, and simvastatin. In
a clinical study of 12 RA patients on tocilizumab 8 mg/kg
and simvastatin, tocilizumab increased metabolism ofChart 12 Recommendations for patients with rheumatoid arthritis
Recommendations Strength Quality
Clinicians should be aware that patients with RA are at increased risk for ASCVD. The association of RA and
systemic lupus erythematosus with ASCVD risk raises concern that other inflammatory conditions may also
be associated with increased ASCVD risk. However, only RA has been studied sufficiently to accurately
quantify the degree to which it increases ASCVD risk.
A High
The association between RA and ASCVD risk is independent of the risk associated with major established
ASCVD risk factors.
A High
For primary prevention of ASCVD, RA may be counted as an additional ASCVD risk factor for risk stratification. B Moderate
Risk stratification is based on the NLA Recommendations for the Patient-Centered Management of
Dyslipidemia – Part 11 with initial risk stratification based on the number of major ASCVD risk factors (with
the caveat that the presence of RA may be counted as an additional risk factor), the use of risk prediction
tools, such as the ATP III Framingham Risk Score or the ACC/AHA Pooled Cohort Equations if two risk
factors are present, and the use of other clinical indicators to help inform clinical judgment, if needed.
B Moderate
Clinicians should be vigilant in ensuring that RA patients are routinely assessed for cardiovascular risk
factors, such as hypertension, dyslipidemia, diabetes, family history of early-onset ASCVD, and smoking.
Calculation of lifetime ASCVD risk can be considered for patients age 20-59 years.
B Moderate
Statins are generally the first-line treatment for dyslipidemia in RA. A Moderate
At this time, atherogenic cholesterol treatment goals for patients with RA and other inflammatory diseases
are the same as described in the NLA Recommendations for Patient-Centered Management of Dyslipidemia
– Part 1.1
B Moderate
If an RA patient has had lipid levels checked during an RA flare, it is recommended that the lipids be re-
checked when their disease is controlled.
B Moderatesimvastatin.733 Whether this interaction has a clinically sig-
nificant effect remains to be determined. Because the
recommendation for tocilizumab is to routinely measure
lipids, the treating physician would be aware of it if the
statin was not effective for lowering LDL-C.
Statin use may also be associated with a reduced clinical
response to rituximab therapy.734 Rituximab is a mono-
clonal antibody directed against the CD20 receptor on
B-cells that eventually depletes the B-cells. The dosing
for rituximab in RA is intravenous infusion at baseline,
2 weeks, and then every 24 weeks (the drug can be
re-dosed at 16 weeks if RA symptoms recur). In an obser-
vational study of RA patients on rituximab and a statin,
patients on a statin had a modestly higher mean RA disease
activity score and required re-dosing of rituximab sooner
than those not on a statin.734 However, a subsequent study
showed no association between statin use and the degree of
B-cell depletion with rituximab,735 suggesting that the
clinical difference in response was not due to a reduced
effect of rituximab.
In summary, although moderate interactions have been
reported between statins and disease-modifying anti-
rheumatic drugs, leading to recommendations to monitor
therapy, there have been no contraindications for this
combination. Furthermore, the effects between statins anddisease-modifying anti-rheumatic drugs were not associ-
ated with an increased incidence of adverse events in the
clinical studies to date.
Research directions
Improving the management of CVD in RA and other
rheumatic diseases is a vibrant area of research. Researchtopics for which additional data are needed include the
development and validation of a cardiovascular risk
calculator specific for RA,736,737 identifying biomarkers
that can improve how cardiovascular risk is stratified in in-
flammatory diseases, and determining whether specific RA
treatments may have beneficial effects for reducing CVD
by targeting specific inflammatory pathways. In addition,
although statins are first-line treatment for dyslipidemia
in RA, there is a need to evaluate other lipid-altering
therapies to assess whether treating to lower goals for a
given risk category with statin add-on therapy would
provide additional benefit for patients with RA and other
inflammatory diseases.See Chart 12 for Recommendations for Patients with
Rheumatoid Arthritis.
Patients with residual risk despite statin and
lifestyle therapy
Meta-analyses from RCTs of statin therapy demonstrate
that progressively more intensive lowering of LDL-C (and
non-HDL-C) is associated with progressively greater risk
reduction, which affirms the direct relationship between
atherogenic cholesterol lowering and ASCVD event
reduction.738–740 A meta-analysis of 26 RCTs involving
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proportional relationship between lowering of LDL-C and
the reduction of major vascular events (nonfatal MI, CHD
death, stroke, and revascularization).355 By combining
patient-level data from each of these studies, the investiga-
tors showed that for every 38.7 mg/dL (1 mmol/L)
reduction in LDL-C with statin therapy, major vascular
events were reduced by 22% (HR 0.78, 95% CI 0.76–
0.80; P , .001) after approximately 5 years of statin
therapy, compared with placebo or less intensive statin
treatment. Reductions in LDL-C of 77.4 and 116.1 mg/dL
would be expected to reduce the risk of a major vascular
event by 40% (1 2 [0.78 x 0.78]) and 53% (1 2
[0.78 ! 0.78 ! 0.78]), respectively. Further support for
the relationship between atherogenic cholesterol lowering
and ASCVD event reduction is that other therapies that
lower blood cholesterol levels through stimulation of
LDL receptor activity, independent of 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibition, including
partial ileal bypass surgery, cholesterol absorption inhibi-
tion and bile acid sequestration in the gut by cholestyr-
amine, also improve ASCVD outcomes.370,383,384,741 Over
a period of approximately 5 years, each 1% reduction in
LDL-C or non-HDL-C is associated with a reduction of
approximately 1% in risk for a CHD event.
The statin therapies currently available to lower blood
cholesterol do not eliminate ASCVD events completely,
which means that many patients receiving lipid-modifying
treatment have residual risk, even if the treatment produces
a robust response and the patient is fully adherent. The best
average LDL-C reduction (w50%) with high intensity
statin therapy would be associated withw50% reduction in
CHD events (CHD death and nonfatal MI) or w40%
reduction in ASCVD events (assuming the individual has a
mean untreated LDL-C of 150 mg/dL and achieves a
75 mg/dL reduction). As these estimates are drawn from
clinical trials that generally lasted w5 years, it is possible
that outcomes could be further improved if treatment is
continued over decades, or if atherogenic cholesterol
concentrations were maintained at even lower levels.
Studies of individuals with genetic variants in the PCSK9
gene and polymorphisms in Niemann-Pick C1-like 1 pro-
tein that result in lower LDL-C levels throughout life
suggest that the ASCVD risk reduction per 1% reduction in
atherogenic cholesterol may be greater, with reductions of
w3% per 1% lower LDL-C concentration over a period of
decades.7,11,742
There are many clinical situations in which the patient’s
cholesterol level is not at goal on maximal tolerated statin
therapy. In these cases, the NLA Expert Panel consensus is
that it is reasonable to consider further atherogenic choles-
terol lowering by adding lipid-altering therapy to ongoing
statin therapy, as long as the patient has sufficient ASCVD
risk to warrant it, and the expected treatment benefit
outweighs the risk for adverse consequences. The following
are considerations and recommendations of how to make
these clinical decisions using the best available information.Candidates for statin combination atherogenic
cholesterol lowering therapy
The following are examples in which more intensive
atherogenic cholesterol lowering may be indicated:
(1) High or very high risk patients with a less-than-
desirable response to moderate or high intensity statin
therapy;740
(2) Patients who have recurrent ASCVD events or progres-
sive atherosclerotic vascular symptoms in spite of high
intensity statin therapy;
(3) Patients with FH, especially with ASCVD or poorly
controlled non-lipid risk factors, and less than optimal
non-HDL-C or LDL-C levels;
(4) Patients after acute coronary syndromes on at least
moderate intensity statin therapy.
Generally, if a patient in the categories above at high or
very high ASCVD risk is not at non-HDL-C and LDL-C
goals, strong consideration should be given to statin
combination therapy (i.e., therapy with a statin in
combination with an additional lipid-altering agent). Clin-
ical ASCVD event benefits of combination therapy
were demonstrated in a recent clinical trial of ezetimibe
added to statin therapy,370 and with investigational
PCSK9 inhibitors added to statin therapy.371,372 In these
instances the clinician should determine whether statin
combination therapies are indicated based on several
considerations:
 Re-evaluation of the patient’s risk factor status (including
family history, smoking, metabolic syndrome criteria)
and quantitative risk scoring (if needed);
 Reconsideration of the nature of the patient’s history of
vascular events;
 Reconsideration of the possible presence of genetic
dyslipidemias (FH, as well as such conditions as
familial combined hyperlipidemia and polygenic
hypercholesterolemia);
 Examination of the affordability of therapy and possible
risks associated with polypharmacy;
 Consideration of the patient’s preferences.
If further assessment of ASCVD risk is desired in
primary prevention situations to make the case for more
intensive atherogenic cholesterol lowering, the presence of
1 or more of the following risk indicators may be
considered:1
(1) CAC: A CAC score $300 Agatston units is considered
an indication of high risk and should encourage optimal
statin intensity and goal attainment.
(2) hs-CRP: An hs-CRP level$2.0 mg/L indicates the pres-
ence of inflammation, which may be related to athero-
genesis and supports more intensive non-HDL-C and
LDL-C lowering to recommended goals. There are
currently no therapies available that specifically lower
hs-CRP, nor is it recommended to follow hs-CRP levels
after atherogenic cholesterol-lowering treatment.
S86 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015(3) Non-HDL-C, apo B, or LDL particle concentration:
Discordance may occur between the LDL-C level
and 1 or more of these parameters, especially in pa-
tients with type 2 diabetes, the metabolic syndrome,
or hypertriglyceridemia. If discordance exists, i.e., the
non-HDL-C, apo B, or LDL particle concentration is
higher than would be anticipated based on the LDL-C
level, further lipid-lowering treatment to reach goal
levels of non-HDL-C and apo B may be considered.
(No specific goals have been recommended for LDL
particle concentration.)
(4) Lp(a): Levels of Lp(a) $50 mg/dL using an isoform
insensitive assay are indicative of increased ASCVD
risk. An elevated Lp(a) is a reason to consider more
intensive non-HDL-C and LDL-C lowering, since no
outcome studies have demonstrated that reducing
Lp(a) per se will reduce risk. Treatment options to
lower Lp(a) are limited as well.
(5) Ankle brachial index: Peripheral artery disease (i.e., ankle
brachial index of,0.90) is one of the strongest risk indi-
cators of ASCVD. The NLA Recommendations for the
Patient-Centered Management of Patient-Centered–Part
1 included it as a criterion for classification of ASCVD,
and treatment goals in such patients are ,100 mg/dL
for non-HDL-C and,70 mg/dL for LDL-C.
(6) LDL-C $160 mg/dL and/or non-HDL-C $190 mg/dL:
Presence of either of these in a patient at low or mod-
erate risk may justify a higher level of treatment. Pa-
tients with genetic dyslipidemias resulting in elevated
atherogenic cholesterol levels are also candidates for
intensive lowering of non-HDL-C (and LDL-C), de-
pending on their risk status.
(7) Severe disturbance in a major ASCVD risk factor, such
as multipack per day smoking or a strong family his-
tory of premature CHD.
(8) CKD: Patients with stage 3B or 4 CKD (estimated
glomerular filtration rate 15–45 mL/kg/1.73 m2) are
at high risk and warrant a lower treatment goal.
Based on this new risk assessment, consideration should
be given for statin combination therapy if patients are not at
their goal non-HDL-C and LDL-C levels, particularly
patients whose ASCVD risk is high or very high and who
are taking the maximally tolerated statin dosage.
Statin combination therapy for additional LDL-C
lowering
Currently, 3 statin combination therapies that lower
LDL-C are reasonable to consider: a cholesterol absorption
inhibitor (ezetimibe), bile acid sequestrant (cholestyramine,
colestipol, colesevelam), or a niacin product (crystalline
niacin and extended release niacin) (Table 25).370,743–752
These agents provide an additive, not synergistic, LDL-C
lowering effect of 10–20% when added to statin therapy.
Cholesterol absorption inhibitor
The best tolerated of the 3 therapies is the cholesterol
absorption inhibitor, ezetimibe; discontinuation of therapydue to adverse reactions occurs in about 5% of patients.
The most common adverse effects are related to gastroin-
testinal symptoms; increases in liver enzyme tests and
creatine phosphokinase levels with muscle symptoms are
occasionally encountered.370,747–750 Ezetimibe is adminis-
tered in a 10 mg tablet once daily. In IMPROVE-IT, ezeti-
mibe with a statin vs a statin alone was evaluated in 18,144
post-acute coronary syndrome patients (Tables 25 and
26).370 The investigators of this 7-year outcome study re-
ported that ezetimibe produced an additional 16.7 mg/dL
(0.4 mmol/L) decrease in LDL-C (on treatment [1-year]
levels of 69.9 and 53.2 mg/dL, respectively) and was asso-
ciated with a statistically significant 10% reduction in a
composite CVD outcome that most closely corresponds
with the outcome used in the CTT analysis.355,370 This de-
gree of risk reduction is similar to the predicted effect based
on the assumption that each 38.7 mg/dL (1 mmol/L)
lowering of LDL-C will produce a reduction of 22% in
ASCVD event risk (16.7 mg/dL O 38.7 mg/dL 5 0.4;
0.4 ! 22% 5 8.8%).
Bile acid sequestrants
These agents are administered as powders dissolved in
water or other fluids (all 3 commercially available forms),
or as tablets (colesevelam). The most common side effects
reported with these agents are gastrointestinal, including
constipation and bloating. Colesevelam appears to be better
tolerated than the other agents and causes gastrointestinal
adverse effects relatively infrequently (i.e., in ,10% of
patients).745,746 The usual dosage is 8 to 16 g/day in divided
doses for cholestyramine and colestipol, and 3.75 g/day for
colesevelam (as powder or tablets). These agents reduce
LDL-C by an additional 15–20% when added to a statin.
Cholestyramine has been shown to reduce CHD events by
19% when used as monotherapy in 3806 adults without
heart disease and an LDL-C concentration of $190 mg/
dL over a 7.4 year observation period (Tables 25 and
26).383,384,743,744 No outcomes data are available for bile
acid sequestrant therapy use in combination with a statin
or other lipid-altering agent. It should be noted that bile
acid sequestrants can worsen TG levels, especially if the
baseline is $200 mg/dL, and therefore should mainly be
used to reduce LDL-C in patients with TG ,200 mg/dL.
Niacin
Niacin products are difficult to tolerate due to a flushing
side effect that requires the drug to be initiated with low
dosages and slowly titrated up to a therapeutic dosage over
weeks, as tolerated. The flushing is not harmful, but is
bothersome. Extended release preparations reduce flushing
symptoms, improve tolerability and have been used suc-
cessfully by experienced lipidologists as statin combina-
tion therapies. Niacin reduces LDL-C by 8–14% when
added to a statin and also reduces TG and increases HDL-
C levels (Table 25).751,752 Niacin has been frequently used
for treating patients who have atherogenic dyslipidemia
consisting of a high TG level (i.e., $200 mg/dL) and a
Table 25 Percentage reduction in LDL-C with statin alone and in combination














Bile acid sequestrants plus statin combination therapy
Ytre-Arne et al743 Simvastatin, 40 mg/d Cholestyramine, 12 g bid 240 257 218
Jacob et al744 Lovastatin, 80 mg/d Cholestyramine, 8 g/d 228 240 218
Pravastatin, 40 mg/d Cholestyramine, 8 g/d 230 239 29
Knapp et al745 Simvastatin, 10 mg/d Colesevelam, 3.8 g/d 228 242 218
Hunninghake et al746 Atorvastatin, 10 mg/d Colesevelam, 3.8 g/d 238 248 210
Ezetimibe plus statin combination therapy
Davidson et al747 Simvastatin various doses Ezetimibe, 10 mg/d 236 250 214
Ballantyne et al748 Atorvastatin various doses Ezetimibe, 10 mg/d 242 254 212
Gagne et al749 Various statins at various doses Ezetimibe, 10 mg/d 24 225 221
Gagne et al750 Simvastatin or atorvastatin with
dose increased from 40 mg to
80 mg/d
Ezetimibe, 10 mg/d 27 227 220
Cannon370 Simvastatin, 40 mg/d Ezetimibe, 10 mg/d 225 244 219
Niacin plus statin combination therapy
Vacek et al751 Lovastatin, 20 mg/d Niacin SR, 1200 mg/d 223 235 212
Advicor Prescribing
Information752
Lovastatin, 20 mg/d Niacin ER, 1000 mg/d 224 231 27
Lovastatin, 40 mg/d Niacin ER, 1000 mg/d 229 237 28
Lovastatin, 40 mg/d Niacin ER, 2000 mg/d 229 243 214
ER, extended release; LDL-C, low-density lipoprotein cholesterol; SR, sustained release.
Jacobson et al NLA Dyslipidemia Recommendations - Part 2 S87low HDL-C level (i.e., ,40 mg/dL), particularly if accom-
panied by an elevated level of non-HDL-C. Crystalline
niacin has been shown to significantly reduce CHD events
by 17% when used as monotherapy at a dosage of 3 g/day
for 6 years in a high risk, male population
(Table 26).386,753 More recently, extended release niacin
was tested as a statin combination therapy in 2 studies
(AIM-HIGH and HPS2-THRIVE), and did not signifi-
cantly reduce ASCVD events compared to statin mono-
therapy in very high risk patients.388,389,755 However, in
both of these studies, niacin was administered to patients
with low average levels of atherogenic cholesterol during
statin treatment, and therefore did not adequately test the
potential benefits of administering statin plus niacin ther-
apy to individuals in need of additional lipid lowering to
achieve atherogenic cholesterol goals. It is important to
consider the balance of risk to benefit with niacin added
to statins since there were higher incidence rates for infec-
tions and gastrointestinal bleeds with niacin in the HPS2-
THRIVE trial. Post hoc analyses of the AIM-HIGH study
showed that the subgroup of subjects with both
TG $200 mg/dL and HDL-C ,32 mg/dL had a significant
event reduction, suggesting that niacin might have benefit
in a targeted population, such as those patients with resid-
ual high non-HDL-C plus concomitant low HDL-C.755 An
analysis from the HPS2-THRIVE study found that niacin
(with laropiprant) was associated with a nominally statisti-
cally significant benefit in the subgroup of patients with
higher baseline LDL-C levels (top tertile $77 mg/dL)and in the subgroup with higher baseline apo B levels
(top tertile $70 mg/dL).389
Based on this information, the NLA recommends that
statin combination therapies be considered for at-risk
patients not at non-HDL-C and/or LDL-C goals while
receiving maximally tolerated statin therapy. Further-
more, the NLA recommends that the following statin
combination therapies be considered in the indicated
order:
1. Ezetimibe 10 mg every day: Ezetimibe is recommended
as a first-line statin combination therapy since it has
been shown to reduce ASCVD events when added to a
statin in a controlled clinical trial and because it has
an important atherogenic cholesterol-lowering efficacy.
2. Colesevelam 625 mg 3 tablets twice a day (or 3.75 g
powder form every day or in divided doses): This ther-
apy is recommended as a second-line statin combination
therapy because the drug class has been shown to reduce
ASCVD events when used alone, it is better tolerated
than the other resins, and it has an important atherogenic
cholesterol-lowering efficacy.
3. Extended release niacin titrated to a maximum of
2000 mg, daily: Niacin in this dosage form is recom-
mended as a third-line statin combination therapy for
atherogenic cholesterol lowering because it has demon-
strated lower ASCVD events when used alone, and may
have benefit when given with a statin to patients with
LDL-C or non-HDL-C not at goal. However, it provides
Table 26 Outcome trials with statin combination therapies
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AIM HIGH388,755 R, DB, PC,
3 y f/u
3414 with CVD ER niacin 1500–2000 mg/d vs
placebo added to simvastatin




214 End point* not
different (P 5 .80)
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ODYSSEY LONG TERM371R, DB, PC,
78 wk f/u
2341 men and women





dose with or without
other lipid-lowering
therapy
Alirocumab 150 mg or placebo
as 1-mL subcutaneous
injection every 2 wk
123 mg/dL;
48 mg/dL
61 HR, 0.52; 95%
CI, 0.31–0.90
(P 5 .02)
OSLER (2 trials)372 R, open-label,
11.1 mo f/u






Evolocumab 140 mg every
2 wk or 420 mg monthly




61 HR, 0.47; 95%
CI, 0.28–0.78
(P 5 .003)
ACS, acute coronary syndrome; CHD, coronary heart disease; CI, confidence interval; CVA, cerebrovascular accident; CVD, cardiovascular disease; DB, double-blind; ER, extended release; HDL-C, high-density
lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; L-C, lovastatin 1 colestipol; MI, myocardial infarction; NA, not applicable; N-C 5 niacin 1 colestipol; PC, placebo
controlled; PCSK9, proprotein convertase subtilisin/kexin type 9; pt, patient; R, randomized; SR, sustained release; TG, triglyceride; UA, unstable angina.
*First event of CHD death, MI, ischemic stroke, ACS hospitalization, coronary, or cerebral revascularization.
†CHD death or nonfatal MI.
‡CV death, MI, documented unstable angina requiring rehospitalization, coronary revascularization ($30 d), or stroke.
xCV death, MI, revascularization, hospitalized for UA.
jjFirst vascular event of CHD death, MI, stroke, or revascularization.





























S90 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015only modest LDL-C lowering efficacy, and use of niacin
in combination with a statin is not recommended for pa-
tients whose LDL-C is ,70 mg/dL, based on RCT
evidence for no benefit and possible harm in this group.Special cases for statin combination and other
combination therapies
In addition to further lowering atherogenic cholesterol in
a patient not at treatment goal, other clinical situations can
occur that require consideration of additional statin com-
bination therapies. These include:
(1) Patients who require multiple LDL-C-lowering thera-
pies (e.g., the patient who is intolerant to statin therapy
or the FH patient who is unable to achieve optimal non-
HDL-C and LDL-C levels with a high intensity statin
and 1 other therapy): In these cases, combining statin
and therapies with different mechanisms of action
and in the order above is recommended, with careful
consideration of the added cost and the potential for is-
sues related to polypharmacy.
(2) Patientswhohave atherogenic dyslipidemia inwhich there
are elevations in TG and VLDL-C (VLDL-C correlates
closely with the TG level) plus low HDL-C (e.g., the pa-
tient with diabetes or metabolic syndrome, often with
elevated non-HDL-C): These patients may benefit from
evaluation of apo B or LDL particle concentration mea-
surement because discordance may be present. Treatment
options include additional atherogenic cholesterol
lowering with statin combination therapies as described
above, and/or other statin combination therapies that
mainly lower TG and VLDL-C, such as fibrates and/or
omega-3 fatty acids (prescription omega-3 fatty acids are
currently only indicated for patients with TG $500
mg/dL). As stated previously, colesevelam may worsen
TG, especially in those with levels $200 mg/dL at base-
line, but it should also be noted that it might improve
glucose control in patients with type 2 diabetes. Niacin
may be used in patientswith stable type 2 diabetes for lipid
management, butmonitoring of glucose control is advised.Fibrate drugs
Of the currently available fibrates, gemfibrozil has been
shown to reduce ASCVD events as monotherapy in primary
prevention high risk males with elevated non-HDL-C390
and for secondary prevention in males with below average
HDL-C.756 This class of drugs can reduce TG and
non-HDL-C in patients with mixed dyslipidemia, and is
considered a first-line choice for patients with severe hyper-
triglyceridemia (TG $500 mg/dL). The only outcomes trial
of a fibrate (fenofibrate) added to a statin was the ACCORD
Lipid study, which failed to demonstrate a benefit in the full
study sample on ASCVD events compared to statin mono-
therapy in type 2 diabetes patients.394 A predefined patient
subgroup in this trial included those with TG in the top
tertile ($204 mg/dL) and HDL-C in the bottom tertile(#34 mg/dL); these patients had a significantly lower
ASCVD event rate with fenofibrate compared to placebo
(229%). Because of a drug-drug interaction with most sta-
tins that increases the risk for myositis, gemfibrozil should
not be used with statins. Fenofibrate and fenofibric acid
have not been found to have this adverse event when com-
bined with statins. Fenofibrate has also been shown to
reduce the progression of diabetic retinopathy and nephrop-
athy, independent of ASCVD outcomes,394,757 and has not
been associated with incident diabetes. Fibrates should
not be used in patients with stage 3B CKD or worse. Based
on the limited available outcomes data, the main clinical
situation in which fenofibrate or fenofibric acid could be
considered as a statin combination therapy would be in
type 2 diabetes patients with a non-HDL-C not at goal,
who also have retinopathy and/or microalbuminuria, and
do not have stage 3B or worse CKD.757,758
Omega-3 fatty acid preparations (EPA only or
EPA 1 DHA)
These agents are effective for reducing TG, and are
indicated for patients with very high TG ($500 mg/dL).
One outcomes trial, JELIS,134 did show a significant reduc-
tion in ASCVD events (19% reduction) in 18,645 high risk
Japanese patients who were treated with statins and were
randomized to receive 1.8 g/day EPA or statin without
EPA (placebo treatments are not allowed in Japan). The
greatest benefit was found in those patients with
TG $150 mg/dL and HDL-C ,40 mg/dL. Until specific
outcomes trials with this class of statin combination therapy
in patients with elevated non-HDL-C levels are completed
(the REDUCE IT166 and STRENGTH studies167 are
ongoing), the NLA Expert Panel will not provide specific
recommendations for their routine use except in patients
with TG $ 500 mg/dL.
A new class for statin combination therapy: PCSK9
inhibitors
Monoclonal antibodies that inhibit PCSK9 (alirocumab
and evolocumab) comprise a new class of statin combi-
nation therapy and have been approved by the FDA for use
in addition to diet and maximally tolerated statin therapy
in adults with heterozygous FH or with clinical ASCVD
who require additional lowering of LDL-C. Two large,
RCTs of PCSK9 inhibitors, including the Open-Label
Study of Long-Term Evaluation against LDL Cholesterol
(OSLER) and the Long-term Safety and Tolerability of
Alirocumab in High Cardiovascular Risk Patients with
Hypercholesterolemia Not Adequately Controlled with
Their Lipid Modifying Therapy (ODYSSEY LONG
TERM), study have demonstrated their effectiveness for
reducing LDL-C and non-HDL-C levels by w60% among
patients at high cardiovascular risk and receiving
maximum tolerated dosages of statins371 and among pa-
tients at various degrees of cardiovascular risk receiving
standard therapy.372 Both these studies provided data
over approximately 1 year. Both drugs lower Lp(a) by
Jacobson et al NLA Dyslipidemia Recommendations - Part 2 S91w25%. Most adverse events occurred with similar fre-
quency between PCSK9 and control groups, although neu-
rocognitive events, injection-site reactions, myalgia, and
ophthalmologic events were reported more frequently
with PCSK9 inhibitors.371,372 In a post-hoc analysis of
the ODYSSEY LONG TERM trial, the rate of major
adverse cardiovascular events was lower with the PCSK9
inhibitor than with placebo (HR 0.52; 95% CI 0.31–
0.90; P 5 .02). A similar effect was reported by the OS-
LER investigators (HR 0.47; 95% CI 0.28–0.78,
P 5 .003). Long term cardiovascular outcomes trials
with both drugs, added to optimal statin therapy in very
high risk patients, are ongoing (Evaluation of Cardiovascu-
lar Outcomes After an Acute Coronary Syndrome During
Treatment with Alirocumab SAR 236553 [REGN727] and
Further Cardiovascular Outcomes Research with PCSK9
Inhibition in Subjects with Elevated Risk).759,760
The PCSK9 inhibitor class has been approved by the
FDA for use as an adjunct to diet and maximally tolerated
statin therapy for the treatment of adults with heterozygous
FH, or clinical ASCVD, who require additional lowering of
LDL-C. Cardiovascular outcomes trials with the PCSK9
inhibitors alirocumab and evolocumab are underway inChart 13 Recommendations for patients with residual risk despite
Recommendations
Fibrates and prescription omega-3 fatty acids are first-line drug choic
although consideration may be given to using statin therapy as a fi
999 without a history of pancreatitis.
In patients with elevated TG (200 to 499 mg/dL) on maximum tolerate
goal but not their non–HDL-C goal, the addition of therapies that p
high-dose omega-3 fatty acids) may be considered to help achieve a
analyses from cardiovascular outcomes studies provide suggestive e
with the addition of a TG-lowering agent to statin therapy, particula
elevated TG and low HDL-C.
For patients not at goal levels for atherogenic cholesterol on maxima
consideration should be given to adding non-statin lipid-altering t
further lowering of atherogenic cholesterol, as long as the patient h
and the expected treatment benefit outweighs the risk for adverse
Recommended statin combination therapies to consider for further low
the following order: first – ezetimibe 10 mg every day, second – col
(or 3.75 g powder form every day or in divided doses), and third –
maximum of 2000 mg, daily.
Until cardiovascular outcomes trials are completed with PCSK9 inhibit
primarily in: 1) patients with ASCVD who have LDL-C $100 mg/dL
maximally-tolerated statin (6ezetimibe) therapy; and 2) heterozyg
have LDL-C $130 mg/dL (non-HDL-C $160 mg/dL) while on maxim
therapy.
In addition, PCSK9 inhibitor use may be considered for selected high ri
ASCVD events) who have atherogenic cholesterol levels below the s
treatment goals (i.e., LDL-C $70 mg/dL [non-HDL-C $100 mg/dL]
judgment, weighing the potential benefits relative to the ASCVD ev
therapy.
PCSK9 inhibitor use may also be considered in selected high or very hig
of statin intolerance (as previously defined by the NLA Statin Expe
additional atherogenic cholesterol lowering, despite the use of oth
would be based on clinical judgment, weighing the potential benefi
the risks and costs of therapy.ASCVD patients who are on maximally-tolerated statin
therapy with LDL-C of 70–99 mg/dL. Until the results of
those trials are available, a conservative approach would be
to use PCSK9 inhibitors primarily in: 1) patients with
ASCVD who have LDL-C $100 mg/dL (non-HDL-C
$130 mg/dL) while on maximally-tolerated statin
(6ezetimibe) therapy; and 2) heterozygous FH patients
without ASCVD who have LDL-C $130 mg/dL (non-
HDL-C $160 mg/dL) while on maximally-tolerated statin
(6ezetimibe) therapy. The risks of this new class appear
low based on the data available from the clinical develop-
ment programs,371,372 and the additional LDL-C reduction
ofw60% when added to statin therapy will allow many pa-
tients to achieve goal LDL-C levels.
Finally, PCSK9 inhibitor use may be considered for
selected high risk patients with ASCVD (e.g., recurrent
ASCVD events) who have atherogenic cholesterol levels
below the specified values listed, but above their treatment
goals (i.e., LDL-C $70 mg/dL [non-HDL-C $100
mg/dL]). PCSK9 inhibitors may also be considered in
selected high or very high risk patients who meet the
definition of statin intolerance, as previously defined by the
NLA Statin Expert Panel,761 and who require substantialstatin and lifestyle therapy
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of other lipid lowering therapies. Such use for these
selected cases would be based on clinical judgment, weigh-
ing the potential benefits relative to the ASCVD event risk
and the risks and costs of therapy. In patients for whom the
clinician is uncertain about the relationship of a statin with
new or worsened muscle symptoms, the use of a statin
myalgia clinical index score334 may be helpful, but none
have been validated.See Chart 13 for Recommendations for Patients with Re-
sidual Risk Despite Statin and Lifestyle Therapy.Improving patient outcomes
Patient adherence
Definition of adherence
In 2003, the World Health Organization defined adher-
ence as the extent to which a person’s behaviors, such as
taking medication, following a diet, or making healthy
lifestyle changes, corresponds with agreed upon recom-
mendations from a healthcare provider.762 Specifically,
medication adherence refers to the patient’s conformance
with the provider’s recommendation with respect to timing,
dosage, and frequency of medication-taking for the pre-
scribed length of time.763,764 Adherence is not a single
construct, but rather is a cluster of behaviors simulta-
neously effected by patient-, provider-, and healthcare
system-related factors.764,765 Poor adherence to medication
may occur in the form of irregular or interrupted intake, and
by lack of persistence. Persistence refers to the duration of
time the patient takes the medication, from initiation to
discontinuation of therapy.763,764
Prevalence and costs of non-adherence
Medication non-adherence is thought to account for 30–
50% of treatment failures and a variety of adverse medical
treatment outcomes, including increased hospitalization
rates and institutionalization for the frail elderly as well as
increased healthcare costs.766 Bosworth et al.767 reported
that only half of the 3.2 billion annual prescriptions in
the United States are taken as prescribed. Poor medication
adherence or non-adherence is estimated to result in 33–
69% of medication-related hospital admissions, and as
many as 125,000 deaths per year in the United
States.767,768
Much of non-adherence is found among patients with
chronic diseases, such as hypertension, hyperlipidemia,
diabetes, and asthma.769 By the year 2020, the number of
Americans affected by at least 1 chronic condition that
will require medication therapy is expected to grow to
157 million. Patients with chronic conditions adhere only
to 50–60% of medications as prescribed,767 and rates of
medication adherence to therapies for chronic conditions
often drop after the first 6 months of therapy.770Medication non-adherence ultimately costs an average
of $2000 per patient in clinician visits annually, while the
direct cost of non-adherence to the US healthcare system is
estimated at $105.8 billion annually.771,772 A substantial
proportion of these costs may be preventable with the use
of strategies targeting improved medication adherence.
Moreover, research findings suggest that improved self-
management of chronic diseases results in an approximate
cost-to-savings ratio of 1:10.768,773
Adherence to lipid-altering medications
Medication non-adherence is particularly troublesome
with cholesterol-lowering medications. Approximately 25–
50% of patients discontinue statins within 1 year of
treatment initiation, and persistence of use further
decreases over time.774,775 Results from studies have been
mixed, but some have found that predictors of statin non-
adherence include younger patient age, female sex, lower
income, and non-Caucasian race.536,776,777 Adherence to
statins is improved when patients have a history of CVD
and have multiple risk factors.777,778
Chi and colleagues779 recently reported the results from
a cross-sectional study of 67,100 CHD patients at Kaiser
Permanente Southern California who were dispensed 2 or
more statin prescriptions between May 2009 and May
2010. The purpose of this study was to determine the rela-
tionship between LDL-C goal attainment and adherence to
statin medications. The medication possession ratio (ratio
of sum of the days of supply divided by the total number
of days between first and last dispensation dates, obtained
through the pharmacy) was calculated to estimate adher-
ence, and a ratio $80% was considered to represent adher-
ence. LDL-C levels ,100 mg/dL and ,70 mg/dL were
observed in 85.8% and 79.8% of patients, respectively.
Almost 80% of patients were adherent to their statin medi-
cation. In this cohort of patients, LDL-C goal attainment
was positively associated with statin adherence, male sex,
Asian/Hispanic ethnicity, taking a larger number of pre-
scriptions, having multiple comorbidities, and having
hypertension.780
Factors associated with medication adherence
It is important to consider that adherence to medications
relates to medication-taking behaviors that are influenced
by the patient’s beliefs about the medications, and by their
trust in the provider who is prescribing the medications.
Many providers are unaware that some of their patients
have strong feelings about ‘‘chemical’’ medications vs
natural therapies, the potential for side effects or interac-
tions with other medications, and the relative efficacy of
generic (vs brand name) medications. Table 27 is a list of
the prevalence of self-reported reasons for primary non-
adherence among patients with a newly prescribed statin
medication.780
The provider-patient relationship and communication
issues must be considered when addressing medication
non-adherence. These provider-patient issues are often related
Table 27 Self-reported reasons for primary nonadherence
from a telephone survey of patients with no record of
redeeming a new statin medication among Kaiser Permanente
Southern California members
Did not pick up cholesterol medication due
to/because... %Yes (n)
General concerns about medication 63.0 (46)
Decided to try lifestyle modification 63.0 (46)
Fear of side effects 53.4 (39)
Did not think medication was needed 38.9 (28)
Did not believe condition was life threatening 34.7 (25)
Fear of drug interactions 16.4 (12)
Already took too many medications and
did not want to take any more
16.4 (12)
Financial hardship 12.3 (9)
Did not understand why provider prescribed
medication
11.0 (8)
Did not understand purpose of medication 8.2 (6)
Did not think medication would be
effective for condition
6.9 (5)
Inconvenient dosing regimen 4.1 (3)
Change in health insurance/drug benefit 2.7 (2)
Taken from Harrison TN, et al. Am J Managed Care. 2013;19:
e133-e139.780 Permission to reprint was obtained.
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suboptimal provider-patient relationship, issues with care
transitions between hospital and home, depression and
cognitive impairment, and a low level of health literacy, which
is found in approximately 90 million US adults.781–783 Health
literacy was defined in Healthy People 2010783 as ‘‘the
degree to which individuals have the capacity to obtain,
process and understand basic health information and services
needed to make appropriate health decisions.’’ From a large
survey administered in person to patients at 4 Veterans
Administration medical centers, Chew et al.782 reported
answers to questions such as: ‘‘How confident are you
filling out forms by yourself?’’; ‘‘How often do you have
someone help you read hospital materials?’’; and ‘‘How often
do you have problems learning about your medical condition
because of difficulty reading hospital materials?’’ By their
responses to these questions, 32.9% of patients were
determined to have inadequate health literacy, 16.9% needed
help reading medical material, 17.1% had problems
learning about their medical condition, and 29.6% were not
confident completing health forms alone.
It is important to consider the sequelae of inadequate
health literacy, including increased annual health care costs
for those with low literacy skills, which has been shown to
be 4 times higher when compared to those with higher
literacy skills.784 Patients with low health literacy and
chronic diseases have less knowledge of their disease and
treatment, and fewer self-management skills than literate
patients. Studies have further revealed that patients with
low literacy skills have a 50% increased risk of hospitaliza-
tion, compared with patients who have adequate literacy
skills.772,780Patients are often self-conscious and feel shame from
their lack of understanding, which prevents them from
seeking help and asking questions for clarification. Health
care professionals need to be alert for clues of low health
literacy from patient behaviors such as seeking help only
when their illness is advanced, making excuses, becoming
angry/demanding or quiet/passive, failing to complete
intake forms, having difficulty explaining concerns or
failing to ask questions, and frequently missing appoint-
ments or tests. Other indicators of a health literacy problem,
suggesting that patients may not be able to read/understand
a medication bottle, include statements, such as ‘‘I forgot
my glasses’’ or ‘‘I’ll bring this home so I can discuss it with
my family’’.772
Lack of provider empathy, and failure to provide pos-
itive reinforcement to the patient have also been identified
as contributors to inadequate adherence. Researchers report
that approximately 70–90% of opportunities for a health
care provider to express empathy to a patient are
missed.764,772,785,786 Patients often do not realize that there
may not be an immediate benefit of therapy, which leads to
their being frustrated and not adhering to, or failing to
persist in taking their medication.762,764,772 Providers
must attempt to understand the patients’ concerns and be-
liefs about their problems, which may not be in concert
with the providers’ understanding.
Medication cost/insurance coverage is traditionally
thought to be a central limiting factor for medication
adherence among those with low socioeconomic
status.787,788 Therefore, it is not surprising that reducing
out-of-pocket costs has been shown to lead to both
improved medication adherence and improved outcomes,
without increasing total health care costs. These findings
have important policy implications, suggesting that chronic
disease pharmaceuticals are cost-effective for in-
surers.764,772 Although cost is a major consideration, other
contributors also play roles, including side effects (or fear
of side effects), having a complex medication regimen,
forgetfulness or inability to track medications, and a belief
by the patient that the medication does not work or that he/
she does not need it.772,788 Queries about these issues will
help the provider to identify and understand reasons for
inadequate medication adherence, which may allow the
development of tailored interventions that more specifically
address the specific factors described by the patient.
In a nested case-control study, Kesselheim et al.789
determined the implications of changing the generic pill
appearance of medications for patients after an MI. Given
that generic prescription drugs made by different manufac-
turers may vary in color or shape, the purpose was to
determine whether use of generic drugs among post-MI
patients was associated with inconsistent appearance of
their medications. Cases had discontinued their index
drug for at least 1 month while controls continued treat-
ment. Controls and cases were matched for therapeutic
class, number of dispensings before non-persistence, age,
and sex. Results demonstrated that 29% of patients
S94 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015(3286 of 11,513) had a change in pill shape or color.
Statins had the most changes in appearance. The odds of
non-persistence in case patients increased by 34% after a
change in pill color and 66% after a change in pill
shape.789 These findings suggest that a change in
medication appearance is a risk factor for non-adherence.
Additional research is warranted to investigate strategies
for minimizing the effects of changes in medication
appearance on subsequent patient adherence.
Statin intolerance and non-adherence
In a cross-sectional, self-administered Internet-based
survey of 10,138 US adult statin users conducted from
September to October, 2011,788 factors associated with
adherence and reasons for switching medication or discon-
tinuation were identified. Among the survey participants,
82.5% were current statin users who adhered to their
prescribed statins (defined as taking at least 80% of their
current prescribed statin dose in the past month) and 12%
were former statin users (i.e., discontinuers). Of the former
statin users, 60% cited muscle aches as the primary reason
for discontinuation, followed by cost (16%) and perceived
lack of efficacy (13%). Discontinuers expressed that they
were less satisfied with their physician’s explanation of
cholesterol treatment, were more likely to research statins
on the Internet, and were less likely to monitor cholesterol
levels. Individuals who changed statins in the past, but were
then adherent to their new statin, reported reasons for
switching as muscle side effects (33%) and cost (32%).
Results of the survey identified that lower income, muscle
pain as a side effect, and taking other concurrent medica-
tions for CVD were predictors of statin non-adherence. In-
vestigators concluded that better health care provider
communication about the importance of statins and poten-
tial adverse effects is necessary for improved adherence and
patient outcomes.
The NLA recently published assessments from an
Expert Panel on Statin Safety regarding statin intoler-
ance,761 and issues of statin-related muscle complaints,334
liver enzyme elevations,790 cognitive complaints,466 and
diabetes risk.336 Statin intolerance was defined by the panel
as adverse symptoms, signs or laboratory abnormalities
attributed by the patient (or provider) to the statin and in
most cases perceived by the patient to interfere unaccept-
ably with activities of daily living (such as sleep, work/
housework, or leisure-time activity), leading to a decision
to stop or reduce statin therapy.761 Myalgia, defined as mus-
cle aches, soreness, stiffness or tenderness, with or without
an abnormal creatine kinase level, is the most frequently
reported side effect of statin use. Myalgia reports generally
range from 1–5% of individuals among patients taking
statins in controlled clinical trials to 11–29% in observa-
tional studies.334
The NLA Statin Safety Panel stated that patients should
be told that if they feel that they have experienced a side
effect (usually muscle aches) while taking a statin,
whether to continue taking the statin is their decision,but it is best guided by advice from their health care
provider.761 Patients should be advised that before stop-
ping a statin due to possible side effects, they should first
speak to their health care provider. Even if statin intoler-
ance is confirmed, in most cases the clinician and patient
should attempt to maintain statin treatment in some form
to reduce the patient’s CVD event risk. Options for
continuing statin therapy include a lower daily dosage of
the same statin (which may still result in a clinically
meaningful reduction in atherogenic cholesterol), less
than daily dosages of the same statin (optimally with a
long-acting statin, such as rosuvastatin or atorvastatin),
or use of an alternative statin in daily or less than daily
dosages. Patients who are initially intolerant to 1 statin
can often tolerate a different statin. The highest tolerated
dose of statin should be targeted, regardless of whether
it will allow the patient to achieve the atherogenic choles-
terol goal, because even modest cholesterol reductions will
improve long-term cardiovascular outcomes. Other
non-statin lipid-lowering drugs are options for patients
with statin intolerance, with or without concomitant statin
therapy, but with consideration of their potential for side
effects, which may also lead to reduced adherence (e.g.,
flushing with niacin).
Strategies to improve medication adherence
Technology is helping with the collection of adherence
information and bringing it to the desktop of the pro-
vider.791 This information might come from the refill data
in the electronic health record, the pharmacy, or the insur-
ance carrier that is monitoring prescription claims.
Advanced health systems frequently also have decision
support tools including information on formularies and
out-of-pocket costs to the patient that may inform the selec-
tion and prescribing of cardiovascular medications.772
Although patient self-report about medication adherence
may suffer from social desirability bias, providers should ask
the patient about adherence to lipid-lowering therapy if
suboptimal adherence is suspected, such as when the
response to therapy is poor. For example, the provider may
ask, ‘‘In the last 2 weeks, you should have taken 14 doses of
your statin medication. How many doses do you think you
have taken?’’ As an alternative, a more formal strategy to
measure self-reported medication-taking behavior may be
used including an updated Morisky Medication Adherence
Scale, nowwith an 8-item scale that was developed for use in
patients taking antihypertension medications.792,793 Use of a
visual analog scale to measure patient adherence might also
allow the provider to more accurately identify non-adherent
patients.772 If medication adherence is less than optimal, the
provider can pursue the reasons for non-adherence and
address barriers.
In very busy primary care or specialty practices, it may
be difficult to find adequate time to review and value this
apparent ‘‘flood’’ of information. New office designs or
strategies are necessary to create a workflow that utilizes
office staff to the fullest extent possible in collecting and
Jacobson et al NLA Dyslipidemia Recommendations - Part 2 S95addressing adherence information, and that does not slow
down the provider or practice. In the ideal Patient Centered
Medical Home model, there are multiple providers and
staff, including nurses and pharmacists that might help with
these patients. Optimal strategies for practices will vary
widely based on the type of patients treated and the staff
available. Training staff in communication and redesigning
roles and workflow to facilitate more provider and staff
time with patients (e.g., face to face, phone, email, text,
messaging via electronic record) will likely be beneficial
for increasing adherence.764,791,794
In the era of the Patient Centered Medical Home,
patient-determined goals and action steps are critical to
positive outcomes. The goal is to help generate ideas (self-
determined goals) to assist with medication adherence
challenges. Open-ended questions such as ‘‘Tell me more
about the trouble you are having?’’ or ‘‘What has helped in
the past?’’ can be used. The providers need to work with
patients to create realistic and actionable steps. Other
questions such as ‘‘What do you want to do to address
the problem?’’ or ‘‘When will you be ready to begin to
make changes that will lead to increased adherence?’’ are
also useful. A follow-through question is ‘‘May I call you
next week to see how this is going?’’
The role of health care providers begins with identifying
the patient’s problem, assessing the patient’s level of under-
standing, and then providing necessary education including
verbal explanations and written materials. The provider
should emphasize that the patient is a partner in decision-
making about the treatment regimen. When discussing
therapeutic options, the provider will need to specifically
relate the reason for prescribing medication to the patient’s
condition. For example, in a patient who is post-MI, the need
for a high-intensity statin is paramount and has been shown to
reduce subsequent cardiovascular events and mortal-
ity.738,795 The provider will need to explain this to the patient
in terms he/she will fully understand.
It is important to discuss the potential side effects of
prescribed atherogenic cholesterol-lowering therapies,
including statin therapy, with all patients, because they
have usually heard or read about the side effects, and may
be worried about taking certain medications based on
rumor or misinformation. Items to discuss with the patient
prescribed statins include the potential for muscle aches, as
described previously.334 The provider should specifically
describe how the muscle ache might feel on statins. Also,
the health care provider should reinforce that the
provider/office staff needs to be contacted if the patient
believes he/she is experiencing an adverse effect. Patients
should be assured that safety labs are checked when the
lipid panel is checked. The provider should also explain
that although statins are 1 ‘‘class’’ of drugs, statins
individually are very different drugs from one another—a
problem with 1 does not usually mean that all statins
need to be avoided.334,761
Shared decision-making is integral to the provider-
patient encounter.1,3,796 A statin prescription should notbe an automatic recommendation for a patient with elevated
cholesterol.1,3 It is critically important to engage the patient
in a discussion, review benefit vs risk of statin therapy,
discuss all treatment options, and consider patient prefer-
ences as described in the NLA’s Recommendations for
the Patient-centered Management of Dyslipidemia–Part 1.1
Providers need to understand and be committed to the
concept that communication is the key to preventing or
overcoming medication adherence-related challenges.
More conversation with the patient and repetition in the
discussion can lead to enhanced adherence. The mnemonic
‘‘SIMPLE’’, described below, affords effective interven-
tions to reduce medication non-adherence.768
S—Simplify the regimen
Providers should consider adjusting or simplifying the
medication regimen when possible.797 This can be accom-
plished by adjusting timing, frequency, amount, and dosage
of medications. Once per day is always preferred, when
feasible, as well as matching the regimen to the patient’s
activities of daily living, and recommending that all medi-
cations be taken at the same time of day if there are no
interaction or food absorption issues. Whenever possible,
the provider should avoid prescribing medications with spe-
cial requirements such as those that need to avoid mealtime
dosing.798 Encouraging use of adherence aids such as pill
organizers or alarms can also be useful.762,764,772,799
I—Impart knowledge
Providers should focus on provider-patient shared
decision-making, discussing more within the health care
team, involving the patient’s family and caregivers in discus-
sions, if appropriate, providing advice on how to cope with
medication costs, and preparing clear written and verbal
instructions for all prescriptions. Providers should consider
limiting instructions to 3 or 4 major points, using plain
language, as well as using written information or pamphlets
along with verbal education at all encounters. Providers can
suggest computerized self-instruction or legitimatewebsites if
patients are interested in accessing health education informa-
tion from the Internet. Discussions should be reinforced
often, especially with low-literacy patients.762,764,768,772
M—Modify patient beliefs and behavior
To modify patients’ beliefs and behavior, providers
should empower patients to self-manage their condition.
To do this properly, providers should create an open
dialogue with each patient, verifying his/her needs,
expectations, and experiences in taking medications.
Providers should also verify what will help patients to
become, and remain, adherent. It is important to ensure that
patients understand that they will be at risk if they do not
take their medications. This can be done by asking
patients to describe the consequences of not taking their
medications as well as having patients restate the positive
benefits of taking their medications (‘‘teach back’’). The
provider should address the patients’ fears, concerns, and
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praise, and, when possible, by arranging incentives such
as coupons, certificates, and reduced frequency of
visits.762,764,772,800,801 Smith et al.797 provided the
following suggestions that providers can implement by
involving their office staff to improve communication
with their patients and, in turn, improve adherence:764
 Improve the convenience of scheduling appointments,
referrals, and refills
 Remind patients to refill early
 Install interactive voice response systems
 Manage compliance-linked financial incentives
 Provide at-home self-management programs
 Provide counseling, repeated monitoring, and feedback
 Use automated telephone or computer-assisted patient
monitoring
 Use manual telephone follow-up
 Deliver appointment and prescription refill reminders
 Send patient mailings that reinforce medication taking
 Teach behavioral strategies
P—Provide communication and trust
To provide communication and to develop trust with
patients, providers should improve their interviewing skills,
use brief motivational interviewing,800 practice active
listening, provide emotional support, use plain language
to provide information, and elicit patients’ input in treat-
ment decisions.762,764,766,768,772,787
L—Leave the bias
In many cases, ethnicity, minority, and socioeconomic
disparities are related to health outcomes and types of care,
including preventive care. Patients from minority popula-
tions, or populations with lower socioeconomic status,
often experience lower levels of patient-centered commu-
nication and display higher verbal passivity with health
care providers compared to those with higher levels of
education.763 Providers should be aware of these issues and
implement strategies to enhance the effectiveness of
communication with these groups.
E—Evaluate adherence
There is no gold standard to evaluate a patient’s
medication adherence; however, providers are encouraged
to use patient self-reporting to inquire about adherence at
every patient encounter, and occasionally to ask the patient
to do a ‘‘brown bag’’ for the next visit, i.e., bring all
prescribed and over-the-counter medications to the visit.
This will afford the provider the opportunity to review the
medications for clarification and reinforcement of the
rationale for particular medications, and to note renewal
dates. The provider should ask direct questions about the
level of adherence to cholesterol-lowering medications or
administer medication adherence scales.762,764,772 Techno-
logical intervention, such as automated phone calls if a
prescription has not been filled, has been shown to reduce
primary non-adherence of statin medications.802Role of team-based collaborative care in improving
adherence
Health care system changes have the potential to over-
come challenges in improving medication adherence. Pro-
viders may work together with the patient by the
introduction of team-based collaborative care (as described
in the next section of these recommendations). In patients
with demonstrated or admitted non-adherence to medica-
tion, it is sometimes helpful for other members of the
provider’s care team (nurse, pharmacist, behavioral health
specialist, etc.) to spend more time with the patient
exploring his or her views and how these might influence
the perception of risk and medication-taking behavior. Such
strategies optimize the patient’s sense of the provider’s
concern for their view/welfare and allow for greater patient-
provider dialogue in arriving at an acceptable treatment
approach.764,772 Team-based care should also improve the
ability to educate patients on the advantages of adherence
to the medication regimen and the purpose of their individ-
ual treatment regimen by improving access to providers
when patients have questions or problems, and by utilizing
reliable technologies to provide information and facilitate
communication between the patient and health care
team.768,770,772
Summary and recommendations
Medication non-adherence in patients with CVD risk
factors is a common problem and is associated with worse
outcomes and higher health system costs. Improving this
situation will depend on actions that include early
recognition of non-adherence and a sustained, coordinated
effort by the entire health care team to prevent and
address non-adherence. Central to adherence is the quality
of the provider-patient relationship. Better communication
has been empirically linked to positive outcomes of care,
including patient satisfaction. An effective provider-
patient dialogue provides increased opportunities for
patients to understand their condition and be interactively
involved with weighing the risks and benefits of thera-
pies.803 Providers can improve outcomes by focusing on
public policy, outpatient practice redesigns that optimally
leverage electronic health record capability, and patient-
specific intervention strategies such as explaining the con-
sequences of non-adherence, suggesting ways to improve
adherence, introducing team-based care, and identifying
roles and responsibilities in team-based care to deliver
optimally improved patient-centered health
outcomes.772,804See Chart 14 for Recommendations for Patient
Adherence.
Team-based collaborative care
Team-based collaborative care has emerged from the
complexity of modern health care; that is, a given health
care provider is responsible for a larger volume of
patients, is held accountable for quality indicators based
Chart 14 Recommendations for patient adherence
Recommendations Strength Quality
The provider should assess adherence to both lifestyle and atherogenic cholesterol-lowering medications at
every patient encounter.
E Low
A multidisciplinary health care team (such as the patient’s primary health care provider; nurses; nurse
practitioners; pharmacists; physician assistants; registered dietitian nutritionists, including certified
diabetes educators in some practices; exercise specialists; social workers; community health workers; and
licensed professional counselors, psychologists, and health educators) is desirable to identify medication
non-adherence and to facilitate strategies to improve adherence by helping patients overcome real (or
perceived) barriers to adherence.
E Low
The multi-faceted approach should be employed by clinicians to improve medication adherence, including: a)
simplify the regimen; b) provide clear education using visual aids and simple, low-literacy educational
materials; c) engage patients in decision-making, addressing their specific needs, values, and concerns; d)
address perceived barriers of taking medication; e) identify suboptimal health literacy and use ‘‘teach-back’’
techniques to increase patient understanding of those behaviors needed to be successful; f) screen and
eliminate drug-drug and drug-disease interactions leading to low adherence or drug discontinuation; and
g) praise and reward successful behaviors.
E Low
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lines, must integrate new technologies to help patients
prevent and manage illnesses, and must communicate with
numerous other practitioners who are involved in the care
of their patients. An effective health care team is widely
recognized as necessary for a patient-centered and coordi-
nated health care delivery system. Central to the success of
team-based care is the expertise and reliability with which
team members work together.805 In 2012, the Institute of
Medicine proposed a definition of team-based health care
adapted from Naylor et al.:806
Team-based health care is the provision of health
services to individuals, families, and/or their commu-
nities by at least two health providers who work
collaboratively with patients and their caregivers—to
the extent preferred by each patient—to accomplish
shared goals within and across settings to achieve
coordinated, high-quality care.805
Recently, the Community Guide Branch of the CDC
published a systematic review of the effectiveness of
team-based care in improving blood pressure outcomes.807
Results from this review can be applied to team-based care
in the setting of lipid management.
Disciplines represented in ‘‘teams’’ and their roles
Several disciplines may be included in health care teams
for optimal lipid management, including the patient; the
patient’s primary health care provider; nurses; nurse
practitioners; pharmacists; physician assistants; registered
dietitian nutritionists; certified diabetes educators; exercise
specialists; social workers; community health workers; and
licensed professional counselors, psychologists, and health
educators. The patient should be recognized as an active
partner in the health care team. The primary care provider
may be a physician, nurse practitioner, or physician assis-
tant, while other team members complement the activities
of the primary care provider(s). For example, nursesprovide process support and are often the first line of
communication between the patient and provider for health
issues when the patient is at home. Team members often
share responsibilities for medication management, active
patient follow-up, medication and lifestyle adherence, and
self-care support. Pharmacists serve as important resources
to health care providers such as assessing the potential for
drug-drug or drug-disease interactions that could lead to
poor outcomes and assessing the patient’s ability to under-
stand and adhere to complex medication regimens. Phar-
macists are directly accessible to patients as a resource for
health and medical information and can conduct preventive
health testing—including services for cholesterol, blood
glucose, and glycated hemoglobin levels. Lifestyle coun-
seling and instructions are best provided by health care
team members with expertise in these areas, such as
registered dietitian nutritionists, exercise specialists, and
licensed professional counselors or psychologists for pur-
poses of dealing with life stressors, anger management and
lifestyle coaching related to smoking cessation and eating
disorders.
Team-based collaborative care and improved
outcomes
The effectiveness of team-based care has been evaluated
with respect to several outcomes: lipid levels and LDL-C
goal attainment, medication and lifestyle adherence,
behavior change, management of statin adverse effects,
and cardiovascular risk reduction. In a 2-year prospective
cluster RCT designed to evaluate the impact of remote
physician-pharmacist team-based care on cholesterol levels
in patients with diabetes, 6963 patients who received
care from 68 physicians in 9 clinics were evaluated.808
All clinicians had access to the health information
technology tool CareManager, which provided point-of-
care prompts, a registry, and performance feedback
with benchmarking. Pharmacists evaluated the records of
Figure 11 Hypotheses for the pathophysiology of atherosclerotic coronary artery disease in HIV-infected patients taking cART.
Antiretroviral therapy (ART) and HIV itself could promote coronary heart disease (CHD) along with environmental and genetic factors.
Adipose tissue and liver dysfunction have been associated with the accumulation of visceral fat, epicardial fat, and liver steatosis leading
to metabolic disturbances (decreased adiponectin and glucose uptake, insulin resistance, dyslipidemia, and increased in situ and systemic
inflammation). Both HIV and combined antiretroviral therapy (cART) have a deleterious effect on adipose tissue. Residual HIV replication
even under potent cART and reactivation of other viruses (eg, cytomegalovirus [CMV]) could lead to permanent immune activation and to a
degree of immune senescence that could favor atherosclerosis. Chronic inflammation could persist under cART potentially due to increased
microbial translocation in the gut, associated with coagulation disorders. Adipose tissue dysfunction, immune activation, and chronic
inflammation could result in vascular and endothelial dysfunction, leading to atherosclerosis and acute ischemic events. CRP, C-reactive
protein; F VII, factor VII; FFA, free fatty acid; HDLc, high-density lipoprotein cholesterol; IL6, interleukin 6; NO, nitrogen oxide;
PAI-1, plasminogen activator inhibitor type 1; PPAR, peroxisome proliferator-activated receptors; RAS, renin angiotensin system; ROS,
reactive oxygen species; sCD14, soluble CD14; TG, triglyceride; TNF, tumor necrosis factor; VSMC, vascular smooth muscle cells. Taken
from: Boccara F, et al. J Am Coll Cardiol. 2013;61:511–523.585 Permission to reprint was obtained.
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treatment recommendations, and electronically sent treat-
ment recommendations to physicians. Patients in the
intervention arm were more likely to achieve goal LDL-C
,100 mg/dL compared with controls (78% vs 50%;P 5 .003). Mean LDL-C was 12 mg/dL lower in the
intervention arm compared to the control arm (P , .001).
Additionally, patients in the intervention arm were 15%
more likely to receive a prescription for a lipid-lowering
medication (P 5 .008).
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conducted to assess the effects of pharmacist intervention
on cardiovascular outcomes. Santschi et al.809 identified 15
randomized controlled trials involving 9111 outpatients
with diabetes in which the interventions in 8 of the studies
were conducted exclusively by pharmacists and the
remainder in collaboration with physicians and other health
care team members. Compared to usual care, pharmacist
involvement led to significant reductions in blood pressure,
total-C, LDL-C, and BMI. Similarly, a systematic review
was conducted to evaluate the effect of US pharmacists
as team members on patient care.810 A total of 298 studies
with evidence of pharmacist involvement in direct care, a
comparison group, and reported patient outcomes were
included. Favorable results were reported for glycated
hemoglobin, LDL-C, blood pressure, and adverse drug ef-
fects (P , .05) in pharmacists’ direct care vs comparative
services. In addition, medication adherence, patient
knowledge, and quality of life/general health were
improved (P , .05) with pharmacist involvement in direct
care. The benefit of pharmacist involvement in disease
management and education was also shown in a recent
study evaluating simvastatin safety concerns.811 Pharma-
cists reviewed the records of patients treated outside the
revised statin labeling and then made recommendations
to providers via the electronic health record. Results
showed that providers accepted the recommendations by
pharmacists 92% of the time without modification and
7% of the time with modification. Therefore, research
indicates improved clinical outcomes with pharmacist
involvement as a direct care team member as well as
acceptance of pharmacist recommendations by primary
providers.
In a nurse-led multidisciplinary intervention designed to
improve the cardiovascular risk profile, 294 secondary
prevention patients underwent a nurse practitioner-led
lifestyle intervention program as well as medical treat-
ment.812 Other team members included a cardiologist and
an internist. LDL-C and systolic blood pressure were
significantly reduced (P , .01), as were the number of
smokers (P , .001) and alcohol consumption (P , .001).
Patients improved their healthy eating habits (P , .001),
however physical activity did not change and BMI
increased during follow-up.
In the Community Guide Systematic Review on team-
based care and improved blood pressure control, lipid
outcomes were evaluated in several studies.807 Studies
included in the systematic review were required to have a
comparison group or an interrupted time-series design
with at least 2 measurements before and after the interven-
tion. Team-based care resulted in improvements in total-C
and LDL-C. The authors noted that the essential features
of interventions that improved outcomes other than blood
pressure were a focus on multiple risk factors and the addi-
tion of nurse practitioners with the ability to prescribe
medications.Team-based collaborative care and improved patient
satisfaction
The impact of team-based care on patient satisfaction
remains inconclusive. The clinical trial by Pape et al.808 on
a physician-pharmacist team-based approach to cholesterol
management showed no difference in patient satisfaction
between study arms. A recent systematic review of RCTs
evaluated whether team-based care improves patient satis-
faction.813 Twenty-six trials of over 15,000 participants
were included. The pooled result of dichotomous data (10
studies) showed that team-based care improved patient
satisfaction compared with usual care (OR, 2.09; 95% CI,
1.54 to 2.84), however in the 7 studies with combined
continuous data, no difference was reported between
team-based care and usual care (standardized mean differ-
ence, 20.02; 95% CI, 20.40 to 0.36).
Strategies for effective team-based collaborative
care
The Community Guide Systematic Review on team-
based care807 offered several strategies for effective team-
based care:
 Facilitate communication and coordination of care sup-
port among various team members;
 Enhance use of evidence-based guidelines by providers;
 Establish regular structured follow-up mechanisms to
monitor patients’ progress and schedule additional visits
as needed;
 Actively engage patients in their own care by providing
them with education about medication, adherence sup-
port, and tools and resources for self-management
(including behavior change).Incorporation of team-based collaborative care into
the Patient Centered Medical Home model
The Patient Centered Medical Home is promoted as a
component of the required changes needed to address
health care quality, access, continuity and cost shortfalls
in the United States. The Patient Centered Medical Home
framework and financial incentives are framed around
meaningful use of electronic health record technology to
adopt a certified electronic health record and to have
registry-like capabilities. The Agency for Healthcare
Research and Quality defined the Patient Centered Medical
Home by 5 attributes: a patient-centered orientation,
comprehensive team-based care, coordinated care, access
to care, and a systems-based approach to quality and
safety.814 Therefore, team-based collaborative care is cen-
tral to the Patient Centered Medical Home model and can
provide a structure to improve the efficiency of care deliv-
ery, support patient access to resources for self-
management activities, and achieve a coordinated and
comprehensive approach to treating lipid disorders, other
risk factors, and chronic cardiovascular conditions.807
Chart 15 Recommendations for team-based collaborative care
Recommendations Strength Quality
Health care teams for optimal lipid and ASCVD risk management may include, where available: the patient;
the patient’s primary health care provider; nurses; nurse practitioners; pharmacists; physician assistants;
registered dietitian nutritionists, including certified diabetes educators in some practices; exercise
specialists; social workers; community health workers; and licensed professional counselors, psychologists,
and health educators.
A High
Health care team members should coordinate care support among various team members, use evidence-based
guidelines/recommendations for dyslipidemia management, establish a structured plan for monitoring
patient progress, and provide patients with a variety of tools and resources to improve their own care.
A High
Team-based collaborative care may be incorporated into the Patient Centered Medical Home as a strategy to
address shortfalls in patient health care quality, access, continuity, and cost.
E Low
S100 Journal of Clinical Lipidology, Vol 9, No 6S, December 2015See Chart 15 for Recommendations for Team-Based
Collaborative Care.
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